U.S. patent application number 11/451774 was filed with the patent office on 2007-05-10 for compositions and methods for treating and diagnosing cancer.
This patent application is currently assigned to The Regents of the University of Michigan. Invention is credited to Michael F. Clarke, Austin L. Gurney, John A. Lewicki, Xinhao Wang.
Application Number | 20070105133 11/451774 |
Document ID | / |
Family ID | 37571044 |
Filed Date | 2007-05-10 |
United States Patent
Application |
20070105133 |
Kind Code |
A1 |
Clarke; Michael F. ; et
al. |
May 10, 2007 |
Compositions and methods for treating and diagnosing cancer
Abstract
The present invention relates to compositions and methods for
treating, characterizing, and diagnosing cancer. In particular, the
present invention provides gene expression profiles and signatures
associated with solid tumor stem cells, as well as novel stem cell
cancer markers useful for the diagnosis, characterization,
prognosis and treatment of solid tumor stem cells. More
particularly, the present invention identifies two profiles of
cancer stem cells useful for the diagnosis, characterization, and
treatment of cancer and cancer metastases. The invention also
provides a variety of reagents such as stem cell gene signatures
for use in the diagnosis and management of cancer.
Inventors: |
Clarke; Michael F.; (Palo
Alto, CA) ; Wang; Xinhao; (Fremont, CA) ;
Lewicki; John A.; (Los Gatos, CA) ; Gurney; Austin
L.; (San Francisco, CA) |
Correspondence
Address: |
Medlen & Carroll, LLP;Suite 350
101 Howard Street
San Francisco
CA
94105
US
|
Assignee: |
The Regents of the University of
Michigan
Ann Arbor
MI
|
Family ID: |
37571044 |
Appl. No.: |
11/451774 |
Filed: |
June 13, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60690001 |
Jun 13, 2005 |
|
|
|
Current U.S.
Class: |
435/6.12 ;
435/366; 435/7.23 |
Current CPC
Class: |
A61P 35/02 20180101;
C12N 5/0693 20130101; C12N 2501/58 20130101; G01N 2333/705
20130101; A61P 35/00 20180101; C12N 5/0695 20130101; C12Q 1/6886
20130101; G01N 33/6887 20130101; G01N 33/57484 20130101 |
Class at
Publication: |
435/006 ;
435/007.23; 435/366 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; G01N 33/574 20060101 G01N033/574; C12N 5/08 20060101
C12N005/08 |
Goverment Interests
[0003] This invention was made with government support under Grant
No. 5P01CA07513606 awarded by the National Institute of Health. The
Government has certain rights in the invention.
Claims
1. An enriched population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
solid tumor stem cells and solid tumor cells, wherein the solid
tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; and express
undetectable levels or low levels of alpha-catenin or
e-cadherin.
2. The enriched population of solid tumor stem cells of claim 1,
wherein the solid tumor stem cells: express undetectable levels or
low levels of e-cadherin; and, express undetectable levels or low
levels of one or more of MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B,
G0S2, IL8, B3GNT5, and FGFBP1.
3. The enriched population of solid tumor stem cells of claim 1,
wherein the solid tumor stem cells: express undetectable levels or
low levels of e-cadherin; and, express undetectable levels or low
levels of one or more of MMP7, Nov, FOSL1, and IL1R2.
4. The enriched population of solid tumor stem cells of claim 1,
wherein the solid tumor stem cells: express undetectable levels or
low levels of e-cadherin; and, express elevated levels of one or
more of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27, TAP1, RNASEL, and
LOC57168.
5. The enriched population of solid tumor stem of claim 1, wherein
the solid tumor stem cells: express undetectable levels or low
levels of e-cadherin; and, express elevated levels of one or more
of SHC1 and FLJ20152.
6. An enriched population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
solid tumor stem cells and solid tumor cells, wherein the solid
tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; and express
undetectable levels or low levels of two or more of e-cadherin,
MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B, G0S2, IL8, B3GNT5, and
FGFBP1.
7. The enriched population of solid tumor stem cells of claim 6,
wherein the solid tumor stem cells: express undetectable levels or
low levels of two or more of e-cadherin, MMP7, Nov, FOSL1, and
IL1R2.
8. An enriched population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
solid tumor stem cells and solid tumor cells, wherein the solid
tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; and, express elevated
levels of two or more of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27,
TAP1, RNASEL, and LOC57168.
9. The enriched population of solid tumor stem cells of claim 8,
wherein the solid tumor stem cells: express elevated levels of SHC1
and FLJ20152.
10. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of one or more of e-cadherin, MMP7, Nov,
FOSL1, IL1R2, SFRP1, KRT6B, G0S2, IL8, B3GNT5, and FGFBP1; and
express elevated levels of one or more of SHC1, FLJ20152, ARNT,
CYFIP2, C17orf27, TAP1, RNASEL, and LOC57168.
11. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of alpha-catenin; and, express undetectable
levels or low levels of one or more of NCSTN, LNX, ARMCX3, D2S448,
TUSC1, GLUL, RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102,
SLC1A4, and DNAJD1.
12. The enriched population of solid tumor stem cells of claim 11,
wherein the solid tumor stem cells: express undetectable levels or
low levels of one or more of NCSTN, LNX, ARMCX3, D2S448, GLUL, and
RB1.
13. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of alpha-catenin; and, express elevated levels
of one or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5,
MET, FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2,
SLC7A5, ARNTL2, PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV,
MAL, IMP-3, and DHRS9.
14. The enriched population of solid tumor stem cells of claim 13,
wherein the solid tumor stem cells: express elevated levels of one
or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, CTSL2, and MFHAS1.
15. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of two or more of alpha-catenin, NCSTN, LNX,
ARMCX3, D2S448, TUSC1, GLUL, RB1, BEX2, SLC12A2, GALC, NGFRAP1,
FGF13, KIAA1102, SLC1A4, and DNAJD1.
16. The enriched population of solid tumor stem cells of claim 15,
wherein the solid tumor stem cells: express undetectable levels or
low levels of two or more of alpha-catenin, NCSTN, LNX, ARMCX3,
D2S448, GLUL, and RB1.
17. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; and, express elevated
levels of two or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2,
CXCL5, MET, FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1,
CTSL2, SLC7A5, ARNTL2, PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2,
MYEOV, MAL, IMP-3, and DHRS9.
18. The enriched population of solid tumor stem cells of claim 17,
wherein the solid tumor stem cells: express elevated levels of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, CTSL2, and MFHAS1.
19. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of one or more of alpha-catenin, NCSTN, LNX,
ARMCX3, D2S448, GLUL, and RB1; and express elevated levels of one
or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5,
ARNTL2, PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3,
and DHRS9.
20. An enriched population of solid tumor stem cells obtained from
a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold compared to
unfractionated tumor cells; are tumorigenic; express undetectable
levels or low levels of alpha-catenin; and, express elevated levels
of MET.
21. A method of classifying a cancer comprising: (a) determining
expression levels of one or more genes comprising alpha-catenin
signature 2 in a cancer sample; (b) comparing the expression levels
of the genes in the cancer sample to alpha-catenin signature 2;
and, (c) classifying the cancer sample to either a high risk or low
risk group based on the comparison in (b).
22. The method of claim 21 wherein determining the expression
levels of one or more genes comprising alpha catenin signature 2 is
by measuring the expression of a corresponding protein or
polypeptide.
23. The method of claim 22 wherein the protein or polypeptide is
detected by immunohistochemical analysis of the cancer sample using
an antibody that binds to the protein or polypeptide.
24. The method of claim 23, wherein said antibody comprises an
anti-CD44 antibody.
25. The method of claim 23, wherein said antibody comprises an
anti-beta cantenin antibody.
26. The method of claim 22 wherein the protein or polypeptide is
detected by ELISA assay using an antibody that binds to the protein
or polypeptide.
27. The method of claim 26, wherein said antibody comprises an
anti-CD44 antibody.
28. The method of claim 26, wherein said antibody comprises an
anti-beta cantenin antibody.
29. The method of claim 22 wherein the protein or polypeptide is
detected using a protein array comprising an antibody that binds to
the protein or polypeptide.
30. The method of claim 29, wherein said antibody comprises an
anti-CD44 antibody.
31. The method of claim 29, wherein said antibody comprises an
anti-beta cantenin antibody.
32. The method of claim 21 wherein determining the expression
levels of one or more genes comprising alpha catenin signature 2 is
by measuring the expression of corresponding mRNA.
33. The method of claim 32 wherein the mRNA is detected using a
polynucleotide array comprising a polynucleotide that hybridizes to
the mRNA.
34. The method of claim 32 wherein the mRNA is detected using
polymerase chain reaction comprising polynucleotide primers to
amplify the mRNA.
35. The method of claim 21 further comprising; providing
diagnostic, prognostic, or predictive information based on the
classifying in (d).
36. A method of classifying a cancer comprising: (a) determining
expression levels of one or more genes comprising alpha-catenin
signature 3 in a cancer sample; (b) comparing the expression levels
of the genes in the cancer sample to alpha-catenin signature 3;
and, (c) classifying the cancer sample to either a high risk or low
risk group based on the comparison in (b).
37. The method of claim 36 wherein determining the expression
levels of one or more genes comprising alpha catenin signature 3 is
by measuring expression of the corresponding protein or
polypeptide.
38. The method of claim 37 wherein the protein or polypeptide is
detected by immunohistochemical analysis on the cancer sample using
an antibody that binds to the protein or polypeptide.
39. The method of claim 38, wherein said antibody comprises an
anti-CD44 antibody.
40. The method of claim 38, wherein said antibody comprises an
anti-beta cantenin antibody.
41. The method of claim 37 wherein the protein or polypeptide is
detected by ELISA assay using an antibody that binds to the protein
or polypeptide.
42. The method of claim 41, wherein said antibody comprises an
anti-CD44 antibody.
43. The method of claim 41, wherein said antibody comprises an
anti-beta cantenin antibody.
44. The method of claim 37 wherein the protein or polypeptide is
detected using a protein array comprising an antibody that binds to
the protein or polypeptide.
45. The method of claim 44, wherein said antibody comprises an
anti-CD44 antibody.
46. The method of claim 44, wherein said antibody comprises an
anti-beta cantenin antibody.
47. The method of claim 36 wherein determining the expression
levels of one or more genes comprising alpha catenin signature 3 is
by measuring the expression of corresponding mRNA.
48. The method of claim 47 wherein the mRNA is detected using a DNA
array comprising a polynucleotide that hybridizes to the mRNA.
49. The method of claim 47 wherein the mRNA is detected using
polymerase chain reaction comprising polynucleotide primers that
specifically amplify the mRNA.
50. The method of claim 36 further comprising; providing
diagnostic, prognostic, or predictive information based on the
classifying in (d).
Description
[0001] This application claims the benefit of the filing date of
U.S. Provisional Appl. No. 60/690,001, filed Jun. 13, 2005, which
is incorporated herein by reference in its entirety.
[0002] U.S. application Ser. No.11/050,282, filed Feb. 3, 2005,
U.S. Appl No. 60/541,527, filed Feb. 3, 2004, and U.S. application
Ser. No. 10/864,207, filed Jun. 9, 2004, are herein incorporated by
reference in their entirety.
FIELD OF THE INVENTION
[0004] The present invention relates to compositions and methods
for treating, characterizing, and diagnosing cancer. In particular,
the present invention provides gene expression profiles and
signatures associated with solid tumor stem cells, as well as novel
stem cell cancer markers useful for the diagnosis,
characterization, prognosis, and treatment of solid tumor stem
cells and cancer.
BACKGROUND OF THE INVENTION
[0005] Breast cancer is the most common female malignancy in most
industrialized countries, as it is estimated to affect about 10% of
the female population during their lifespan. Although its mortality
has not increased along with its incidence, due to earlier
diagnosis and improved treatment, it is still one of the
predominant causes of death in middle-aged women. Despite earlier
diagnosis of breast cancer, about 1-5% of women with newly
diagnosed breast cancer have a distant metastasis at the time of
the diagnosis. In addition, approximately 50% of the patients with
local disease who are primarily diagnosed eventually relapse with
the metastasis. Eighty-five percent of these recurrences take place
within the first five years after the primary manifestation of the
disease.
[0006] On presentation, most patients with metastatic breast cancer
have only one or two organ systems involved. As the disease
progresses over time, multiple sites usually become involved.
Indeed, metastases can be found in nearly every organ of the body
at autopsy. The most common sites of metastatic involvement
observed are locoregional recurrences in the skin and soft tissues
of the chest wall, as well as in axilla, and supraclavicular area.
The most common site for distant metastasis is the bone (30-40% of
distant metastasis), followed by lung and liver. Metastatic breast
cancer is generally considered to be an incurable disease. However,
the currently available treatment options often prolong the
disease-free state and overall survival rate, as well as increase
the quality of the life. The median survival from the manifestation
of distant metastases is about three years.
[0007] Current methods of diagnosing and staging breast cancer
include the tumor-node-metastasis (TNM) system that relies on tumor
size, tumor presence in lymph nodes, and the presence of distant
metastases as described in the American Joint Committee on Cancer:
AJCC Cancer Staging Manual. Philadelphia, Pa.: Lippincott-Raven
Publishers, 5th ed., 1997, pp 171-180, and in Harris, J R: "Staging
of breast carcinoma" in Harris, J. R., Hellman, S., Henderson, I.
C., Kinne D. W. (eds.): Breast Diseases. Philadelphia, Lippincott,
1991. These parameters are used to provide a prognosis and select
an appropriate therapy. The morphologic appearance of the tumor can
also be assessed but because tumors with similar histopathologic
appearance can exhibit significant clinical variability, this
approach has serious limitations. Finally assays for cell surface
markers can be used to divide certain tumors types into subclasses.
For example, one factor considered in the prognosis and treatment
of breast cancer is the presence of the estrogen receptor (ER) as
ER-positive breast cancers typically respond more readily to
hormonal therapies such as tamoxifen than ER-negative tumors. Yet
these analyses, though useful, are only partially predictive of the
clinical behavior of breast tumors, and there is much phenotypic
diversity present in breast cancers that current diagnostic tools
fail to detect.
[0008] Traditional modes of cancer therapy include radiation
therapy, chemotherapy, and hormonal therapy. Yet because of the
difficulty in predicting the clinical course of early stage breast
cancer from standard clinical and pathologic features, current
practice is to offer systemic chemotherapy to most women even
though the majority of these women can have a good outcome in the
absence of chemotherapy. Chemotherapy has severe side effects and
itself carries a 1% mortality rate, and thus unnecessary suffering
and deaths could be avoided if patients could be divided into high
and low risk subgroups. Thus, there exists a need for improved
methods of classifying tumors for better prognosis and treatment
selection.
[0009] Furthermore, although current therapies can often prolong
the disease-free state and overall survival when used on high-risk
patients, they are limited by their lack of specificity and the
emergence of treatment-resistant cancer cells. Approximately two
thirds of people diagnosed with cancer will die of their cancer
within five years. Thus there is a great need for the
identification of additional genes that can serve as selective
therapies for the treatment of cancer.
[0010] Colorectal cancer is the third most common cancer and the
fourth most frequent cause of cancer deaths worldwide.
Approximately 5-10% of all colorectal cancers are hereditary with
one of the main forms being familial adenomatous polyposis (FAP),
an autosomal dominant disease in which about 80% of affected
individuals contain a germline mutation in the adenomatous
polyposis coli (APC) gene. Colorectal carcinoma has a tendency to
invade locally by circumferential growth and for lymphatic,
hematogenous, transperitoneal, and perineural spread. The most
common site of extralymphatic involvement is the liver, with the
lungs the most frequently affected extra-abdominal organ. Other
sites of hematogenous spread include the bones, kidneys, adrenal
glands, and brain.
[0011] The current staging system for colorectal cancer is based on
the degree of tumor penetration through the bowel wall and the
presence or absence of nodal involvement. This staging system is
defined by three major Duke's classifications: Duke's A disease is
confined to submucosa layers of colon or rectum; Duke's B disease
has tumors that invade through muscularis propria and can penetrate
the wall of the colon or rectum; and Duke's C disease includes any
degree of bowel wall invasion with regional lymph node
metastasis.
[0012] Surgical resection is highly effective for early stage
colorectal cancers, providing cure rates of 95% in Duke's A and 75%
in Duke's B patients. The presence of positive lymph node in Duke's
C disease predicts a 60% likelihood of recurrence within five
years. Treatment of Duke's C patients with a post surgical course
of chemotherapy reduces the recurrence rate to 40%-50%, and is now
the standard of care for these patients. Because of the relatively
low rate of reoccurrence, the benefit of post surgical chemotherapy
in Duke' B has been harder to detect and remains controversial.
However, the Duke's B classification is imperfect as approximately
20-30% of these patients behave more like Duke's C and relapse
within five years. Thus there is a clear need to identify better
prognostic factors for selecting Duke's B patients that are likely
to relapse and would benefit from therapy.
[0013] During normal animal development, cells of most or all
tissues are derived from normal precursors, called stem cells
(Morrison et al., Cell 88(3): 287-98 (1997); Morrison et al., Curr.
Opin. Immunol. 9(2): 216-21 (1997); Morrison et al., Annu. Rev.
Cell. Dev. Biol. 11: 35-71 (1995)). Stem cells are cells that: (1)
have extensive proliferative capacity; 2) are capable of asymmetric
cell division to generate one or more kinds of progeny with reduced
proliferative or developmental potential; and (3) are capable of
symmetric cell divisions for self-renewal or self-maintenance. In
adult animals, some cells (including cells of the blood, gut,
breast ductal system, and skin) are constantly replenished from a
small population of stem cells in each tissue. The best-known
example of adult cell renewal by the differentiation of stem cells
is the hematopoietic system where developmentally immature
precursors (hematopoietic stem and progenitor cells) respond to
molecular signals to form the varied blood and lymphoid cell
types.
[0014] Solid tumors are composed of heterogeneous cell populations.
For example, breast cancers are a mixture of cancer cells and
normal cells, including mesenchymal (stromal) cells, inflammatory
cells, and endothelial cells. Classic models of cancer hold that
phenotypically distinct cancer cell populations all have the
capacity to proliferate and give rise to a new tumor. In the
classical model, tumor cell heterogeneity results from
environmental factors as well as ongoing mutations within cancer
cells resulting in a diverse population of tumorigenic cells. This
model rests on the idea that all populations of tumor cells would
have some degree of tumorigenic potential. (Pandis et al., Genes,
Chromosomes & Cancer 12:122-129 (1998); Kuukasjrvi et al.,
Cancer Res. 57: 1597-1604 (1997); Bonsing et al., Cancer 71:
382-391 (1993); Bonsing et al., Genes Chromosomes & Cancer 82:
173-183 (2000); Beerman H et al., Cytometry. 12(2): 147-54 (1991);
Aubele M & Werner M, Analyt. Cell: Path. 19: 53 (1999); Shen L
et al., Cancer Res. 60: 3884 (2000).).
[0015] An alternative model for the observed solid tumor cell
heterogeneity is that solid tumors result from a "solid tumor stem
cell" (or "cancer stem cell" from a solid tumor) that subsequently
undergoes chaotic development through both symmetric and asymmetric
rounds of cell divisions. In this stem cell model, solid tumors
contain a distinct and limited (possibly even rare) subset of cells
that share the properties of normal "stem cells", in that they
extensively proliferate and efficiently give rise both to
additional solid tumor stem cells (self-renewal) and to the
majority of tumor cells of a solid tumor that lack tumorigenic
potential. Indeed, mutations within a long-lived stem cell
population can initiate the formation of cancer stem cells that
underlie the growth and maintenance of tumors and whose presence
contributes to the failure of current therapeutic approaches.
[0016] Although great strides have been made understanding the
genetic changes that lead to cancer (e.g. breast cancer and
colorectal cancer), the lack of reliable tumor assay for de novo
human cancer cells has hindered the ability to understand the
effects of these mutations at the cellular level. Also, the lack of
identified cancer markers for solid tumor stem cells has hindered
the development of diagnostics and therapeutics for cancer patients
(e.g. breast cancer patients). As such, what is needed is a
reliable tumor assay as well as the identification of cancer
markers for solid tumor stem cells.
SUMMARY OF THE INVENTION
[0017] The present invention relates to compositions and methods
for treating, characterizing, and diagnosing cancer. In particular,
the present invention provides gene expression profiles and
signatures associated with solid tumor stem cells, as well as novel
stem cell cancer markers useful for the diagnosis,
characterization, prognosis, and treatment of solid tumor stem
cells. The present invention further provides cancer stem cell gene
signatures derived from solid tumor stem cell markers that when
detected in a tumor sample act as significant predictors of poor
clinical outcome, including high risk of metastasis and death.
[0018] In some embodiments, the present invention provides methods
of detecting solid tumor stem cells, comprising; a) providing a
tissue sample from a subject, and b) detecting at least one stem
cell cancer marker (e.g., 1, 2, 3, 5, 10, . . . etc.) from Tables
4-9 in the tissue sample under conditions such that the presence or
absence of solid tumor stem cells in the tissue sample is
determined. In a further embodiment, the present invention provides
methods of detecting solid tumor stem cells, comprising: a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and, b)
detecting those cancer cells that express low levels or
undetectable levels of e-cadherin or alpha catenin as compared to
normal breast epithelial cells. In some embodiments, the mark is
e-cadherin or alpha catenin. Those cancer cells expressing low
levels or undetectable levels of e-cadherin or alpha catenin are
confirmed to be solid tumor stem cells by demonstrating their
tumorigenicity. In a further embodiment of the present invention a
method of detecting solid tumor stem cells is provided comprising:
a) obtaining a mixture of solid tumor stem cells and solid tumor
cells from, for example, a tissue sample from a subject; and b)
detecting those cancer cells that express low levels or
undetectable levels of e-cadherin and also express low or
undetectable levels of one or more of MMP7, Nov, FOSL1 or IL1R2
(e.g., e.g., the levels being compared to normal breast epithelia).
Those cancer cells expressing low or undetectable levels of
e-cadherin and one or more of MMP7, Nov, FOSL1 or IL1R2 are
confirmed to be solid tumor stem cells by demonstrating their
tumorigenicity. In a further embodiment of this invention a method
of detecting solid tumor stem cells is provided comprising: a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and, b)
detecting those cancer cells that express low levels or
undetectable levels of e-cadherin and express elevated levels of
one or both of SHC1 or FLJ20152 (e.g., e.g., the levels being
compared to normal breast epithelia). Those cancer cells expressing
low or undetectable levels of e-cadherin and elevated levels of one
or both of SHC1 or FLJ20152 are confirmed to be solid tumor stem
cells by their tumorigenicity. In a further embodiment of the
present invention a method of detecting solid tumor stem cells is
provided comprising: a) obtaining a mixture of solid tumor stem
cells and solid tumor cells from, for example, a tissue sample from
a subject; and b) detecting those cancer cells that express low
levels or undetectable levels of alpha-catenin and also express low
or undetectable levels of one or more of NCSTN, LNX, ARMCX3,
D2S448, GLUL or RB1 (e.g., e.g., the levels being compared to
normal breast epithelia). Those cancer cells expressing low or
undetectable levels of alpha-catenin and low or undetectable levels
of one or more of NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1 are
confirmed to be solid tumor stem cells by demonstrating their
tumorigenicity. In yet another embodiment, the present invention
provides methods of detecting solid tumor stem cells, comprising a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and b) detecting
those cancer cells that express low levels or undetectable levels
of alpha-catenin and also express elevated levels of one or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A
or MFHAS1 (e.g., e.g., the levels being compared to normal breast
epithelia). Those cancer cells expressing low or undetectable
levels of alpha-catenin and elevated levels of one or more of EDG2,
CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A or
MFHAS1 are confirmed to be solid tumor stem cells by demonstrating
their tumorigenicity. In another embodiment of the present
invention, a method of detecting solid tumor stem cells is provided
comprising: a) obtaining a mixture of solid tumor stem cells and
solid tumor cells from, for example, a tissue sample from a
subject; and b) detecting those cancer cells that express low
levels or undetectable levels of alpha-catenin and express elevated
levels of MET (e.g., e.g., the levels being compared to normal
breast epithelia). Those cancer cells expressing low or
undetectable levels of alpha-catenin and elevated levels of MET are
confirmed to be solid tumor stem cells by demonstrating their
tumorigenicity. In still a further embodiment of the present
invention, a method of detecting solid tumor stem cells and then
separating those solid tumor stem cells into one or more
populations of solid tumor stem cells is provided comprising: a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and, b)
separating those cells that express low levels or undetectable
levels of e-cadherin from those cells expressing low levels or
undetectable levels of alpha-catenin (e.g., e.g., the levels being
compared to normal breast epithelia). In each case, those cancers
cells expressing low levels or undetectable levels of either
e-cadherin or alpha-catenin are confirmed to be solid tumor stem
cells by demonstrating their tumorigenicity.
[0019] In a further embodiment of the present invention a method of
detecting solid tumor stem cells is provided comprising: a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and b) detecting
those cancer cells that express low levels or undetectable levels
of two or more of e-cadherin MMP7, Nov, FOSL1 or IL1R2 (e.g., e.g.,
the levels being compared to normal breast epithelia). Those cancer
cells expressing low or undetectable levels of two or more of
e-cadherin, MMP7, Nov, FOSL1 or IL1R2 are confirmed to be solid
tumor stem cells by demonstrating their tumorigenicity. In a
further embodiment of the present invention a method of detecting
solid tumor stem cells is provided comprising: a) obtaining a
mixture of solid tumor stem cells and solid tumor cells from, for
example, a tissue sample from a subject; and b) detecting those
cancer cells that express low levels or undetectable levels of two
or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1
(e.g., e.g., the levels being compared to normal breast epithelia).
Those cancer cells expressing low or undetectable levels of two or
more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1 are
confirmed to be solid tumor stem cells by demonstrating their
tumorigenicity. In yet another embodiment, the present invention
provides methods of detecting solid tumor stem cells, comprising a)
obtaining a mixture of solid tumor stem cells and solid tumor cells
from, for example, a tissue sample from a subject; and b) detecting
those cancer cells that express elevated levels of two or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A
or MFHAS1 (e.g., e.g., the levels being compared to normal breast
epithelia). Those cancer cells expressing elevated levels of two or
more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A or MFHAS1 are confirmed to be solid tumor stem cells
by demonstrating their tumorigenicity. In another embodiment, the
present invention provides methods of detecting solid tumor stem
cells, comprising a) obtaining a mixture of solid tumor stem cells
and solid tumor cells from, for example, a tissue sample from a
subject; and b) detecting those cancer cells that express elevated
levels of SHC1 and FLJ20152 (e.g., the levels being compared to
normal breast epithelia). Those cancer cells expressing elevated
levels of SHC1 and FLJ20152 are confirmed to be solid tumor stem
cells by demonstrating their tumorigenicity. In another embodiment,
the present invention provides methods of detecting solid tumor
stem cells, comprising a) obtaining a mixture of solid tumor stem
cells and solid tumor cells from, for example, a tissue sample from
a subject; and b) detecting those cancer cells that express
elevated levels of SHC1 and FLJ20152 (the levels being compared to
normal breast epithelia). Those cancer cells expressing elevated
levels of SHC1 and FLJ20152 are confirmed to be solid tumor stem
cells by demonstrating their tumorigenicity.
[0020] In particular embodiments, detecting the solid tumor stem
cells comprises determining the presence of (or absence of), or an
expression level for at least one stem cell cancer marker. In other
embodiments, the detecting comprises detecting mRNA expression of
the at least one stem cell cancer marker. In particular
embodiments, the detecting comprises exposing the stem cell cancer
marker mRNA to a nucleic acid probe complementary to the stem cell
cancer marker mRNA.
[0021] In certain embodiments, the detecting comprises detecting
polypeptide expression of the at least one stem cell cancer marker.
In other embodiments, the detecting comprises exposing the stem
cell cancer marker polypeptide to an antibody specific to the stem
cell cancer marker polypeptide and detecting the binding of the
antibody to the stem cell cancer polypeptide. In further
embodiments, the subject comprises a human subject. In additional
embodiments, the tissue sample comprises tumor tissue. In some
embodiments, the tumor tissue sample is a post-surgical tumor
tissue sample (e.g. tumor biopsy).
[0022] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least 75% solid tumor stem cells and less than 25% solid tumor
cells (alternatively at least about 90% solid tumor stem cells and
less than 10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express low levels or undetectable
levels of e-cadherin or alpha-catenin as compared to normal
epithelium. In another embodiment, the present invention provides
an isolated population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
at least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; express low levels or undetectable
levels of e-cadherin; and, express low levels or undetectable
levels of one or more of MMP7, Nov, FOSL1, or IL1R2 (e.g., the
levels being compared to normal breast epithelia). In still another
embodiment, the present invention provides an isolated population
of solid tumor stem cells obtained from a solid tumor of epithelial
origin, wherein the population comprises at least about 75% solid
tumor stem cells and less than 25% solid tumor cells (alternatively
at least about 90% solid tumor stem cells and less than 10% solid
tumor cells), wherein the solid tumor stem cells: are tumorigenic;
express low levels or undetectable levels of e-cadherin; and,
express elevated levels of SHC1 or FLJ20152 (e.g., the levels being
compared to normal breast epithelia). In yet another embodiment,
the present invention provides an isolated population of solid
tumor stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises at least about 75% solid tumor
stem cells and less than 25% solid tumor cells (alternatively at
least about 90% solid tumor stem cells and less than 10% solid
tumor cells), wherein the solid tumor stem cells: are tumorigenic;
express low levels or undetectable levels of e-cadherin; express
low levels or undetectable levels of one or more of MMP7, Nov,
FOSL1, or IL1R2; and, express elevated levels of SHC1 or FLJ20152
(e.g., the levels being compared to normal breast epithelia).
[0023] In another embodiment, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; and express low levels or undetectable
levels of two or more of e-cadherin, MMP7, Nov, FOSL1, or IL1R2
(e.g., the levels being compared to normal breast epithelia). In
another embodiment, the present invention provides an isolated
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises at least about
75% solid tumor stem cells and less than 25% solid tumor cells
(alternatively at least about 90% solid tumor stem cells and less
than 10% solid tumor cells), wherein the solid tumor stem cells:
are tumorigenic; and, express elevated levels of SHC1 and FLJ20152
(e.g., the levels being compared to normal breast epithelia). In
still another embodiment the present invention provides an isolated
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises at least about
75% solid tumor stem cells and less than 25% solid tumor cells
(alternatively at least about 90% solid tumor stem cells and less
than 10% solid tumor cells), wherein the solid tumor stem cells:
are tumorigenic; express low levels or undetectable levels of one
or more of e-cadherin, MMP7, Nov, FOSL1, or IL1R2 (e.g., the levels
being compared to normal breast epithelia); and, express elevated
levels of SHC1 or FLJ20152 (e.g., the levels being compared to
normal breast epithelia).
[0024] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least 75% solid tumor stem cells and less than 25% solid tumor
cells (alternatively at least about 90% solid tumor stem cells and
less than 10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express low levels or undetectable
levels of alpha-catenin; and, express low levels or undetectable
levels of one or more of NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1
(e.g., the levels being compared to normal breast epithelia). In
still another embodiment, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; express low levels or undetectable
levels of alpha-catenin; and, express elevated levels of one or
more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, CTSL2, or MFHAS1 (e.g., the levels being compared to
normal breast epithelia). In yet another embodiment, the present
invention provides an isolated population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises at least about 75% solid tumor stem cells and
less than 25% solid tumor cells (alternatively at least about 90%
solid tumor stem cells and less than 10% solid tumor cells),
wherein the solid tumor stem cells: are tumorigenic; express low
levels or undetectable levels of alpha-catenin; express low levels
or undetectable levels of one or more of NCSTN, LNX, ARMCX3,
D2S448, GLUL or RB1; and, express elevated levels of one or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, CTSL2, or MFHAS 1 (e.g., the levels being compared to
normal breast epithelia). In another embodiment, the present
invention provides an isolated population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises at least about 75% solid tumor stem cells and
less than 25% solid tumor cells (alternatively at least about 90%
solid tumor stem cells and less than 10% solid tumor cells),
wherein the solid tumor stem cells: are tumorigenic; express low
levels or undetectable levels of alpha-catenin; and, elevated
levels of MET (e.g., the levels being compared to normal breast
epithelia).
[0025] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least 75% solid tumor stem cells and less than 25% solid tumor
cells (alternatively at least about 90% solid tumor stem cells and
less than 10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express low levels or undetectable
levels of two or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448,
GLUL or RB1 (e.g., the levels being compared to normal breast
epithelia). In another embodiment, the present invention provides
an isolated population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
at least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; and, express elevated levels of two or
more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, CTSL2, or MFHAS1 (e.g., the levels being compared to
normal breast epithelia). In still another embodiment, the present
invention provides an isolated population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises at least 75% solid tumor stem cells and less
than 25% solid tumor cells (alternatively at least about 90% solid
tumor stem cells and less than 10% solid tumor cells), wherein the
solid tumor stem cells: are tumorigenic; express low levels or
undetectable levels of one or more of alpha-catenin, NCSTN, LNX,
ARMCX3, D2S448, GLUL or RB1 (e.g., the levels being compared to
normal breast epithelia); and express elevated levels of one or
more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, CTSL2, or MFHAS1 (e.g., the levels being compared to
normal breast epithelia).
[0026] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least 75% solid tumor stem cells and less than 25% solid tumor
cells (alternatively at least about 90% solid tumor stem cells and
less than 10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express low levels or undetectable
levels of e-cadherin or alpha-catenin as compared to normal
epithelium. In another embodiment, the present invention provides
an isolated population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
at least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; express low levels or undetectable
levels of e-cadherin; and, express low levels or undetectable
levels of one or more of MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B,
G0S2, IL8, B3GNT5, or FGFBP1. (e.g., the levels being compared to
normal breast epithelia). In still another embodiment, the present
invention provides an isolated population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises at least about 75% solid tumor stem cells and
less than 25% solid tumor cells (alternatively at least about 90%
solid tumor stem cells and less than 10% solid tumor cells),
wherein the solid tumor stem cells: are tumorigenic; express low
levels or undetectable levels of e-cadherin; and, express elevated
levels of one or more of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27,
TAP1, RNASEL, or LOC57168 (e.g., the levels being compared to
normal breast epithelia). In yet another embodiment, the present
invention provides an isolated population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises at least about 75% solid tumor stem cells and
less than 25% solid tumor cells (alternatively at least about 90%
solid tumor stem cells and less than 10% solid tumor cells),
wherein the solid tumor stem cells: are tumorigenic; express low
levels or undetectable levels of e-cadherin; express low levels or
undetectable levels of one or more of MMP7, Nov, FOSL1, IL1R2,
SFRP1, KRT6B, G0S2, IL8, B3GNT5, or FGFBP1; and, express elevated
levels of one or more of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27,
TAP1, RNASEL, or LOC57168 (e.g., the levels being compared to
normal breast epithelia).
[0027] In another embodiment, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least about 75% solid tumor stem cells and less than 25% solid
tumor cells (alternatively at least about 90% solid tumor stem
cells and less than 10% solid tumor cells), wherein the solid tumor
stem cells: are tumorigenic; and express low levels or undetectable
levels of two or more of e-cadherin, MMP7, Nov, FOSL1, IL1R2,
SFRP1, KRT6B, G0S2, IL8, B3GNT5, or FGFBP1 (e.g., the levels being
compared to normal breast epithelia). In another embodiment, the
present invention provides an isolated population of solid tumor
stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises at least about 75% solid tumor
stem cells and less than 25% solid tumor cells (alternatively at
least about 90% solid tumor stem cells and less than 10% solid
tumor cells), wherein the solid tumor stem cells: are tumorigenic;
and, express elevated levels of two or more of SHC1, FLJ20152,
ARNT, CYFIP2, C17orf27, TAP1, RNASEL, or LOC57168 (e.g., the levels
being compared to normal breast epithelia). In still another
embodiment, the present invention provides an isolated population
of solid tumor stem cells obtained from a solid tumor of epithelial
origin, wherein the population comprises at least about 75% solid
tumor stem cells and less than 25% solid tumor cells (alternatively
at least about 90% solid tumor stem cells and less than 10% solid
tumor cells), wherein the solid tumor stem cells: are tumorigenic;
express low levels or undetectable levels of one or more of
e-cadherin, MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B, G0S2, IL8,
B3GNT5, or FGFBP1 (e.g., the levels being compared to normal breast
epithelia); and express elevated levels of one or more of SHC1,
FLJ20152, ARNT, CYFIP2, C17orf27, TAP1, RNASEL, or LOC57168 (e.g.,
the levels being compared to normal breast epithelia).
[0028] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least 75% solid tumor stem cells and less than 25% solid tumor
cells (alternatively at least about 90% solid tumor stem cells and
less than 10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express low levels or undetectable
levels of alpha-catenin; and, express low levels or undetectable
levels of one or more of NCSTN, LNX, ARMCX3, D2S448, TUSC1, GLUL,
RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102, SLC1A4, and
DNAJD1 (e.g., the levels being compared to normal breast
epithelia). In still another embodiment, the present invention
provides an isolated population of solid tumor stem cells obtained
from a solid tumor of epithelial origin, wherein the population
comprises at least about 75% solid tumor stem cells and less than
25% solid tumor cells (alternatively at least about 90% solid tumor
stem cells and less than 10% solid tumor cells), wherein the solid
tumor stem cells: are tumorigenic; express low levels or
undetectable levels of alpha-catenin; and, express elevated levels
of one or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5,
MET, FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2,
SLC7A5, ARNTL2, PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV,
MAL, IMP-3, and DHRS9 (e.g., the levels being compared to normal
breast epithelia). In yet another embodiment, the present invention
provides an isolated population of solid tumor stem cells obtained
from a solid tumor of epithelial origin, wherein the population
comprises at least about 75% solid tumor stem cells and less than
25% solid tumor cells (alternatively at least about 90% solid tumor
stem cells and less than 10% solid tumor cells), wherein the solid
tumor stem cells: are tumorigenic; express low levels or
undetectable levels of alpha-catenin; express low levels or
undetectable levels of one or more of NCSTN, LNX, ARMCX3, D2S448,
TUSC1, GLUL, RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102,
SLC1A4, and DNAJD1; and, express elevated levels of one or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5, ARNTL2,
PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, and
DHRS9 (e.g., the levels being compared to normal breast epithelia).
In another embodiment, the present invention provides an isolated
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises at least
about75% solid tumor stem cells and less than25% solid tumor cells
(alternatively at least about90% solid tumor stem cells and less
than10% solid tumor cells), wherein the solid tumor stem cells: are
tumorigenic; express low levels or undetectable levels of
alpha-catenin; and, elevated levels of MET (e.g., the levels being
compared to normal breast epithelia).
[0029] In certain embodiments, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least75% solid tumor stem cells and less than25% solid tumor cells
(alternatively at least about90% solid tumor stem cells and less
than10% solid tumor cells), wherein the solid tumor stem cells: are
tumorigenic; and, express low levels or undetectable levels of two
or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, TUSC1, GLUL,
RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102, SLC1A4, and
DNAJD1 (e.g., the levels being compared to normal breast
epithelia). In another embodiment, the present invention provides
an isolated population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
at least about75% solid tumor stem cells and less than25% solid
tumor cells (alternatively at least about90% solid tumor stem cells
and less than10% solid tumor cells), wherein the solid tumor stem
cells: are tumorigenic; and, express elevated levels of two or more
of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5, ARNTL2,
PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, and
DHRS9 (e.g., the levels being compared to normal breast epithelia).
In still another embodiment, the present invention provides an
isolated population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises at
least75% solid tumor stem cells and less than25% solid tumor cells
(alternatively at least about90% solid tumor stem cells and less
than10% solid tumor cells), wherein the solid tumor stern cells:
are tumorigenic; express low levels or undetectable levels of one
or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, TUSC1, GLUL,
RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102, SLC1A4, and
DNAJD1 (e.g., the levels being compared to normal breast
epithelia); and express elevated levels of one or more of EDG2,
CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A,
MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5, ARNTL2, PRSS1,
PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, and DHRS9
(e.g., the levels being compared to normal breast epithelia).
[0030] In certain embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively5-6 fold
or10-fold) compared to unfractionated tumor cells; are tumorigenic;
and, express low levels or undetectable levels of e-cadherin or
alpha-catenin as compared to normal epithelium. In another
embodiment, the present invention provides an enriched population
of solid tumor stem cells obtained from a solid tumor of epithelial
origin, wherein the population comprises solid tumor stem cells and
solid tumor cells, wherein the solid tumor stem cells: are enriched
at least two-fold (alternatively5-6 fold or10-fold) compared to
unfractionated tumor cells; are tumorigenic; express low levels or
undetectable levels of e-cadherin; and, express low levels or
undetectable levels of one or more of MMP7, Nov, FOSL1, or IL1R2
(e.g., the levels being compared to normal breast epithelia). In
still another embodiment, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively5-6 fold
or10-fold) compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of e-cadherin; and,
express elevated levels of SHC1 or FLJ20152 (e.g., the levels being
compared to normal breast epithelia). In yet another embodiment,
the present invention provides an enriched population of solid
tumor stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises solid tumor stem cells and solid
tumor cells, wherein the solid tumor stem cells: are enriched at
least two-fold (alternatively5-6 fold or10-fold) compared to
unfractionated tumor cells; are tumorigenic; express low levels or
undetectable levels of e-cadherin; express low levels or
undetectable levels of one or more of MMP7, Nov, FOSL1, or IL1R2;
and, express elevated levels of SHC1 or FLJ20152 (e.g., the levels
being compared to normal breast epithelia).
[0031] In yet other embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively5-6 fold
or10-fold) compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of two or more of
e-cadherin, MMP7, Nov, FOSL1, or IL1R2 (e.g., the levels being
compared to normal breast epithelia). In still another embodiment,
the present invention provides an enriched population of solid
tumor stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises solid tumor stem cells and solid
tumor cells, wherein the solid tumor stem cells: are enriched at
least two-fold (alternatively5-6 fold or 10-fold) compared to
unfractionated tumor cells; are tumorigenic; express elevated
levels of SHC1 and FLJ20152 (e.g., the levels being compared to
normal breast epithelia). In another embodiment, the present
invention provides an enriched population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises solid tumor stem cells and solid tumor cells,
wherein the solid tumor stem cells: are enriched at least two-fold
(alternatively5-6 fold or 10-fold) compared to unfractionated tumor
cells; are tumorigenic; express low levels or undetectable levels
of one or more of e-cadherin, MMP7, Nov, FOSL1, or IL1R2; and,
express elevated levels of SHC1 or FLJ20152 (e.g., the levels being
compared to normal breast epithelia).
[0032] In certain embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; and, express low levels or undetectable levels of
e-cadherin or alpha-catenin as compared to normal epithelium. In
another embodiment, the present invention provides an enriched
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises solid tumor
stem cells and solid tumor cells, wherein the solid tumor stem
cells: are enriched at least two-fold (alternatively 5-6 fold or
10-fold). compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of e-cadherin; and,
express low levels or undetectable levels of one or more of MMP7,
Nov, FOSL1, IL1R2, SFRP1, KRT6B, G0S2, IL8, B3GNT5, or FGFBP1
(e.g., the levels being compared to normal breast epithelia). In
still another embodiment, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; express low levels or undetectable levels of
e-cadherin; and, express elevated levels of one or more of SHC1,
FLJ20152, ARNT, CYFIP2, C17orf27, TAP1, RNASEL, or LOC57168 (e.g.,
the levels being compared to normal breast epithelia). In yet
another embodiment, the present invention provides an enriched
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises solid tumor
stem cells and solid tumor cells, wherein the solid tumor stem
cells: are enriched at least two-fold (alternatively 5-6 fold or
10-fold) compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of e-cadherin; express
low levels or undetectable levels of one or more of MMP7, Nov,
FOSL1, IL1R2, SFRP1, KRT6B, G0S2, IL8, B3GNT5, or FGFBP1; and,
express elevated levels of one or more of SHC1, FLJ20152, ARNT,
CYFIP2, C17orf27, TAP1, RNASEL, or LOC57168 (e.g., the levels being
compared to normal breast epithelia).
[0033] In yet other embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; express low levels or undetectable levels of two or
more of e-cadherin, MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B, G0S2,
IL8, B3GNT5, or FGFBP1 (e.g., the levels being compared to normal
breast epithelia). In still another embodiment, the present
invention provides an enriched population of solid tumor stem cells
obtained from a solid tumor of epithelial origin, wherein the
population comprises solid tumor stem cells and solid tumor cells,
wherein the solid tumor stem cells: are enriched at least two-fold
(alternatively 5-6 fold or 10-fold) compared to unfractionated
tumor cells; are tumorigenic; express elevated levels of two or
more of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27, TAP1, RNASEL, or
LOC57168 (e.g., the levels being compared to normal breast
epithelia). In another embodiment, the present invention provides
an enriched population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
solid tumor stem cells and solid tumor cells, wherein the solid
tumor stem cells: are enriched at least two-fold (alternatively 5-6
fold or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; express low levels or undetectable levels of one or
more of e-cadherin, MMP7, Nov, FOSL1, IL1R2, SFRP1, KRT6B, G0S2,
IL8, B3GNT5, or FGFBP1; and, express elevated levels of one or more
of SHC1, FLJ20152, ARNT, CYFIP2, C17orf27, TAP1, RNASEL, or
LOC57168 (e.g., the levels being compared to normal breast
epithelia).
[0034] In certain embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; and, express low levels or undetectable levels of
alpha-catenin; and, express low levels or undetectable levels of
one or more of NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1 (e.g., the
levels being compared to normal breast epithelia). In still another
embodiment, the present invention provides an enriched population
of solid tumor stem cells obtained from a solid tumor of epithelial
origin, wherein the population comprises solid tumor stem cells and
solid tumor cells, wherein the solid tumor stem cells: are enriched
at least two-fold (alternatively 5-6 fold or 10-fold) compared to
unfractionated tumor cells; are tumorigenic; express low levels or
undetectable levels of alpha-catenin; and, express elevated levels
of one or more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5,
MET, FOXQ1, CDKN2A, CTSL2, or MFHAS1 (e.g., the levels being
compared to normal breast epithelia). In yet another embodiment,
the present invention provides an enriched population of solid
tumor stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises solid tumor stem cells and solid
tumor cells, wherein the solid tumor stem cells: are enriched at
least two-fold (alternatively 5-6 fold or 10-fold) compared to
unfractionated tumor cells; are tumorigenic; express low levels or
undetectable levels of alpha-catenin; express low-levels or
undetectable levels of one or more of NCSTN, LNX, ARMCX3, D2S448,
GLUL or RB1; and, express elevated levels of one or more of EDG2,
CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A or
MFHAS1 (e.g., the levels being compared to normal breast
epithelia). In another embodiment, the present invention provides
an enriched population of solid tumor stem cells obtained from a
solid tumor of epithelial origin, wherein the population comprises
solid tumor stem cells and solid tumor cells, wherein the solid
tumor stem cells: are enriched at least two-fold (alternatively 5-6
fold or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; express low levels or undetectable levels of
alpha-catenin; and, elevated levels of MET (e.g., the levels being
compared to normal breast epithelia).
[0035] In certain embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; and, express low levels or undetectable levels of two
or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, GLUL or RB1
(e.g., the levels being compared to normal breast epithelia). In
still another embodiment, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; express elevated levels of two or more of EDG2, CAV1,
CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A, CTSL2, or
MFHAS1 (e.g., the levels being compared to normal breast
epithelia). In yet another embodiment, the present invention
provides an enriched population of solid tumor stem cells obtained
from a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold
(alternatively 5-6 fold or 10-fold) compared to unfractionated
tumor cells; are tumorigenic; express low levels or undetectable
levels of one or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448,
GLUL or RB1; and, express elevated levels of one or more of EDG2,
CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A,
CTSL2, or MFHAS1 (e.g., the levels being compared to normal breast
epithelia).
[0036] In further embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; and, express low levels or undetectable levels of
alpha-catenin; and, express low levels or undetectable levels of
one or more of NCSTN, LNX, ARMCX3, D2S448, TUSC1, GLUL, RB1, BEX2,
SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102, SLC1A4, and DNAJD1 (e.g.,
the levels being compared to normal breast epithelia). In still
another embodiment, the present invention provides an enriched
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises solid tumor
stem cells and solid tumor cells, wherein the solid tumor stem
cells: are enriched at least two-fold (alternatively 5-6 fold or
10-fold) compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of alpha-catenin; and,
express elevated levels of one or more of EDG2, CAV1, CAV2, DCBLD2,
IGFBP3, S100A2, CXCL5, MET, FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1,
PKCA, UPP1, CTSL2, SLC7A5, ARNTL2, PRSS1, PRSS2, PRSS3, VNN1,
RAB38, ZBED2, MYEOV, MAL, IMP-3, and DHRS9 (e.g., the levels being
compared to normal breast epithelia). In yet another embodiment,
the present invention provides an enriched population of solid
tumor stem cells obtained from a solid tumor of epithelial origin,
wherein the population comprises solid tumor stem cells and solid
tumor cells, wherein the solid tumor stem cells: are enriched at
least two-fold (alternatively 5-6 fold or 10-fold) compared to
unfractionated tumor cells; are tumorigenic; express low levels or
undetectable levels of alpha-catenin; express low levels or
undetectable levels of one or more of NCSTN, LNX, ARMCX3, D2S448,
TUSC1, GLUL, RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102,
SLC1A4, and DNAJD1; and, express elevated levels of one or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5, ARNTL2,
PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, and
DHRS9 (e.g., the levels being compared to normal breast epithelia).
In another embodiment, the present invention provides an enriched
population of solid tumor stem cells obtained from a solid tumor of
epithelial origin, wherein the population comprises solid tumor
stem cells and solid tumor cells, wherein the solid tumor stem
cells: are enriched at least two-fold (alternatively 5-6 fold or
10-fold) compared to unfractionated tumor cells; are tumorigenic;
express low levels or undetectable levels of alpha-catenin; and,
elevated levels of MET (e.g., the levels being compared to normal
breast epithelia).
[0037] In certain embodiments, the present invention provides an
enriched population of solid tumor stem cells obtained from a solid
tumor of epithelial origin, wherein the population comprises solid
tumor stem cells and solid tumor cells, wherein the solid tumor
stem cells: are enriched at least two-fold (alternatively 5-6 fold
or 10-fold) compared to unfractionated tumor cells; are
tumorigenic; and, express low levels or undetectable levels of two
or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448, TUSC1, GLUL,
RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102, SLC1A4, and
DNAJD1 (e.g., the levels being compared to normal breast
epithelia). In still another embodiment, the present invention
provides an enriched population of solid tumor stem cells obtained
from a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold
(alternatively 5-6 fold or 10-fold) compared to unfractionated
tumor cells; are tumorigenic; express elevated levels of two or
more of EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5,
ARNTL2, PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3,
and DHRS9 (e.g., the levels being compared to normal breast
epithelia). In yet another embodiment, the present invention
provides an enriched population of solid tumor stem cells obtained
from a solid tumor of epithelial origin, wherein the population
comprises solid tumor stem cells and solid tumor cells, wherein the
solid tumor stem cells: are enriched at least two-fold
(alternatively 5-6 fold or 10-fold) compared to unfractionated
tumor cells; are tumorigenic; express low levels or undetectable
levels of one or more of alpha-catenin, NCSTN, LNX, ARMCX3, D2S448,
TUSC1, GLUL, RB1, BEX2, SLC12A2, GALC, NGFRAP1, FGF13, KIAA1102,
SLC1A4, and DNAJD1; and, express elevated levels of one or more of
EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A, MFHAS1, IL27RA, KLRF1, PKCA, UPP1, CTSL2, SLC7A5, ARNTL2,
PRSS1, PRSS2, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, and
DHRS9 (e.g., the levels being compared to normal breast
epithelia).
[0038] In other embodiments, the methods further comprise c)
providing a prognosis to the subject. In some embodiments, the at
least one stem cell cancer marker is from Table 8. In some
embodiments, the at least one stem cell cancer marker comprises:
Bmi-1, eed, easyh1, easyh2, rnf2, yy1, smarcA3, smarcA5, smarcD3,
smarcE1, mllt3, FZD1, FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9,
FZD10, WNT2, WNT2B, WNT3, WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC,
and (TCF4). In some embodiments, the at least one stem cell marker
comprises: e-cadherin, alpha-catenin; e-cadherin and MMP7, Nov,
FOSL1, IL1R2, SHC1, or FLJ20152; alpha-catenin and NCSTN, LNX,
ARMCX3, D2S448, GLUL, RB1, EDG2, CAV1, CAV2, DCBLD2, IGFBP3,
S100A2, CXCL5, MET, FOXQ1, CDKN2A or MFHAS1.
[0039] In other embodiments reagents and methods for predicting the
clinical outcome including metastasis and death are provided using
the cancer stem cell markers of the present invention. The
invention provides various diagnostic methods using the reagents,
identified herein, related to solid tumor stem cells. The
diagnostic methods of this invention include a method of
classifying a cancer comprising: a) obtaining a tumor biopsy from a
patient; b) determining expression or activity of one or more of
genes encoding a protein or polypeptide selected from a solid tumor
stem cell gene signature; and c) classifying the tumor as belonging
to a high or low risk tumor class based on the results of (b). In
another embodiment of the invention, the method further comprises
further providing a diagnosis, prognosis, selection of a therapy,
or a means for monitoring a therapy based on the classification of
the tumor. According to certain of the inventive methods the
presence or amount of a gene product, e.g. a polypeptide or a
nucleic acid, encoded by a solid tumor stem cell gene is detected
in a sample derived from a subject (e.g. a sample of tissue or
cells obtained from a tumor or a blood sample obtained from a
subject). In general the subject is a human, however the subject
can also be an animal of another kind. The subject can be an
individual who has or can have a tumor. The sample can be subject
to a number of processing steps prior to or in the course of
detection. In certain embodiments of the invention the gene product
is a polypeptide that is detected using an antibody capable of
binding to the polypeptide. In certain embodiments of the invention
the antibody is used to perform immunohistochemical staining on a
sample obtained from a subject. In certain embodiments of the
invention solid tumor stem cell gene mRNA expression is measured
using a microarray. In other embodiments of the invention solid
tumor stem cell gene mRNA is measured by quantitative PCR using a
set of primers designed to amplify a portion of the gene. Other
detection means are know to one of ordinary skill in the art e.g.
see U.S. Pat. No.6,057,105.
[0040] In certain embodiments, the present invention provides a
method of classifying a cancer comprising: (a) providing a cancer
sample; (b) determining expression levels of one or more genes
comprising alpha-catenin signature 2 in cancer sample; (c)
comparing the expression levels of the genes comprising the
alpha-catenin profile in the cancer sample to a alpha-catenin
signature2; and (d) classifying the cancer sample to either a high
risk or low risk group based on the comparison in (c). The method
of classifying a cancer can further comprise providing diagnostic,
prognostic, or predictive information based on the classifying in
(d). In certain embodiments the method of determining the
expression levels of one or more genes comprising alpha catenin
signature 2 is by measuring the expression of the corresponding
protein or polypeptide. In some embodiments the protein or
polypeptide is detected by immunohistochemical analysis of the
cancer sample using an antibody that binds to the protein or
polypeptide. In other embodiments the protein or polypeptide is
detected by ELISA assay using an antibody that specifically binds
to the protein or polypeptide. In still other embodiments the
protein or polypeptide is detected using a protein array comprising
an antibody that specifically binds to the protein or polypeptide.
In some embodiments the antibody that binds to the protein or
polypeptide is an anti-CD44 antibody. In other embodiments the
antibody that binds to the protein or polypeptide is an
anti-beta-catenin antibody. In other certain embodiments the method
of determining the expression levels of one or more genes
comprising alpha catenin signature 2 is by measuring the expression
of the corresponding mRNA. In some embodiments the mRNA is detected
using a polynucleotide array comprising a polynucleotide that
specifically hybridizes to the mRNA. In other embodiments the mRNA
is detected using polymerase chain reaction comprising
polynucleotide primers that specifically amplify the mRNA.
[0041] In certain embodiments, the present invention provides a
method of classifying a cancer comprising: (a) providing a cancer
sample; (b) determining expression levels of one or more genes
comprising alpha-catenin signature 3 in the cancer sample; (c)
comparing the expression levels of the genes comprising the
alpha-catenin profile in the cancer sample to the alpha-catenin
signature 3; and (d) classifying the cancer sample to either a high
risk or low risk group based on the comparison in (c). The method
of classifying a cancer can further comprise providing diagnostic,
prognostic, or predictive information based on the classifying in
(d). In certain embodiments the method of determining the
expression levels of one or more genes comprising alpha catenin
signature 3 is by measuring the expression of the corresponding
protein or polypeptide. In some embodiments the protein or
polypeptide is detected by immunohistochemical analysis of the
cancer sample using an antibody that binds to the protein or
polypeptide. In other embodiments the protein or polypeptide is
detected by ELISA assay using an antibody that specifically binds
to the protein or polypeptide. In still other embodiments the
protein or polypeptide is detected using a protein array comprising
an antibody that specifically binds to the protein or polypeptide.
In some embodiments the antibody that binds to the protein or
polypeptide is an anti-CD44 antibody. In other embodiments the
antibody that binds to the protein or polypeptide is an
anti-beta-catenin antibody. In other certain embodiments the method
of determining the expression levels of one or more genes
comprising alpha catenin signature 3 is by measuring the expression
of the corresponding mRNA. In some embodiments the mRNA is detected
using a polynucleotide array comprising a polynucleotide that
specifically hybridizes to the mRNA. In some embodiments the mRNA
is detected using polymerase chain reaction comprising
polynucleotide primers that specifically amplify the mRNA.
[0042] In particular embodiments, the present invention provides
methods for reducing the size of a solid tumor (e.g. in research
drug screening, or therapeutic applications) comprising contacting
cells of a solid tumor with a biologically (e.g. therapeutically)
effective amount of a composition comprising at least one agent
directed against at least one stem cell cancer marker shown in
Tables 4-9. In some embodiments, the biologically effective amount
is an amount sufficient to cause cell death of or inhibit
proliferation of solid tumor stem cells in the solid tumor. In
other embodiments, the biologically effective amount is an amount
that interference with the survival pathways (e.g. notch related
genes) or self-renewal pathways (e.g. WNT pathways) of the solid
tumor stem cell.
[0043] Examples of solid tumors from which solid tumor stem cells
can be isolated or enriched for according to the invention include,
but are not limited to, sarcomas and carcinomas such as, but not
limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma,
osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer,
prostate cancer, squamous cell carcinoma, basal cell carcinoma,
adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,
papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,
oligodendroglioma, meningioma, melanoma, neuroblastoma, and
retinoblastoma. The invention is applicable to sarcomas and
epithelial cancers, such as ovarian cancers and breast cancers.
[0044] In additional embodiments, the at least one agent is an
antibody, peptide or small molecule. In further embodiments, the
antibody, peptide, anti-sense, siRNA, or small molecule is directed
against an extracellular domain of the at least one stem cell
cancer marker. In some embodiments, the at least one stem cell
cancer marker is selected from the group consisting of: Bmi-1, eed,
easyh1, easyh2, rnf2, yy1, smarcA3, smarcA5, smarcD3, smarcE1,
mllt3, FZD1, FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9, FZD10, WNT2,
WNT2B, WNT3, WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC, and (TCF4). In
a further embodiment, the at least one stem cell marker is selected
from the group consisting of: e-cadherin, alpha-catenin, MMP7, Nov,
FOSL1, IL1R2, SHC1, FLJ20152, NCSTN, LNX, ARMCX3, D2S448, GLUL,
RB1, EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A or MFHAS1.
[0045] In other embodiments, the present invention provides methods
for reducing the size of a solid tumor, comprising contacting cells
of a solid tumor with a biologically (e.g. therapeutically)
effective amount of a composition comprising at least one agent
that modulates the activity of at least one stem cell cancer marker
shown in Tables 4-9. In some embodiments, the present invention
provides methods for killing or inhibiting the proliferation of
solid tumor stem cells comprising contacting the solid tumor stem
cells with a biologically effective amount of a composition
comprising at least one agent targeted to at least one stem cell
cancer marker shown in Tables 4-9. In certain embodiments, the
methods further comprise identifying the death of or the prevention
of the growth of the solid tumor stem cells following the
contacting. In additional embodiments, the cell death is caused by
apoptosis. In other embodiments, the biologically effective amount
is an amount that interferes with the survival pathways (e.g. notch
related genes) or self-renewal pathways (e.g. WNT pathways) of the
solid tumor stem cell. In other embodiments, the at least one stem
cell cancer marker is selected from the group consisting of: Bmi-1,
eed, easyh1, easyh2, rnf2, yy1, smarcA3, smarcA5, smarcD3, smarcE1,
mllt3, FZD1, FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9, FZD10, WNT2,
WNT2B, WNT3, WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC, and (TCF4). In
further embodiments, the at least one stem cell marker is selected
from the group consisting of: e-cadherin, alpha-catenin, MMP7, Nov,
FOSL1, IL1R2, SHC1, FLJ20152, NCSTN, LNX, ARMCX3, D2S448, GLUL,
RB1, EDG2, CAV1, CAV2, DCBLD2, IGFBP3, S100A2, CXCL5, MET, FOXQ1,
CDKN2A and MFHAS1.
[0046] In particular embodiments, the solid tumor stem cells
express cell surface marker CD44, ESA, or B38.1. In other
embodiments, the solid tumor stem cells fail to express at least
one LINEAGE marker selected from the group consisting of CD2, CD3,
CD10, CD14, CD16, CD31, CD45, CD64, and CD140b (see, e.g., U.S.
App. Pub. Nos. US20040037815A1, and US20020119565, both of which
are herein incorporated by reference).
[0047] In other embodiments, the present invention provides methods
for selectively targeting a solid tumor stem cell comprising, (a)
identifying at least one stem cell cancer marker from Tables 4-9
present on a solid tumor stem cell; and (b) obtaining an agent or
set of agents that selectively binds to or regulates the at least
one stem cell cancer marker. In some embodiments, the agent
genetically modifies the solid tumor stem cell. In particular
embodiments, the agent comprises a bi-specific conjugate. In
further embodiments, the agent comprises an adenoviral vector.
[0048] In some embodiments, the present invention provides methods
for forming a tumor in an animal, comprising: introducing purified
solid tumor stem cells (e.g. a cell dose of) into an animal,
wherein: (a) the solid tumor stem cells are derived from a solid
tumor; and (b) the solid tumor stem cells are enriched at least
2-fold relative to unfractionated tumor cells based on the presence
of at least one stem cell cancer marker in Tables 4-9. In other
embodiments, the animal is an immunocompromised animal. In certain
embodiments, the animal is an immunocompromised mammal, such as a
mouse (e.g., a nude mouse, SCID mouse, NOD/SCID mouse, Beige/SCID
mouse; and microglobin deficient NOD/SCID mouse). In particular
embodiments, the number of cells in the cell dose is about 100
cells and about5.times.10.sup.5 cells.
[0049] In certain embodiments, the present invention provides kits
for detecting solid tumor stem cells in a subject, comprising: a) a
reagent capable of specifically detecting at least one stem cell
cancer marker from Tables 4-9 in a tissue or cell sample from a
subject, and, optionally, b) instructions for using the reagent for
detecting the presence or absence of solid tumor stem cells in the
tissue sample. In further embodiments, the reagent comprises a
nucleic acid probe complementary to mRNA from the at least one stem
cell cancer marker. In other embodiments, the reagent comprises an
antibody or antibody fragment.
[0050] In some embodiments, the present invention provides methods
of screening compounds, comprising: a) providing i) a solid tumor
stem cell and ii) one or more test compounds; and b) contacting the
solid tumor stem cell with the test compound; and c) detecting a
change in expression of at least one stem cell cancer marker shown
in Tables 4-9 in the presence of the test compound relative to the
absence of the test compound. In particular embodiments, the
detecting comprises determining an expression level for the at
least one stem cell cancer marker. In particular embodiments, the
detecting comprises detecting mRNA expression of the at least one
stem cell cancer marker. In some embodiments, the detecting
comprises detecting polypeptide expression of the at least one stem
cell cancer marker. In additional embodiments, the solid tumor stem
cell is in vitro. In other embodiments, the solid tumor stem cell
is in vivo. In further embodiments, the test compound comprises a
drug (e.g. small molecule, antibody, antibody-toxin conjugate,
siRNA, etc.).
[0051] In some embodiments, the present invention provides
compositions comprising at least two agents (e.g. small molecule,
antibody, antibody-toxin conjugate, siRNA, etc.), wherein each of
the agents modulates the activity of at least one stem cell cancer
marker shown in Tables 4-9. In additional embodiments, the
composition comprises at least three agents.
[0052] In particular embodiments, the present invention provides
methods of distinguishing tumorigenic from non-tumorigenic cancer
cells, comprising: detecting the presence of .beta.-catenin in a
cancer cell such that the localization of .beta.-catenin in the
cancer cell is determined to be primarily nuclear or primarily
cytoplasmic. In some embodiments, the method further comprises
identifying the cancer cell as tumorigenic if the .beta.-catenin
localization is primarily nuclear, or identifying the cancer cell
as non-tumorigenic if the .beta.-catenin localization is primarily
cytoplasmic.
[0053] In certain embodiments, the present invention provides
methods of distinguishing a tumorigenic from a non-tumorigenic
cancer cell, comprising; a) providing; i) a cancer cell, and ii) a
composition comprising an agent configured to bind .beta.-catenin;
and b) contacting the cancer cell with the composition under
conditions such that the localization of .beta.-catenin in the
cancer cell is determined to be primarily nuclear and cytoplasmic
or primarily cytoplasmic and membrane associated, and c)
identifying the cancer cell as tumorigenic if the .beta.-catenin
localization is primarily nuclear and cytoplasmic, or identifying
the cancer cell as non-tumorigenic if the .beta.-catenin
localization is primarily cytoplasmic and membrane associated.
DESCRIPTION OF THE FIGURES
[0054] FIG. 1 shows isolation of tumorigenic cells.
[0055] FIG. 2 shows the DNA content of tumorigenic and
non-tumorigenic breast cancer cells.
[0056] FIG. 3 shows histology from the CD24.sup.+ injection site
(a), (20.times. objective magnification) revealed only normal mouse
tissue while the CD24.sup.-/low injection site (b), (40.times.
objective magnification) contained malignant cells. (c) A
representative tumor in a mouse at the CD44.sup.+CD24.sup.-/low
Lineage.sup.- injection site, but not at the
CD44.sup.+CD24.sup.+Lineage.sup.31 injection site. T3 cells were
stained with Papanicolaou stain and examined microscopically
(100.times. objective). Both the non-tumorigenic (c) and
tumorigenic (d) populations contained cells with a neoplastic
appearance, with large nuclei and prominent nucleoli.
[0057] FIG. 4 shows the phenotypic diversity in tumors arising from
CD44+CD24-/lowLineage-cells.
[0058] FIG. 5 shows the expression of Wnt (left panel) and Frizzled
(right panel).
[0059] FIG. 6 shows the isolation of normal tumor fibroblasts and
endothelial cells.
[0060] FIGS. 7 shows infection of breast cancer stem cells with an
adenovirus vector.
[0061] FIG. 8 shows subcellular localization of .beta.-catenin.
[0062] FIG. 9 shows inhibition of .beta.-catenin signaling in
cancer cells.
[0063] FIG. 10 shows expression of alpha-catenin and E-cadherin
from microarray analysis in tumorigenic (TG), non-tumorigenic
(NTG), and normal breast epithelium (NBE) in three primary tumors:
T1, T2, T3 and three passaged tumors: SUM, PE13, PE15.
[0064] FIG. 11 shows gene expression levels as determined by
microarray analysis for A) the alpha-catenin gene signature.
[0065] FIG. 12 shows shows gene expression levels as determined by
microarray analysis for the E-cadherin gene signature in
tumorigenic cells (TG) from three tumor samples: SUM, PE13, PE15,
T1, T2, and T3 and in normal breast epithelium.
[0066] FIG. 13 shows the effect of a small molecule inhibitor of
gamma secretase, L-685,458, on the volume of tumors arising from
cancer stem cells in a xenograft model. A) The average tumor volume
from L-685-458 treated (n=5) versus control (n=7) animals is
plotted for each day measured over 37 days. B) The tumor volume of
individual L-685-458 treated and control mice is plotted for each
day measured.
[0067] FIG. 14 shows expression levels of alpha-catenin and
e-cadherin using real-time PCR in tumorigenic cells (TG) from three
breast tumors: T1, T2, and T3
[0068] FIG. 15 shows expression levels of alpha-catenin and
e-cadherin using real-time PCR in tumorigenic (TG) and
nontumorigenic (NTG) cells from a colon tumor sample compared to
normal colon epithelium (NC).
[0069] FIG. 16 shows the correlation of A) the alpha-catenin tumor
stem cell signature.
[0070] FIG. 17 shows the correlation of the E-cadherin tumor stem
cell signature with five gene expression patterns that distinguish
different tumor subclasses: Luminal A, Luminal B, ERBB2, Basal, and
Normal-like.
GENERAL DESCRIPTION
[0071] This invention is based on the discovery of solid tumor stem
cells (also referred to as cancer stem cells from a solid tumor) as
a distinct and limited subset of cells within the heterogenous cell
population of established solid tumors. These cancer stem cells
share the properties of normal stem cells in that they extensively
proliferate and efficiently give rise both to additional solid
tumor stem cells (self-renewal) and to the majority of tumor cells
of a solid tumor that lack tumorigenic potential. Identification of
cancer stem cells from solid tumors relied on their expression of a
unique pattern of cell-surface receptors that could be used to
isolate them from the bulk of non-tumorigenic tumor cells and on
the assessment of their properties of self-renewal and
proliferation in culture and in xenograft animal models. An ESA+;
CD44+; CD24-/low; Lineage- population greater than 50-fold enriched
for the ability to form tumors relative to unfractionated tumor
cells was discovered (Al-Hajj et al., 2003).
[0072] The present invention relates to compositions and methods
for treating, characterizing and diagnosing cancer. In particular,
the present invention provides gene expression profiles associated
with solid tumor stem cells, as well as novel markers useful for
the diagnosis, characterization, and treatment of solid tumor stem
cells. Suitable markers that can be targeted (e.g. for diagnostic
or therapeutic purposes) are the genes and peptides encoded by the
genes that are differentially expressed in solid tumor stem cells
as shown in Tables 4-9. The differentially expressed genes, and the
peptides encoded thereby, can be detected (e.g. quantitatively) in
order to identify the presence of solid tumor stem cells, and to
determine and screen molecules suitable for reducing the
proliferation (or killing), interfering with self-renewal pathways,
or interfering with survival pathways of any solid tumor stem cells
that are present. The differentially expressed genes, and peptides
encoded thereby, shown in these tables are also useful for
generating therapeutic agents targeted to one or more of these
markers (e.g. to inhibit or promote the activity of the
marker).
[0073] In order to identify solid tumor stem cell markers, cells
from 5 patients, AML stem cells and non-tumorigenic cancer cells
from 6 patients, normal hematopoietic stem cells (HSC5), normal
hematopoietic cells, normal colon epithelial cells, and normal
breast epithelial cells were analyzed for differential
expression.
[0074] The present invention also provides solid tumor stem cells
that differentially express from other cells one or more of the
markers provided in Tables 4-9. The solid tumor stem cells can be
isolated from humans or other animals. The expression can be either
to a greater extent or to a lesser extent. The other cells can be
selected from normal cells, hematopoietic stem cells, acute
myelogenous leukemia (AML) stem cells, or any other class of
cells.
[0075] The invention provides a method of selecting cells of a
population, which results in a purified population of solid tumor
stem cells (e.g. from a patient to select or test therapeutic
agents are some for the patient). The present invention also
provides a method of selecting a purified population of tumor cells
other than solid tumor stem cells, such as a population of
non-tumorigenic (NTG) tumor cells. The present invention provides
methods of raising antibodies to the selected cells. The invention
provides diagnostic methods using the selected cells. The invention
also provides therapeutic methods, where the therapeutic is
directed to a solid tumor stem cell (e.g. directed to one of the
stem cells cancer markers identified herein directly or
indirectly).
[0076] Accordingly, the invention provides methods of selecting
cells, diagnosing disease, conducting research studies, and
treating solid tumors using selection methods, diagnostic methods
and therapeutics directed to specific genes on a given pathway.
Included are one or more of the following genes and gene products:
Bmi-1, eed, easyh1, easyh2, mf2, yy1, smarcA3, smarcA5, smarcD3,
smarcE1 and mllt3, as well as those shown in Tables 4-9. Many of
these genes are differentially expressed in solid tumor stem cells
as compared with normal cells and non-tumorigenic cancer cells, as
shown herein.
[0077] The invention provides in vivo and in vitro assays of solid
tumor stem cell function and cell function by the various
populations of cells isolated from a solid tumor. The invention
provides methods for using the various populations of cells
isolated from a solid tumor (such as a population of cells enriched
for solid tumor stem cells) to identify factors influencing solid
tumor stem cell proliferation. By the methods of the present
invention, one can characterize the phenotypically heterogeneous
populations of cells within a solid tumor. In particular, one can
identify, isolate, and characterize a phenotypically distinct cell
population within a tumor having the stem cell properties of
extensive proliferation and the ability to give rise to all other
tumor cell types. Solid tumor stem cells are the tumorigenic cells
that are capable of re-establishing a tumor following
treatment.
[0078] This invention using the microarray data of this invention
identifies two clearly defined molecular signatures of cancer stem
cell gene expression referred to as signature 1 (alpha-catenin
signature) and signature 2 (e-cadherin signature) (See Table 9 and
FIG. 10, 11 ). These signatures can detect the presence of cancer
stem cells, enabling the characterization, isolation, targeting,
and treatment of cancer. Using the knowledge of the alpha-catenin
and E-cadherin cancer stem cell gene signatures one can: develop
diagnostic assays for the presence or absence of cancer stem cells;
isolate enriched populations of cancer stem cells; conduct research
studies; develop assays that enable identification of agents that
impact the behavior of cancer stem cells; develop drugs that impact
cancer stem cells; treat solid tumors using selection methods,
diagnostic methods, and therapeutics; and identify additional
markers of cancer stem cells for the further isolation and
targeting of specific populations of cancer stem cells. Also, the
discovery that the signature 1 and signature 2 gene expression of
the present invention include alterations in the expression of
alpha-catenin and E-cadherin respectively indicates that signature
1 and signature 2 cancer stem cells are associated with changes in
the capability to metastasize. Thus the gene expression signatures
of the present invention further enable the monitoring and
treatment of metastases.
[0079] The invention thus provides a method for selectively
targeting diagnostic or therapeutic agents to solid tumor stem
cells. The invention also provides an agent, such as a biomolecule,
that is selectively targeted to solid tumor stem cells (e.g.
directed to one of the solid tumor stem cell cancer markers
disclosed herein). In some embodiments, the stem cell cancer marker
this targeted is part of a self-renewal or cell survival pathway.
One example of such a marker is Bmi-1, which was shown to be
required for maintenance of adult self-renewing hematopoietic stem
cells (see, e.g., Park et al., Nature,2003, 15; 423(6937): 302-5,
herein incorporated by reference). In other some embodiments, the
cancer diagnosed or targeted expresses an alpha-catenin or an
E-cadherin gene expression pattern that is high correlated with an
alpha-catenin signature. More specifically the cancer stem cell
displays either: 1) low or undetectable levels of alpha-catenin
expression in combination with an increase or decrease in one or
more signature 1 gene markers including, for example, low or
undetectable levels of Nicastrin expression or an increase in EDG2,
DCBLD2, or c-Met expression or 2) low or undetectable levels of
e-cadherin expression in combination with an increase or decrease
in one or more signature 2 gene markers including, for example, low
or undetectable levels of MMP7, Nov, or IL1R2 expression or an
increase in SHC1 expression.
[0080] In certain embodiments, the present invention provides
methods for screening for anti-cancer agents; for the testing of
anti-cancer therapies; for the development of drugs targeting novel
pathways; for the identification of new anti-cancer therapeutic
targets; the identification and diagnosis of malignant cells in
pathology specimens; for the testing and assaying of solid tumor
stem cell drug sensitivity; for the measurement of specific factors
that predict drug sensitivity; and for the screening of patients
(e.g., as an adjunct for mammography).
[0081] The present invention further identifies for the first time
a cancer stem cell gene signature, the alpha-catenin signature,
comprising stem cell markers that are predicitive of clinical
outcome including metastsis and overall survival. The alpha-catenin
signature as well as one or more of the individual predictor genes
that comprise the alpha-catenin signature are established as
predictive of a poor prognosis. In some embodiments of the present
invention the alpha-catenin signature or individual predictor genes
are used clinically to classify tumors as low or high risk and to
assign a tumor to a low or high-risk category. The alpha-catenin
signature can further be used to provide a diagnosis, prognosis,
and select a therapy based on the classification of a tumor as low
or high risk as well as to monitor the diagnosis, prognosis, and/or
therapy over time. In another embodiment, the alpha-catenin
signature can be used experimentally to test and assess lead
compounds including, for example, small molecules, siRNAs, and
antibodies for the treatment of cancer.
[0082] In certain embodiments a cancer stem cell profile, including
an alpha-catenin gene profile, can be detected in a tumor sample by
quantifying expression levels of polynucleotides by, for example,
RT-PCR. The polynucleotides selected for quantification by RT-PCR
are those polynucleotides comprising the cancer stem cell gene
signature. Alternatively the cancer stem cell profiles, including
the alpha-catenin gene profiles, can be detected in a tumor sample
by quantifying expression levels of proteins by, for example,
quantitative immunofluorescence or ELISA. The proteins selected for
quantification are those proteins encoded by genes comprising the
cancer stem cell gene signature. In some embodiments the
alpha-catenin gene profile is detected in a tumor sample by
microarray analysis using microarrays that comprise an
alpha-catenin gene signature. These microarrays can detect the
presence of an alpha-catenin profile by expression levels of
polynucleotides, for example mRNA, in a patient sample or,
alternatively, by expression levels of proteins in a patient sample
using, for example, antibodies. In another some embodiment, an
alpha-catenin profile is detected in a sample by real-time PCR
using primer sets that specifically amplify the genes comprising
the cancer stem cell signature. In other embodiments of the
invention, microarrays are provided that contain polynucleotides or
proteins (e.g., antibodies) that detect the expression of the genes
comprising an alpha-catenin signature for use in prognosis.
[0083] Other features, objects, and advantages of the invention
will be apparent from the detailed description below. Additional
guidance is provided in WO 02/12447 and WO 03/50502 by the Regents
of the University of Michigan, both of which are incorporated
herein by reference.
DEFINITIONS
[0084] To facilitate an understanding of the present invention, a
number of terms and phrases are defined below.
[0085] As used here, the term "antibody" includes monoclonal
antibodies (including full length monoclonal antibodies),
polyclonal antibodies, multispecific antibodies (e.g., bispecific
antibodies), and antibody fragments so long as they exhibit the
desired biological activity (e.g. able to bind a stem cell cancer
marker as described herein). Antibodies can be conjugated to other
molecules (e.g., toxins).
[0086] As used herein, the term "antibody fragments" refers to a
portion of an intact antibody. Examples of antibody fragments
include, but are not limited to, linear antibodies; single-chain
antibody molecules; Fc or Fc' peptides, Fab and Fab fragments, and
multispecific antibodies formed from antibody fragments.
[0087] As used herein, "humanized" forms of non-human (e.g.,
murine) antibodies are chimeric antibodies that contain minimal
sequence, or no sequence, derived from non-human immunoglobulin.
For the most part, humanized antibodies are human immunoglobulins
(recipient antibody) in which residues from a hypervariable region
of the recipient are replaced by residues from a hypervariable
region of a non-human species (donor antibody) such as mouse, rat,
rabbit or nonhuman primate having the desired specificity,
affinity, and capacity. In some instances, Fv framework region (FR)
residues of the human immunoglobulin are replaced by corresponding
non-human residues. Furthermore, humanized antibodies can comprise
residues that are not found in the recipient antibody or in the
donor antibody. These modifications are generally made to further
refine antibody performance. In general, the humanized antibody
will comprise substantially all of at least one, and typically two,
variable domains, in which all or substantially all of the
hypervariable loops correspond to those of a nonhuman
immunoglobulin and all or substantially all of the FR residues are
those of a human immunoglobulin sequence. The humanized antibody
can also comprise at least a portion of an immunoglobulin constant
region (Fc), typically that of a human immunoglobulin. Examples of
methods used to generate humanized antibodies are described in U.S.
Pat. No. 5,225,539 to Winter et al. (herein incorporated by
reference).
[0088] "Enriched", as in an enriched population of cells, can be
defined phenotypically based upon the increased number of cells
having a particular marker (e.g. as shown in Tables 4-9) in a
fractionated set of cells as compared with the number of cells
having the marker in the unfractionated set of cells. However, the
term "enriched can be defined functionally by tumorigenic function
as the minimum number of cells that form tumors at limit dilution
frequency in test mice. For example, if 500 tumor stem cells form
tumors in 63% of test animals, but 5000 unfractionated tumor cells
are required to form tumors in 63% of test animals, then the solid
tumor stem cell population is 10-fold enriched for tumorigenic
activity. The stem cell cancer markers of the present invention can
be used to generate enriched populations of cancer stem cells. In
some embodiments, the stem cell population is enriched at least 1.4
fold relative to unfractioned tumor cells (e.g. 1.4 fold, 1.5 fold,
2 fold, 5 fold, 10 fold, . . . , 20 fold, . . . ).
[0089] "Isolated" in regard to cells, refers to a cell that is
removed from its natural environment (such as in a solid tumor) and
that is isolated or separated, and is at least about 30%, 50%, 75%
free, or about 90% free, from other cells with which it is
naturally present, but which lack the marker based on which the
cells were isolated. The stem cell cancer markers of the present
invention can be used to generate isolated populations of cancer
stem cells.
[0090] As used herein, the terms "low levels", "decreased levels",
"low expression", "reduced expression" or "decreased expression" in
regards to gene expression are used herein interchangeably to refer
to expression of a gene in a cell or population of cells,
particularly a cancer stem cell or population of cancer stem cells,
at levels less than the expression of that gene in a second cell or
population of cells, for example normal breast epithelial cells.
"Low levels" of gene expression can refer to expression of a gene
in a cancer stem cell or population of cancer stem cells at levels:
1) half that or below expression levels of the same gene in normal
breast epithelial cells and2) at the lower limit of detection using
conventional techniques. "Low levels" of gene expression can be
determined by detecting decreased to nearly undetectable amounts of
a polynucleotide (mRNA, cDNA, etc.) in cancer stem cells compared
to normal breast epithelium by, for example, quantitative RT-PCR or
microarray analysis. Alternatively "low levels" of gene expression
can be determined by detecting decreased to nearly undetectable
amounts of a protein in cancer stem cells compared to normal breast
epithelium by, for example, ELISA, Western blot, or quantitative
immunfluorescence.
[0091] The terms "high levels", "increased levels", "high
expression", "increased expression" or "elevated levels" in regards
to gene expression are used herein interchangeably to refer to
expression of a gene in a cell or population of cells, particularly
a cancer stem cell or population of cancer stem cells, at levels
higher than the expression of that gene in a second cell or
population of cells, for example normal breast epithelial cells.
"Elevated levels" of gene expression can refer to expression of a
gene in a cancer stem cell or population of cancer stem cells at
levels twice that or more of expression levels of the same gene in
normal breast epithelial cells. "Elevated levels" of gene
expression can be determined by detecting increased amounts of a
polynucleotide (mRNA, cDNA, etc.) in cancer stem cells compared to
normal breast epithelium by, for example, quantitative RT-PCR or
microarray analysis. Alternatively "elevated levels" of gene
expression can be determined by detecting increased amounts of a
protein in cancer stem cells compared to normal breast epithelium
by, for example, ELISA, Western blot, quantitative
immunfluorescence, etc.
[0092] The term "undetectable levels" or "loss of expression" in
regards to gene expression as used herein refers to expression of a
gene in a cell or population of cells, particularly a cancer stem
cell or population of cancer stem cells, at levels that cannot be
distinguished from background using conventional techniques such
that no expression is identified. "Undetectable levels" of gene
expression can be determined by the inability to detect levels of a
polynucleotide (mRNA, cDNA, etc.) in cancer stem cells above
background by, for example, quantitative RT-PCR or microarray
analysis. Alternatively "undetectable levels" of gene expression
can be determined by the inability to detect levels of a protein in
cancer stem cells above background by, for example, ELISA, Western
blot, or immunofluorescence.
[0093] As used herein, the term "receptor binding domain" refers to
any native ligand for a receptor, including cell adhesion
molecules, or any region or derivative of such native ligand
retaining at least a qualitative receptor binding ability of a
corresponding native ligand.
[0094] As used herein, the term "antibody-immunoadhesin chimera"
comprises a molecule that combines at least one binding domain of
an antibody with at least one immunoadhesin. Examples include, but
are not limited to, the bispecific CD4-IgG chimeras described in
Berg et al., PNAS (USA) 88:4723-4727 (1991) and Charnow et al., J.
Immunol., 153:4268 (1994), both of which are hereby incorporated by
reference.
[0095] As used herein, the terms "cancer" and "cancerous" refer to
or describe the physiological condition in mammals in which a
population of cells are characterized by unregulated cell growth.
Examples of cancer include, but are not limited to, carcinoma,
lymphoma, blastoma, sarcoma, and leukemia. More particular examples
of such cancers include squamous cell cancer, small-cell lung
cancer, non-small cell lung cancer, adenocarcinoma of the lung,
squamous carcinoma of the lung, cancer of the peritoneum,
hepatocellular cancer, gastrointestinal cancer, pancreatic cancer,
glioblastoma, cervical cancer, ovarian cancer, liver cancer,
bladder cancer, hepatoma, breast cancer, colon cancer, colorectal
cancer, endometrial or uterine carcinoma, salivary gland carcinoma,
kidney cancer, liver cancer, prostate cancer, vulval cancer,
thyroid cancer, hepatic carcinoma and various types of head and
neck cancer.
[0096] "Metastasis" as used herein refers to the process by which a
cancer spreads or transfers from the site of origin to other
regions of the body with the development of a similar cancerous
lesion at the new location. A "metastatic" or "metastasizing" cell
is one that loses adhesive contacts with neighboring cells and
migrates via the bloodstream or lymph from the primary site of
disease to invade neighboring body structures.
[0097] The term "epitope" as used herein refers to that portion of
an antigen that makes contact with a particular antibody.
[0098] When a protein or fragment of a protein is used to immunize
a host animal, numerous regions of the protein can induce the
production of antibodies which bind specifically to a given region
or three-dimensional structure on the protein; these regions or
structures are referred to as "antigenic determinants". An
antigenic determinant can compete with the intact antigen (i.e.,
the "immunogen" used to elicit the immune response) for binding to
an antibody.
[0099] The terms "specific binding" or "specifically binding" when
used in reference to the interaction of an antibody and a protein
or peptide means that the interaction is dependent upon the
presence of a particular structure (i.e., the antigenic determinant
or epitope) on the protein; in other words the antibody is
recognizing and binding to a specific protein structure rather than
to proteins in general. For example, if an antibody is specific for
epitope "A," the presence of a protein containing epitope A (or
free, unlabelled A) in a reaction containing labeled "A" and the
antibody will reduce the amount of labeled A bound to the
antibody.
[0100] As used herein, the terms "non-specific binding" and
"background binding" when used in reference to the interaction of
an antibody and a protein or peptide refer to an interaction that
is not dependent on the presence of a particular structure (i.e.,
the antibody is binding to proteins in general rather that a
particular structure such as an epitope).
[0101] As used herein, the term "subject" refers to any animal
(e.g., a mammal), including, but not limited to, humans, non-human
primates, rodents, and the like, which is to be the recipient of a
particular treatment. Typically, the terms "subject" and "patient"
are used interchangeably herein in reference to a human
subject.
[0102] As used herein, the term "subject suspected of having
cancer" refers to a subject that presents one or more symptoms
indicative of a cancer (e.g., a noticeable lump or mass) or is
being screened for a cancer (e.g., during a routine physical). A
subject suspected of having cancer can also have one or more risk
factors. A subject suspected of having cancer has generally not
been tested for cancer. However, a "subject suspected of having
cancer" encompasses an individual who has received an initial
diagnosis but for whom the stage of cancer is not known. The term
further includes people who once had cancer (e.g., an individual in
remission).
[0103] As used herein, the term "subject at risk for cancer" refers
to a subject with one or more risk factors for developing a
specific cancer. Risk factors include, but are not limited to,
gender, age, genetic predisposition, environmental exposure,
previous incidents of cancer, preexisting non-cancer diseases, and
lifestyle.
[0104] As used herein, the term "characterizing cancer in subject"
refers to the identification of one or more properties of a cancer
sample in a subject, including but not limited to, the presence of
benign, pre-cancerous or cancerous tissue, the stage of the cancer,
and the subject's prognosis. Cancers can be characterized by the
identification of the expression of one or more cancer marker
genes, including but not limited to, the cancer markers disclosed
herein.
[0105] The terms "cancer stem cell", "tumor stem cell", or "solid
tumor stem cell" are used interchangeably herein and refer to a
population of cells from a solid tumor that: (1) have extensive
proliferative capacity; (2) are capable of asymmetric cell division
to generate one or more kinds of differentiated progeny with
reduced proliferative or developmental potential; and (3) are
capable of symmetric cell divisions for self-renewal or
self-maintenance. These properties of "cancer stem cells", "tumor
stem cells" or "solid tumor stem cells" confer on those cancer stem
cells the ability to form palpable tumors upon serial
transplantation into an immunocompromised mouse compared to the
majority of tumor cells that fail to form tumors. Cancer stem cells
undergo self-renewal versus differentiation in a chaotic manner to
form tumors with abnormal cell types that can change over time as
mutations occur. The solid tumor stem cells of the present
invention differ from the "cancer stem line" provided by U.S. Pat.
No. 6,004,528. In that patent, the "cancer stem line" is defined as
a slow growing progenitor cell type that itself has few mutations
but which undergoes symmetric rather than asymmetric cell divisions
as a result of tumorigenic changes that occur in the cell's
environment. This "cancer stem line" hypothesis thus proposes that
highly mutated, rapidly proliferating tumor cells arise largely as
a result of an abnormal environment, which causes relatively normal
stem cells to accumulate and then undergo mutations that cause them
to become tumor cells. U.S. Pat. No. 6,004,528 proposes that such a
model can be used to enhance the diagnosis of cancer. The solid
tumor stem cell model is fundamentally different than the "cancer
stem line" model and as a result exhibits utilities not offered by
the "cancer stem line" model. First, solid tumor stem cells are not
"mutationally spared". The "mutationally spared cancer stem line"
described by U.S. Pat. No. 6,004,528 can be considered a
pre-cancerous lesion, while the solid tumor stem cells described by
this invention are cancer cells that themselves contain the
mutations that are responsible for tumorigenesis. That is, the
solid tumor stem cells ("cancer stem cells") of the invention would
be included among the highly mutated cells that are distinguished
from the "cancer stem line" in U.S. Pat. No. 6,004,528. Second, the
genetic mutations that lead to cancer can be largely intrinsic
within the solid tumor stem cells as well as being environmental.
The solid tumor stem cell model predicts that isolated solid tumor
stem cells can give rise to additional tumors upon transplantation
(thus explaining metastasis) while the "cancer stem line" model
would predict that transplanted "cancer stem line" cells would not
be able to give rise to a new tumor, since it was their abnormal
environment that was tumorigenic. Indeed, the ability to transplant
dissociated, and phenotypically isolated human solid tumor stem
cells to mice (into an environment that is very different from the
normal tumor environment), where they still form new tumors,
distinguishes the present invention from the "cancer stem line"
model. Third, solid tumor stem cells likely divide both
symmetrically and asymmetrically, such that symmetric cell division
is not an obligate property. Fourth, solid tumor stem cells can
divide rapidly or slowly, depending on many variables, such that a
slow proliferation rate is not a defining characteristic.
[0106] As used herein "tumorigenic" refers to the functional
features of a solid tumor stem cell including the properties of
self-renewal (giving rise to additional tumorigenic cancer stem
cells) and proliferation to generate all other tumor cells (giving
rise to differentiated and thus non-tumorigenic tumor cells) that
allow solid tumor stem cells to form a tumor.
[0107] As used herein, the terms "stem cell cancer marker(s)",
"cancer stem cell marker(s)", "tumor stem cell marker(s)", or
"solid tumor stem cell marker(s)" refer to a gene or genes or a
protein, polypeptide, or peptide expressed by the gene or genes
whose expression level, alone or in combination with other genes,
is correlated with the presence of tumorigenic cancer cells
compared to non-tumorigenic cells. The correlation can relate to
either an increased or decreased expression of the gene (e.g.
increased or decreased levels of mRNA or the peptide encoded by the
gene).
[0108] "Gene expression profile" refers to identified expression
levels of at least one polynucleotide or protein expressed in a
biological sample.
[0109] A "gene profile," "gene pattern," "expression pattern" or
"expression profile" refers to a specific pattern of gene
expression that provides a unique identifier of a biological
sample, for example, a breast or colon cancer pattern of gene
expression, obtained by analyzing a breast or colon cancer sample
and in those cases can be referred to as a "breast cancer gene
profile" or a "colon cancer expression pattern". "Gene patterns"
can be used to diagnose a disease, make a prognosis, select a
therapy, and/or monitor a disease or therapy after comparing the
gene pattern to a cancer stem cell gene signature.
[0110] The terms "cancer stem cell gene signature", "tumor stem
cell gene signature", "cancer stem cell signature", "tumor stem
cell signature", "tumorigenic gene signature", and "TG gene
signature" are used interchangeably herein to refer to gene
signatures comprising genes differentially expressed in cancer stem
cells compared to other cells or population of cells, for example
normal breast epithelial tissue. In one some embodiment the cancer
stem cell gene signature comprises genes differentially expressed
in cancer stem cells versus normal breast epithelium by a fold
change, for example by 2 fold reduced and/or elevated expression,
and further limited by using a statistical analysis such as, for
example, by the P value of a t-test across multiple samples. In
some embodiments, the genes differentially expressed in cancer stem
cells are divided into cancer stem cell gene signatures based on
the correlation of their expression with a chosen gene in
combination with their fold or percentage expression change.
[0111] The terms "alpha-catenin signature", "alpha-catenin gene
signature", "alpha catenin gene expression signature", "signature
1", or "cancer stem cell signature 1" as used herein refer to a
distinct subset of cancer stem cell signatures. Cancer stem cells
expressing an alpha-catenin gene signature are referred to as
displaying a "signature 1 gene expression" or as "signature 1",
"signature 1 type", or "alpha-catenin signature" cancer stem cells.
The alpha-catenin signature comprises: 1) undetectable or low level
expression as compared to normal human breast epithelium of one or
more of a distinct set of genes comprising: alpha-catenin (CTNNA1);
nicastrin (NCSTN); ligand of numb-protein X (LNX); armadillo repeat
containing, X-linked3 (ARMCX3); melanoma associated gene (D2S448);
tumor suppressor candidate 1 (TUSC1); glutamine synthase (GLUL);
retinoblastoma 1 (RB1); brain expressed X-linked 2 (BEX2); solute
carrier family 12, member2 (SLC12A2); galactosylceramidase (GALC);
nerve growth factor receptor associated protein 1 (NGFRAP1);
fibroblast growth factor 13 (FGF13); KIAA1102; solute carrier
family 1, member 4 (SLC1A4); and DnaJ homolog, subfamily D, member
1 (DNAJD1) and/or 2) elevated expression compared to normal human
breast epithelium of one or more of a distinct set of genes
comprising: endothelial differentiation, lysophosphatidic acid
G-protein coupled receptor 2 (EDG2); caveolin 1 (CAV1); caveolin 2
(CAV2); discoidin, CUB and LCCL domain containing 2 (DCBLD2);
insulin-like growth factor binding protein 3 (IGFBP3); S100A2;
CXCL5; c-Met (MET); forkhead box Q1 (FOXQ1); cyclin-dependent
kinase inhibitor 2A (CDKN2A); malignant fibrous histiocytoma
amplified sequence 1 (MFHAS1); interleukin 27 receptor, alpha
(IL27RA); killer cell lectin-like receptor subfamily F, member 1
(KLRF1); protein kinase C, alpha (PKCA); uridine phosphorylase 1
(UPP1); cathepsin L2 (CTSL2); solute carrier family 7, member 5
(SLC7A5); aryl hydrocarbon receptor nuclear translocator-like 2
(ARNTL2); protease, serine,1, 2, and 3 (PRSS1, PRSS2, PRSS3); vanin
1 (VNN1); RAB38; zinc finger, BED domain containing 2 (ZBED2);
myeloma overexpressed gene (MYEOV); MAL; IGF-II mRNA-binding
protein 3 (IMP-3); and dehydrogenase/reductase SDR family, member 9
(DHRS9). In some embodiments of the present invention a
undetectable or low level of alpha-catenin expression is
accompanied by 1) undetectable or low level expression of one or
more of the genes including: nicastrin (NCSTN); ligand of
numb-protein X (LNX); armadillo repeat containing, X-linked3
(ARMCX3); melanoma associated gene (D2S448); glutamine synthase
(GLUL); and retinoblastoma 1 (RB1) and/or 2) elevated expression of
one or more of a distinct set of genes that includes: endothelial
differentiation, lysophosphatidic acid G-protein coupled receptor 2
(EDG2); caveolin 1 (CAV1); caveolin 2 (CAV2); discoidin, CUB and
LCCL domain containing 2 (DCBLD2); insulin-like growth factor
binding protein 3 (IGFBP3); S100A2; CXCL5; c-Met (MET); forkhead
box Q1 (FOXQ1); cyclin-dependent kinase inhibitor 2A (CDKN2A);
cathepsin L2 (CTSL2); and malignant fibrous histiocytoma amplified
sequence 1 (MFHAS1). In another embodiment, the alpha-catenin
signature comprises undetectable or low level expression of two or
more of the genes: alpha-catenin; NCSTN; LNX; ARMCX3; D2S448; GLUL;
and RB1. In another embodiment, the alpha-catenin signature
comprises elevated expression of two or more of the genes EDG2;
CAV1; CAV2; DCBLD2; IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A;
CTSL2; and MFHAS1. Alternatively the alpha-catenin signature
comprises: 1) undetectable or low level expression of one or more
of the genes: alpha-catenin; NCSTN; LNX; ARMCX3; D2S448; GLUL; and
RB1 and2) elevated expression of one or more of the genes: EDG2;
CAV1; CAV2; DCBLD2; IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A;
CTSL2; and MFHAS1.
[0112] The terms "E-cadherin signature", "E-cadherin gene
signature", "E-cadherin gene expression signature", "signature 2",
or "cancer stem cell signature 2" as used herein refer to a
distinct subset of cancer stem cell signatures. Cancer stem cells
expressing an E-cadherin gene signature are referred to as
displaying a "signature 2 gene expression" or as "signature 2",
"signature 2 type", or "E-cadherin signature" cancer stem cells.
The E-cadherin signature comprises: I) undetectable or low level
expression compared to normal breast epithelium of one or more of
the genes comprising: e-cadherin (CDH1); matrix metalloproteinase 7
(MMP7); nephroblastoma overexpressed gene (Nov); FOS-like antigen 1
(FOSL1); interleukin I receptor, type II (IL1R2); secreted
frizzled-related protein 1 (SFRP1); keratin 6B (KRT6B); putative
lymphocyte G0/G1 switch gene (G0S2); interleukin 8 (IL8);
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5
(B3GNT5); and fibroblast growth factor binding protein 1 (FGFBP1)
and/or 2) the increased expression compared to normal breast
epithelium of one or more of the genes comprising Src homology 2
domain containing transforming protein 1 (SHC1); FLJ20152; aryl
hydrocarbon receptor nuclear translocator (ARNT); cytoplasmic FMR1
interacting protein 2 (CYFIP2); chromosome 17 open reading frame 27
(C17orf27); transporter 1, ATP-binding cassette, sub-family B
(TAP1); RNASEL; and similar to aspartate beta hydroxylase
(LOC57168). In some embodiments of the present invention
undetectable or low level expresion of E-cadherin is accompanied by
undetectable or low level expression of one or more of the genes
that includes: matrix metalloproteinase 7 (MMP7); nephroblastoma
overexpressed gene (Nov); FOS-like antigen 1 (FOSL1); and
interleukin 1 receptor, type II (IL1R2) and/or 2) elevated
expression of one or more of the genes that includes: SHC (Src
homology 2 domain containing) transforming protein 1 (SHC1) and
FLJ20152. In another embodiment, the E-cadherin signature comprises
undetectable or low level expression of two or more of the genes:
E-cadherin; MMP7; Nov; FOSL1; and IL1R2. In another embodiment, the
E-cadherin signature comprises elevated expression of the genes
SHC1 and FLJ20152. Alternatively the E-cadherin signature
comprises: 1) undetectable or low level expression of one or more
of the genes: E-cadherin; MMP7; Nov; FOSL1; and IL1R2 or 2)
elevated expression of one or more the genes: SHC1 and
FLJ20152.
[0113] As used herein, the term "a reagent that specifically
detects expression levels" refers to reagents used to detect the
expression of one or more genes (e.g., including but not limited
to, the cancer markers of the present invention). Examples of
suitable reagents include but are not limited to, nucleic acid
probes capable of specifically hybridizing to the gene of interest,
aptamers, PCR primers capable of specifically amplifying the gene
of interest, and antibodies capable of specifically binding to
proteins expressed by the gene of interest. Other non-limiting
examples can be found in the description and examples below.
[0114] As used herein, the term "detecting a decreased or increased
expression relative to non-cancerous control" refers to measuring
the level of expression of a gene (e.g., the level of mRNA or
protein) relative to the level in a non-cancerous control sample.
Gene expression can be measured using any suitable method,
including but not limited to, those described herein.
[0115] As used herein, the term "detecting a change in gene
expression in a cell sample in the presence of said test compound
relative to the absence of said test compound" refers to measuring
an altered level of expression (e.g., increased or decreased) in
the presence of a test compound relative to the absence of the test
compound. Gene expression can be measured using any suitable
method.
[0116] As used herein, the term "instructions for using said kit
for detecting cancer in said subject" includes instructions for
using the reagents contained in the kit for the detection and
characterization of cancer in a sample from a subject.
[0117] As used herein, "providing a diagnosis" or "diagnostic
information" refers to any information that is useful in
determining whether a patient has a disease or condition and/or in
classifying the disease or condition into a phenotypic category or
any category having significance with regards to the prognosis of
or likely response to treatment (either treatment in general or any
particular treatment) of the disease or condition. Similarly,
diagnosis refers to providing any type of diagnostic information,
including, but not limited to, whether a subject is likely to have
a condition (such as a tumor), information related to the nature or
classification of a tumor as for example a high risk tumor or a low
risk tumor, information related to prognosis and/or information
useful in selecting an appropriate treatment. Selection of
treatment can include the choice of a particular chemotherapeutic
agent or other treatment modality such as surgery or radiation or a
choice about whether to withhold or deliver therapy.
[0118] As used herein, the terms "providing a prognosis",
"prognostic information", or "predictive information" refer to
providing information regarding the impact of the presence of
cancer (e.g., as determined by the diagnostic methods of the
present invention) on a subject's future health (e.g., expected
morbidity or mortality, the likelihood of getting cancer, and the
risk of metastasis).
[0119] The term "low risk" in regards to tumors or to patients
diagnosised with cancer refers to a tumor or patient with a lower
probability of metastasis and/or lower probability of causing death
or dying within about five years of first diagnosis than all the
tumors or patients within a given population.
[0120] The term "high risk" in regards to tumors or to patients
diagnosised with cancer refers to a tumor or patient with a higher
probability of metastasis and/or higher probability of causing
death or dying within about five years of first diagnosis than all
the tumors or patients within a given population.
[0121] As used herein, the term "post surgical tumor tissue" refers
to cancerous tissue (e.g., biopsy tissue) that has been removed
from a subject (e.g., during surgery).
[0122] As used herein, the term "subject diagnosed with a cancer"
refers to a subject who has been tested and found to have cancerous
cells. The cancer can be diagnosed using any suitable method,
including but not limited to, biopsy, x-ray, blood test, and the
diagnostic methods of the present invention.
[0123] As used herein, the terms "biopsy tissue", "patient sample",
"tumor sample", and "cancer sample" refer to a sample of cells,
tissue or fluid that is removed from a subject for the purpose of
determining if the sample contains cancerous tissue, including
cancer stem cells or for determining gene expression profile of
that cancerous tissue. In some embodiment, biopsy tissue or fluid
is obtained because a subject is suspected of having cancer. The
biopsy tissue or fluid is then examined for the presence or absence
of cancer, cancer stem cells, and/or cancer stem cell gene
signature expression.
[0124] As used herein, the term "gene transfer system" refers to
any means of delivering a composition comprising a nucleic acid
sequence to a cell or tissue. For example, gene transfer systems
include, but are not limited to, vectors (e.g., retroviral,
adenoviral, adeno-associated viral, and other nucleic acid-based
delivery systems), microinjection of naked nucleic acid,
polymer-based delivery systems (e.g., liposome-based and metallic
particle-based systems), biolistic injection, and the like. As used
herein, the term "viral gene transfer system" refers to gene
transfer systems comprising viral elements (e.g., intact viruses,
modified viruses and viral components such as nucleic acids or
proteins) to facilitate delivery of the sample to a desired cell or
tissue. As used herein, the term "adenovirus gene transfer system"
refers to gene transfer systems comprising intact or altered
viruses belonging to the family Adenoviridae.
[0125] As used herein, the term "site-specific recombination target
sequences" refers to nucleic acid sequences that provide
recognition sequences for recombination factors and the location
where recombination takes place.
[0126] As used herein, the term "nucleic acid molecule" refers to
any nucleic acid containing molecule, including but not limited to,
DNA or RNA. The term encompasses sequences that include any of the
known base analogs of DNA and RNA including, but not limited to,
4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine,
pseudoisocytosine, 5-(carboxyhydroxylmethyl) uracil,
5-fluorouracil, 5-bromouracil,
5-carboxymethylaminomethyl-2-thiouracil,
5-carboxymethylaminomethyluracil, dihydrouracil, inosine,
N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil,
1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N6-methyladenine, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil,
5-methoxyuracil, 2-methylthio-N6-isopentenyladenine,
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine,
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,
N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.
[0127] The term "gene" refers to a nucleic acid (e.g., DNA)
sequence that comprises coding sequences necessary for the
production of a polypeptide, precursor, or RNA (e.g., rRNA, tRNA).
The polypeptide can be encoded by a full length coding sequence or
by any portion of the coding sequence so long as the desired
activity or functional properties (e.g., enzymatic activity, ligand
binding, signal transduction, immunogenicity, etc.) of the
full-length or fragment are retained. The term also encompasses the
coding region of a structural gene and the sequences located
adjacent to the coding region on both the 5' and3' ends for a
distance of about 1 kb or more on either end such that the gene
corresponds to the length of the full-length mRNA. Sequences
located 5' of the coding region and present on the mRNA are
referred to as 5' non-translated sequences. Sequences located 3' or
downstream of the coding region and present on the mRNA are
referred to as 3' non-translated sequences. The term "gene"
encompasses both cDNA and genomic forms of a gene. A genomic form
or clone of a gene contains the coding region interrupted with
non-coding sequences termed "introns" or "intervening regions" or
"intervening sequences." Introns are segments of a gene that are
transcribed into nuclear RNA (hnRNA); introns can contain
regulatory elements such as enhancers. Introns are removed or
"spliced out" from the nuclear or primary transcript; introns
therefore are absent in the messenger RNA (mRNA) transcript. The
mRNA functions during translation to specify the sequence or order
of amino acids in a nascent polypeptide.
[0128] As used herein, the term "heterologous gene" refers to a
gene that is not in its natural environment. For example, a
heterologous gene includes a gene from one species introduced into
another species. A heterologous gene also includes a gene native to
an organism that has been altered in some way (e.g., mutated, added
in multiple copies, linked to non-native regulatory sequences,
etc). Heterologous genes are distinguished from endogenous genes in
that the heterologous gene sequences are typically joined to DNA
sequences that are not found naturally associated with the gene
sequences in the chromosome or are associated with portions of the
chromosome not found in nature (e.g., genes expressed in loci where
the gene is not normally expressed).
[0129] As used herein, the term "gene expression" refers to the
process of converting genetic information encoded in a gene into
RNA (e.g., mRNA, rRNA, tRNA, or snRNA) through "transcription" of
the gene (e.g., via the enzymatic action of an RNA polymerase), and
for protein encoding genes, into protein through "translation" of
mRNA. Gene expression can be regulated at many stages in the
process. "Up-regulation" or "activation"refers to regulation that
increases the production of gene expression products (e.g., RNA or
protein), while "down-regulation" or "repression" refers to
regulation that decrease production. Molecules (e.g., transcription
factors) that are involved in up-regulation or down-regulation are
often called "activators" and "repressors," respectively.
[0130] In addition to containing introns, genomic forms of a gene
can also include sequences located on both the 5' and3' end of the
sequences that are present on the RNA transcript. These sequences
are referred to as "flanking" sequences or regions (these flanking
sequences are located5' or 3' to the non-translated sequences
present on the mRNA transcript). The 5' flanking region can contain
regulatory sequences such as promoters and enhancers that control
or influence the transcription of the gene. The 3' flanking region
can contain sequences that direct the termination of transcription,
post-transcriptional cleavage and polyadenylation.
[0131] The term "siRNAs" refers to short interfering RNAs. In some
embodiments, siRNAs comprise a duplex, or double-stranded region,
of about18-25 nucleotides long; often siRNAs contain from about two
to four unpaired nucleotides at the 3' end of each strand. At least
one strand of the duplex or double-stranded region of a siRNA is
substantially homologous to or substantially complementary to a
target RNA molecule. The strand complementary to a target RNA
molecule is the "antisense strand;" the strand homologous to the
target RNA molecule is the "sense strand," and is also
complementary to the siRNA antisense strand. siRNAs can also
contain additional sequences; non-limiting examples of such
sequences include linking sequences, or loops, as well as stem and
other folded structures. siRNAs appear to function as key
intermediaries in triggering RNA interference in invertebrates and
in vertebrates, and in triggering sequence-specific RNA degradation
during posttranscriptional gene silencing in plants.
[0132] The term "RNA interference" or "RNAi" refers to the
silencing or decreasing of gene expression by siRNAs. It is the
process of sequence-specific, post-transcriptional gene silencing
in animals and plants, initiated by siRNA that is homologous in its
duplex region to the sequence of the silenced gene. The gene can be
endogenous or exogenous to the organism, present integrated into a
chromosome or present in a transfection vector that is not
integrated into the genome. The expression of the gene is either
completely or partially inhibited. RNAi can also be considered to
inhibit the function of a target RNA; the function of the target
RNA can be complete or partial.
[0133] As used herein, the terms "nucleic acid molecule encoding,"
"DNA sequence encoding," and "DNA encoding" refer to the order or
sequence of deoxyribonucleotides along a strand of deoxyribonucleic
acid. The order of these deoxyribonucleotides determines the order
of amino acids along the polypeptide (protein) chain. The DNA
sequence thus codes for the amino acid sequence.
[0134] As used herein, the terms "an oligonucleotide having a
nucleotide sequence encoding a gene" and "polynucleotide having a
nucleotide sequence encoding a gene," means a nucleic acid sequence
comprising the coding region of a gene or in other words the
nucleic acid sequence that encodes a gene product. The coding
region can be present in a cDNA, genomic DNA or RNA form. When
present in a DNA form, the oligonucleotide or polynucleotide can be
single-stranded (i.e., the sense strand) or double-stranded.
Suitable control elements such as enhancers/promoters, splice
junctions, polyadenylation signals, etc. can be placed in close
proximity to the coding region of the gene if needed to permit
proper initiation of transcription and/or correct processing of the
primary RNA transcript. Alternatively, the coding region utilized
in the expression vectors of the present invention can contain
endogenous enhancers/promoters, splice junctions, intervening
sequences, polyadenylation signals, etc. or a combination of both
endogenous and exogenous control elements.
[0135] As used herein the term "portion" when in reference to a
nucleotide sequence (as in "a portion of a given nucleotide
sequence") refers to fragments of that sequence. The fragments can
range in size from four nucleotides to the entire nucleotide
sequence minus one nucleotide (10 nucleotides,20, 30, 40, 50, 100,
200, etc.).
[0136] The phrases "hybridizes", "selectively hybridizes", or
"specifically hybridizes" refer to the binding or duplexing of a
molecule only to a particular nucleotide sequence under stringent
hybridization conditions when that sequence is present in a complex
mixture (e.g., a library of DNAs or RNAs). See, e.g., Andersen
(1998) Nucleic Acid Hybridization Springer-Verlag; Ross (ed.1997)
Nucleic Acid Hybridization Wiley.
[0137] The phrase "stringent hybridization conditions" refers to
conditions under which a probe will hybridize to its target
subsequence, typically in a complex mixture of nucleic acid, but to
no other sequences. Stringent conditions are sequence-dependent and
will be different in different circumstances. Longer sequences
hybridize specifically at higher temperatures. An extensive guide
to the hybridization of nucleic acids is found in Tijssen,
Techniques in Biochemistry and Molecular Biology--Hybridization
with Nucleic Probes, "Overview of principles of hybridization and
the strategy of nucleic acid assays" (1993). Generally, stringent
conditions are selected to be about 5-10.degree. C. lower than the
thermal melting point (Tm) for the specific sequence at a defined
ionic strength. The Tm is the temperature (under defined ionic
strength, pH, and nucleic concentration) at which 50% of the probes
complementary to the target hybridize to the target sequence at
equilibrium (as the target sequences are present in excess, at Tm,
50% of the probes are occupied at equilibrium). Stringent
conditions will be those in which the salt concentration is less
than about1.0 M sodium ion, typically about 0.01 to 1.0 M sodium
ion concentration (or other salts) at pH 7.0 to 8.3 and the
temperature is at least about 30.degree. C. for short probes (e.g.,
10 to 50 nucleotides) and at least about 60.degree. C. for long
probes (e.g., greater than 50 nucleotides). Stringent conditions
can also be achieved with the addition of destabilizing agents such
as formamide. For high stringency hybridization, a positive signal
is at least two times background, or 10 times background
hybridization. Exemplary high stringency or stringent hybridization
conditions include: 50% formamide, 5.times.SSC, and 1% SDS
incubated at 42.degree. C. or 5.times.SSC and 1% SDS incubated at
65.degree. C., with a wash in 0.2.times.SSC and 0.1% SDS at
65.degree. C. For PCR, a temperature of about 36.degree. C. is
typical for low stringency amplification, although annealing
temperatures can vary from about 32.degree. C. and 48.degree. C.
depending on primer length. For high stringency PCR amplification,
a temperature of about 62.degree. C. is typical, although high
stringency annealing temperatures can range from about
50-65.degree. C., depending on the primer length and specificity.
Typical cycle conditions for both high and low stringency
amplifications include a denaturation phase of 90-95.degree. C. for
30-120 sec, an annealing phase lasting 30-120 sec., and an
extension phase of about 72.degree. C. for 1-2 min.
[0138] The terms "in operable combination," "in operable order,"
and "operably linked" as used herein refer to the linkage of
nucleic acid sequences in such a manner that a nucleic acid
molecule capable of directing the transcription of a given gene
and/or the synthesis of a desired protein molecule is produced. The
term also refers to the linkage of amino acid sequences in such a
manner so that a functional protein is produced.
[0139] The term "isolated" when used in relation to a nucleic acid,
as in "an isolated oligonucleotide" or "isolated polynucleotide"
refers to a nucleic acid sequence that is identified and separated
from at least one component or contaminant with which it is
ordinarily associated in its natural source. Isolated nucleic acid
is such present in a form or setting that is different from that in
which it is found in nature. In contrast, non-isolated nucleic
acids as nucleic acids such as DNA and RNA found in the state they
exist in nature. For example, a given DNA sequence (e.g., a gene)
is found on the host cell chromosome in proximity to neighboring
genes; RNA sequences, such as a specific mRNA sequence encoding a
specific protein, are found in the cell as a mixture with numerous
other mRNAs that encode a multitude of proteins. However, isolated
nucleic acid encoding a given protein includes, by way of example,
such nucleic acid in cells ordinarily expressing the given protein
where the nucleic acid is in a chromosomal location different from
that of natural cells, or is otherwise flanked by a different
nucleic acid sequence than that found in nature. The isolated
nucleic acid, oligonucleotide, or polynucleotide can be present in
single-stranded or double-stranded form. When an isolated nucleic
acid, oligonucleotide or polynucleotide is to be utilized to
express a protein, the oligonucleotide or polynucleotide will
contain at a minimum the sense or coding strand (i.e., the
oligonucleotide or polynucleotide can be single-stranded), but can
contain both the sense and anti-sense strands (i.e., the
oligonucleotide or polynucleotide can be double-stranded).
[0140] "Amino acid sequence" and terms such as "polypeptide",
"protein", or "peptide" are not meant to limit the amino acid
sequence to the complete, native amino acid sequence associated
with the recited protein molecule.
[0141] The term "native protein" as used herein to indicate that a
protein does not contain amino acid residues encoded by vector
sequences; that is, the native protein contains only those amino
acids found in the protein as it occurs in nature. A native protein
can be produced by recombinant means or can be isolated from a
naturally occurring source.
[0142] As used herein the term "portion" when in reference to a
protein (as in "a portion of a given protein") refers to fragments
of that protein. The fragments can range in size from four amino
acid residues to the entire amino acid sequence minus one amino
acid.
[0143] The term "Southern blot" refers to the analysis of DNA on
agarose or acrylamide gels to fractionate the DNA according to size
followed by transfer of the DNA from the gel to a solid support,
such as nitrocellulose or a nylon membrane. The immobilized DNA is
then probed with a labeled probe to detect DNA species
complementary to the probe used. The DNA can be cleaved with
restriction enzymes prior to electrophoresis. Following
electrophoresis, the DNA can be partially depurinated and denatured
prior to or during transfer to the solid support. Southern blots
are a standard tool of molecular biologists (J. Sambrook et al.,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press,
NY, pp 9.31-9.58 [1989]).
[0144] The term "Northern blot" as used herein refers to the
analysis of RNA by electrophoresis of RNA on agarose gels to
fractionate the RNA according to size followed by transfer of the
RNA from the gel to a solid support, such as nitrocellulose or a
nylon membrane. The immobilized RNA is then probed with a labeled
probe to detect RNA species complementary to the probe used.
Northern blots are a standard tool of molecular biologists (J.
Sambrook, et al., supra, pp 7.39-7.52 [1989]).
[0145] The term "Western blot" refers to the analysis of protein(s)
(or polypeptides) immobilized onto a support such as nitrocellulose
or a membrane. The proteins are run on acrylamide gels to separate
the proteins, followed by transfer of the protein from the gel to a
solid support, such as nitrocellulose or a nylon membrane. The
immobilized proteins are then exposed to antibodies with reactivity
against an antigen of interest. The binding of the antibodies can
be detected by various methods, including the use of radiolabeled
antibodies.
[0146] The term "transgene" as used herein refers to a foreign gene
that is placed into an organism by, for example, introducing the
foreign gene into newly fertilized eggs or early embryos. The term
"foreign gene" refers to any nucleic acid (e.g., gene sequence)
that is introduced into the genome of an animal by experimental
manipulations and can include gene sequences found in that animal
so long as the introduced gene does not reside in the same location
as does the naturally occurring gene.
[0147] As used herein, the term "vector" is used in reference to
nucleic acid molecules that transfer DNA segment(s) from one cell
to another. The term "vehicle" is sometimes used interchangeably
with "vector." Vectors are often derived from plasmids,
bacteriophages, or plant or animal viruses.
[0148] The term "expression vector" as used herein refers to a
recombinant DNA molecule containing a desired coding sequence and
appropriate nucleic acid sequences necessary for the expression of
the operably linked coding sequence in a particular host organism.
Nucleic acid sequences necessary for expression in prokaryotes
usually include a promoter, an operator (optional), and a ribosome
binding site, often along with other sequences. Eukaryotic cells
are known to utilize promoters, enhancers, and termination and
polyadenylation signals.
[0149] The terms "overexpression" and "overexpressing" and
grammatical equivalents, are used in reference to levels of mRNA to
indicate a level of expression approximately 1.5-fold higher (or
greater) than that observed in a given tissue in a control or
non-transgenic animal. Levels of mRNA are measured using any of a
number of techniques known to those skilled in the art including,
but not limited to Northern blot analysis. Appropriate controls are
included on the Northern blot to control for differences in the
amount of RNA loaded from each tissue analyzed (e.g., the amount of
28S rRNA, an abundant RNA transcript present at essentially the
same amount in all tissues, present in each sample can be used as a
means of normalizing or standardizing the mRNA-specific signal
observed on Northern blots). The amount of mRNA present in the band
corresponding in size to the correctly spliced transgene RNA is
quantified; other minor species of RNA which hybridize to the
transgene probe are not considered in the quantification of the
expression of the transgenic mRNA.
[0150] As used herein, the term "in vitro" refers to an artificial
environment and to processes or reactions that occur within an
artificial environment. In vitro environments can consist of, but
are not limited to, test tubes and cell culture. The term "in vivo"
refers to the natural environment (e.g., an animal or a cell) and
to processes or reaction that occur within a natural
environment.
[0151] The terms "test compound" and "candidate compound" refer to
any chemical entity, pharmaceutical, drug, and the like that is a
candidate for use to treat or prevent a disease, illness, sickness,
or disorder of bodily function (e.g., cancer). Test compounds
comprise both known and potential therapeutic compounds. A test
compound can be determined to be therapeutic by screening using the
screening methods of the present invention. In some embodiments of
the present invention, test compounds include antisense
compounds.
[0152] As used herein, the term "sample" includes a specimen or
culture obtained from any source, as well as biological and
environmental samples. Biological samples can be obtained from
animals (including humans) and encompass fluids, solids, tissues,
and gases. Biological samples include blood products, such as
plasma, serum and the like. Environmental samples include
environmental material such as surface matter, soil, water,
crystals and industrial samples. Such examples are not however to
be construed as limiting the sample types applicable to the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0153] The present invention provides compositions and methods for
treating, characterizing, and diagnosing cancer. In particular, the
present invention provides gene expression profiles associated with
solid tumor stem cells, as well as novel markers useful for the
diagnosis, characterization, and treatment of solid tumor stem
cells.
I. Stem Cells and Solid Tumor Stem Cells
[0154] Common cancers arise in tissues that contain a large
sub-population of proliferating cells that are responsible for
replenishing the short-lived mature cells. In such organs, cell
maturation is arranged in a hierarchy in which a rare population of
stem cells give rise to the mature cells and perpetuate themselves
through a process called self renewal (Akashi & Weissman,
Developmental Biology of Hematopoiesis, Oxford Univ. Press, NY,
2001; Spangrude et al., 1988, Science 241:58-61; Baum et al., 1992,
PNAS 89:2804-8; Morrison et al., 1995, PNAS 92:10302-6; Morrison et
al., 1996, Immunity 5:207-16; Morrison et al., 1995, Annu. Rev.
Cell Dev. Biol. 11:35-71; Morrison et al., 1997, Dev. 124:1929-39;
Morrison & Weissman, 1994, Immunity 1:661; Morrison et al.,
1997, Cell 88:287-98; Uchida et al., 2000, PNAS 97:14720-5;
Morrison et al., 2000, Cell 101:499-510). Due to their rarity, stem
cells should be isolated in order to study their biological,
molecular, and biochemical properties. Although it is likely that
they give rise to most tissues, stem cells have been rigorously
identified and purified in only a few tissues. The stem cells that
give rise to the lympho-hematopoietic system, called hematopoietic
stem cells (HSCs), have been isolated from mice and humans and are
the best characterized stem cells. The utility of tissue containing
HSCs has been demonstrated in cancer therapy with their extensive
use for bone marrow transplantation to regenerate the
hematolymphoid system following myeloablative protocols (Baum et
al., Bone Marrow Transplantation, Blackwell Scientific
Publications, Boston, 1994). The prospective isolation of HSCs from
patients can result in a population that is cancer free for
autologous transplantation (Tricot et al., 1998, Blood 91:4489-95;
Negrin et al., 2000, Biol Blood Marrow Transplantation 6:262-5;
Michallet et al., 2000, Exp. Hematol. 28:858-70; Veona et al.,
2002, Br. J. Haematol. 117:642-5; Barbui et al., 2002, Br. J.
Haemat. 116:202-10).
[0155] Understanding the cellular biology of the tissues in which
cancers arise, and specifically of the stem cells residing in those
tissues, provides new insights into cancer biology. Several aspects
of stem cell biology are relevant to cancer. First, both normal
stem cells and cancer stem cells undergo self-renewal, and emerging
evidence suggests that similar molecular mechanisms regulate
self-renewal in normal stem cells and their malignant counterparts.
Next, it is quite likely that mutations that lead to cancer
accumulate in normal stem cells. Finally, it is likely that tumors
contain a "cancer stem cell" population with indefinite
proliferative potential that drives the growth and metastasis of
tumors (Southam & Brunschwig, 1961, Cancer 14:971-78; Bruce
& Gaag, 1963, Nature 199:79-80; Wodinsky et al., 1967, Cancer
Chemother. Rep. 51:415-21; Bergsagel & Valeriote, 1968, Cancer
Res. 28:2187-96; Park et al., 1971, J. Natl. Cancer Inst.
46:411-22; Hamburger & Salmon, 1977, Science 197:461-3; Lagasse
& Weissman, 1994, J. Exp. Med. 179:1047-52; Reya et al., 2001,
Nature 414:105-11; Al-Hajj et al., 2002, PNAS100:3983).
[0156] HSCs are the most studied and best understood somatic stem
cell population (Akashi & Weissman, Developmental Biology of
Hematopoiesis, Oxford Univ. Press, NY, 2001). Hematopoiesis is a
tightly regulated process in which a pool of hematopoietic stem
cells eventually gives rise to the lymphohematopoietic system
consisting of the formed blood elements, e.g., red blood cells,
platelets, granulocytes, macrophages, and B- and T-lymphocytes.
These cells are important for oxygenation, prevention of bleeding,
immunity, and infections, respectively. In the adult, HSCs have two
fundamental properties. First, HSCs need to self-renew in order to
maintain the stem cell pool; the total number of HSCs is under
strict genetic regulation (Morrison et al., 2002, J. Immunol.
168:635-42). Second, they must undergo differentiation to maintain
a constant pool of mature cells in normal conditions, and to
produce increased numbers of a particular lineage in response to
stresses such as bleeding or infection.
[0157] In the hematopoietic system, multipotent cells constitute
0.05% of mouse bone marrow cells and are heterogeneous with respect
to their ability to self-renew. There are three different
populations of multipotent cells: long-term self-renewing HSCs,
short-term self-renewing HSCs, and multipotent progenitors without
detectable self-renewal potential (Morrison & Weissman, 1994,
Immunity 1:661; Christensen & Weissman, 2001, PNAS 98:14541-6).
These populations form a hierarchy in which the long-term HSCs give
rise to short-term HSCs, which in turn give rise to multipotent
progenitors (FIG. 1 in Morrison & Weissman, 1994, Immunity
1:661). As HSCs mature from the long-term self-renewing pool to
multipotent progenitors they become more mitotically active but
lose the ability to self-renew. Only long-term HSCs can give rise
to mature hematopoietic cells for the lifetime of the animal, while
short-term HSCs and multipotent progenitors reconstitute lethally
irradiated mice for less than eight weeks (Morrison & Weissman,
1994, Immunity 1:661).
[0158] Despite the fact that the phenotypic and functional
properties of mouse and human HSCs have been extensively
characterized (Baum et al., 1992, PNAS 89:2804-8), our
understanding of the fundamental stem cell property, self-renewal,
is minimal (Weissman, 2000, Science 287:1442; Osawa et al., 1996,
Science 273:242-5; Reya et al., 2001, Nature 414:105-11). In most
cases, HSCs differentiate when exposed to combinations of growth
factors that can induce extensive proliferation in long-term
cultures (Domen et al., 2000, J. Exp. Med. 192:1707-18). Although
recent progress has been made in identifying culture conditions
that maintain HSC activity in culture for a limited period of time
(for example see Miller & Eaves, 1997, PNAS 94:13648-53), it
has proven to be exceedingly difficult to identify tissue culture
conditions that promote a significant and prolonged expansion of
progenitors with transplantable HSC activity.
[0159] Maintenance of a tissue or a tumor is determined by a
balance of proliferation and cell death (Hanahan & Weinberg,
2000, Cell 100:57-70). In a normal tissue, stem cell numbers are
under tight genetic regulation resulting in maintenance a constant
number of stem cells in the organ (Phillips et al.,1992, PNAS
89:11607-11; Muller-Sieburg et al., 2000, Blood 95:2446-8; Morrison
et al., 2002, J. Immunol. 168:635-42). By contrast, cancer cells
have escaped this homeostatic regulation and the number of cells
within a tumor that have the ability to self renew is constantly
expanding, resulting in the inevitable growth of the tumor. As
would be expected, many of the mutations that drive tumor expansion
regulate either cell proliferation or survival. For example, the
prevention of apoptosis by enforced expression of the oncogene
Bcl-2 promotes the development of lymphoma and also results in
increased numbers of HSCs in vivo, suggesting that cell death plays
a role in regulating the homeostasis of HSCs (Domen et al., 1998,
Blood 91:2272-82; Domen et al., 2000, J. Exp. Med. 191:253-64). In
fact, the progression to experimental acute myelogenous leukemia in
mice requires at least 3, and likely 4 independent events to block
the several intrinsically triggered and extrinsically induce
programmed cell death pathways of myeloid cells (Traver et al.,
1998, Immunity 9:47-57). Proto-oncogenes such as c-myb and c-myc
that drive proliferation of tumor cells are also essential for HSCs
development (Prochowinki & Kukowska, 1986, Nature 322:848-50;
Clarke et al., 1988, Mol. Cellular Biol. 8:884-92; Mucenski et al.,
1991, Cell 65:677-89; Danish et al., 1992, Oncogene 7:901-7).
[0160] Since cancer cells and normal stem cells share the ability
to self-renew, it is not surprising that a number of genes
classically associated with cancer can also regulate normal stem
cell development (reviewed in Reya et al., 2001, Nature 414:105-11
and Taipale & Beachy, 2001, Nature 411:349-54). In combination
with other growth factors, Shh signaling has also been implicated
in the regulation of self-renewal by the finding that cells highly
enriched for human hematopoietic stem cells
(CD34.sup.+Lin.sup.-CD38.sup.-) exhibited increased self-renewal in
response to Shh stimulation in vitro (Bhardwaj et al., 2001, Nat.
Immunol. 2:172-80). Several other genes related to oncogenesis have
been shown to be important for stem cell function. For example,
mice deficient for tal-1/SCL, which is involved in some cases of
human acute leukemia, lack embryonic hematopoiesis (Shivdasani et
al., 1995, Nature 373:432-4) suggesting that it is required for
intrinsic or extrinsic events necessary to initiate hematopoiesis,
for maintenance of the earliest definitive blood cells, or for the
decision to form blood cells downstream of embryonic HSCs
(Shivdasani et al., 1995, Nature 373:432-4; Porcher et al., 1996,
Cell 86:47-57). Members of the Hox family have also been implicated
in human leukemia. Enforced expression of HoxB4 can affect stem
cell functions (Buske et al., 2002, Blood 100:862-681; Antonchuk
& Humphries, 2002, Cell 109:39-45). One of the major targets of
the p53 tumor suppressor gene is p21.sup.cip1. Bone marrow from
p21.sup.cip1 deficient mice has a reduced ability to serially
reconstitute lethally irradiated recipients. Failure at serial
transfer could result from exhaustion of the stem cell pool, loss
of telomeres, or loss of transplantability (Cheng et al., 2000,
Science 287:1804-8). In mice, bmi-1, a gene that cooperates with
c-myc to induce lymphoma (van Lohuizen et al.,1991, Nature
353:353-55; van der Lugt et al., 1994, Genes & Dev. 8:757-69),
is required for the maintenance of adult HSCs and leukemia cells.
Thus, many genes involved in stem cell fate decisions are also
involved in malignant transformation.
[0161] Two other signaling pathways implicated in oncogenesis in
both mice and humans, the Wnt/.beta.-catenin and Notch pathways,
can play central roles in the self-renewal of both normal and
cancer stem cells. The Notch family of receptors was first
identified in Drosophila and has been implicated in development and
differentiation (Artavanis-Tsakonas et al.,1999, Science
284:770-6). In C. elegans, Notch plays a role in germ cell
self-renewal (Berry et al., 1997, Dev 124:925-36). In neural
development transient Notch activation initiates an irreversible
switch from neurogenesis to gliogenesis by embryonic neural crest
stem cells (Morrison et al., 2000, Cell 101:499-510). Notch
activation of HSCs in culture using either of the Notch ligands
Jagged-1 or Delta transiently increased primitive progenitor
activity that could be observed in vitro and in vivo, suggesting
that Notch activation promotes either the maintenance of progenitor
cell multipotentiality or HSC self-renewal (Shelly et al., 1999, J.
Cell Biochem. 73:164-75; Varnum-Finney et al., Nat. Med.
6:1278-81). While the Notch pathway plays a central role in
development and the mouse int-3 oncogene is a truncated Notch4
(Gallahan & Callahan, 1997, Oncogene 14:1883-90), the role for
Notch in de novo human cancer is complex and less well understood.
Various members of the Notch signaling pathway are expressed in
cancers of epithelial origin and activation by Notch by chromosomal
translocation is involved in some cases of leukemia (Ellisen et
al., 1991, Cell 66:649-61; Zagouras et al., 1995, PNAS 92:6414; Liu
et al., 1996, Genomics 31:58-64; Capobianco et al., 1997, Mol. Cell
Biol. 17:6265-73; Leethanakul et al., 2000, Oncogene 19:3220-4).
Microarray analysis has shown that members of the Notch pathway are
often over-expressed by tumor cells (Liu et al., 1996, Genomics
31:58-64; Leethanakul et al., 2000, Oncogene 19:3220-4). A
truncated Notch4 mRNA is expressed by some breast cancer cell lines
(Imatani & Callahan, 2000, Oncogene 19:223-31). Overexpression
of Notch1 leads to growth arrest of a small cell lung cancer cell
line, while inhibition of Notch1 signals can induce leukemia cell
lines to undergo apoptosis (Shelly et al., 1999, J. Cell Biol.
73:164-75; Artavanis-Tsakonas, 1999, Science 284:770-6; Jehn et
al., 1999, J. Immunol. 162:635-8). Work by Miele and colleagues
showed that activation of Notch-1 signaling maintains the
neoplastic phenotype in Ras-transformed human cells (Weizen et al.,
2002, Nat. Med. 8:979-86). They also found that in de novo cancers,
cells with an activating Ras mutation also demonstrated increased
expression of Notch-1 and Notch-4.
[0162] Wnt/.beta.-catenin signaling also plays a pivotal role in
the self-renewal of normal stem cells and malignant transformation
(Cadigan et al., 1997, Genes & Dev. 11:3286-305; Austin et al.,
1997, Blood 89:3624-35; Spink et al., 2000, EMBO 19:2270-9). The
Wnt pathway was first implicated in MMTV-induced breast cancer
where in deregulated expression of Wnt-1 due to proviral insertion
resulted in mammary tumors (Tsukamoto et al., 1988, Cell 55:619-25;
Nusse et al., 1991, Cell 64:231). Subsequently, it has been shown
that Wnt proteins play a central role in pattern formation. Wnt-1
belongs to large family of highly hydrophobic secreted proteins
that function by binding to their cognate receptors, members of the
Frizzled and low-density lipoprotein receptor-related protein
families, resulting in activation of .beta.-catenin (Cadigan &
Nusse, 1997, Dev 11:3286-305; Leethanakul et al., 2000, Oncogene
19:3220-4; Reya et al., 2000, Immunity 13:15-24; Wu et al., 2000,
Dev. 127:2773-84; Taiple & Beachy, 2001, Nature 411:349-54). In
the absence of receptor activation, .beta.-catenin is marked for
degradation by a complex consisting of the Adenomatous Polyposis
Coli (APC), Axin and glycogen synthase kinase-3.beta. proteins
(Austin et al., 1997, Blood 89:3624-35; van den Berg et al., 1998,
Blood 92:3189-202; Gat et al., 1998, Cell 95:605-14; Chan et al.,
1999, Nat. Genet. 21:410-3; Hedgepeth et al., 1999, Mol Cell Biol.
19:7147-57; Spink et al., 2000, EMBO 19:2270-9; Leethanakul et al.,
2000, Oncogene 19:3220-4). Wnt proteins are expressed in the bone
marrow, and activation of Wnt/.beta.-catenin signaling by Wnt
proteins in vitro or by expression of a constitutively active
.beta.-catenin expands the pool of early progenitor cells and
enriched normal transplantable hematopoietic stem cells in tissue
culture and in vivo (Austin et al., 1997, Blood 89:3624-35; van den
Berg et al., 1998, Blood 92:3189-202; Reya et al., 2001, Nature
414:105-11). Inhibition of Wnt/.beta.-catenin by ectopic expression
of Axin, an inhibitor of .beta.-catenin signaling, leads to
inhibition of stem cell proliferation both in vitro and in vivo.
Other studies suggest that the Wnt/.beta.-catenin pathway mediates
stem or progenitor cell self-renewal in other tissues (Gat et al.,
1998, Cell 95:605-14; Korinek et al., 1998, Nat. Genet. 19:379-83;
Zhu & Watt, 1999, Dev. 126:2285-98; Chan et al., 1999, Nat.
Genet. 21:410-3). Higher levels of .beta.-catenin are seen in
keratinocytes with higher proliferative potential than those seen
in keratinocytes with lower proliferative capacity (Gat et al.,
1998, Cell 95:605-14; Chan et al., 1999, Nat. Genet. 21:410-3; Zhu
& Watt, 1999, Dev. 126:2285-98). Like their normal
hematopoietic stem cell counterparts, enforced expression of an
activated .beta.-catenin increased the ability of epidermal stem
cells to self renew and decreased their ability to differentiate.
Mice that fail to express TCF-4, one of the transcription factors
that is activated when bound to .beta.-catenin, soon exhaust their
undifferentiated crypt epithelial progenitor cells, further
suggesting that Wnt signaling is involved in the self renewal of
epithelial stem cells (Korinek et al., 1998, Nat. Genet. 19:379-83;
Taipale & Beachy, 2001, Nature 411:349-54).
[0163] Activation of .beta.-catenin in colon cancer by inactivation
of the protein degradation pathway, most frequently by mutation of
APC, is common (Hedgepeth et al., 1999, Mol. Cell. Biol.
19:7147-57; Leethanakul et al., 2000, Oncogene 19:3220-4; Spink et
al., 2000, EMBO 19:2270-9; Taipale & Beachy, 2001, Nature
411:349-54). Expression of certain Wnt genes is elevated in some
other epithelial cancers suggesting that activation of
.beta.-catenin is secondary to ligand activation in such cancers
(Nusse, 1992, J. Steroid Biochem. Mol Biol. 43:9-12; Cadigan &
Nusse, 1997, Genes & Dev. 11:3286-305; Kirkoshi et al., 2001,
Int. J. Oncol. 19:997-1001; van de Wetering et al., 2002, Cell
111:241-50; Weeraratna et al., 2002, Cancer Cell 1:279-88; Saitoh
et al., 2002, Int. J. Oncology 20:343-8; Saitoh et al., 2002, Int.
J. Mol. Med.9:515-9). There is evidence that constitutive
activation of the Wnt/.beta.-catenin pathway can confer a
stem/progenitor cell phenotype to cancer cells. Inhibition of
.beta.-catenin/TCF-4 in a colon cancer cell line induced the
expression of the cell cycle inhibitor p21.sup.cip-1 and induced
the cells to stop proliferating and to acquire a more
differentiated phenotype (van de Wetering et al., 2002, Cell
111:241-50). Enforced expression of the proto-oncogene c-myc, which
is transcriptionally activated by .beta.-catenin/TCF-4, inhibited
the expression of p21.sup.cip-1 and allowed the colon cancer cells
to proliferate when .beta.-catenin/TCF-4 signaling was blocked,
linking Wnt signaling to c-myc in the regulation of cell
proliferation and differentiation. Although many studies have
implicated the Wnt/.beta.-catenin pathway in breast cancer,
activating mutations of .beta.-catenin are rare in this disease and
no studies have definitively linked this pathway to human breast
cancer (Candidus et al., 1996, Cancer Res. 56:49-52; Sorlie et al.,
1998, Hum. Mutat. 12:215; Jonsson et al., 2000, Eur. J. Cancer
36:242-8; Schlosshauer et al., 2000, Cancinogenesis 21:1453-6; Lin
et al., 2000, PNAS 97:4262-6; Wong et al., 2002, J. Pathol.
196:145-53).
[0164] The implication of roles for genes like Notch, Wnt, c-myc
and Shh in the regulation of self-renewal of HSCs and perhaps of
stem cells from multiple tissues suggests that there can be common
self-renewal pathways in many types of normal somatic stem cells
and cancer stem cells. It is important to identify the molecular
mechanisms by which these pathways work and to determine whether
the pathways interact to regulate the self-renewal of normal stem
cells and cancer cells.
[0165] The Wnt pathway is involved in the self-renewal of normal
stem cells and activating mutations of Wnt induce breast cancer in
mice. This pathway plays a role in tumor formation by human breast
cancer stem cells isolated from some patients. Furthermore,
evidence suggests that the ability of different populations of
breast cancer cells to form tumors differs. Interestingly, the
expression of members of the Wnt/Frizzled/.beta.-catenin pathway
are heterogeneously expressed by different populations of cancer
cells and expression of particular members of the pathway can
correlate with the capacity to form tumors.
[0166] The different populations of cancer cells and tumor cells
drive the proliferation of breast cancer cells. Activated
.beta.-catenin is seen in the cancer cells in a significant number
of patients. The tumors that contain cancer cells with this pathway
constitutively active behave differently than those without
constitutively activated .beta.-catenin.
II. Xenograft Model of Human Breast Cancer
[0167] Although cell lines have led to remarkable advances in our
understanding of the molecular and biochemical changes in cancer
cells, their use in the identification of effective cancer
therapies is somewhat limited. Cell lines are imperfect predictors
of drug efficacy in de novo tumors (Brown, 1997, Oncol. Res.
9:213-5; Hoffman, 1999, Invest. New Drugs 17:343-359). Several
factors likely account for this deficiency. Cancer cell lines are
selected from a sub-population of cancer cells that are
specifically adapted to growth in tissue culture and the biological
and functional properties of these cell lines can change
dramatically (Leglise et al., 1988, Blood Cells 13:319-37; Ikeda et
al., 1993, Exp. Hematol. 21:1686-94; Weidmann et al., 1997,
Leukemia 11:709-13; Dorrell et al., 2000, Blood 95:102-10).
Furthermore, cancer cells from only a minority of breast cancer
tumors establish cell lines or xenograft tumors (Ethier et al.,
1993, Cancer Res. 53:627-35; Krasna et al., 2002, Breast Cancer Res
Treat. 71:219-35). The phenotypic and functional characteristics of
these cell lines can change drastically relative to their
properties in vivo (Leglise et al., 1988, Blood Cells 13:319-37).
For example, the marker expression of both normal hematopoietic and
leukemic tissue culture cells can change rapidly in tissue culture
and often does not reflect that of the original stem cells from
which they were derived (Furley et al., 1986, Blood 68:1101-7;
Leglise et al., 1988, Blood Cells 13:319-37; Ikeda et al., 1993,
Exp. Hematol. 21:1686-94; Dorrell et al., 2000, Blood 95:102-10).
Even when conditions are devised to permit the proliferation of
normal stem cells in culture, the conditions often promote
self-renewal or differentiation in a way that prevents the stem
cells in culture from recapitulating the hierarchy of cell
populations that exist in vivo. Taken together, these observations
suggest that the biological properties of cancer cell lines can
differ markedly from the cancer cells from which they were derived.
This likely explains at least in part why the cell lines often are
poor predictors of a drug's efficacy in the clinic.
[0168] Thus, the lack of an effective method to consistently grow
primary human breast cancer cells in vitro or in vivo for long
periods of time has severely limited our ability to understand the
biology of this disease. The most efficient xenograft models report
the engraftment of pieces of breast cancer tumors in the ovarian,
but not mammary, fat pad of SCID mice approximately 60-75% of the
time (Sakakibara et al., 1996, Cancer J. Si Am.2:291-300).
Engraftment of dissociated cells is not possible in this model, and
cancer cells isolated from pleural effusions only form tumors in
immunodeficient mice approximately 10% of the time (Hoffman, 1999,
Invest. New Drugs 17:343-59). The present invention (see Example 1
below) provides a xenograft model in which one is able to establish
tumors from primary breast tumors via injection of tumors in the
mammary gland of severely immunodeficient mice. The xenograft of
the present invention allows one to do biological and molecular
tests to characterize the clonogenic breast cancer cell as well as
other cell types. Importantly, the xenograft tumors developed in
accordance with the present invention contain the phenotypically
diverse cancer cell types found in the human tumors from which they
were derived and the different populations of cancer cells differ
markedly in their ability to form tumors (Al-Hajj et al., 2003,
PNAS 100:3983).
[0169] The development of an efficient xenograft model in
accordance with the present invention (see e.g., Example 1), has
for the first time reliably allows dissociated solid tumor cells
obtained from a patient to form tumors. Importantly, this enables
one to routinely analyze biochemical pathways in an individual
patient's cancer cells and to do molecular manipulations that allow
one to understand the cellular consequences of specific genetic
pathways on tumor formation by de novo human solid tumor cancer
cells.
III. Solid Tumor Stem Cells Cancer Markers
[0170] The present invention provides markers whose expression is
specifically altered in solid tumor stem cells (e.g. up regulated
or down regulated). Such markers find use in the diagnosis and
characterization and alteration (e.g., therapeutic targeting) of
various cancers (e.g. breast cancer).
[0171] Example 4, provided below, describes methods used to
identify solid tumor cancer markers. Some cancer markers are
provided below in Tables 4-9, as well as Notch4. While these tables
provide gene names, it is noted that the present invention
contemplates the use of both the nucleic acid sequences as well as
the peptides encoded thereby, as well as fragments of the nucleic
acid and peptides, in the therapeutic and diagnostic methods and
compositions of the present invention. TABLE-US-00001 TABLE 4 Up
Regulated in UPTG versus UPNTG S100A8, KRT18, CEACAM6, IFITM2,
HLA-C, S100P, S100A9, H2BFT, HLA-C, FXYD3, S100A10, KRT19, TUBB,
HLA- DPA1, CEACAM5, LCN2, FTH1, RPS26, IFITM2, S100A7, CAP,
HUMMHCW1A, HLA-DRB3, CD63, S100A6, HSPB1, HLA-B, MGLL, PTS, HLA-A,
RAI3, DAF, UBC, HLA-A, KDELR3, SERF2, CTSB, CEACAM6, PDLIM1, SHC1,
GOLPH2, GABARAP, AQP3, COL3A1, AHCYL1, FXYD3, ITM2B, BF, RBMS1,
DUSP1, PSAP, ARHGDIB, ENO1, ATP6V0E, MUC1, RARRES1, CD81, TRIM44,
ASS, CD59, PRG1, HLA-E, TXNIP, INHBA, CSTB, H2AFO, HLA-DRB4, RAB31,
P4HB, LOC92689, B2M, CSNK2B, MGST3, DKFZp564I1922, C4B, UCP2, FN1,
COL1A2, LOC51186, LTF, TIMP1, NPC2, TSPAN-1, COL1A2, SLPI, CIB1,
IQGAP1, SPARC, FN1, CCNI, SPTBN1, H2AFO, BTN3A3, FN1, SEPX1, GFPT1,
ANXA11, CD74, RAB25, APP, PSEN1, IFI27, FHL2, CPB1, BACE2, PSMD8,
LGALS1, PLAT, EIF3S4, ANXA2P2, PILB, IFI30, ATP6V0E, LOH11CR2A,
LBP, HLA-DRB1, MIC2, OPN3, SVIL, FDFT1, PTGIS, ORMDL2, PIG7, ERBB3,
GSN, FN1, GOT2, BCL6, WBSCR21, ANXA1, CLU, PIK3R3, TNFSF10, NBL1,
PEX11B, CDKN1A, SAS, RIC-8, RABAC1, ADD3, ARPC5, GUK1, NQO1,
FER1L3, PPAP2A, TSPAN-3, PLOD2, TGM2, LOC51760, TST, TM9SF1,
LGALS3BP, C14orf1, D2S448, OPTN, GPX1, MBC2, PTGES, DPYSL2, PEN-2,
DAG1, GM2A, DKFZP564G2022, FAT, SLC21A11, ACADVL, ABLIM1, HLA-DPB1,
COPA, PPP1R7, DAF, SSBP2, TES, MUC16, PPL, MGC10765, SECTM1, C3,
NNMT, ARF3, SEPW1, H1F2, SERPINB1, KIAA0746, RDGBB, ELF3, TUBB4,
VCAM1, FOXO1A, EGFL6, ATP1A1, PLS3, LMNA, TGFBI, DD96, GLRX, PROSC,
IL1R1, SERPINB2, KRT7, RGS16, TNFAIP1, SYNGR2, PAFAH1B3, GPI,
C6orf37, ATF3, HLA-DMA, FLJ22418, DCN, FOXO3A, HLA-DQB1, CPD, DF,
HTATIP2, MUC5B, CTSB, PBEF, H11, CAPNS1, Z39IG, MAGED2, TNFSF13,
HLA-DRB3, H2BFQ, SGK, P4HA2, VPS28, NDUFB8, PON3, ENSA, EDF1,
SERPINB6, FDPS, RGS3, CREB3, PRNP, YWHAB, A2M, HLA-DQB1, PDGFRA,
CLMN, INHBB, SURF1, NFIL3, S100A11, HPGD, CLDN7, DAB2, NT5C2,
PLXNB2, GSTP1, AP2B1, COL3A1, HRMT1L1, SRPR, RNASE6PL, ANXA8,
PROML1, C1S, GALNT6, BAT3, BC- 2, GLS, CD14, FYCO1, SQSTM1, CSPG2,
DEFB1, BAT3, GALNT2, SPARC, WT1, DUSP6, MONDOA, MACF1, ATP2C1,
THBS2, CD53, PGM3, HLA-DRB6, COL1A1, SCAP2, KIAA0436, CYR61,
TNFSF13, SLC6A14, CUGBP2, LAMP1, CCL22, CLU, CD163, ANXA3, MBLL39,
IL4R, SERPINB1, CNP, TUBB4, FLJ20265, MAFB, EFEMP1, DPP7, SYNE-2,
PLSCR1, PDE4DIP, P2Y5, RAGA, SIAT1, N4WBP5, SPUVE, BPAG1, DEPP,
BASP1, CTSB, HLA-E, KIAA0308, GAS1, ABR, ABCA1, GRN, WDR1, PM5,
CYFIP2, SGP28, FLRT2, ACACA, LUM, FLJ21432, FEM1C, RIN2, PCDH7,
SLC7A7, FLJ21347, SOX9, MB, S100A8, DAP, MVP, SPP1, TM9SF1, DOC1,
COL5A2, RNF24, GLB1, GRN, HLA-DRB5, ENPP2, CSGlcA-T, KIAA0937,
H2BFT, JUP, KYNU, APOL6, GM2A, C1orf24, SYNGR3, COL6A1, CRYM, LXN,
FARP1, p100, ANK1, NPC1, RBPMS, VLDLR, ARHC, UBE1, HDLBP, LYZ, DCN,
PLAB, SERPINE2, EGLN3, FSTL1, LAPTM5, TRIM29, ACTN4, MUC1, SH3GLB1,
BIK, ZNF91, CLIC4, NARF, LIM, SLC1A1, KIAA0746, APOC1, TYROBP,
FLNB, EMP1, UBE2L6, KRT6B, MAN2A1, GCN5L1, APEH, F-LAN-1, PRKCZ,
CD163, HLA-DQA1, KIAA1668, MUC5B, LAIR1, BCL2L13, CXX1, MPZL1,
NR3C1, AHR, FLJ12389, ATP6V0C, MD-1, H2BFA, HSPC023, OSBPL8, ZNF36,
TRIM14, UGTREL1, CTSL, COL5A1, PDGFC, UBE2N, SF1, ARHGEF10,
SH3GLB1, HLA-G, KIAA0084, HT012, SULF1, TTC1, UBAP1, PGLS, M6PR,
TEM7, NPR2L, GRN, EXT2, DCN, HLA-DMB, HLA-DQB1, NAGK, MMP19, LBP,
ATP10B, CLN3, SP100, CSPG2, VIM, IGFBP3, ANK1, DUSP3, STAT3, CED-6,
KIAA0196, SOX9, NKX3-1, TGFBR2, CAV1, TREM1, PTD009, GPX2, LAPTM5,
HSPC022, SSA1, ABS, CPD, DXS9928E, DUSP6, PGBD5, CNN3, PIP5K1B,
FLJ13840, CLDN4, ABCA3, BPAG1, CAPZB, PPIB, ACTA2, CDH11, FLJ10815,
HLA-DPA1, FLJ20539, MUC4, CAV2, ACAA2, CEACAM1, GALNT10, MYO10,
C9orf9, PAM, C6orf29, MGC: 5244, RetSDR2, ATP2B4, DHCR7, GP, LOXL2,
MIR, DCTD, BCKDK, RTP801, KIF1B, ENTPD3, PAFAH1B1, LGMN, UBE2L3,
PTPRH, RPS6KA2, ALDH1A2, FHL1, GALT, AP1M2, MAF, C4BPA, POLR2J,
KIAA0790, TM4SF3, HPGD, THY1, NCALD, PADI2, KIAA0557, SMARCA1,
CD83, AZGP1, SMARCA1, MRPS11, RAGD, PIGB, FYN, TM7SF1, HLA-E, BRE,
PLA2G4C, NOS1, ID3, HLA-DQB1, SSSCA1, PPP1R14B, HLA- DPA1, ANK1,
PRKCH, CALU, PEF, DOK5, COL9A2, ATP2C1, DPH2L1, MUC5B, LOC113146,
NDN, PIG3, HLA-DRA, GPS2, CX3CL1, C1QB, TGFBR3, APOC1, BIN1, CBR3,
TGIF, EFEMP2, SCDGF-B, TUBB-5, MAP4K4, CCL3, CCR1, RNF10, RGL,
CD1C, FBLN1, GW112, ALTE, ALP, PLAC1, ISG20, PTE1, NPD009,
LOC55893, AP3B1, PRKAR2B, KRT9, COPZ2, LYN, FLJ21478, DKFZP566C243,
NUMA1, ANAPC5, FLJ10134, ADPRTL1, ITGAM, PIP, FLJ22559, IFI16,
TMPRSS4, HAIK1, PCSK7, ANK1, FCER1G, IMPA2, HLA-DQA1, IFNAR2, NEO1,
PRKCQ, SMARCD3, CECR1, FLJ11286, TBC1D1, MS4A6A, C1orf16, LRRN1,
MRPL23, PUM1, SMA3, PDE4B, SLC22A4, MMP2, ICA1, SLC22A1L, RRP22,
GBA, TMEM8, DUSP2, TREX1, SLC6A8, C3AR1, BSCL2, ARFGAP3, TRIM2,
SERPINB8, TNFRSF6, LDB1, CCND2, RGS2, MEIS1, HRIHFB2122, IF,
P1P373C6, UPK1B, WDR10, CGI-49, PSMB8, RARRES1, SLC16A1, DPYD,
DNPEP, FLJ20254, COL5A1, FLJ11017, CCR5, MX2, PIAS1, CAPG,
CDC42EP3, IL1RL1LG, SCGB2A1, RNH, INPP4B, B3GALT4, PLAU, DFNA5,
KIAA0852, CRIP2, TIP-1, ZNF142, HSD17B2, MYO1B, PCOLCE, FLJ22169,
APOE, DAB2, CXCR4, NAG, SNCAIP, GBP1, ASRGL1, SLC6A8, REC8,
SLC7A11, CPE, MPZL1, TDO2, GALNT12, CDKN2A, KIAA1395, LGALS8, FLNC,
NPR2L, GRB10, MGC15523, PTPRC, CAPN9, IFI16, NBL1, CRYL1, PSMC2,
IGF1, BIN1, HNOEL-iso, DKFZp566O084, FGB, GPNMB, TLR5, FLJ20686,
UROS, CX3CR1, HCA112, PRKCB1, BDKRB2, CLTB, KIAA0652, KIAA1668,
DCN, HLA-DQB1, C6orf9, CPR8, TIMP2, PSMB10, LTBP2, FLJ20452,
HTATIP, LAMA4, GLUL, SH3BP2, HES2, KIAA1115, KDR, PROCR, TNFSF10,
FGFR1, ELF4, F8A, BAG1, COL5A1, THY1, H2BFG, TOSO, KRT15, AIF1,
LY75, KRT17, CEACAM1, GAK, AGTR1, ASB8, KIAA0792, CDKN1C, C1R,
PTGS1, TM4SF6, XT3, HLA-B, DKFZP434B044, ALDH1A3, NID2, U2AF1RS2,
H2BFL, FUT3, PVALB, ITPR3, PODXL, QPRT, PTRF, PSMC4, ACATE2,
MAP2K3, ATP2B4, CEACAM1, CALB2, TTR, TRIM38, JM5, FLJ21135,
FLJ23221, FLJ20452, GATA6, RABL4, KIAA1199, IGFBP7, MGC14376,
CITED2, CASP4, MEIS2, PHLDA1, OXA1L, IL1RL1, FLII, EFEMP1, PYGL,
LMO4, GPR3, G1P3, APOE, ZNF193, AP1S2, PTGDS, TEM7, LOC51279, SLA,
BTG1, INE2, WIT-1, LBH, CXCL1, RAB31, POMZP3, COL6A3, EXTL3,
MGC4309, LOC114990, KYNU, NAB1, CYP2J2, SMURF1, BRAF, HLA-DQA1,
CAV1, KIAA0779, CHKL, SEC6, CG1I, FLJ20920, CGI-49, EIF3S10, P4HB,
GYG, DYRK2, DKK1, MAF, TRIM22, CENTA2, FLJ20113, NR3C1, CYP1B1,
HSD11B2, RRP46, FOLR1, HHLA1, THY28, H3FB, FOS, GAA, FLJ13171,
RHOBTB3, ZNF32, HOXA5, CFLAR, PAX6, KIAA0076, CTSS, ALOX15B,
PCOLN3, P3, AKR1B1, LOXL1, H1F3, BIN1, GMDS, FLJ10631, SIAT4A,
PIM1, LRMP, SLI, TFPT, RAGD, DSCR1L1, SETMAR, KIAA0657, GPRC5B,
TIMM22, ARHGEF6, H2BFA, PPFIBP2, SALL2, FLJ21820, ABCD1, CPA3,
SNX7, CUTL1, PALMD, ERCC1, MSTP9, PTPN3, GAL3ST-4, C6orf9, PTPRT,
RGC32, AD-017, CRELD1, FLJ10097, RNASE1, S100A4, RORC, CMAR, USF2,
FLJ13544, CASP3, SMUG1, RAF1, MYL9, GFR, PDGFRA, DPP4, ARL7,
SLC3A2, RHD, FGL2, RBMS1, EGFR, PRO1580, FCGR3A, PTENP1, H4FH,
MSCP, CSGlcA-T, ADAMTS5, TNFAIP6, PRKCDBP, PRKG1, CAPN1, OAS1,
H2BFH, SCHIP1, FLJ21736, BMP1, IQGAP2, KRT5, LMO2, HIC, PLAGL1,
AQP6, ZNF42, PHLDA1, YBX2, INPP1, CHST6, MGC4171, PL6, SPPL2B,
EPHA2, CRYAB, MST1, ZNF211, MD-2, CRI1, KIAA0057, PACE4, LOC93349,
RALGPS1A, LAMB3, HLX1, RIN3, SERPINB5, PLD1, DLC1, PIPOX, PTHR2,
UBE2G2, CHI3L2, KIAA1111, TGFB2, PLAUR, ID1, ALOX5, IGF1, REPS2,
CDH2, BCHE, SNFT, FLJ11286, MAPRE2, MAOA, SERPING1, PTGER3,
KIAA0602, PGM3, MATN2, DNASE1L1, PGD, FZD2, PPAP2C, GOLGA1, ADAT1,
TEX13B, MGP, FLJ20084, ART1, EVI2A, SART2, RFXANK, FBLN5, DPYSL3,
ZNF187, RBMS1, MLN, NRXN3, WASF3, DSC3, PPAP2A, EEF1A2, UBE2H,
GABRQ, TFEB, MGC3123, GFPT2, WIG1, FBLN1, PTPRF, MEPE, SLC6A8,
IL1B, GAC1, EPHX1, C11orf9, OSF-2, FLJ10111, SRPX, DAPK1, RBM10,
MBD4, MECP2, ILVBL, KIAA0375, JAM3, PRSS25, KIAA0913, TNFRSF6,
CSRP2, CCL4, C20orf19, CA2, SLC7A8, BNC, PHEMX, ADAMTS1, XRCC1,
PEMT, H2AFA, NEU1, OPTN, NRP1, TPM1, WISP3, GPX6, MRPL2, HP, BIKE,
PLXN3, FACL5, MGC15419, FLJ11506, GLS, MAPK7, KIAA1053, CDH3, CST3,
KIAA0752, ROR1, TAP2, SBLF, AKAP13, USP21, PP35, ELOVL1, CYBA,
KHSRP, MRC1, FLJ12057, H2AFN, MSN, TPM1, SLC16A3, ADD1, IL1RAPL1,
SPTAN1, FLJ10847, SNAI2, FLJ12986, GSPT2, FLJ10450, MAN1C1, MEF2A,
VEGFC, RANBP3, MGC17330, SCD, F5, PIK3CD, SELPLG, LOX, VAX2, MSF,
RANGAP1, BIKE, ARHGEF7, FLJ20300, MYLK, GMPR2, CENTD2, PPP1R9A,
ANG, DNAJB2, IDH3G, ODAG, ADPRTL3, COG7, KIAA0429, NEDD4L, ALEX2,
ATP6IP2, PTGES, MAN1B1, CYP3A43, AP3S2, DEFA6, PTGER3, FCGBP,
CPSF1, NNMT, HAMP, CGI-38, BAZ2A, HLA- DRA, SP110, CA5B, UBE1L,
BTN3A2, KIAA0842, T1A-2, PTGER4, PTGDS, MARCO, EPB41L1, IL13RA2,
CXCL6, APOA1, NPAS2, ETV5, HFL3, EPB41L3, CHI3L1, SSB1, EVI2B,
KIAA1608, MEIS3, FLJ13385, NQO1, BGN, MOX2, dJ222E13.1, GMFG,
TBC1D2, SKIP, RABGGTA, MRPL28, FLJ21034, CRY2, SLC4A2, MGC20727,
HAP1, CYBB, GRIT, PTN, FUT2, CDSN, STAF65(gamma), BENE, ENPP2,
PAK4, CUBN, ICSBP1, NPAS2, FLJ23516, FLJ23537, AADAC, MFAP2, ERCC4,
STK13, MCAM, GPR65, CYP17, FLJ20373, TNS, TRA1, NPY, PTPLA,
PNLIPRP1, RBMS1, TM7SF2, MKL1, NCF2, AP4M1, ITGB4, SLC11A1, PSCDBP,
NFE2L3, ELAC2, CBFA2T1, S100A12, PACE4, KIAA1395, HLA-G, EDN1,
FLJ20730, IGLJ3, UNC93B1, RPL29, RIL, TCF8, RYR3, TCFL4, MCRS1,
HML2, FLJ10357, FLJ22405, FLJ20627, HFE, DKFZp564K142, ATP10D,
SLC12A4, P311, FLJ13055, ADCY9, EYA1, ACO2, CIAS1, EHD3, ZFPM2,
MGC11279, MALT1, NDUFS8, IL10RB, TCF3, HLALS, DKFZp761K1423, DDX8,
G0S2, SLC16A3, CCL18, ZDHHC4, FKBP1A, HRH1, GSA7, PTPRM, HBP17,
APPBP2, TNRC15, JM1, PSME3, HFL2, BCL11B, SCARA3, APEG1, LHFP,
IGF1, PDGFRL, MUC13, IGF1, NXF2, HRMT1L3, ARHD, KIAA0582, KIAA0977,
FCN1, LAMP3, DNAJC6, ALDH3B1, TNXB, MAPK3, FLJ13491, APOA1, RBP4,
OAS3, CLTB, GP2, MID1, FGR, DISC1, PP1044, PSAP, CHODL, FLJ22173,
TPD52L2, DD5, PSIP1, HSPB7, EMP3, KRT6A, C5R1, ENO2, PF4, SYN1,
PLSCR3, HMGCS2, BCAR3, LOC51693, ANGPTL2, TAHCCP1, LOC51063,
KIAA0561, GJB3, CPVL, PCBD, CGI-96, PKIA, NR3C1, GAS7, FBN1, MPV17,
SLC21A3, ARHGAP6, FMO1, CSPG2, FLJ22531, STX7, SCN1B, TETRAN,
FGF23, CLECSF12, CDKN1C, HF1, GSTT1, VILL, BLAME, ROD1, TAPBP- R,
HLA-G, HT017, CHP, SLC25A10, LST1, FLJ11196, VAMP2, NR0B2, CSNK2A1,
SLIT3, MAPK7, CXCL2, GYG2, PGS1, CDYL, VNN2, CLN5, NPAS2, MLL,
TRPM4, LYPLA3, MYO7A, PSMB1, PAFAH2, PITX1, GRB10, TIMELESS,
APOBEC3G, KIAA0819, GALNT10, PTPRO, NMB, FLJ12298, RAMP1, OR2F1,
HPGD, CALB1, CCR7, KIAA1614, SLC2A3, OLFM1, DKFZP564G202, FEZ1,
AKR1C3, ACADS, CALB1, PIK4CB, FOXA2, FLJ20581, RRAS, BHLHB3, HUNK,
MLLT3, RBMS2, KIAA0620, SLC29A2, SIRT5, SLC27A2, FLJ21458, DTR,
ACTN1, KIAA0429, SLC21A9, FLJ10211, LOC63920, FLJ12377, ARPC4,
TSSC4, MEF2D, RPL10, NOV, CGI-72, FAIM2, TBX2, GABRD, C1orf24,
MGC2615, NR1H3, FLJ14675, AQP5, ZNFN1A3, SSPN, SIGLEC7, COL5A2,
HLA-DOB, SLC12A3, Apg4B, HERC3, HEM1, EBI2, ZNF323, FLJ20950,
FASTK, C6orf32, LILRB2, SPP2, DHPS, UBE2B, MET, ST14, EGR3,
SIGLEC5, SAMHD1, PGCP, PTPNS1, SPARCL1, FLJ22160, RANBP2, IL15RA,
OXT, FLJ21168, PTPN14, BAIAP3, TPM4, NCR3, TEK, H2BFE, SLC34A2,
SLC26A2, KIAA0870, MET, SENP3, PTGER4, CGI-48, PDGFB, CD86, GTF2H4,
KIAA0053, PTX3, BIMLEC, CAMK4, PROS1, AOX1, KIAA0931, COL4A1, USF2,
PLINP-1, TM6SF1, PTPRG, SNX17, SLC5A4, MSTP032, PCTP, PQBP1, CDV-1,
AD037, RNASE6, SNAI1, KIAA0872, MEF2C, ZNF3, LOC157542, FCER1A,
PRB1, SIRT3, DKFZP434K046, ABCC6, NPC1L1, BCL2A1, LOC64167, GS3955,
UP, CLECSF6, MGC20727, CHN2, CD3D, BAD, KIAA0435, PECAM1, IGSF4,
BCAS3, C8A, ZNF131, MGC10771, SEC14L1, SERPINH1, IL1F6, KLK11,
THBD, FKSG28, KIAA0173, HKE2, PFTK1, FLJ11560, APOL1, CHRM4, ALLC,
MS4A4A, SLC1A1, BBP, ILT11, SAMSN1, IGF2R, FLJ20421, PBX2,
MAP1LC3B, 37872.00, NCK1, FGFR2, CD86, FLJ23506, SCD, FCGR2B,
CYP4A11, S100A2, AP2S1, PLAGL1, PTGIS, PCOLCE2, SLC2A3,
DKFZP761N09121, GPR105, OSBPL3, RPLP2, DKFZP586I2223, CD36, BBOX1,
VNN3, AKR1B10, ZFHX1B, DKFZp434H2215, RoXaN, RSN, GALNS, PROSC,
PCDHA3, PLXNA2, CCR8, BACH1, NPAT, SPAG6, DGCR13, CAPN5, OSBPL3,
CYP-M, FLJ13902, FLJ13659, ADAMTS3, IL1RAP, ELF1, HYAL1, WNT2, CCS,
TREM2, KIAA1036, FLJ20574, FLJ13215, CUGBP2, FLJ20010, GABRE, RCE1,
SCIN, HLALS, MGC10940, ADARB1, PLA2G7, KIAA1237, KIAA0889,
FLJ22593, CD244, NEK9, TAT, RAP1GDS1, SMA5, MYH11, APAA, MERTK,
GJA4, TNFRSF1B, MRPS12, HSF1, COL11A2, DAB2, PCQAP, WDR4, ABCA8,
CLPS, ARHN,
PHF3, AKAP12, LST1, MGC12904, FLJ11539, ZFP36L2, SERPINF1, MGAM,
PRG4, RAB5EP, CASP2, DIPA, AQP3, VAMP5, DXS1283E, COL4A2, MMP10,
CD97, MGAT3, FCN2, KIAA0475, FGF9, CTSZ, SQV7L, H326, PLD3, TRPC1,
OR7E24P, GRIA2, KIP2, BARX2, MHC2TA, RECQL, NUP214, DHRS2, P2RY1,
KIAA1155, HLA-DRB4, CAPN6, TLR7, AHCYL1, TRGC2, NEB, POU2F1, CPSF1,
APOB48R, CLDN9, FLJ21276, AEBP1, MN1, PKD2, PACRG, CALM1, TSPAN-3,
KIAA0233, ATP6V0E, TRIM34, DKFZP564J102, CNOT8, STC1, NFE2, FCN3,
CKIP-1, PLA2G4A, TRGC2, DES, CDC42EP2, HSD3B1, CSN10, PRKACB, RDH5,
CDW52, XYLT2, HPN, WIZ, GOLGA2, CSHL1, GLRX, PCDHB11, TNFSF18,
KLRD1, 384D8-2, WHSC1, TNFRSF10C, EVPL, TNFRSF5, SIAH2, GYPB, PMM1,
DPYSL3, FLJ14297, ZNF42, BSN, OMG, AXL, ACK1, PKD2, KIAA0711,
FLJ00060, GUCA1A, PAPPA, CBLN1, FRCP1, BTD, FLJ20591, FGG, CXCL14,
NPR1, CAMK2G, HLCS, SECP43, BCAT1, MSR1, IGFBP4, C13orf1, PRO2577,
KIR2DL4, BAALC, FLJ21919, CNTF, LOC51295, ENTPD1, TAPBP-R, CAP350,
PKD2L1, EVX1, NR1H2, FLJ13868, ERCC3, DKFZp434L0850, NR3C1, DMD,
BST1, CARD15, SKD3, CASP1, PCDHA6, NR4A1, HAS2, COPEB, R29124_1,
THPO, AQP6, MGC10848, RAB6B, ABP1, APOB, UTRN, MICA, SSTR4,
FLJ23056, C6orf32, ROM1, FLJ90005, KCNN4, MGA, HSPC219, CGEF2,
CDC42BPB, CCR4, GLS, MAGE-E1, PILR(ALPHA), PGK2, KIAA0657, SF3A2,
NOTCH4, CLECSF2, FBLN2, B4GALT1, WNT2B, NRBP, LTB, FLJ22021, CDH6,
TUBGCP2, GCN1L1, ZIC4, HR44, AGA, SIAT9, EMP1, EPOR, IGKC, TAHCCP1,
PECR, FLJ21477, EDG1, MS4A2, BCAS4, FLJ22404, DPYS, PRCC, POLD4,
BIKE, GAS7, KIAA1000, ZFP, WNT7B, MUC4, FLJ10477, CD1D, MGC4614,
CCR1, NEU3, SIX3, FLJ10640, GPR51, STOM, SERPINE1, HLA-DQB1, PTN,
DNCLI2, EN2, FLJ20378, IFP38, LOC90326, IGLJ3, NCYM, KIAA1107, GP2,
PLAUR, CD47, BIN1, MGC14799, IGFBP1, SSX1, IDUA, RECK, CD6, IGHM,
ADD2, AKAP2, HSF4, MDS032, FLJ20086, TNXB, IGFBP3, KLKB1, PRB4,
KCNF1, PDE9A, SIPA1, SMARCB1, COL4A6, PDE10A, NFATC1, CDH16,
COL6A1, ZNF272, LDB2, HCRTR2, B1, ATP12A, FLJ11710, LOC116150,
KIAA1049, HSPC157, FLJ20701, IGSF6, TOMM22, TGFB1, PTGER2, CHML,
FAAH, COL6A1, DGUOK, LRRN3, B7, KIAA0876, C1orf22, CYP2A13, CXCL5,
CD5L, FBXL6, GALNT2, GJA10, COL15A1, TEX13A, 7h3, TRD@, RIL, OTC,
SAST, KLF8, TUBA8, MGC45806, FLJ13479, GRP, LRP4, CD84, WBSCR14,
EPOR, BRAP, zizimin1, DNAJC4, FLJ20356, SERPINA2, FLJ10432, CD209L,
NRP1, PGDS, PLA2G2A, TNFRSF4, PRO2214, DNAJB6, RDHL, FOSL2, DEPP,
FLJ20241, MMP11, HLA-DQB1, RBM10, 8D6A, MAX, CUGBP2, CKTSF1B1,
ISL1, CREBBP, ACTA1, NUDT2, OR1A2, GPR86, SH3BP2, APAF1, PRO1386,
IGL@, EVI5, KIAA0443, MFNG, XCL1, ITM2A, IGLJ3, SIN3B, CCL18,
NRXN3, AQP7, HLF, SEC14L1, DNM1, KIAA0551, STK17B, GNS, IL10,
MGC20727, COL5A1, SEMA3B, C11ORF30, CASP10, ORM2, NPEPPS, CALCRL,
ALK, SH3BGRL3, FOXD1, MNDA, LCP2, ANK1, GSTA1, FLJ20856, ALOX15,
L1CAM, DRF1, TM4SF9, SLC24A1, NR4A1, ATP7A, PCLO, TSHR, CAMK1G,
MSR1, GLIPR1, KIAA1069, LYN, FLJ00001, MIG2, DLGAP2, TF, SOD2,
ELMO1, BMP2, SLC12A5, PSG11, EPB41L3, CAMK2B, TGM4, SCN11A, CALU,
F11, GPR75, KIAA1053, SIX1, WBSCR5, RIN3, CCNT2, CABIN1, NR2C2,
TRPM1, ABCD2, VDU1, FLJ20811, GJB3, ASAHL, RAB1A, HAND1, BAI2,
EDG8, TNFSF13, HPIP, PTPRN2, PRO0618, PRKCI, PSTPIP1, FACL4, ETV4,
CACNA1D, WISP1, PRLR, FEZ2, CCL25, PCNX, SNX10, LILRA2, KIAA1086,
MKRN3, PRG1, HGC6.1.1, GUCA1B, RIG, FLT1, HLA-C, KIAA0427, LILRB2,
MAP2K5, FLJ11125, EFNA5, DUOX1, LIG4, MRE11A, DEFB126, DNAJC9,
RQCD1, ABCB8, HPR, MRS3/4, KPI2, NR1I3, FBXW7, HS3ST3B1, LAD1,
SHMT1, CITED2, DNALI1, POLYDOM, PFKFB4, KIAA1029, UTY, SCAND2,
ZNF215, FOSL1, CDH17, PCSK5, ACE2, ERG, FLJ11619, KIAA1466,
KIAA0675, IL18, FLJ21562, BTN3A3, FACL6, FANCA, ANKRD6, CALCR,
CSF1, FLJ13262, CALR, TFEC, SSTR2, HBD, MGC10986, GTF3C2, HRC,
RHOK, KIAA1117, KIAA0924, ITGB1, DEFCAP, FLJ12525, TBXA2R, GLIPR1,
AVPR2, CCNE2, TBXAS1, RGS5, HAGE, FOXO3A, SYK, 384D8-2, ABO,
24432.00, MASS1, PF4V1, CASP5, CNGA1, FLJ14251, SLC9A3, UPK3B,
DLG1, COL17A1, PCDHB12, OSIL, HFE, KIAA0495, KCNJ15, KIAA0997,
RGS11, PITX3, FLJ13055, UBE2I, PRO2176, CACNB4, FOXH1, RASA2, PML,
BCAT1, EDG2, OCRL, ATPAF2, PMS2, POU2F3, PTPN21, SUPT6H, HAN11,
ROR1, COPEB, KIAA1654, DKFZP434B204, TNIP3, EPAG, CACNB2, NEK2,
XRCC4, IL6ST, TNRC11, CAPN11, 37870.00, PLA2G4B, NPEPL1, RASGRP1,
HABP4, CYLD, C15orf5, ITGB3, FLJ23093, NPPC, MCOLN1, GAD2, TRO,
LOC51063, OGN, NR1H4, MTRR, SS-56, NT5E, C22orf4, SLC4A5, SGCG,
C8orf1, LGALS2, ELK1, TRPM8, MGC2655, NR3C2, PPARG, MXD3, SERPINB3,
PRO0461, GNAI1, AVPR2, PEG10, SPINK1, CLDN1, STC1, KIAA1045, F2,
GNG11, FY, H4F2, D21S2056E, CAPZB, KIAA0599, C1orf29, RGS12, GCG,
NCOA2, FOXL2, UGT1A8, PKLR, NRG1, ITGA7, CNOT3, SPRY2, PIK3R1, ZF,
PTPRR, KSR, TCEB3L, IREB2, PRO0899, PAWR, SOX18, Gene Symbol,
RPL28, FLJ13352, C20orf114, PIGR, ERAP140, MYO5B, EGR1, LOC124220,
TCEB2, BACE2, NMES1, KIAA1324, MGC45416, WASF2, APOA1BP, FLJ32115,
ATP6V0E, TIMP2, H2AFJ, C9orf5, RASD1, KIAA1437, H2AFJ, RDH-E2,
DKFZp434G171, GUK1, FLJ20671, CAPNS1, KIAA1671, H19, FLJ23153,
NDUFB10, FLJ13593, GLTP, TLP19, ENPP5, MGC39329, MRPL41, ARF3,
LOC51255, HSPCA, BRI3, FLJ14525, LOC113246, RAP2B, FLJ14117,
GLCCI1, PPP3CA, PHP14, MIR, ADCY4, FLJ11320, MSTP028, Cab45,
TNFSF13B, ZNFN2A1, MGC14327, KIAA1404, RAB34, RBMS1, ARHU, SPUVE,
LOC54516, SAMHD1, LOC170394, SAMHD1, PIGR, CYP4X1, NFIA, KIAA1715,
CTHRC1, DKFZp547A023, KIAA1434, MYBBP1A, MGC4248, H4F2, H4FH,
NPD007, MGC14839, FLJ21791, HDLBP, C8orf13, FLJ23393, FLJ11046,
DKFZp434C0328, BCAT1, BAT5, FLJ31235, LOXL4, RNF7, MGC2803, CLDN1,
KIAA2002, STMN3, MYO5B, CTSS, ATP1B1, MGC4309, UBE2H, DKFZp762H185,
LOC115265, MGC13045, SH3KBP1, MGC4604, TRIM47, C9orf5, SDCBP2,
AP1S2, C20orf110, LOC51234, SAT, dJ55C23.6, CKLFSF7, PCDHA10,
MGC11115, MGC15397, LOC116238, TRIM8, FLJ25157, NAV1, KIAA1870,
ALS2CR9, GCNT1, GALNT4, HSCARG, PPP1R1B, PHP14, TGFBR3, ARIH2,
MGC1842, SELM, AKAP2, MAFB, FLJ23091, MBNL, TEM8, CFL2, KIAA1554,
SEMA4B, FLJ10961, SCAP2, KIAA1244, RIG-I, TRABID, TRIM56, MK-STYX,
TMEM9, FAD104, GLTSCR2, MGC: 13379, MGC40555, FLJ14251, NOL6,
FLJ23499, DHRSX, DKFZP564D166, CED-6, LOC57168, KIAA1337, CRB3,
EMILIN-2, GJB2, ECGF1, CHDH, LOC120224, ZNF75A, EPSTI1, NESHBP,
FLJ10210, FBXO25, MS4A6A, NOTCH2, FLJ39885, FOXP1, ORMDL2,
MGC11134, MS4A6A, HSPC195, KIAA1913, UACA, C1orf13, USP28, LCMR1,
GBA2, DKFZp547D065, TH1L, RORC, PAK1, MGC2555, KIAA0146, FLJ20186,
SCAMP2, NGEF, C14orf58, CED-6, LOC55893, GTAR, MGC24103, MS4A6A,
DAG1, KIAA1394, FLJ20073, MGC13114, FBXO32, CD44, CTL2, ARNT,
C21orf63, CLIC6, C20orf64, FLJ90586, RBPMS, LOC51242, MGC45441,
CLMN, FLJ35564, MGC4604, DRCTNNB1A, CGI-125, DKFZp547A023,
MGC39325, CD109, FLJ23499, EHD3, MGC4840, USP21, DKFZP761E1824,
FLJ22215, IL17D, MGC16028, MS4A7, GALNT2, CDKN2B, LOC90550,
CKLFSF3, FS, KIAA1949, MRPL10, MGC45714, MAP4K1, SLC4A11, HPS3,
DNAJC5, LOC120224, FLJ11036, KIAA1337, FLJ10697, SENP2, SART1,
MGC2474, SCD, FLJ14486, KIAA1214, CARD6, KIAA1691, MLL5, C20orf102,
FBXW5, RARA, SLC13A3, FLJ33817, NRP2, BACE, LOC55971, FLJ14855,
LOC133957, GPR108, MRPL41, MGC10485, CMG2, C8orf2, PIAS3,
DKFZp434G118, KIAA1500, APXL2, MGC16028, COG1, UBE2H, CMG2, CTSB,
LOC143903, CANX, PAG, CP, FLJ40432, LOC137392, DKFZP586F1524,
SAMHD1, DKFZp761A052, HSPC002, C20orf23, DKFZp434N061, SLB, PSMB7,
MGC4342, DKFZP434P106, FLJ22678, SYTL4, DKFZP566J2046, LOC51249,
PARVA, FLJ23091, YR-29, LOC55893, OGN, CPNE2, KIAA1784, Spir-2,
DNAJA4, TMOD4, FLJ30726, C9orf19, SNX8, DUSP16, FLJ34633, FLJ25785,
OSAP, B2M, DERMO1, ZNFN1A4, SCYL1, C16orf44, MAF1, MGC12435, MSCP,
JAK3, PPP1R16A, MGC4607, G6PT1, MGC16212, FLJ22283, SRA1, HBP1,
CTL2, HCC-4, SPTB, C6orf37, KIAA1337, SNCAIP, SMOC2, PYGO2,
FLJ12770, FLJ40432, BMF, SLC27A4, C1orf19, SLC5A1, CHRM1, FLJ14457,
DKFZp434F054, SES2, MGC45474, BTC, APOA5, DKFZP434P106, KIAA1522,
ZNF317, a1/3GTP, PCDHB3, MGC26963, HSPC182, SNX9, NFAT5, C4orf7,
NCAG1, KIAA1363, TAF6L, NAV1, KIAA1361, ZDHHC9, MGC2615, PHLDA1,
AD-003, LOC90268, FLJ10101, PCDHB16, SLC2A12, CKLFSF2, FLJ23518,
SEMA6D, PS1D, SLC31A1, MGC10485, SLC5A2, ARHGAP9, NKD2, ETS1,
FLJ90586, REN, FLJ14981, DKFZp761H0421, DKFZp434F2322, MUM2, SPP2,
MGC4734, FLJ13687, BANK, CNTN3, TLR8, HM13, FLJ36525, SLC12A6,
DAPP1, VANGL1, MSH5, P5CR2, HAVCR2, CXCL14, GALNT5, ANKH, MGC29463,
FLJ00028, TMPRSS6, AMOTL1, ODF3, MGC4604, ARG2, FLJ10052, FLJ13881,
PP2135, SLC12A4, MGC10500, MAP1B, DKFZp547I094, FLJ30473, FLJ12886,
ST6GALNAC6, ESDN, SEC15B, FLJ33903, LATS2, ZNFN1A1, SLC16A10,
DSCR1L2, PSMB5, GPR34, FLJ20557, CGI-85, HCA127, DKFZp434I1930,
FLJ90811, LOC113026, FBXO18, MGC8721, BLVRA, MGC10974, PRO1635,
MAP4K1, HKE2, FLJ32122, FLJ35867, FLJ10392, WFDC3, C21orf6,
FLJ23654, DKFZP586D0824, C21orf91, ENTPD2, RGNEF, GPRC5C, RALBP1,
FLJ31052, C11ORF30, FLJ30803, ITGA11, KIAA1053, AGTRAP, NDUFS2,
FLJ32069, ACTR1A, SLC2A4RG, PPARBP, FLJ10055, C20orf167, FLJ12649,
KIAA1909, IFIT2, EMR2, CD5, HT036, SERPINB9, MAP1LC3A, IGKC,
ZD52F10, FLJ32028, BTEB1, FLJ20539, CCL28, MGC21621, KIAA1130,
KIAA1554, FLJ31937, RPL29, GSA7, FLJ25067, FLJ20989, LOC92689,
FLJ12604, MS4A6A, ELA1, SMOC1, C1QG, MGC14421, KIAA1576, FLJ20245,
LOC155066, PRDM6, DAP10, PCDHB14, FLJ25124, SNRK, ADAMTS16, SES2,
SECP43, EPSTI1, KIAA1948, NOL6, PALMD, PAG, MGC39807, TTY7, NUDE1,
KIAA1210, HRB2, USP21, C9orf19, LOC93589, DKFZp434E1822, MGC10561,
RNO2, GLCCI1, MGC3234, AMOTL1, FLJ33868, B3GNT5, FAM11A, SBBI31,
FLJ23654, SLT, CPM, DKFZp762K222, NSE1, KIAA1817, NYD-SP21, LUC7L,
FLJ13063, SIAT6, CASP14, FLJ11896, GPR92, FLJ25027, EVC, HOXA3,
HTGN29, MGC4281, MGC15548, GSN, AD023, FLJ14311, TAGAP, KIAA1276,
CGN, ZDHHC12, FLJ21736, FGFR2, LOC91461, GNG2, BACH1, KIAA1921,
KIAA1957, FLJ10111, KIAA1145, ARHGEF7, STARD4, retSDR3, HBXAP,
ARFGAP1, NY-REN-60, RIG-I, X102, AF1Q, SYTL4, ICAP-1A, KIAA0872,
LOC148932, SCML1, NOL6, Hes4, LOC57038, TRPM6, ABCC13, CGI-85,
DRLM, BCAR1, NR0B1, MCOLN2, KIAA1836, MGC35048, VIL1, LOC124245,
MRP63, TTYH2, FLJ14735, PRIC285, KIAA1999, GALNT7, EGR4,
DKFZp434F2322, PHACS, LOC51219, LOC132158, PRO0971, SUI1, SKD3,
RNF26, TTTY6, TNRC18, CTXL, FLJ12666, FLJ39957, FACL5, POLK,
SLC25A13, FLJ31318, ZFP91, MGC19825, TPM2, PPP1R14C, LOC142820,
ALDOA, EGFR-RS, FBXO27, PRO0038, MGC10992, NPCR, HCMOGT-1, RSP3,
PPP1R9A, KCNMB3, GPR55, ZFP28, PRO1635, C20orf154, FLJ32203,
MS4A6A, KIAA1647, KIAA1607, BAZ2B, FLJ32752, ZNF216, PP2135,
KIAA1357, MGC16207, KIAA1694, GBP1, FLJ10474, FLJ10826, ELAVL3,
LOC90668, CPXM, MGC2452, FLJ20273, MIC2L1, FAD104, GPR107,
MGC15419, SORCS2, ST6GalNAcI, RP4-622L5, DKFZP434F011, TNKS2,
DKFZp761K2222, Ells1, SLC4A11, KIAA1163, CALN1, KIAA1828, MEGF10,
GRIN3A, REV1L, BHLHB5, ADMP, DKFZp667I133, MGC13275, KIAA1889,
DKFZP434A236, GPS2, FLJ20309, NAV1, MGC2603, ARHU, FLJ33071, NUMBL,
CDGAP, FLJ35713, DKFZp761A132, FLJ10300, FLJ12634, GTF3A, NEO1,
RRAD, MGC10966, PTPN2, FLJ10292, ACPP, CISH, DOT1L, POLRMT,
CGI-149, KIAA1202, DKFZp761J139, MGC40178, GATA4, EVIN2, MS4A8B,
FLJ10057, NDUFV3, SF3b10, RP2, FLJ21032, CLG, MGC3040, ODZ2, AQP1,
DKFZp566F0947, CCL27, TARD9, MGC40222, DKFZp564C236, SDS-RS1,
SNCAIP, ENDOGLYX1, CGI-30, FLJ10314, MGC20470, KLHL6, KIAA0212,
PRO0899, KIAA1894, FLN29, FLJ20373, GTF2I, GJC1, BHLHB3, CPNE5,
GPC6, IL6R, RRN3, DKFZP564J047, C20orf99, CED-6, DKFZP434P1735,
TGIF2LY, LOC83690, GPR110, FLJ34922, FLJ20211, FREQ, USP26,
MGC15634, ZSIG11, ZFHX2, C7, UNKL, LOC151835, MGC21854, FLJ25410,
EGLN2, KIF9, KIAA1550, CIP1, DNAJC9, FLJ14768, MGC2599, LOC57018,
DDX12, MGC33993, SLC22A3, KIAA1399, DKFZP434F091, EG1, SE70-2,
DKFZP564I1171, CDH26, TRPC7, DKFZP566K1924, C20orf60, ROR2, KLHL5,
SCARA3, PRO1580, MGC15523, DKFZp434C0328, FLJ31528, CR1L, FLJ32734,
NXF3, MGC41906, CLECSF9, SSBP4, ZNFN1A4, FBXO22, NCAG1, MAP2,
KIAA1529, TIGD5, SNX9, FLJ32001, RPC5, AK2, KIAA1887, ACK1,
FLJ37312, ARSD, FLJ31564, LOC51136, MYEOV, GNAI1, MGC12335,
FLJ20356, KIAA1617, HNT, C21orf59, LOC221468, ENAM, PB1, TBXAS1,
NMNAT, MGC10204, TNKS1BP1, LOC57401, FLJ32194, ENTH, APOA1, ITGA6,
MGC12458, FLJ23403, BCL10, H19, C7orf2, DNER, PDE11A, MAF,
FLJ10378, MGC14276, TLE1, SH3GLB2, TTTY8, KCNH3, LOC90693,
ENDOGLYX1, LOC144402, CGI-105, LOC153222, ASAH2, MGC4415, KIAA1495,
SFRS12, and AGPAT3.
[0172] TABLE-US-00002 TABLE 5 Up Regulated in UPTG versus HSC CFL1,
S100A8, SERPINA3, UBC, MUC1, SFN, ANXA2, ANXA2, COX7A2, HSPA1A,
KRT18, ANXA2, OAZ1, TMSB10, CA12, DNCL1, CEACAM6, ASAH1, RAC1,
ARF4, TACSTD2, MYL6, MSF, JTB, CKAP4, TFF1, IER3, GATA3, IFITM2,
SFN, MTCH1, TPM1, CD24, NET-6, MLC-B, MLPH, QP-C, SCGB2A2, S100P,
S100A9, COX6A1, CAPN2, COX5B, CD24, H2BFT, XBP1, FXYD3, RNP24, PTS,
GSPT1, COX6C, TIP-1, HIG1, RPS16, SAT, HSPCA, TPD52L1, TMSB4X,
S100A10, JTB, RBPMS, KRT19, FLJ10830, TUBB, JTB, ITGB1, CEACAM5,
MT2A, LIV-1, HN1L, LCN2, LOC51142, LGALS3, RAB13, FTH1, TCTEL1,
IFITM2, S100A7, PSMB4, MAGED1, FLJ20151, DBI, COX6B, C20orf24,
ARHA, NFIB, PTP4A2, NDUFB2, CALM1, ATP1B1, GNG5, CD63, NAT1,
S100A6, EIF4B, ESR1, HSPB1, TAGLN2, ALCAM, NDUFS6, AGR2, C8FW, TXN,
HDLBP, NDUFA4, PPIC, GLO1, RAB11A, LPP, HDGF, CALM1, MGLL, PTS,
ARF1, DC12, SNRPD2, C4A, RAI3, NDUFA6, ATP6V1D, MLCB, TEGT, DSP,
PNN, ACTN1, NIFIE14, NDUFB4, DAF, VAV3, UBC, SSR2, MKNK2, HSPC014,
KDELR3, TACSTD1, DKFZP564A2416, ASAH1, DDR1, ENAH, KDELR2, DNCI2,
PPP1R11, PP, SERF2, CTSB, SSR4, GNAS, PGM1, CEACAM6, PDLIM1, GATA3,
MGC3178, SHC1, GOLPH2, GNAS, VAMP3, S100A14, GABARAP, ALDOA,
TAX1BP1, LASP1, NFIB, CCT3, AQP3, DBI, VCL, GNAS, ALDOA, COL3A1,
ATP5J2, MGC16723, USP9X, TMEM4, MTX1, HSPC134, ZMPSTE24, UQCR,
AHCYL1, GOCAP1, HT011, EDF1, CRIP1, FXYD3, MRPL9, RIP60, TIMM17A,
BF, RER1, DC50, CTBP2, HEBP2, YIF1P, LOC54499, APMCF1, UGDH, PSAP,
SPEC1, FLJ12619, TUFT1, COX5B, LRP10, ATP6V0E, CYP27A1, PON2, NQO1,
PTPRK, EIF4EL3, GNAS, CLTA, MDH2, TCEB2UBE3A, TM9SF2, MUC1,
RARRES1, PRDX4, MIF, TPD52, CD81, DSTN, HRY, HSPC051, SMBP, HDGF,
C14orf2, BRD3, NHP2L1, PPP2CB, DLG5, ASS, ENSA, MAGED1, CD59,
SHAPY, CAST, JDP1, HK1FBXO9, RPL38, INHBA, EMS1, HRI, APP, HAX1,
FKBP11, GOLGB1, SPINT2, GORASP2, CD24, HSPA1B, FLJ13593, MGC5466,
E2F4, PRO1855, UBE2V1, KIAA0882, RPL36AL, CSTB, ATP5I, OASIS,
DKFZP564K0822, RCP, MAGED1, PSMB5, NDUFS2, YWHAZ, KIAA0310, RPL38,
FLJ20273, RAB3-GAP150, PSMA5, ATP2A2, C20orf97, TUBB2, RAB31,
C9orf7, HIG1, INSR, TPM1, GSPT1, PSME2, CSNK1A1, P4HB, EIF2S1,
LOC92689, NDUFA3, KIF5B, PAM, MT1H, SHAPY, FLJ10898, GUSB, BNIP3,
KIAA0992, FLOT1, PSMB7, TAF10, CSNK2B, EPRS, PIG7, DAP3, ECHS1,
AP3D1, COX8, PMP22, LOC54499, ALDH3B2, MGST3, PRDX2, PTD011, COX5B,
CAST, LASS2, PSMB2, MT1X, MYD88, DKFZp564I1922, FLJ20719, C4B,
H2AFL, FLOT1, PIN4, TCEB1, WFDC2, SQRDL, CSTA, PTD009, PTPRF, DAD1,
PDEF, FN1, GPX4, DDR1, ARHD, COL1A2, PDEF, HSPC009, MEA, ABCD3,
CYB5, MLCB, PRO1489, PDEF, RPS11, IDH1, SLC12A7, H2BFB, SH3BP4,
CD24, SLC38A1, RAB31, LTF, TIMP1, SH3YL1, SEMA3F, TSPAN-1,
KIAA0852, NDUFA8, COL1A2, SLPI, PSMD4, RPL27A, GNAS, KIAA0876, DP1,
CEBPD, CIB1, IQGAP1, TSG101, MGC3077, CYB5, FN1, LOC51128, EMP2,
CETN2, PACSIN2, PBEF, MRPL24, CTSB, SDFR1, MLP, TM4SF1, C20orf3,
PRKAR2A, MGC5178, FN1, FLJ20054, MMP24, SEPX1, GFPT1, ANXA11, ADFP,
GMFB, AP3S2, PTBP1, BAG1, FLJ10496, CYB5, CXADR, RAB25, FH, APP,
CDR2, PSEN1, RFP, SEC22L1, GGPS1, ARMET, USP7, FLJ20847, EFA6R,
HSPA4, RDBP, TNFSF10, DDR1, KIAA0429, PLP2, RABGGTB, BAG3, IFI27,
GATA3, LAMP2, CD24, MRPS14, FHL2, CGI-130, CPB1, SCAMP3, NESCA,
BACE2, PSMD8, LGALS1, MPHOSPH6, FLJ14154, COPZ1, CALR, HK2, WIRE,
PTP4A1, TRA1, DKFZP564G2022, CTSH, CRAT, PLAT, ANXA2P2, YME1L1,
PILB, ITGB5, KIAA1026, FKBP4, TBL2, PIGT, WSB2, IFI30, TUBB2,
E2IG5, YME1L1, ATP6V0E, RAB4A, LOH11CR2A, PLU-1, KIAA0483, SLC2A1,
LBP, MGC11256, FMOD, TLE1, POLR2H, TOB1, NSF, TACC2, OPN3, USP3,
PSMB1, TMP21, DUSP4, RAB2, SVIL, FDFT1, NFE2L1, PTGIS, RPP20, PGLS,
ORMDL2, NR2F6, PIG7, ERBB3, TRAP1, DDR1, SDC4, HSA243666, PLU-1,
ATP6V1E1, DAAM1, GSN, MCP, KIAA0143, P17.3, PIN4, WARS, FN1, TFG,
COPB2, ERP70, MRPS18A, C22orf5, LYSAL1, POLR2I, SAR1, ATP6V0B,
TUFM, NDUFB2, BCL6, PDCD6IP, TRIM33, UBE2N, WBSCR21, NEDD5,
LOC51123, GMFB, PFN2, KRTHB1, NANS, CLU, TOMM20-PENDING, NDUFS8,
MT1G, ANK3, PIK3R3, IL13RA1, TNFSF10, DNPEP, TNRC9, NIPSNAP1,
BRP44L, PEX11B, FLJ13612, FLJ22028, POLB, ANXA4, SEC61G, PREI3,
CDKN1A, MT1L, SAS, PSMD5, COBL, CARD10, UBE2D3, RABAC1, CPD,
C21orf97, PAM, MRPS10, CGI-109, GBP2, TC10, NMA, FASTK, P4HA1,
GTF2I, COG2, MYO6, LMNA, TCF3, C14orf3, PEA15, PRKCBP1, GALNT3,
IRS1, ACP1, GUK1, MBD2, PTD008, RBM4, TNFRSF10B, KIAA0266, NQO1,
DNAJA1, FACL3, FER1L3, CD59, PPAP2A, FACL3, KIAA1598, TGM2, MTMR9,
LOC51760, TST, TM9SF1, LGALS3BP, P24B, D2S448, RPL27, KDELR2, TJP1,
OPTN, NME2, HRI, F12, RABIF, TJP2, ATP1B1, GGPS1, FLJ10116, PTGES,
SCO2, PEN-2, PSMB3, CDS2, RAD23B, PPM1A, ARL3, TXNDC4, GOLGA5DDX32,
DAG1, VIL2, TPBG, GM2A, EIF2S2, NEUGRIN, DKFZP564G2022, KIAA0934,
ADM, CSRP1, GRIM19, FAT, SLC21A11, ACADVL, NDUFA2, GALNAC4S-6ST,
EIF5, RAB1B, NME1, ASPH, MUT, ARF4, FBXL11, COPA, UBL5, CSNK1E,
ATP5I, CCND1, HT021, PPP1R7, LOC56851, SRP54, DAF, CTBP2, TLE2,
HSD17B1, SRD5A1, SLC9A3R1, MUC16, PPL, MGC10765, EPB41L4B, SECTM1,
CHPPR, SORD, VTI1B, CRABP2, EFNA1, HERPUD1, CDYL, MRPS17, SGPL1,
DUSP14, SSBP1, C20orf35, C3, HSPC163, ATP6V1G1, YF13H12, FLJ13052,
ABCC10, STUB1, NNMT, RAB20, CALU, PLCB1, NR2F2, HSPE1, TM4SF1, RSN,
FLJ20813, TPARL, SEPW1, H1F2, GRHPR, HSPA1A, RAB2L, SARS, FIBP,
PSMB6, RER1, BCL10, ATP9A, IDS, PPIB, RAB2, Cab45, PYCR1, GSTM3,
SEC24A, MAPT, FLJ10579, ADAM9, FLJ21603, DNAJB1, C20orf116,
DKFZP564G0222, RDGBB, RRAS2, AKAP9, KIAA1243, DCI, ELF3, PDE4A,
CRIM1, CORO1B, PXMP4, S100A13, DPP3, GTF2H2, PSMB8, TUBB4, MRPL33,
STK39, VCAM1, MAOB, DKFZP566C134, CSNK1A1, FLJ20761, EGFL6, ATP1A1,
APH-1A, FLJ22055, TOP1, RCL, SMT3H2, POLR2K, LMNA, ID4, JTV1, CLN5,
AKIP, TGFBI, LLGL2, ITGAVPPP2R5A, IFNGR1, JAG1, DD96, PGRMC2,
SNRPE, MGC19606, DJ971N18.2, CKAP1, MGC3180, HYOU1, PACE-1,
FLJ22662, KIAA0674, ALS2CR3, EPLIN, MYO1C, CD164, PCMT1, IL1R1,
SERPINB2, HSD17B4, FOLR1, HRIHFB2122, FLJ22457, MXI1, TCFL1, POR1,
FLJ20375, H4FD, KRT7, TFAP2B, MRPL15, SLC5A6, RGS16, TNFAIP1,
FLJ14146, HOXB7, PIK4CB, RPS20, C11orf24, SYNGR2, NCKAP1, APG3,
RHBDL2, ASC, C1orf9, KIAA0247, HRB, PAFAH1B3, SNK, ASB13, LSM1,
GPI, MCJ, CASK, HOXB7, RBBP6, PKIG, SMARCA4, BLVRB, HYPK, SUCLG2,
KIAA0494, SLC2A10, HIG2, TSTA3, TNRC9, SEC23B, SELENBP1, RAB6C,
VAPB, ZNF144, PCNP, SULT1A3, NQO2, SMP1, FLJ30656, NUBP2, FLJ20152,
ATP5H, FLJ22418, DCN, SOD2, FLJ20958, YWHAZ, TRPS1, CYP51, SUCLG2,
CGI-45, ZFP103, MID2, CPD, TFAP2C, C1orf37, dJ222E13.1, ICMT,
UNC84A, CALM1, DF, SUPT16H, BZRP, SLC9A1, FLJ13110, AT1P1, MUC5B,
CTSB, GJA1, SDHC, SUCLG2, MGC3067, PBEF, IL27w, HSD17B7, GRSF1,
CD9, H11, FLJ10099, NITI, LAMC1, HBXIP, NDUFV2, STX12, SDHA, D123,
Z39IG, RPL5, PA200, SC4MOL, HSPC171, STXBP1, CACNG4, MAGED2,
MGC4368, MPZL1, ZDHHC7, RPA40, IGSF3, FLJ22638, SPTLC2, MTVR1,
FLJ21016, SGK, NCOA1, MAP4, GLRX2, P4HA2, JAG1, MTVR1, FLJ22940,
NDUFB8, ISGF3G, B4GALT5, EMS1, C22orf2, LRPAP1, PON3, EIF5A,
ENSADKFZP564F0522, FLJ11273, EPS8R1, EDF1, ISG20, EPS8R1, FLJ10525,
PSMD4, NINJ1, TSSC3, FDPS, RGS3, CREB3, UBE2D1, ProSAPiP1, CAST,
WBSCR20A, MAPKAPK2, RPP38, YWHAB, A2M, RBX1, PDGFRA, EFS2, RAB9A,
RAD23B, BAZ1A, BCL3, SNX4, CLMN, HRY, INHBB, NPD009, AHNAK, TNRC9,
S100A11, MYO1C, LDLR, KIAA0102SCYE1, LARP, GNA11, NDUFA7, CKAP1,
KPNA1, NDUFS7, RDH11, RAP140, MTCH2, HPGD, ITGB4BP, CLDN7, CGI-147,
GTF2IRD1, LRRFIP1, DAB2, DKFZp667G2110, LGALS8, MARS, MGC14480,
MGC3038, PLXNB2, ZFP36L1, DBI, AP2B1, PLS1, CYC1, PPIF, COL3A1,
PDHB, NSAP1, PFDN2, GAS2L1, DMBT1, FZD1, GBA, DNCL2A, VCP, MYO1B,
ANXA8, C11orf13, DSS1, KIF13B, CECR5, GARS, COPB, NFE2L1, DLG3,
FLJ12443, NALP2, APM2, KIAA0790, C1S, HN1, GALNT6, CLPP, STK24,
PP3111, MTA1, CAMTA2, BAT3, FADD, BC-2, CLOCK, UAP1, AAK1, MGC3121,
CD14, CDC2L5, FYCO1, SQSTM1, UBE3B, CSPG2, EIF5, DEFB1, MTMR6,
KIAA0643, 101F6, SLC35A2, TNKS2, TPMT, WWP1, LHFPL2, NEDD8, PC326,
PTK2, FLJ20748, FOXA1, IDE, FLJ20275, CACNB3, CDC42, TEX27, KIF3B,
PP3501, CDCP1, HNRPU, TULIP1, SPARC, DVL1, GMDS, EZF-2, AP2S1,
GNA11, SEMA4C, WT1, KIAA0010, LAMA5, PTDSR, ETFB, KIAA0284, TFF3,
GRHPR, RPL37A, G1P2, MGC11242, FLJ23189, FKBP9, MGC35048, RTN1,
ASL, PTK9, THBS2, SDHC, HIS1, DSTN, MGC3047, PAFAH1B1, AGPAT1,
PGM3, AKR7A3, COL1A1, KIAA0436, GDI1, CYR61, RNPEP, SGPL1, APBA3,
GNB2, SOCS5, FGFR3, RGS19IP1, ORC5L, SLC6A14, KIAA0229, FLJ22028,
LAMP1, SNRPD3, MAPK13, DNAJA3, FLJ22471, CKMT1, PSMB4, CCL22, CLU,
CD163, ANXA3, ATOX1, GTF2E2, ANXA6, FLJ21127, BMPR1A, WBSCR20C,
MBLL39, IL4R, SEC24D, SLC19A2, RNASEH1ALAS1, ACAA1, DPM3, ABL1,
TUBB4, EFNB2, CALR, ARPC1B, MCP, SH3GL1, ECT2, LOC51619, NEK11,
MAFB, EFEMP1, G10, DPP7, FUT2, ATP6V0E, SLC22A5, SSH-3, SYNE-2,
PH-4, CTBP2, BATF, PDE4DIP, TRIP6, P2Y5, RNASE4, CANX, CD2AP,
HIP1R, FH, ADCY2, SPUVE, FLJ10462, QSCN6, CLTA, SLC31A1, DEPP,
CLTB, KIAA0544, CTSB, MARS, PAK4, PHIP, HIP2, FLJ23375, ARHGAP8,
TNFRSF12A, KRT8, UBE2V1, PDPK1, KIAA0251, PPGB, GAS1, RAD17, PIAS3,
37872.00, ABCA1, FLJ10375, KIAA0217, SPR, GRN, EIF2B4, ITGB5, RPN1,
APLP2, WDR1, SDC1, MGC2963, PM5, MGC5178, TBCE, EEF1D, SGP28,
FEM1B, FLJ10829, FLRT2, KIAA0934, PCDHGC3, COPS6, PART1, ACACA,
AMPH, LUM, FLJ23338, EPHB4, FBP1, WSB2, HBP1, EVA1, MUS81, POLR2K,
KIAA0103, HPS1, LOC55831, FEM1C, RIN2, DKFZP564O092, ENDOFIN,
DHCR24, FLJ20604, LOC90141, PCDH7, SLC7A7, SLC12A2, FLJ21047,
S100A11P, CGI-115, TOM1L1, C1orf34, SOX9, MB, EIF4EL3, S100A8,
APLP2, TDP1, FGF13, URG4, RARRES3, FLJ12910, DAP, RFX5, MVP,
FLJ21749, PAXIP1L, FLJ20152, ATF7IP, GPSN2, RIL, VEGF, TM4SF6,
SPP1, NVL, CALR, CKAP1, AKAP1, HSPC166, TMPRSS3, TM9SF1, LOC56902,
ENT3, GRB2, COG5, DOC1, COL5A2, RLN2, GRN, ADCY9, KIAA0690, ENPP2,
ILF1, SLC35A3, SLC39A1, C20orf11, PCDHGA1, CGI-148, WBSCR20A,
CSGlcA-T, KIAA0937, KIAA0674, LTBP1, H2BFT, SEMA3C, SULT1A1, ERP70,
KIAA1078, KIAA0869, PLA2G12, PACE-1, KIAA0984, AUP1, RBSK, AMOTL2,
SULT1A3, LANCL2, PAIP1, JUP, PPP3CB, KYNU, SH120, PRKCI, ARG2,
OSBPL2, APOL6, GATM, LOC113251, GM2A, FLJ12436, CD24, SYNGR3,
HSPA1A, CTNND1, SEC61A1, IFRD2, PCK2, PSMA3, COL6A1, ARHGEF5, RAI,
VPS45A, BECN1, GNPI, PA200, PXF, BZW1, KIAA0876, KIAA0471, ATP6V1D,
CRYM, KCNS3, FARP1, ANK1, FLJ20234, PLU-1, NPC1, ZNF339, RNF14,
RBPMS, SEC13L1, KIAA1630, SIX2, SGSH, RPA3, VLDLR, ENPP1, ITSN1,
AP2B1, ARHC, SWAP2, UBE1, MARK4, MK-STYX, HDLBP, ZNF185, KIAA0227,
GOLGA3, KIAA0033, RAB26, SHANK2, ALDH3A2, DCN, HT008, PLAB, IMPDH1,
GRIT, FARP1, MAPK13, ERBB2, TGOLN2, RALA, ARHE, ABCF2, PRSS11,
PLCD1, HSPC111, TRIM29, ARL1, ACTN4, MUC1, DJ434O14.5, FLJ11619,
SH3GLB1, TCN1, FLJ11149, BIK, ZNF91, PRSS8, CYB5R1, TRIM16, EPS15R,
NARF, SLC11A2, AUTS2, LIM, SLC1A1, ALDH7A1, TC10, SC65, IRF7,
HLXB9, RAB17, KIAA0746, PCDHGC3, APOC1, AKAP1, EPS8R1, TBCC, DDAH2,
TYROBP, N33, FLNB, DKFZp564A176, PREI3, JAG2, UGCG, OSR2, KRT6B,
CDC42EP4, TPD52, C20orf149, FLJ12975, MAN2A1, GCN5L1, MCF2L,
FLJ22386, STHM, RAB26, AP1S1, GMPPB, CYP2B6, F-LAN-1, PRKCZ,
DC-TM4F2, KIAA0556, FLJ12619, CD163, DAZAP1, TIMM13, MADH2, COL4A5,
POGK, FXC1, POP4, NET1, ARHGEF5, NS, KMO, PTP4A2, LOC57228, MUC5B,
AUH, BAIAP3, SFMBT, CD44, BYSL, FLJ20085, PARG1, C4.4A, PSMD4,
GSK3B, PSMD12, EIF2AK3, SCARB1, DP1, STRN3, FLJ23263, CTSD,
HSGP25L2G, TFIP11, MPZL1, SNAPC3, RBM3, PP591, TGFB1I1, GRHPR, AHR,
FLJ12389, SORT1, KDELR3, ATP6V0C, MD-1, D8S2298E, XAP135, HSPC023,
C9orf7, C21orf97, DNCH1, ZNF36, PPP1R7, VIL2, RAB2, MYH9, TRIM14,
UGTREL1, CTSL, KIAA0977, RPC62, UBE2N, DCAMKL1, FUCA1, ATP7B, RBSK,
ST5, CGI-90, NOH61, FLJ10925, RAB22A, RTN2, KIAA0089, SH3GLB1,
CDS1, MGC5466, WFS1, AMMECR1, COX17, ACOX2, FLJ10101, HT012, LMNA,
PRDX2, SULF1, KIAA0923, FLJ22637, SCA1, PAIP1, CAP2, CMT2, ZNF217,
CYB561, PAPSS2, STX18, FZD4, DDXx, UBAP1, ITPKC, PTS, PGLS, LAD1,
DSC2, STOML1, DDX16, PTP4A1, FLJ10901, SLC12A8, NME3, TEM7, NPR2L,
ACY1, GNB1, GRN, PLEK2, KRAS2, ARHGAP8, FLJ11856, DCN, LOC55871,
NAGK, FLJ14154, FLJ22709, TP53TG1, STK6, COX5B, MICA, EPPK1,
EPS8R2, MMP19, WWP1, TUBG1, LBP, ATP10B, CLN3, UBE2G1, SULF1,
FLJ30002, SYN47, CSPG2, CACNB3, IGFBP3ELOVL1, DTNA, ANK1, C12orf22,
EPN3, IDE, DKFZp761F2014, SEC22L1, ILF2, ACTR1A, FLJ10052, STAT3,
CED-6, FLJ10359, SOX9, PIASY, KIAA1169, CAV1, HOXB2, FLJ22191,
LOC57117, PMVK, BLNK, TREM1, HSRTSBETA, EIF4EBP1, SIGIRR, TSLRP,
C20orf44, PTD009, PP1665, HMG20B, RTCD1, PDE8A, CNNM2, GNA11, GPX2,
KIAA0599, FLJ13868, DBN1, GEMIN6, PMM2, SPTAN1, PFN1, DCTN1, UBE2A,
GPR107, MRPS2, SNARK, SSA1, SH120, UBPH, CPD, HOXC6, DXS9928E,
TEAD3, PGBD5, ST14, CNN3, KIAA0256, MGC3262, FLJ13840, CLDN4,
FLJ11939, ABCA3, OAZIN, MRPL17, PPP2R4, CGI-135,
KIAA0802, AP1M2, SCN10A, PPIB, MRPL40, ZK1, FLJ12517, CDH11,
CDC42EP2, CLN3, CGI-152, FLJ10815, C11orf13, MADH1, FLJ20539, HMGE,
KIAA0923, LAP1B, PTGDS, FLJ20559, SFXN1, KRTHB6, UNC13, MUC4, FUT8,
NET1, NEBL, BCS1L, RAI16, CAV2, FAAH, CEACAM1, LEF1, GALNT10, NAGA,
ABHD3, STOML2, C1orf27, OSTF1, KIAA0227, PCLO, MYO10, THBS1, LANO,
HMCS, H3FK, SPS, C9orf9, PITPN, SCRIB, PAM, NPDC1, ASNS, SLC33A1,
HSPA6, HMBS, FLJ21918, FLJ11939, C6orf29, PRSS15, ENC1, HTR4,
SSH-3, RECK, NAV2, TRN-SR, MRS2L, FLJ20366, LOC51754, LGALS8,
KIAA1040, B4GALT1, FLJ21841, KIAA0237, IL8RA, MLF1, ANXA9, VRP,
LOXL2, MIR, ATP5D, KIAA0632, FLJ20174, FRAT2, DDX26, BCKDK,
ATP6V0A4, KIF1B, ENTPD3, RAB1A, EGLN1, KIAA0268, LGMN, PTPRH, KMO,
UGCGL1, AKR7A3, RIG-I, CYB5R2, FLJ11773, RPS6KA2, CLCN3, PTPN18,
GNG12, PKP3, ALDH1A2, NEK3, UQCRC1, ZNF236, RASAL1, RPL14,
FLJ12287, AP1M2, C4BPA, MAF, FLJ10815, FLJ90798, TRAM, POLR2J,
TLN2, DNASE2, PEX11A, KIAA0790, TM4SF3, HPGD, TRIP10, THY1,
CGI-143, TPR, AQR, CTNND1, HOXC10, CDC42EP4, PLEC1, PSFL, PTP4A1,
FLJ22353, NCALD, INPP5E, MKRN4, PADI2, SMARCA1, KIAA0317, EHD1,
AZGP1, SMARCA1, NOVA1, MRPS11, FLJ23091, HOXC4, OCRL, CKAP4, CD44,
CD2BP2, FLJ10055, TM7SF1, PVRL2, ID4, DJ434O14.5, SLC7A8,
DKFZP564I122, MIPEP, PLA2G4C, KPNB2, DAXX, NOS1, ID3, MRC2, SSSCA1,
PPP1R14B, MTHFS, HSPA5, ELF5, MARCKS, KIAA0514, RRAS2, ADRM1, ANK1,
KIAA1324, PSEN2, UBXD2, CALU, DOK5, KCNMA1, COL9A2, ATP2C1, FGFR2,
DPM2, KIAA0895, DPH2L1, MUC5B, SSR1, LOC113146, KIAA0644, LOC51042,
DNAL4, PIG3, GPS2, CX3CL1, INHBC, C1QB, PDPK1, RPLP2, HRI, MGC4825,
TGFBR3, LAMC2, PEX7, HFE, DJ434O14.5, FLJ20296, MGC5347, FLJ10521,
RARA, KLC2, SLC21A2, SPTAN1, APOC1, LARGE, STK38, GCC1, SNX13,
TNNT1, NTRK3, TGIF, H3FH, KIAA0485, KIAA1416, EFEMP2, SMARCE1,
KREMEN2, UMPK, KIAA0268, DDEF2, VAMP3, CGTHBA, OSBPL10, CGI-96,
MGC3248, TUBB-5, PXMP3, RBM9, LOC51257, LAMC1, SLC30A5, PPARD,
KIAA0349, MAP4K4, GNG4, CCL3, GPRC5C, CCR1DKFZP586B0923, RNF10,
SCGB1D2, VIPR1, RGL, TESK1, AK3, KIAA0649, SCARB2, MGC2494,
FLJ20048, EPS8, DNAJC1, MOB, FLJ11200, CD1C, AGPAT1, FBLN1, GW112,
ICT1, CGI-141, DSCR1, PIP5K1C, PRY, ALP, PRDM4, PLAC1, ISG20,
FLJ20457, TCF-3, PTE1, TNK1, MAGED1, FLJ13782, NPD009, UCHL3,
PRELP, LOC55893, KIAA0451, AK1, LMCD1, NET-7, AP3B1, OS4, ABI-2,
NOTCH3, KRT9, COPZ2, CGI-58, RISC, DKFZP566C243, ATP6V1C1, TRIM38,
PTOV1, PDGFB, PIP, IDN3, FLJ10199, BCAT2, HOXA11, PDXK, NEDD4L,
MGC29816, TPD52, TMPRSS4, HAIK1, SUPT4H1, WNT5A, PCSK7, ANK1,
FCER1G, FLJ13397, ERO1L, BPGM, HLA-DQA1, DCXR, KIAA1094, NEO1,
FKBP4, SMARCD3, TPSG1, FLJ21940, APBA2BP, TMPRSS6, TBC1D1, MS4A6A,
U2AF1RS2, MGC11308, MRPL23, PCDHA12, SMA3, CELSR3, SLC22A4, MGEA6,
ICA1, STX4A, EFS2, RRP22, X123, GBA, DNAJB1, TGFB3, CRAT, FLJ11159,
TMEM8, GALE, FLJ20555, DDX3, TULP3, TACC2, SLC6A8, C3AR1, BSCL2,
TRIM2, ELF3, SPTBN5, SERPINB8, FLJ23259, TNFRSF6, MIPEP, CELSR2,
LDB1, MOG1, PXF, HPIP, HMOX2, SURB7, HRIHFB2122, FLJ22056, CLASP2,
IF, HSKM-B, UPK1B, WDR10, IQGAP1, PSPHL, DUSP4, FLJ10856, RARRES1,
ALAD, PARVA, KIAA0608, DNPEP, GMPPA, FLJ20254, IDE, COL5A1, GFER,
PSMA7, FLJ11017, ZNF144, MYC, PEX14, CCR5, ARL1, NME5, NDUFB7,
PPAP2B, C21orf80, CAPG, MRPL52, MIG2, HSPC039, DPH2L2, SRD5A1,
SDR1, RAB36, SCGB2A1, PRDM4, ASM3A, FRA, GLUD1, FLJ13187, CARM1,
RPS6KB2, LOC55565, B3GALT4, ALOX5AP, PLAU, DMN, DFNA5, CGI-36,
TC10, SLC38A6, KIAA0852, CRIP2, HSPC003, NSFL1C, FLJ20605, GPC1,
FLJ10504, MKLN1, TIP-1, SCAM-1, IL13RA1, UPLC1, FLJ20171, LOC88523,
HSD17B2, MYO1B, ZNF364, CDK7, MAP7, PCOLCE, IL13RA1, SSNA1, ESRRA,
CPS1, APOE, MY014, CHK, THBS3, DAB2, PCMT1, MAP7, SLC7A4, APPD,
ITCH, KIAA0255, BCMP1, AKAP9, SNCAIP, MRPS7, PIGPC1, HIVEP1,
SLC6A8, DKFZP564O0823, CRK, BAIAP2, SLC7A11, CPE, MPZL1, TDO2,
FUT1, STAB2, CDKN2A, CGI-12, TPM4, IL1RN, MGC4504, KIAA1395, COQ7,
CARHSP1, PARVA, FLNC, C11orf24, NPR2L, GFPT1, ARVCF, CAPN9, SRRM2,
NBL1, KIAA1078, SURF5, ARHGEF4, F23149_1, FKBP11, KIAA1102, IGF1,
RBT1, HNOEL-iso, LAMB2, DKFZp566O084, FGB, GPNMB, TLR5, CX3CR1,
THBS1, GORASP1, HCA112, AQP3, BDKRB2, SLC4A7, CLTB, MRPS18A, CTSK,
CELSR2, KIAA0652, NKX3-1, MXD4, ALDH4A1, DYSF, ECGF1, DCN, PSME3,
TIMP2, HOXB6, EGFR-RS, EPS8R1, ECM1, LTBP2, PRPS1, CDA08,
HUMAUANTIG, MGC955, FLJ22678, LAMA4, GLUL, MAGED2, HES2, FASN,
CYB561, IDH3A, MPPE1, PRKAR1A, KDR, DICER1, PROCR, TNFSF10, HAGH,
FBXO3, TC10, PRKAR1A, ZNF20, AK1, ALDH3A2, FSTL3, ZNF408, PTP4A1,
PMS2L9, BAG1, DKFZp667G2110, MUC2, KIAA0265, ZFP100, KCNK1, IFI35,
THY1, FLJ23186, H2BFG, ARSA, KRT15, ICA1, FLNA, BPHL, PCTK1, TUBA2,
KRT17, SHANK2, CEACAM1GAK, VARS2, AGTR1, ASB8, MPZL1, RFPL3, DNM1L,
SPUF, KIAA0792, NUCKS, C1R, HRASLS3, TM4SF6, SPINT1, XT3, SLC16A5,
FLJ21079, MST1, MMP9, DKFZP434B044, NY- REN-24, ALDH1A3, NID2,
KIAA0409, ANKRD5, KIAA0513, U2AF1RS2, IGF2R, H2BFL, FUT3, LEC2,
LY6E, CSH2, SRCAP, DKFZp434G2311, CHST4, PPP2R1B, PVALB, FLJ12960,
ITPR3, PODXL, PARD3, PRSS22, FLJ10697, MGC2376, SLC39A4, MRPS16,
QPRT, GFRA1, BRD2, CNGB3, LAK, C5orf8, PPP2R3A, HCGII-7, ANK1,
OAZ3, PSMC4, ACATE2, DKFZP434L0117, EDAR, PPFIA3, GRB7, MCM3AP,
CALB2, APXL, ABI-2, TTR, CSNK1D, DJ1042K10.2, TRIM38, PSCD2,
HSPC134, SREBF1, HUS1, PSK, C12orf5, SPOCK, EDG4, FLJ10769, ANKRD3,
FLJ21135, PPP2R4, CED-6, GATA6, MGC10963, ZNF14, CPR2, KIAA1199,
HIP1R, NOL3, ZNF306, FLJ14298, RAGE, IDH3A, GPR107, KIAA0368,
RPA40, MEIS2, PHLDA1, CELSR1, N33, BLZF1, FLJ22637, IL1RL1, GOLGA1,
SAR1, FGFR2, FLII, ANK3, SIRT7, BAP29, EFEMP1, FLJ20277, DXS1283E,
LAMB1, TLE2, TJP1, PDE8A, RCV1, HYAL2, ERdj5, KIAA0350, CLSTN2,
MDK, LOC51762, APOE, KIAA0964, SSH-3, TJP3, ZNF193, PRDX2, PTGDS,
TEM7, DNAJB4, POLR2D, DKFZP586J1624, JAM1, LHX3, FLJ10252,
KIAA0451, INE2, WIT-1, FLJ23209, CXCL1, RAI2, KIAA0857, FLJ21062,
KIAA1096, ARF4L, THBS1, RAB31, SS18, NDRG3, TGOLN2, FLJ10665,
COL6A3, TAZ, AGRN, PGC, SOX11, MCP, EXTL3, ACRV1, NELL2, MGC4309,
LOC114990, KYNU, SNX11, ANGPTL2, CYP2J2, SMURF1, SDCCAG16, BRAF,
NFYA, ADD1, LIG3, CAV1, BIRC1, TJP3, STEAP, NDUFA2, MYBPC3, CINP,
KIAA1096, ACLY, TUBB, GREB1, MARK3, TEAD4, CG1I, UNG2, SLC30A5,
FLJ20920, ACAA1, EIF3S10, SEC5, SLC31A2, MGC10993, VEGF, P4HB,
TFPI2, DKK1, ARPC1A, CHST1, MAF, FLJ90798, KIAA0682, GRP58,
CACNA2D2, MAPKAP1, GPR27, ICAM1, RPL39L, CYP1B1, PIGO, KIF5B,
HSD11B2, CLDN3, FLJ20255, SNX16, FKBP10, STK23, DRD2, SPA17, FOLR1,
WNT16, KIAA1010, FLJ11467, EFNA4, H3FB, RAB5C, EHD1, SLC7A11,
RHOBTB3, COQ7, SLC21A11, FLJ14827, SPRR1A, PVR, MAST205, CFLAR,
PAX6, N33, ADAM10, GNA11, ZFP26, GPR48, KRT4, C2, CRIM1, MGC3121,
FLJ23471, GGCX, PPP4C, PAWR, PTHLH, KIAA1219, SRP72, ETV6, ALOX15B,
SLC24A3, SLC25A4, RDS, DAXX, ICAM1, LOXL1, GMDS, TRAF4, NTHL1,
LISCH7, GAS2L1, TRIM10, SIAT4A, FLJ22584, SLI, ITGB5, TFPT, CD8A,
DSCR1L1, KIAA0779, GPRC5B, PP591, SEC31B-1, PPFIBP2, CYP27B1,
DOC-1R, COP9, KIAA1193, MST1R, HBS1L, RARG-1, FZD7, KIAA0626,
SMT3H1, RALGDS, SOX13, FLJ22612, NFE2L1, CST7, KCNJ5, PALMD,
KIAA0644, MRPL9, ERCC1, MSTP9, PTPN3, SUPV3L1, GAL3ST-4, SUHW1,
PRSS16, C6orf9, PTPRT, CGI-112, TBX3, ARD1, KDELR3, CGA, TSPY,
SPAG1, CRELD1, FLJ20967, RNASE1, LRP3, LARP, SOX11, TULIP1, RORC,
HARC, RPL5, FLJ13544, MAP3K12, KIAA1096, PLA2G10, RAB2, FLJ12681,
FLJ23469, PP1057, MAPT, TMEM4, PSME3, FLJ21963, SGCB, GLI3, PRRG2,
MYL9, GFR, HOMER-3, PDGFRA, DPP4, D15Wsu75e, KPNA1, SGCD, RABGGTB,
MMP24, FGL2, ATF6, STX10, ARHGEF12, UPK1B, EGFR, MCAM, CYP3A43,
FCGR3A, FLJ10534, FLJ12571, FLJ20422, CD80, KIAA1023, C21orf18,
H4FH, TEL2, MSCP, PEX10, B4GALT2, ADAMTS5, CSGlcA-T, TNFAIP6,
PRKCDBP, TRIP11, PTN, FGD1, NPEPPS, CAPN1, H2BFH, LOC51337,
FLJ21736, VAV3, FLJ11198, KIAA0923, NONO, ALDOB, AQP6, FLJ20315,
PHLDA1, VDR, KIR3DL7, YBX2, DUSP3, MGC11271, CHST6, MGC4171, PL6,
SH3BGR, SPPL2B, EPHA2, CRYAB, MST1, RGS16, CLPTM1, MD-2, KIAA0152,
PACE4, DKFZp564K142, RALGPS1A, DKFZP564A022, RTN1, LAMB3, PLD1,
SERPINB5, ENSA, DKFZP586N0721, PLAA, FKBP14, LRIG1, RARA, BN51T,
PTHR2, PPP1R3C, HSPC002, CNTNAP2, HNF4A, CHI3L2, TGFB2, CGI-58,
PPFIA1, KIAA0440, PLAUR, SNTB2, ID1, ALOX5, IGF1, OPCML, TAGLN2,
UBXD2, M11S1, REPS2, BCHE, SRD5A1, TED, EIF5, KIAA0595, BAIAP1,
KIAA1718, TRA@, STS, C11orf17, ASNA1, MAOA, PTGER3, NPY1R, SMARCA4,
PGM3, PCTK1, MATN2, FLJ23393, MGC2821, MGC2376, FZD2, SLC7A6,
PPAP2C, PHKA1, GOLGA1, WARS, GADD45G, LIV-1, NEK1, C22orf3, VAMP4,
C18B11, MGP, KIAA0040, IGLJ3, FLJ21125, BTD, G3BP, CLEC1, NUP98,
MLN, NRXN3, FBXL7, DLG1, PLA2G5, CYP26A1, OR52A1, DSC3, PPAP2A,
C20orf121, UBE2H, EEF1A2, ATP10A, TFEB, GABRQ, GFPT2, WIG1, FBLN1,
PTPRF, MEPE, RAMP3, COL13A1, SLC6A8, PPP1R10, COL18A1, GAC1, EPHX1,
C11orf9, OSF-2, ETS1, INSIG1, FLJ10111, CEACAM7, DCX, C14orf58,
MIRO-2, SRPX, EPHA1, CRK, CPE, TIMM17A, LCN7, CENTG2, FLJ10534,
C6orf18, FLJ12671, VEGF, SPANXA1, MECP2, EPHB3, TSTA3, ILVBL, F7,
BAZ1B, MGEA5, E4F1, PPP1R13B, PZP, KIAA0913, CSRP2, DKFZP564K2062,
CA2, SLC7A8, BNC, ADAMTS1, PIASY, MGC11061, FER1L4, FKSG28, ZAP128,
FLJ21610, ATRN, NEU1, H2AFA, IL10RA, BNIP3, NRP1, WISP3, C8orf4,
TGFA, FLJ11526, MRPL2, HP, DHPS, SLC7A8, GPX5, PLXN3, CDC34,
POLR3K, FLJ11506, KIAA0980, PDCD8, EVI5, CST3, KIAA0752, C1orf16,
CYP4F3, ROR1, MAP3K9, HSPC121CDKN2A, CAPN9, DUSP8, APOD, CCRK,
DDX26, USP21, PP35, ABCA1, IGHG3, IL1RL1, ELOVL1, HPIP, FLJ12650,
KIAA1078, IL17R, H2AFN, FLJ13352, ELK1, TPM1, TLN2, PPIC, SLC16A3,
FZD3, CARS, TNFSF8, zizimin1, GALGT, DSCR6, TP53TG1, SPTAN1, FBXL2,
H2AFX, HMGE, TCEB3, PLN, FLJ10847, SNA12, STC2, MACF1, ARF1,
UGT1A9, PCDH7, MAN1C1, NESG1, EVIN1, FKBPL, KIAA0417, VDR, SPUF,
SCGN, IGSF4, ARK5, F5, LIMK2, POP3, RGS5, LOX, ADORA2A, PEX14,
VAX2, RANGAP1, MSF, TNFAIP1, C6.1A, ARHGEF7, LPIN1, KIAA0876, ZFX,
FLJ22635, PLIN, TRIM2, EDG2, POF1B, IF2, PPP1R9A, ANG, STC1,
DNAJB2, ODAG, KIAA0763, FLJ11274, FLJ20151, MARCKS, ECGP, MFNG,
COG7, KIAA0429, NEDD4L, ATP6IP2, DONSON, MUC6, PTGES, SOAT1,
MAN1B1, TNFRSF9, SEC61A2, KIAA0500, AP3S2, KIAA1089, B4GALT4,
PTGER3, TLR2, FCGBP, ZDHHC3, KIAA0716, MMP12, CYP2A6, GRAF,
LOC54499, NNMT, COL8A2, OXTR, NOL3, ZNF79, HRASLS, HAMP, AIF1,
CGI-38, SPUF, BAZ2A, FLRT3, PDEF, PDK3, SLC4A7, HMOX1, IFNA21,
HKE4, CA5B, KLK8, PLUNC, NCBP2, KIAA0703, T1A-2, MSX2, FLJ20374,
ANXA2P3, DLG3, PON2, IL17BR, AGRN, PRDM11, TNFRSF6B, STXBP2, PTGDS,
MARCO, UBE2G2, EPB41L1, PDGFA, IL13RA2, CXCL6, CGI-96, APOA1,
MRF-1, NPAS2, MRPL41, LENG4, FGF1, TRAM, AMBP, GPLD1, CHI3L1, AQP1,
SSB1, KIAA1608, MEIS3, FLJ13385, IL1RAPL2, NQO1, MINK, KIAA0843,
DKFZp564A176, MOP3, BGN, BIG1, FLJ13110, dJ222E13.1, SWAP70,
DKFZP586L151, TBC1D2, MAGEA3, ARF3, CSNK1A1, KRTHA6, FLJ21034,
GPR58, KIAA1735, MGAT4A, GNA11, SLC4A2, H41, HAP1, CYBB, MARK1,
GRIT, ETFDH, FUS1, PTN, FUT2, CDSN, MAP3K6, CHST8, BENE, ATF5,
ENPP2, PEX13, PAK4, CUBN, SLC39A2, MYO6, DRIL1, SELT, SLC25A22,
HFE, KIAA0237, PKD1, NPAS2, ZNF3, FLJ23516, SIX2, LIMR, STAM2,
NEIL1, VIL2, MATN3, FLJ23537, AADAC, MCAM, GPR65, TP53TG1, CAP350,
CYP17, EMS1, DKFZp547O146, TNS, MGC13523, ASTN2, TRA1, NPY, CEBPD,
PNLIPRP1, PNMT, TM7SF2, NCF2, AP4M1, ITGB4, SLC11A1, LIM, CBFA2T1,
FLJ20184, RAI14, WBSCR20B, BAIAP2, COPS7A, PNMA2, KIAA0923, PACE4,
FLJ10261, KIAA1395, EDN1, ADAMDEC1, LTBR, KIAA0509, RIL, LPPCALD1,
MCRS1, HML2, FLJ22965, FLJ21870, ME1, FLJ22405, RIT1, FLJ11565,
KIAA0481, FLJ20627, XLKD1, RAB5C, AMPD1, PDCD4, BMPR1A, SLC26A6,
KIAA0939, FLJ10874, KCNK15, ARHGEF9, HDLBP, MCF2L, AQP1, FLJ13055,
PVRL3, RNPEPL1, GPC4, ADCY9, PTPN13, MGC2656, TSNAXIP1, ACO2, IRX5,
IF2, CIC, KIAA0976, BDH, ZFPM2, PSEN2, C20orf46, NDUFS8, GGA2,
FLJ10490, TPD52L1, HLALS, ALFY, FLJ20699, UEV3, AES, DKFZp761K1423,
JAG2FLJ13195, DDX8, G0S2, ITPK1, SEMA6B, SLC16A3, CCL18, HUMPPA,
EIF4G1, HRH1, GSA7, FASTK, HBP17, FLJ14117, LOC146542, APPBP2,
TNRC15, CLDN11, SCARA3, H2BFJ, APEG1, PPP5C, TDRD1, IRS3L, IGF1,
PDGFRL, MUC13, DUSP10, KPNA6, FLJ22795, OASL, HRMT1L3, MOS,
SCGB1A1, PEX11A, ARHD, KIAA0977, MMP24, FCN1, ACP1, LAMP3, AKAP6,
ALDH3B1, TNXB, NF1, APOA1, RBP4, CLTB, GP2, FBXO2, DRG2, DLG3,
PCDHB3, FOLR2, NCBP1, SOX13, HOXD4, FGR, EFEMP2, KIAA0625, TULP2,
GPRK5, EVIN1, CHODL, CDH8, FLJ22173, OR10J1, IFNGR1, PRO1787,
ACADSB, LAMP1, HSPB7, PCSK2, KRT6A, C5R1, DUSP5, MGC1136, TPSD1,
HMGCS2, BCAR3, MOCS2, KIAA1233, VSNL1, UBD, ANGPTL2, GENX-3414,
FLJ12547, HMGCS1, KDELR1, CPT1A, VAMP2, GSTZ1, GJB3, MRPS12, PCBD,
FLJ23322, PASK, ARGBP2, SEL1L, FST, FARP2, HSF2BP, CGI-96, MGC2601,
PBX2, FZD1, ABAT, TSHB, KIAA0874, RHEB2, FMO1, NCDN, CSPG2,
KIAA0844, FLJ22531, COL4A3BP, ACE2, NAV3, SULT2B1, TETRAN, RODH-4,
MADHIP, HT009, ACR, CLECSF12, SULT1B1, ELMO3, NICE-1, HSA243396,
NDRG2, GSTT1, BLAME, TAPBP-R, SERPINA1, CNNM4, TCF3, SSX5, MPDU1,
CHP, FLJ11183, NOL6, FLJ23129, FLJ11196, DKFZP761I2123, KNSL3,
DTNA, BDKRB1, CSNK2A1, ID4, OCLN, CLCN2, SLIT3,
MAPK7, EZF-2, GYG2, K6HF, ALS2CR3, TMEM2, NPAS2, HOXB9, MAN1B1,
APOBEC2, HFSE-1, DNAJC7, POU5F1, PSMB1, PAFAH2, FLJ13852, CCK,
PITX1, NTE, ABL2, CLN8, KIAA0819, GALNT10, FLJ13841, NEFL,
ARHGAP12, APOC2, PTPRO, HSPA6, NMB, OR2F1, MPP2, HPGD, CALB1,
ADRBK2, AMBP, PPP1R1A, CCR7, C20orf28, TRA@, EFNA3, CX3CL1, F25965,
CD2BP2, CDC42EP1, OLFM1, C20orf31, SNAPC3, MIRO-2CALB1, PIK4CB,
FOXA2, C11ORF4, RRAS, HUNK, TGFB2, RBMS2, MASP1, ATP6V1C1, NMU,
PCDHGA1, SLC29A2, PPIE, GGA2, FLJ20535, POU5F1, MGC5509, CITED1,
ATP6V0E, LIPE, ACTN1, SLC26A10, SLC21A9, WNT4, RBMS2, MRPS15, P8,
KIAA1609, FBXL11, TGM2, CHRNA1, TSSC4, SBBI31, KIAA0356, OLFM1,
SEMACAP3, CD6, ITGA2, GTF2H1, FAIM2, FLJ21313, STAT5B, TBX2, GABRD,
AVIL, MGC2615FJX1, FLJ14675, IL1RL2, AK3, ZNFN1A3, SSPN, RELN,
SIGLEC7, COL5A2, HLA-DOB, SLC12A3, HFE, PLINP-1, Apg4B, MGC39851,
HIPK2, HSPC159, PSK-1, ABCA12, MMP15, PKP3, HERC3, RECQL4,
DKFZp434C0923, UNC84A, FTS, AZGP1, FASTK, ARFGEF2, DSCAM, MED8,
SPP2, P2RY6, RPIP8, DHPS, ST14, SAMHD1, MGC32043, SPARCL1,
FLJ22160, GHR, YAP1, MTMR3, SLC20A2, PART1, PTPN14, BAIAP3, EPPB9,
ED1, TPM4, TEK, PRO1942, H2BFE, LEPR, NAPG, MGC29761, SLC34A2,
ZNF358, GRB14, CMKLR1, KIR-023GB, MET, PBX1, CYP2D6, SLC7A8,
IL13RA1, ARNT2, GTF2H4, CD86, BM88, CEACAM1, BIRC1, CAMTA1, PDZK1,
MOCS1, GLYAT, ChGn, RQCD1, CRA, BAIAP2, PTX3, CYR61, VAMP4, HSPA4,
HUG1, GBL, EPS8R3, PTPRU, DLGAP1, GEMIN7, MADH6, PTPRG, NFX1,
KIAA1028, RNASE6, AD037, PI15, SNAI1, LOC157542, ACTG2, SLC35A3,
SIRT3, NPR2, NPC1L1, HCK, DDR2, SLC5A2, OASIS, FLJ21511, LRP2,
RGS10, ALDH8A1, COL4A3, GS3955, CLECSF6, UP, MKL1, MADH6, PRDM5,
WNT1, SPAG4, SORBS1, ASPH, PLK, IGSF1, ARHF, CAPN2, LIG3, SULF1,
CCKBR, TEAD4, C8A, MGC10771, FCGR2A, SEC14L1, KLK11, SPIN2,
C8orf17, THBD, FKSG28, NEURL, FLJ10647, LTB4R, CHRM4, C3orf4, ALLC,
SLC3A1, SLC1A1, MS4A4A, EDNRA, ILT11, IGHMBP2, MGC4276, IGF2R,
FLJ20421, PBX2, 37872.00, FLJ23604, FOXI1, LUC7L, CD86, PVR, SCD,
GPR37, UNC119, NXPH4, FCGR2B, S100A2, MORF, BMPR2, AKT1, FLJ11715,
IL13, TADA3L, NFATC4, PPP3CC, CARM1, PTGIS, PLOD, CD36, BBOX1,
VNN3, AKR1B10, SEMA6A, E2IG4, HOXC13, RNASE4, DKFZp434H2215, EKI1,
MGC5356, KIAA0752, RUNX2, ACCN2, GALNS, CABYR, PCDHA3, SSX2,
GOT1NPAT, CORO2A, DGCR13, CAPN5, GPM6A, GLRB, NPEPPS, RIPK1, CYP-M,
GLRA3, BIGM103, UTX, NY-REN-45, ATP1A3, ANXA2P1, IL1RAP, PRO1600,
WNT2, HYAL1, SH2D1A, TREM2, TUB, KIAA1036, KCNB1, CNN1, BLAME,
PITX1, DXS542, ADORA1, TNXB, GABRE, FABP3, PGRMC1, FLJ20513, SCIN,
FLJ13052, CP, LIMK1, MSF, EDN2, FLJ20623, ESRRG, KIAA1237, INADL,
KIAA0889, HS3ST3A1, FLJ22593, ASIC4, FLJ21144, FLJ11827, TAT,
FLJ20584, SMA5, NCOA3, GLP1R, PRODH, FABP3, FDXR, DEFA4, SORBS1,
MRPS12, HSF1, EEF1E1, CTLA4, WDR4, ASB7, ABCA8, CLPS, PSMA7, ARHN,
PEG10, AKAP12, MGC12904, FLJ10312, FLJ11539, RAD1, SERPINF1, MGAM,
PVT1, PTHLH, STS, PRG4, SYNCOILIN, CASP2, FLJ12168, MARCKS, HTR3B,
RECQL, COL4A2, CD97, TRIM36, MGAT3, GRIN1, SOX4, KIAA0475,
DKFZP586M1120, SLC2A4RG, CTSZ, SQV7L, PLD3, OR7E24P, CDK5, GRIA2,
PRLR, MHC2TA, CST6, LOC56920, NUP214, BET1L, FIGF, THBS4, HLA-DRB4,
CAPN6, TLR7, MBTPS1, KIAA0992, BG1, FLJ12681, MAK, APOH, TNFAIP6,
CRYAA, PKD2, IGFBP2, TSPAN-3, ATP6V0E, KIAA1579, MGC20727,
KIAA1093, LOC55565, HS322B1A, LOC51285, STC1, KIAA0992, CGI-01,
TRGC2, EPHB4, DES, CNOT4, MAP4, CDC42EP2, HSD3B1, RDH5, XYLT2,
CHRD, SPBPBP, PDP, MYBL1, HPN, GOLGA2, LOC63929, EXO70, PCDHB11,
KIAA1036, ANGPTL4, TNFRSF10C, EVPL, TEAD1, SIAH2, PMM1, DPYSL3,
FLJ14297, TACSTD2, BSN, FAP, SEMA3A, RER1, AXL, PROL4, CASKIN2,
RENT1, CLDN3, DRAP1, ADAMTS7, TCEB2, EPB41L1, GUCA1A, FLJ22659,
PAPPA, CBLN1, FRCP1, IL1F9, ITCH, MMP26, STRN3, CEBPD, COL21A1,
BTD, KIAA1034, MIG2, FLJ20591, FGG, ASCL1, CXCL14, PDE1A, OR7C1,
HLCS, PTPN21, HUMMLC2B, SECP43, BCAT1, DRD2, TAT, MSR1, OMD,
IGFBP4, C13orf1, FLJ21919, FLJ11807, AMELX, KIAA0346, FLJ21916,
OLIG2, L1CAM, TAPBP-R, Cab45, NR1H2, TCP10, KRTHB5, PCDHA9, TNC,
DKFZp434L0850, FLJ11011, SKD3, SPINK4, DZIP1, FLJ23548, FLJ23420,
TFEB, PCDHA6, LOC160313, FLJ10496, R29124_1, THPO, AQP6, KIR3DL2,
MGC10848, C21orf18, ACCN2, TBL1X, RAB6B, BHMT2, APOB, IGSF4,
PAPSS2, RBP1, TCF2, R30953_1, CD3G, ZXDA, TNFRSF10C, FLJ21665,
CYSLTR2, IL6ST, ZNF214, AICDA, PTAFR, FLJ12806, BA526D8.4, CYP2C9,
TWIST, PPP2R5C, MASP2, DUSP9, CGEF2, GABRB1, CDC42BPB, TNFRSF5,
CCR4, PYY, PILR(ALPHA), BIRC7, LANGERIN, H2AFI, PLCE1, OGG1, TAZ,
PDCD5, SE57-1, FKBP2, FBLN2, RBM9, 384D8-2, WNT2B, NRBP, CDH6,
G6PD, C1orf22, LSM4, STX6, ZIC4, FPRL1, CALCB, AGPAT3, SHB, TOM1,
AGA, ZIC1, SIAT9, PTPRZ1, MSC, DKFZP566F0546, FLJ32069, CD28,
PPP2R3A, ASTN2, ARHGEF11, JPH3, FLJ21477, GH1, HOXD3, MS4A2, SVIL,
DPYS, F2RL1, ECGF1, PRCC, POLD4, OAZIN, CHRNA3, KIAA1000,
DKFZP586D2223, DAZ4, WNT7B, MUC4, GCNT3, OR1E1, CLSP, CD1D, CCR1,
ORCTL3, EEA1, SIX3, FLJ10140, FLJ10884, HNRNPG-THSD3B2, SERPINE1,
RHO, MUC4, PTN, DNCLI2, TNFRSF10B, LOC90326, NR6A1, NCYM, SCGB1D1,
EPHB1, NOX4, DJ122O8.2, PLAUR, PDE4C, PIP5K1A, MGC14799, IGFBP1,
IDUA, IGHM, NAPA, PARD3, LIM2, ADD2, HSF4, CABP5, TF, TNXB, NET-5,
ITGA3, IGFBP3, GDF10, PRB4, KCNF1, ATP11A, KIR2DL2, SMARCB1, MBP,
IGL@, NFATC1, CDH16, RHO6, CCL20, FLJ20605, ASIP, LDB2, HCRTR2,
HOXD3, GPR87, VCX-8rLOC116150, TPM3, LRP1B, MAGEA6, FLJ20701, PAX3,
IGSF6, TOMM22, GALNT3, CHML, COL6A1, FAAH, B7, RANBP1, KIAA0876,
CYP2A13, CD5L, C21orf2, RYBP, GJA10, COL15A1, TEX13A, SCNN1B, TRD@,
RIL, ITGB8, PLEKHA1, GRIN2A, FSHB, PDK2, SAST, PRPF18, FLJ13479,
GRP, SLC4A8, SMURF1, GK2, INSL4, FLJ20311, GLRA3, KIAA0828, DLX2,
EPOR, RRBP1, SDC2, zizimin1, CCND1, P2RY2, CD28, B4GALT4, ARHGDIG,
TBL3, IL17, FLJ20519, FAT2, UPK1A, SERPINA2, CD209L, NRP1, ACINUS,
RREB1, TNFRSF4, PRO2214, DKFZp761O0113MAP3K7, SPRR2B, DNA11, NOVA1,
DEPP, LOC51725, SCAMP-4, TLR4, MAX, PRDM16, KRTHA5, PCDHB1, GNAL,
P37NB, ISL1, SH2D3A, TFPI2, CREBBP, ACTA1, ALP, OR1A2, CGI-58,
SH3BP2, APAF1, CD209, DKK4, IL18RAP, ESMI, PAX2, EVI5, MFNG, ATF5,
CUGBP1, FLJ10376, CMKLR1, SLC23A1, MGC34772, FLJ23033, IGLJ3,
AMACR, SIN3B, CCL18, CSPG4, FLJ20241, DNM1, FHR-4, GNS, GDF11, PAL,
PPFIA2, CASP10, ORM2, SPTAN1, SPUF, CALCRL, USH1C, ALK, FLJ11850,
FOXD1, SH3BGRL3, MNDA, EPB41L4A, MMP16, ANK1, WISP2, GSTA1, FER1L3,
MGC33190, DAZ2, CHST3, DRF1, TM4SF9, CDC25C, ACVR1B, LU, SGCE,
POP2, PCLO, COL18A1, TSHR, Eu-HMTase1, MSR1, GPD2, CLDN17,
KIAA1069, CYLC1, ABCB11, MIG2, LY6H, ARFRP1, BMP2, ACOX1, FZR1,
CAMK2B, HUMCYT2A, LILRB5, ENPP3, IL4, SCN11A, CALU, IGKC, THEA,
OPRL1, KIAA1053, SIX1CABIN1, SCN7A, THOP1, NR2C2, FLJ23462TRPM1,
RAB3D, CREBL1, ABCD2, VDU1, GAL, CPN2, FLJ10408, PHLDA1, RAB1A,
HAND1, MGC5347, BAI2, EDG8, GPR30, PCDHB8, TYRO3, PRO0618, PRKCI,
UCP3, GSG1, PRO1048, HRH3, SARDH, FLJ10803, WISP1, PRLR, RIPX,
NNAT, SFN, APBB2, TLL1, PCNX, KYNU, MKRN3, HGC6.1.1, PLN, RIPX,
CDC2L5, ATP11A, SPI1, RIGPDK3, AFAP, KIAA0427, CYP4F12, EFNA5,
FLJ11125, DUOX1, FLJ21240, DNAJC9, RQCD1, DLG5, PIGO, ABCB8KCNA5,
KIAA0409, FLJ12891, SHMT1, DNALI1, POLYDOM, PFKFB4, SHOX2, DGKE,
ELF2, MUC5B, WHN, SCAND2, LOC160313, FLJ23510, AK5, FLJ11871,
ITGB5, CPS1, DBT, CDH17, FCGR2B, PCK1, PLXNA2, ACE2, CD7, FLJ11619,
ZDHHC11, FLJ21562, FLJ20211, MGC2821, FLJ20624, ICK, PARK2, PNAS-4,
CLECSF6, PCDH11XFGFR3, PTGER3, PROX1, HRC, EPB41L2, KIAA1117, ATSV,
LAMC2, ITGB1, TRA@, PAK2, DKFZp762C186, OCM, HNF4A, AVPR2, FTCD,
TNNI3, HR, SLC35A2, PP1665, GA, RGS5, OPLAH, GDF1, OR3A2, FOXO3A,
TNRC21ABO, ITSN1, PVR, CNGA1, UPK3B, PCDHB12, ALCAM, HFE, KCNJI5,
KIAA0997, RGS11, NDUFB7, ADAM28, FLJ13055, PRO2176, CACNB4, RIN3,
SLC5A7, FOXH1, PKDREJ, FLJ10232, DGKA, retSDR4, EDG2, SEMA3E,
SARCOSIN, THPO, PTPN21, POU2F3, MAP1A, ZFP37, SUPT6H, ADAMTS6,
ASMT, DKFZp434C0328, ROR1, FLJ22800, VAMP1, KIAA1654, RBM8A, EPAG,
TNIP3, INSM1, XRCC4, IL6ST, UNC84A, UBE4B, CAPN11, NPEPL1, TAS2R10,
FLJ23093, NPPC, PTPN21, SLC22A8GAD2, LOC51063, OGN, MAGEA8, GUCY2C,
NT5E, SGCG, C8orf1, LGALS2, PRKAR1B, DEDD, PPARG, PDGFB, PRO0461,
ALFY, TNFRSF11A, DNAJC9, KCND2, PEG10, SPINK1, GCM1, VHL, CLDN1,
PRSS7, H4F2, D21S2056E, CXCR6, LIFR, KIAA0599, TNXB, EHD1, ARNTL2,
CGR11, SOCS1, PKLR, ZFP318, ZF, CHRNA1, DKFZp434M0331, DES, TMOD3,
SP140, KSR, BS69, IREB2, PAWR, CACNA2D1, C21orf62, Gene Symbol,
OAZ1, CFL1, RPL28, JAM1, CGI-119, NICE-3, RNP24, JTBFLJ12806, ARHA,
FLJ13352, SYNE-1, TRPS1CGI-119, NDUFB9C20orf114, JAM1, RALA,
FLJ30532, PIGR, MRPS24, MYO5B, LOC155465, STUB1, MGC14353, ARF1,
C20orf24, EGR1, ANAPC11, MRPS15, MIR, PIGPC1, MRPS21, CL25084,
H41LOC124220, RAB10, B4GALT1, PPP1CB, MGST1, TCEB2, MGC19825,
HSPC163BACE2, BRI3BP, FLJ14511, MRPL47, NMES1, FLJ14735, DAD1,
KIAA1324, ENAH, PSMB2, RHPN2, HTPAP, DKFZp761P0423, C20orf108,
MGC45416, TMEM9, UBQLN1STK35, APOA1BP, GRLF1, SPEC1INSR, LOC150678,
SMP1, FLJ32115STUB1, HLA-C, ORF1-FL49, TAF10, RAB40C, DPP3, AIBZIP,
LOC55971, SSR3, ATP6V0E, SNX6, SNAPAP, ALS2CR9, KPNB2, EPC1, NTN4,
C20orf52, H2AFJ, UGCG, IMAGE3451454, EEF2K, MRPL14, E2IG5, MRPL36,
GPCR1, E2IG5, MGC14151, RASD1, CGI-141, AGR2, KIAA1437, HSPC210,
BTBD6, H2AFJ, MGC14151, FLJ20048PSMB4, MGST1, FLJ31364, EGLN1,
MRPL53, LOC88745, IRX3NFKBIEUNC5H2, TAF13, RDH-E2, MGC12966,
DKFZp434G171, GUK1, FLJ20671, FLJ20623, CAPNS1, PFN1, KIAA1671,
FGG, H19, C20orf149, CAPZA1, RAB18, FLJ23153, CGI-19ABCF1, TCEA3,
NDUFB10, NDUFB10, RNF7MAL2, NUCKS, RPL23A, LOC51290, TMEPAI, APH2,
FLJ13593ATP6V0B, TLP19, SLC17A5, ENPP5, C20orf24, AKIP, D1S155E,
FLJ20171, MGC39329, MRPL41, NDUFV3, KIAA1096, LRG, BPNT1, LOC51255,
CISHPGK1, PLEKHA1, HSPCA, COPZ1, DKFZP434L1435, TMEPAI, BRI3, AKIP,
KIAA1191, LOC92840, CLDN12, FLJ14525, C20orf149, CDC42, TMPRSS3,
LOC199692, FLJ22174, LOC113246PKIB, RAP2B, HIBADH, LOC57038,
FLJ14117, EDG3, MBC3205MGC2550, RCP, NUDT5, LOC51260, SIPL,
KIAA1223, HINT2, HN1, ERdj5, PHP14, MRPS36MRPL32, C6orf49, CAPN13,
MIR, RNF19, ATP11A, LOC51128, FLVCR, ADCY4, KIF5B, ARV1, RAB5EP,
PX19, RREB1, MIR16, LOC51248SMAP-5, SYTL2, FLJ11320, MSTP028, OCLN,
MGC14833, SMBPRDH13, MGC40107, KIAA1165, SPPL2A, Cab45, MGC20781,
LOC51241, MGC11266, DKFZP566J2046, FLJ14624, CKLFSF6, LOC147184,
DKFZP566F084, FLJ20203, FLJ10856, MGC11034IMUP, CAMK2D, MK-STYX,
RAB3D, C20orf142, DNAJB11, MGC23908, FLJ10074SURF4MGC11102HSCARG,
MGC14327, HYPK, HSPC121, TOB1SRA1, MGC14832, JAM1, MGC27385, PX19,
FNTB, MIR, LOC56932, POSH, MPP5, MRPL52, MIG-6, LTB4DH, ZAK,
FLJ22649, SCGB3A1, MGC33974, FLJ21016MGAT4B, KIAA1404RBMS1,
DKFZp761H0421, ARHU, FLJ12697, CGI-149, SPUVE, TINF2, RPL17,
LOC54516, WTAP, MAGI-3SAMHD1, FLJ11011, FLJ10052FLJ23751UCK1,
LOC170394, TP53INP1, HOXD8, XPR1, MGC10540, SORBS1, BCCIPFLRT3,
FLJ22558, FLJ11200, SAMHD1, PIGR, FAM3B, CYP4X1, NFIA, KIAA1715,
FLJ20160, CTHRC1, DKFZp547A023HSPC121, LOC84661, LOC113386SH120,
GNPNAT1, FLJ32499, UBXD1, LOC90120, HBLD1, MGC13186, SPEC1,
MYBBP1A, MGC4248, DKFZP434I1735, LOC127018, FLJ37318, FLJ20421,
PTGFRN, p25, PIGM, MGC43399, ERdj5, SYT13, IHPK2TH1L, FLJ20727,
POLE4ASH1, KIAA1130, LOC55829, MGC10084, ZPR9, KIAA1458, CNN3,
WASLFLJ20097, SURF4, HSPC163YAP1, H4FH, MGC40214KIAA1200,
C20orf139, PKIB, CGI-36, CLMN, SET7, SEC10L1, MGC22825, FLJ10525,
LOC113386SELENBP1, SLMAP, VPS29, KIAA1972, MTCH2, NPD007,
OLD35DNCLI1MGC14839, SH120 UBPH, APOA1BPLANPL, UBQLN1, FLJ11101,
C8orf13, DKFZp434A2417, C14orf31, C14orf100, MMP24, CRIM1,
FLJ23393, MGC45714, INADL, SEI1, OPN3, CGI-97, MGC21874, C14orf47,
KIF3B, FLJ11046, C(27)-3BETA-HSD, RAB18, IR1899308,
MGC17299KIAA1223, KIAA1322, RAB23FLJ32205, DKFZp434K114, EHF,
ShrmL, KIAA1434, KIF1B, ERO1L, MGC15397, BAT5, C20orf45, FLJ31235,
LOXL4, FLJ20707, Cab45RNF7, MGC2803, FLJ36445, CLDN1,
DKFZp761N0624FLJ20308, MGC33338, MYO5BRBM8A, MGC10765, C14orf9,
FLJ32642, ATP1B1, MGC4309, KIAA1272, LOC154467KIAA1483, UBE2H,
EHD4, UBE2J2, FLJ20085, DKFZp762H185, MGC20486, MGC26847, MGC15854,
LOC115265, NEK6, SPRR2AMGC13045, MGC4604, LOC51256,
ANKRD9FLJ31208TRIM47, AP1G1DNAJC1DKFZP434I116, LNX, SDCBP2MacGAP,
FLJ14957, C20orf110, SURF4, RAB5EPC12orf4, GL004, DC-TM4F2, SAT,
DKFZP434A0225, GK003, dJ55C23.6, JUB, LOC89894, LOC115294,
C20orf129, PCDHA10, HSPC242RAB18, COX15, MGC11115, MRPL27,
MGC15397, FLJ11752, LOC116238, C9orf25, LOC51760, MGC45408TBX3,
HSZFP36, TRIM8MGC22793, BAL, FLJ25157, C20orf155, RPL35A,
ZNF265ILF2, MGC23166, FBXO6, KIAA1870, DKFZp761D0614, ZNF398,
ALS2CR9, MGC26818, EMS1, FLJ90119, GALNT4, LOC54516, BRI3, HSCARG,
PPP1R1B, GPR54, FLJ14299, PPP2R2A, MGC5391, SDCCAG28, PHP14,
TGFBR3, MGC1842, MLLT4, DFFA, SELM, MAPKAP1, MGC10974, AD-003,
FLJ10902, MEF-2, MURR1, MGC2541, GSR, MGC19825, MAFB, LOC139231,
FLJ23091TEM8, RERGKIAA1553, CFL2, CEBPG, KIAA1554, SEMA4BPDCD4,
PNAS-131, MGC31963,
HT002, HRD1, MESDC2, PRO2605, PTGFRN, KIAA1244, MGC10999, MGC10715,
CGI-85, KIAA0779, NUCKS, FLJ13881, LOC127829, HR, KIAA1538,
KIAA1255, STUB1, KIAA1841, CALM2, RIG-I, HOXB8N4WBP5, HTPAP,
CXCL16NAC1, TRABID, LOC135154, TRIM56, MK-STYX, Eu-HMTase1FLJ30794,
DIRC2PTPN23, GBP2, TRIM11, KIAA1976, MRPS26, TMEM9, FLJ23420,
MGC14817, MK-STYX, IDS, EPI64, KIAA1724, MGC2477, FAD104MGC32065,
MRAS, DKFZP761L0424MGC4840, FLJ20739, GFRA1, FLJ23867, MGC40555,
FLJ14251, FLJ38628, MGC2941, MGC22805, NOL6, MESDC1, FLJ22865,
FLJ25357, DLG5 ARHGEF5, HYPK, DHRSX, PCDHB2, FLJ90165,
C17orf26PVRL2, DKFZP564D166, NOR1, GLIS2, SPPL3, TTC8,
FLJ14502CED-6, MGC14141, MLZE, LOC57168, KIAA1337, KIAA0217, CRB3,
KIAA1350, PPM1AFLJ20273CCL28, PDP, MGC14859, GJB2, GPR,
ECGF1LOC92399, HOXB9, LOC90522, KIAA1951, MANBAL, MGC11386, RIPK1,
NLNHCC8LOC115548NUP88, TMEM8, CHDH, FLJ20507FGFR1FLJ30803,
KIAA1280, FLJ13089, LOC120224, ZNF75A, DNAJC5, SDOS, MRPS15,
MGC2628, FLJ11236, TRIM39, NESHBPFLJ10839SULF2., FLJ10210, METL,
FLJ12707, HUMAGCGB, FLJ13195, FLJ21016, BOK, FBXO25, OSBPL5,
DKFZP434N1511, KIAA1813, VANGL2, LOC124446, HDCMA18P, C20orf7,
MGC1314, MS4A6AANLN, MGC40499, KIAA1337, FLJ10116, NOTCH2, RRP40,
PFKFB4FLJ14681, KIAA1026, C1orf6, MGC5384, LOC85865, PHAX,
MGC11134, FEM1A, LACTB, TIM50L, ARNT, MS4A6A, PPIL1, C20orf3,
MRPS15PGGT1B, CXADR, LBP-32, FLJ22004, FLJ32069, UACA, MGC2747,
FLJ13187C1orf28, CBX6, C1orf13, NY-BR-1, FLJ20748, KIAA1821,
FLJ31751, LSR68, TRAD, USP28, FLJ10702, GBA2, B7-H3, DKFZp547D065,
TH1L, TSGA2, RORC, ETL1, FLJ30634, MGC10702, TEX27MGC33602,
MGC2555, LOC55893, LOC128439, EDIL3, KIAA0146, RFXANK, HS6ST1,
NEK6, FLJ20186, MGC15416HSPC159, SCAMP2, LOC133619, NGEF,
C14orf58LOC91012, MGC12972, MGC11034, CYT19KIAA0819, LOC55893PHCA,
KCNK6, CRIPT, CDW92MGC3195, GTARPAPOLG, MGC24180, KIAA1126MTA3,
MGC24103, moblak, MS4A6A, DAG1, KIAA1394, MGC13114, KIAA1337,
FLJ40021, DPP9, KIAA0789ZNF144, TMPIT, MGC13114SYAP1, FBXO32,
BOCCD44, LSM10, KIAA1673, CTL2C21orf63MGC2560, ZFP385, TM4SF9,
DNAH5, PGGT1B, DKFZp586M1819, ID4, CLIC6, C20orf64, YAP1, FLJ21615,
GRP58, LOC149267, C20orf7FLJ37933, FLJ90586, FLJ22626, LOC51242,
MGC4604, SDCCAG28, KIAA1321, TEAD2, RPS3A, LOC90701, FLJ32915,
FLJ31434, PUNC, TRPS1, MGC45441, LIN7B, DKFZP434H0820FLJ32468,
DNALI1, COX4I2, HOXC9, FLJ20337CLMN, BCAA, OPN4, DGAT2, PRDM6,
DKFZp761J1523, KIAA1244, ICMT, FGF11, C21orf97, C20orf169, VPS18,
SIRT2, MGC15677, MGC4604FHOD2, DKFZp547M072, CGI-125, NLN,
MAP1LC3AFLJ31842, PGLYRP, FLJ32069, DKFZp547A023, MGC39325, RRP40,
KIAA1880, LOC116254LOC51061SYTL2, KIAA0076, KIAA1580,
GPT2MGC4840KIAA1345FLJ12577, Tenr, CCT5, FANCF, USP21, KIAA1273,
DKFZP434F091, MGC13007MGC16131, SEC5FLJ22215, FBXO22, MGC16491,
MGC16028, MGC2601MGC15906, C20orf45C17orf28, IL17BR, STK11IP,
SEC61A1, STAU2, FAPP2, FLJ25429, CAC-1, ROCK1, MS4A7,
DKFZp434D0215, FLJ20442, HFELOC148523, LOC90353, HIPK2, ERBB2IP,
CDKN2B, CGI-09, DPP7, DUSP16, CGN, CLONE24922MSCP, DKFZp547E052,
MGC45714, MGC5370, MAP4K1SLC4A11, MGC26568, PPIL2, MGC27034,
FBXO30, DKFZp547C195, MIC2L1, DHRSXHTPAP, VIK, FLJ23841,
DKFZP434D146, HPS3, IPP, SEMA6ADNAJC5, ULBP2, LOC120224,
FLJ11036LOC90580, LOC92906, WDR5, RAB35FLJ10697, MAPT, FLJ14825,
KIAA1295, MGC2217, ACTR8, SENP2, LMLN, LTB4DH, MGC11257, MGC15476,
SART1, TNNI3, LOC128153, SCDPRO1912, KIAA1896, LOC80298, FLJ20533,
SMCR7CGI-69LOC114977KIAA1691, C20orf102, VIP, FBXW5, TRIM35,
SLC30A5, JAG1SLC13A3, COQ4, OVCOV1, GLI4, RPC8, FLJ31153,
C20orf162, NRP2ENAHARH2LOC55971, FLJ20038CerCAM, UBE4B,
LOC57168ALS2CR9, SLC21A11, GPR108MRPL41, KIAA0831KIAA1970,
DKFZp762I137INPP4B, ZFP67HSPC189, PF1PCDHB6C2orf9KIAA1468,
FLJ14399, DKFZp434G118, KIAA1500, FLJ14681KIAA0869FLJ22558APXL2,
MGC16028, APMCF1, LOC90990, PCDH18, DKFZP564J0863, COG1UBE2H,
KIAA1970, CTSB, MGC30052, FLJ90575, MMP28, MASS1, MGC13034, RIPK3,
CCT4FLJ12519, GOLGA3RCPCP, MGC20983, FLJ35207 EML4,
TRUB1MRPL41ZNF213, RP42, FLJ20813, SAMHD1, KRTAP4-8, C4orf1FBXO8,
EPB41L4B, ZNF75A, STK36, PAWR FLII, DKFZp761A052, C20orf23, AKIP,
MGC4643, VTI1A, LOC223082, PDK4, PSMB7, KIAA1710, MGC13272,
MGC4342, GNG12, N33, FLJ14800, FLJ21924, LOC220074, FLJ22474,
DKFZP434P106, FLJ13236, PTENP1, FLJ21159KIAA1441, CGI-85, FAM3D,
DKFZP566J2046, LOC116441, TEAD1 LOC51249, PARVA, HSPC230,
MGC5442FLJ23091LOC55893, PDCD6IP, OGN, TRIM41, MGC42105, CPNE2,
DKFZp547J144, KIAA1784, KIAA1337, SLC30A1RNAC, KIAA0429NRXN3,
Spir-2, GGCX, KIAA1694, DNAJA4, CAPN13, NAP1L, RPS27LTMOD4KIAA1557,
FLJ21415DKFZP564G092, CLN8PARVA, FLJ40021KIAA1708PC326, NOSTRIN,
LOC129642, KIAA1301, CGI-85, MGC13102, LZIC, KIAA2025, FAPP2,
FLJ22679, SNX8, ZNT6, DUSP16, PANK2, FLJ14834, DKFZp434C0328, ROD1,
FLJ34633, FLJ13391, ARHJ, FLJ11753, B29, OSAP, B2M, CYGB, DERMO1,
MIR, WDR20, C20orf155, FLJ32919, MGC2408, CLGSCYL1DKFZp761A132,
DKFZp451G182, FLJ90119, FLJ36991, SDCCAG43, PPP1R16A, MGC19764,
FLJ13263, GNG2FLJ12517, MRPL20, MGC16212, SRA1, GEMIN7, FLJ37953,
HBP1, KIAA1737, CTL2, KIAA1754, FOXA1, MGC13096, HDAC3BOC,
FLJ30973, BRUNOL5SEL1L, SPTB, POU4F1, KIAA1337, MIZIP, NAGSCGI-72,
PRO1853TRAF4, MGC32124, SNCAIPDKFZp434O0515, SMOC2,
FLJ12770LOC113828, FLJ40432DKFZP434K0427, SFPQ, RNB6, BMF, GSH-2,
REV1L, SLC27A4C1orf19, SLC5A1KIAA0478, SPPH1, FZD8,
MGC26877LOC150379STK36, LIMD1, KIAA1694, FLJ25357ELAVL2, BM-002,
ProsteinFLJ20374, STK35, FLJ31434, CHRM1, DLC1, FLJ36155, FLJ21939,
MGC21675LOC51320, FCRH3, FLJ10948, MGC27034, MGC14801, MGC11102,
SEC14L2KIAA1393, DKFZP434A0225, DKFZp434F054, SHANK2, OSGEP,
MGC45474, ARHGAP8, BTCIL1F7GRLF1, DKFZP434B172, MRPL35, PAPOLG,
MGC33662, XPO5CTEN, DSCR9, ITGB6FLJ14768, STEAP2KIAA1522, FLJ32069,
PCDHB3C20orf136, XRN2MARK1, DKFZp547O146, FLJ12517, FLJ10597GK001,
CITED4, IGL@, GALNT13MGC26963, RASAL2FLJ20605, LOC112609, NLGN3,
C7orf2, HSPC182, DTNASNX9, ALS2CR9KIAA1219KIAA1190C14orf31HSPC065,
KIAA1221, FLJ10252, C4orf7, KIAA1363, NCAG1, NAV1, C14orf28, KLP1,
ZDHHC9, MGC2615, SMUG1, PHLDA1, AD-003, BRPF3, ASCL2MGC15523, RELA,
ROPN1, FZD4, ZDHHC4, KRTAP3-1, PCDHB16KIAA1036, SLC2A12MSTP043,
FLJ32731AMID, FLJ30277, CKLFSF2, TLR7, SEMA6DNOPE, DKFZP434P0111,
SDS3, KSP37, PDCD6SNX14, A1BG, SLC31A1, MK-STYX, SNTG1LOC80298,
FLJ25534, MGC10485, FLJ10035, NEUGRIN, BK65A6.2, NKD2,
TJP2TRPS1FLJ20753, PPP1R1A, LOC123169, LOC112817, ZNF341, TM4SF9,
FLJ90586Spir-1REN, FLJ10210, CEGF3, NOXA1, FLJ14981, RIMS1,
PCDH20FLJ20360, DKFZp761H0421, MSX1, DKFZp434F2322FLJ10188, SPP2,
MUM2SYT12, pknbeta, MGC11349, RNF40MGC4734, MAP1LC3A, FLJ13687,
CNTN3, MGC19604, TLR8, FBXW7, HM13, TLE1AKIP, SMURF2, FLJ21963,
MRPL44, PRKAG3, DREV1HSA243666, FENS-1LOC51693 FLJ10486, HAVCR2,
HDAC3, AHRR, CXCL14, CGI- 09MGC13251DKFZp434E2321,
C14orf102KIAA1434, PHCAKIAA1145, FLJ00028, AMOTL1, TMPRSS6, ODF3,
MGC4604, DJ667H12.2, VGL2FLJ10052FLJ13881, UK114, DSG2SLC12A4TBCD,
MAP1B, OSBPL10GALNT10, DKFZp547I094MGC35352OSBPL6, TRIM7, FLJ30473,
MGC2562, DLG1, DKFZp434P0531, KIAA1554ESDNKIAA1910,
SEC15BKIAA1172DSCR1L2, PSMB5OSBP2, GPR34, MGC15854, HDAC5LOC90990,
DKFZP564B1023, CASP2NUP133Spir-2, LOC151534, C22orf23, FLJ90811,
DKFZp434I1930, NET-2, LOC113026, HOOK3MGC8721, BLVRA, PLA2G12,
DAPP1, FBG3 MGC10974, LOC114990, DKFZp547M2010, FLJ20542,
LOC144455CGI-94BRUNOL5HKE2, PRND, WFDC3FLJ30990, FLJ23654,
KIAA0876, NDUFS1WASL, KRT6IRS, KIAA1684, RU2, DKFZP434K0427,
DKFZp434B217, KIAA1549 DKFZp434F2322, MGC4126ENTPD2, GPRC5C,
RGNEFFLJ31052CEGF3SYN2, C11ORF30MGC3038, ITGA11KIAA1053LOC57822,
LOC130589, RASGRP4, DKFZp434H2111, NFIA DKFZp434C0328, FLJ20209,
NDUFS2SENP8SLC2A4RG, p25, C20orf167KIAA1909, MGC4238, MGC16372,
CD5, IGKC, KCNQ4, ZD52F10CCL28, FLJ20539KIAA1357, EPB41L4B,
MGC14128, SLC1A5RHEB2, HSPC182, FLJ22527, MGC21621,
MGC5370KIAA1130, KIAA1554C9orf11 FLJ31937IMP-2C20orf51, KRTAP17-1,
DKFZP434E2318, DKFZP564B1162RPL29, PRO1489HSPA9BKIAA1688,
KIAA1324NCOA5, AXIN2, LOC92689, KIAA1272FLJ14642, FLJ37440,
FLJ12604, RGS8, MS4A6AZNF216, LOC84570, KIAA1126, SMOC1,
TSCOTMGC18257, RDH13, C1QGKIAA1576, ZFP28GNA14,
FLJ39155FLJ32069LOC155066, MGC19764FLJ10159, MGC16309LOC55862,
PCDHB1437867.00, LOC56851, SNRK, MGC13017, ADAMTS16AGMATPCDHB10,
LOC113179, NOL6, C20orf55, PALMD, GFER, BNIP-S, KIAA1337AXIN2,
MGC39807, LIP8KIAA1053, MGC45378FLJ11273,
FLJ23129DKFZp586I1420KIAA1210COX7B2, TCF7L2, USP21, DKFZp564O1278,
FAAHDPCR1NUMBMGC35285JUBEVX1, LMO4AMOTL1, C2orf7TMPRSS3,
ARHGEF7CSRP2BP SBBI31, SSBP4, FLJ23654, CPMDKFZp762K222,
DPP9CA5BKIAA1817C14orf92, MYO3A, VIK, CACNG4, NYD-SP21LUC7L,
SFRS12, LIPHDIS3, GCC1, FLJ10504, CASP14, KIAA1387, DAB2IP,
KIAA2028C20orf40GPR92FLJ32658FLJ25027, UQCRC1, EVC,
COG1FLJ25555MOV10 ALDRL6, HTGN29MGC12466, IBA2, MGC15548ADD3, GSN,
C14orf50MGC22805MGC39650, KIAA1203FLJ14311, HRMT1L1, MASS1, CGN,
IGHG3, ESPN, ZDHHC12, PCDHB4THRSP, FGFR2, LOC91461FLJ25604DRAPC1,
ARL8BACH1, KIAA1921, GPR81, KIAA1145ARHGEF7, retSDR3,
C20orf6ARFGAP1NSE1TPSG1MRPL4, KIAA1870, X102, KIAA0599, CACNG6,
FLJ22301, ZIC2, KIAA0599, MGC4796 HT036, DQX1, SYTL4ICAP-1A,
KIAA0350, KIAA0872, GMPPB, FLJ37953, LMLN, NOL6, POLR2J2Hes4,
LOC57038, TRPM6, ABCC13, BCAR1FLJ30803FLJ32069KIAA1909,
TIMM8BEML4MGC15606MGC35048, NRP2 PCA3, IL17BR, DKFZp727A071,
MGC14128, GABRB3, MRP63, PGBD2GATA5, FLJ14735, ENTPD6,
SYNE-2PRIC285, MGC2555, LOC90378GLCATS, GCN5L1, DKFZp434F2322,
MSCPFLJ30681, ZNFN1A4PRO0971TTTY6C14orf47CTXLFTCD, MGC2835MGC12435,
STYXFLJ12076C20orf106TEX11MGC19825, TPM2HOXD10, KIAA1554, FLJ20014,
FLJ20748, PPP1R14C, ARHV, ALDOAEGFR-RSC20orf92FLJ14594MSCP,
PRO0038SLC25A15, RSP3, PPP1R9A, EPHA7MGC35521GFAP, ICEBERGFOXP3,
FLJ33516GPR55, ZNF398, PRO1635FLJ33903FLJ32203, ORMDL3, LOC51315,
FLJ32752ELP2LIMD1KIAA1357DOCK1, FLJ14721, STC1ALAS2, HMT-1PADI1,
PTPN23FLJ10210, FLJ10826, ELAVL3, LOC90668 FLJ32069, NOL6,
LGALS1LOC55971, FLJ20273, SSB1FAD104, GPR107TRA@, SORCS2,
LOC91010FGFRL1, UQCR, SEC14L2, DENRST6GalNAcI, KISEGLN1,
ZNF219SNAP29, TNKS2QP-CSLC4A11, PURB, KIAA1163, FOXP1, C12orf22,
TCF7L2, CDH23, FLJ13955KIAA1828, FLJ33008LOC115704, SLC13A3ASB1,
DKFZp762I194, CPNE4, GRIN3A, MSTP043, BHLHB5ADMPRBM6, MGC13275,
KIAA1889, KRTAP3-3LOXL2, LOC51290, C11orf23FLJ20309, MGC26778NAV1,
ARHUFLJ23749, FLJ33071NUMBL, PTPNS1L2MGC3040SMAP-5,
MGC2835CDGAPCHFR, FLJ90440, DKFZp434G0522FLJ10300, TRIP11, HSFY,
HOOK3, GTF3A, FLJ12634, NEO1TEAD2PTPN2, BCL2L1, KIAA1557 KPNB2,
ACPP, CISH, DKFZP434P106, ASPH, DOT1L, FLJ22944SRGAP1, OLFM2,
SIN3A, ASB12, CECR7MGC40397NFKBIA, POLRMT, CGI-149C21orf84, MTMR9,
GATA4, XYLT1, PCDHB7SEC15L, C20orf160 MGC33302C1orf19, COL12A1,
EGLN3, FLJ21032MGC3040, ODZ2, ING5, C12orf2HS6ST2AQP1,
MGC10981MGC33607FLJ14399PRACDCAL1, MGC40222, TMOD3, TEFSDS-RS1,
LOC115098KIAA1573MLL3, FLJ14103AK3 ARPM1, CARD14MGC12916, ALS2CR12,
FLN29, FLJ12697TOB2, N33GTF2I, BHLHB3GPC6, CAMK2D, KRTAP4-13, BDP1,
DKFZp761H079, DKFZP564J047CED-6, EB-1, MGC4659 GPR110, DOCK1,
FLJ20211, SCN11A, LOC118471, LOC151568 ZFHX2SLA/LP, PCANAP7, HDAC3,
POU5F1, GGTL3, C7, FLJ25410, SCAND2, C20orf136, FLJ21616, EB-1,
FLJ25067, KIF9KIAA1276, LOC55864, FLJ32771, DKFZp667B1218,
DNAJC9LOC51319, FLJ10902, FLJ36525, MESDC2DDX12MGC33993 KIAA1399,
LLT1, DKFZP434F091, FLJ12697GPR24, SE70-2, NANSFLJ12571, IL-17RC,
TRIM7, NXPH1, ROR2, C20orf60, KLHL5, ZNF265, BECN1SCARA3, PRO1580,
MGC35392DKFZP434N178, PEX5R, FLJ31528, LOC135763CLECSF9, MGC41906,
FBXO11ZNFN1A4, SPINOFBXO22, IHPK3 C20orf167MAP2FLJ25270, STRBP,
MUC13KIAA1878, SNX9MGC26143 KIAA1887, KIAA1712ASB4, BRUNOL4PDE11A,
ARG99, FLJ30162, ATP6V1G3, MGC10702,
ARSDKCNJ2CAMK2DMGC12335KIAA1617HNTEB-1, GRP58, C21orf59, KIAA1720,
LOC221468CCL27CGI- 62MGC10204, TNKS1BP1RRP40,
FRABINDLX6APOA1FLJ30532, FLJ23403C7orf2 DNER, PDE11A, MAFMGC14276,
DLL1, LOC146542, SH3GLB2KIAA1952LOC93109ENDOGLYX1MGC10724, IL4I1,
CGI-105, C14orf44, PAX6ASAH2MGC12435, PGA5, and AGPAT3.
[0173] TABLE-US-00003 TABLE 6 Down Regulated In UPTG Verses UPNTG
CD24, HSPD1, EIF3S6, TIMM17A, DENR, PAI-RBP1, KIAA0101, H2AFZ,
SLC38A1, HNRPH1, RPS11, DEK, ZNF131, HSA9761, MGC3077, CD24, CCT6A,
RNPC2, ANKT, CSE1L, RABGGTB, HSA9761, SIP, HMGB2, SEMA3F, HINT1,
HMGB1, SERP1, RPL27A, FH, DUSP4, SET, KIAA0179, HMGN3, TOP2B, OAT,
NUDT4, PCNA, BMI1, SIP, SDCCAG1, PBP, MAC30, SFRS5, ATP1B3, EIF4E,
CRABP2, LRPPRC, DKC1, MRP63, STK6, CARD10, MRPS18B, TCF3, TCF3,
MGC2747, FLJ20422, IF2, NCL, EIF5, TFAP2B, TIMM9, PPP1CC, ZWINT,
HSD17B1, ATP5O, CBX3, CRFG, PXMP4, UBA2, RNASE3L, USP7, LANPL,
PTTG1, RANBP7, YES1, CDC2, RBM15, GMPS, PSMD1, TCF3, HSP105B, EMS1,
NONO, TOMM20-PENDING, LDHB, DKFZP586L0724, DDX27, JMJ, CENPF,
LRPPRC, ID4, EIF1A, PSMC6, ID2, SEC13L, TYMS, LUC7A, SNRPA1, RRM1,
RARG-1, SMAP, FEN1, TCN1, ZNF146, ABCE1, DC8, MTCH2, FLJ20152,
CCNB1, CKS2, FLJ23445, TDG, DNMT1, MAC30, RPA40, GMNN, APOBEC3B,
STMN1, EIF1A, MTHFD1, MGC5560, USP1, ZRF1, EIF5A, WDR3, FLJ20530,
RPS21, BAZ1A, MCM6, MICB, OPA1, LAMA5, ECT2, RAD21, RNASEH1,
FLJ13081, STXBP3, PAI-RBP1, OSR2, FLJ20006, KIAA0186, C19orf2,
NUP107, TAF2, GCSH, FLNB, ZNF363, SEMA4C, RAE1, GSS, NEK2, GTSE1,
PAI-RBP1, ABCE1, FLJ20986, MAD2L1, VEGF, LZLP, KIAA1025, KIAA0092,
ANP32B, SRRM1, NXT2, TOPBP1, FLJ20485, SFRS7, SMC4L1, CPSF6, LIN7C,
FARSL, NDUFB6, FLJ12888, LANPL, ENDOFIN, KR18, FLJ11029, DLG7,
WDR12, DC12, CDC5L, SLC35A3, PIGF, PRKRIR, MTO1, CASP6, FLJ11149,
FLJ22637, LDHB, PPID, GTPBG3, HMMR, SLC31A1, POLE2, KIAA0984,
DJ434O14.5, RAB6KIFL, ASE-1, HNRPA1, FLJ23468, CALR, MELK,
SLC25A13, TFDP1, RES4-25, DC13, CGI-111, ARH, FLJ14547, TSN,
CYP2B6, PDX1, LCE, FANCG, DHFR, KIAA0020, QDPR, MTIF2, HLXB9,
SART3, JAG2, CKAP2, PRC1, SNRPD1, LOC51184, RAN, DLD, PREI3, SRRM2,
RAD1, CCNB2, FLJ13657, KIAA1116, RACGAP1, FLJ13576, DKFZp564B0769,
RFC3, KIAA1630, CCT6A, TIP120A, RUVBL2, FLJ23277, DDX18, PMSCL1,
LEPROTL1, SCGB1D2, TIMM13, C4orf1, KRTHB6, DD5, C1D, PNN, ORC6L,
KIAA0170, ASK, DLEU1, SFRS3, SLC19A1, HIP2, PPP2R1B, BIRC5, EPS15,
MGC13138, HNRPD, STK6, HSPA8, METAP1, KIAA0776, HSPC128, KIAA0419,
MAGOH, CHORDC1, APPBP1, UBL3, RAD51, LOC55871, GLRA2, CUL4A,
ARHGAP8, KIAA0648, COX17, SUDD, RAP1GDS1, FLJ14639, BCL9, EZH2,
TRIP13, FLJ11210, TOMM70A, PTP4A1, AMD1, DUT, KPNA2, CYP3A4, RFC4,
OPA1, RNF6, IBTK, LBR, MGC13138, KIAA0097, KIAA0532, OIP2, VRP,
HDAC9, KLC2, FLJ20700, AD24, ALMS1, FLJ21901, DKFZp547P234,
FLJ10656, TOP2A, MYC, TAF4, POLR2E, KIAA0528, CRY1, MST4, ETFA,
HOXC6, MTX2, HMGCR, RPC5, TOPK, DKFZP564I052, CENTA1, FLJ20758,
KCNMA1, KNSL6, CGI-30, MRS2L, PAICS, ZNF85, DJ434O14.5, RABGGTB,
HEY1, KIAA0485, KTN1, KIAA1012, CDC20, DKFZP434L0718, CEPT1, MYNN,
FLJ10637, ANXA9, RNPS1, RBBP4, SSH-3, LOC90355, CAMLG, KPNB2,
FLJ23259, VRK1, FBXO5, HSP70-4, DNAJC9, MYCBP, S164, NTRK3, TAF9,
SPG4, DKFZp667G2110, CDKN3, INHBC, PEX11A, CDC27, HMGB3, THOC1,
FLJ12151, DKFZp564B0769, HSU79266, DMN, C10orf3, THOC2, NDUFA6,
GCSH, PPAT, RHAG, SMC2L1, SE70-2, KPNB2, LSM6, FLJ10377, IL1RN,
KIAA0547, FLJ14007, SCLY, KIAA0379, UBE3A, HTATSF1, LOC51685, AGL,
BET1, FLJ13782, UMPK, SMARCE1, LSM5, CENPF, EEF1E1, TPT, FLJ10719,
IF2, CGI-12, UCHL5, FLJ20628, ERN2, BLM, FLJ21940, PDCD2, STRIN,
UMPS, MRPS30, APBA2BP, TCEB1, CREB1, MGC9084, NOLA1, BUB1B,
MGC10471, RFC5, RRP4, FLJ13187, CCT5, HSA6591, CHAF1A, FACL3,
IMPA1, FLJ23558, CDC25A, CDC5L, BTN2A1, FLJ20422, ELF2,
DKFZp586F1019, FLJ22624, LOC51659, CRFG, WHSC2, HN1L, OAZ3, CD1A,
CLPX, CABC1, CLASP2, HSPA9B, KIAA0007, SLC1A3, NPM3, SUSP1,
SLC16A5, M6A, UBE2J1, TBC1D4, C20orf1, TBXA2R, UVRAG, MLH3,
FLJ20331, PEG10, PRPF4B, KIAA0332, MPZL1, KPNB1, FLJ10204, TFAM,
FLJ20281, FLJ10604, LAT1- 3TM, KIF2, RBM12, MKI67, HRB2, KIAA0056,
ZAP3, COX11, SNRPD1, AMD1, TRN-SR, FLJ20641, RB1CC1, KIF4A,
FLJ20093, TPR, RAD50, PPP1R12A, HNRPD, PIR51, PSPH, TTC4, HIC2,
SLC39A4, RLF, KNSL7, NOL3, ZNF-U69274, EIF4ENIF1, PDCD4, CTSC,
CYP2C9, KIAA0677, BCL11A, LOC56906, TIA1, SYN2, RNAC, RDX, FOXM1,
HRASLS3, STAG2, HMMR, KIAA0376, CAPN10, CHEK1, NICE-4, MRPL19, TSN,
DKFZP434M154, PPID, NEK4, SMC5, MGC1223, SUV39H1, ESPL1, RANBP2,
FLJ23018, SNAPC4, LGN, HYA22, JAG2, KIAA0644, NPR3, FOP, PKMYT1,
APPBP2, HSPC135, C20orf20, EIF4E, ZNF239, FLJ20909, CNTNAP2,
ZNF292, LIPT1, FZD7, KIAA0971, SSH-3, MRE11A, KIAA0090, PAWR,
SMC2L1, CGI-112, SOX13, HBB, KIAA1193, CAP350, RRS1, MTCP1, HBA1,
GRPR, LCT, RAD51C, PRKDC, SPAG5, POLQ, BRCA1, GNAI3, FLJ14346,
ZNF24, CENPA, E2F3, DDX18, SFRS2, PSP1, FLJ14827, BFAR, FANCC,
DMXL1, CUL3, C6orf15, BCLG, SIL, LOC133619, MGC2306, KIAA1096,
GMEB2, ASCL1, EBP, FZD3, PRDM2, KNSL1, FJX1, PPP1R3D, SRP72,
DKFZP564D0462, CCNF, PAI-RBP1, PRO1496, RBBP6, TEB4, SP192, DCTN4,
B4GALT2, SRF, ZNF200, DNCLI1, SCYE1, PPI5PIV, FLJ22087, SLC29A1,
FLJ12439, VDR, TIMELESS, TAF15, CGA, FLJ21816, SHMT2, SRISNF2L,
DKFZP547E2110, OIP5, MGC2603, FLJ11896, C18B11, IGLJ3, PPARBP, DCX,
TAF5, MGC5306, LIM, PTER, PPIL2, FLJ10998, NSEP1, KIAA0332, MCM4,
DLAT, KIAA0453, RPL23AP7, TTF1, WRN, TTK, MARK3, SF3B3, FLJ20552,
TIMM8A, PANK3, LIN7C, FLJ20225, FLJ10287, MFN2, FLJ21908, REV3L,
MGC5566, ZNF42, MSH5, HCAP-G, FLJ20591, SPHK1, E2F1, FLJ14054,
CCNE2, MGC4701, C1orf33, BITE, MCM5, KCNK15, AGTPBP1, FLJ20274,
CLPTM1, LANCL1, FLJ20125, FLJ11785, BARD1, MYOC, RB1CC1, FLJ23151,
RFC1, SLC25A12, FLJ10330, TMPO, KIAA0157, STC2, UBCE7IP5, MGC5306,
COL13A1, TMSNB, PTTG3, FLJ40452, MADH6, IF2, SRP72, FLJ20003, USP2,
YY1, FLJ23053, KIAA0276, TIA1, PRDM10, OXTR, HRASLS, BAZ1B, M96,
SLC7A5, CYP26A1, PB1, TCBAP0758, TLE3, POLD3, LIV-1, HNRPL,
FLJ10407, CHAT, UPF3B, RAMP3, TIMM17A, G3BP, PCDH7, FLJ90754, MCLC,
EPHB3, STXBP6, CSTF2T, GYG2, PRKCBP1, RRN3, FBXL2, MDM1, PNN,
SMPD2, TTF2, TFR2, GDAP2, FLJ10989, MATR3, PRO1598, PAF53, OGT,
HNRPH3, H326, VDR, KIAA0843, UTX, KIAA1172, RYBP, FLJ20005, SCML2,
SF3B1, KLHL3, NOLC1, ING1L, KIAA1467, ROBO1, TGIF2, C8orf4, NUDE1,
PDCD4, FLJ11004, AKR1C1, DKC1, COCH, FLJ20666, HSPC121, FLJ10261,
PMFBP1, RAD1, SLC4A4, FGFR2, SMARCC1, BAZ1A, CGI-130, NESG1,
FLJ13909, GRM6, FLJ13942, SOX12, FDX1, LGN, GRIN1, BTN2A1, NCBP2,
NMU, CDC6, OAZ, CDC7L1, CNNM4, NOL3, FLJ10038, KIR2DS1, KPNB3,
SLC4A4, FLJ22390, SLC6A13, NY-REN-24, KIAA0923, LOC113251, SIP,
ERCC6, DKFZP586A0522, RAB11B, ZNF197, WHIP, KIAA0040, KIF5C,
GTF2H3, PAPA-1, HNRPH3, NDST1, C9orf12, KIAA1069, MAC30, PPP2R1B,
ZNF363, KIAA0931, NFRKB, MGC12760, HSU79274, SELP, RAB33B, MYH11,
TIAL1, MCM10, DKFZP434F1735, KIAA0553, SAFB, FLJ12455, DRIM, CFLAR,
KIAA0542, HTR1B, SMC4L1, TIMP3, MLLT2, ARHGAP1, KIAA0255, WASF1,
POP1, KIAA0286, PASK, DACH, SF3B3, CDC2, RCL, IL2RA, IRX5, DUT,
FLJ12684, FLJ20640, NSPC1, ABCG1, T, ZNF174, PPP4R2, SPAG4,
FLJ21596, ZNF11B, FLJ13449, HBA1, E2F3, CDC2, BICD1, RAP2A, CSTF2,
LSM8, DYRK1A, FLJ21940, H2AFP, DATF1, ANGPT1, C20orf46, FLJ20147,
ZAP, CASP2, KIF14, DDX17, TRIAD3, TAX1BP1, PEX7, KIAA0182, TIMM44,
CIAO1, FLJ13490, MED6, FBLN1, SMN1, OR10H3, ARP3BETA, DLAT, TXNRD2,
RC3, HUMGT198A, MTHFS, CAT56, CRSP6, DCLRE1A, ACRV1, TAF1, PPAT,
SEMA4G, CXCL9, CUL2, AGRN, ZFP100, KIR2DS3, RECQL4, PTPN13,
LOC93081, IRF4, IGL@, CYP2B7, CLASP1, MCF2L, KLK5, COPS7B, B3GALT3,
DKC1, YES1, CHPPR, MGC21654, TROAP, FLJ23311, MKL1, KIAA0650,
MRPS34, SMARCC1, PEX11A, ZNF212, GABRR2, NUP98, SIGLEC7, ZFD25,
RRM1, TFIP11, M96, AD024, AP1S2, TIMM17A, GM2A, TAS2R1, RARG, GDI2,
FARS1, ROBO4, RINZF, FOXF2, CASP10, CITED1, RPGRIP1, PHTF1,
37870.00, PP35, MGC4659, KIAA0092, EPHB1, KCNJ10, HOXD4, NUP160,
PTPRD, PRODH, PTBP2, PFKFB2, SGK2, ACADSB, BRIX, EML4, EDNRA,
CHRNB3, NUP155, KIAA0648, SEMACAP3, LOC57406, AND-1, CRSP2, STAG1,
SH3BP2, NR6A1, MGC2827, HNRPH3, SIP1, FLJ21986, CTH, PDEF, HABP2,
RPGR, COQ7, TTTY2, FLJ11767, LOC81691, HSPC111, MGC39851, TAP2,
NUFIP1, GABRA4, CDH2, SMTN, ZNF305, C8orf1, ULBP1, VAMP1, FLJ20477,
LHX6, CD6, NSBP1, KLF3, SLC13A3, LOC55862, LCK, CDC25C, CGI-32,
DKFZP434D193, MBD4, GNB3, BAIAP3, FARS1, CHRNB1, GCAT, KIAA0342,
STK18, MPHOSPH10, CRMP1, UNC84A, CACNB1, KIAA1053, KIAA0953,
SERPINA5, FLJ20433, SIGLEC6, DKFZp762E1312, LAT, SORD, GGA2,
FLJ21945, FGFR4, DBR1, LMNB2, ADCYAP1, NR4A1, LIM, AGC1, FDX1,
FLJ20244, ZNF24, DCLRE1B, IL23A, EIF2S1, INCENP, FLJ21820, ZNF264,
KIAA0964, CASP8, ORC2L, CHAC, TNFRSF13B, MOST2, ABCB9, DIO3,
RABL2A, FAIM, DCT, CLCA1, TRIM29, GK, GNA14, TDPGD, FLJ20186,
RAD54L, SSX3, FLJ10193, HT010, HEC, KIR2DL5, CASQ2, TRA@, ZNF335,
ING3, HSPC055, ITIH2, BUB1, MADCAM1, AXOT, KIAA0295, RPL17, NRXN1,
P2RX5, GASC1, NUP210, ZNF236, RAD21, ANKTM1, EDNRA, HSPD1, CORO2B,
NY-REN- 58, FKBP1B, AQP8, KIAA0922, SNRPA1, ARIH2, ASGR2, C6orf35,
IL1RN, SLC38A3, NFYC, CACNG4, SEZ6L, GLP1R, NUFIP1, G2AN, FLJ13949,
FABP7, S100A1, TRIM36, LOC93408, API5, PADI3, TADA3L, EPN2, TNFSF4,
MIP, RIPK2, F5, KCNJ3, HADHA, MS4A1, NEK3, KIAA0275, DTR, MNAT1,
ZNF223, FNTA, NRCAM, POLG2, ADH6, CAP2, KCNJ5, SFRP1, APOBEC3C,
IL7R, P125, UGCGL2, ASIC4, AMFR, HSN44A4A, RAB5A, OXCT, RAB3GAP,
D6S1101, OTOR, LTBP1, RIN1, LDB1, PRKAB2, KIAA1006, PLK, PRO2000,
MOCS1, RGNEF, PDZ-GEF1, INA, MASP2, RSC1A1, RoXaN, CLDN6, HSAJ2425,
KIAA0469, ING4, REM, KIAA0092, SKP2, OGT, CBL, KIAA1240, QKI,
ETFDH, PPP2R1B, MDS031, CED-6, SLC11A2, GPX5, CRKL, PC4, FLJ10858,
APOC4, CUGBP1, REG1B, DKFZP564B147, C14orf104, PAX4, TRA@, RECQL5,
ENG, CDC2L1, FLJ22087, HYA22, DEFA4, GIOT-3, ASPM, ANK3, TNFAIP2,
SLIT2, WBSCR20B, EIF5A, PTHLH, ATPW, CASP8AP2, HSPB3, RPS4Y,
UNC84A, FLJ20624, CHST5, STARD5, SSX2, IL22, TAF1B, FEM1B, KCNA1,
GPR15, C1orf34, CGI-07, WDR8, SLA, HGC6.2, GRIN1, CXorf6, KIAA1034,
EDG4, CUL4B, CSPG3, TFEB, P164RHOGEF, FLJ13105, CENPE, APP, MYL6,
FLJ23441, PON1, ENDOG, SERPINC1, PGRMC1, TUBB5, CHRD, PAK6,
FLJ20045, PELP1, FLJ12735, DXS542, SH2D1A, PRO1728, HOXA6, NEUROD4,
CGI-100, FLJ13386, AND-1, TBL3, GZMM, FLJ90005, FGFR1, LOC51231,
FNBP1, P11, PPP1R15A, VDR, CPSF6, S164, C20orf14, KIAA0217, SGT,
KIAA0332, DKFZP586E1923, FLJ10884, MCF2, MAP4, AAK1, HS3ST3A1,
LOC90806, ALDH3A2, MUF1, NCKAP1, FLJ10618, LILRB3, GAGE5, TMEM1,
CD6, ADAM22, BM039, NEF3, ITCH, PPP2R2B, PLG, SNAPC1, DXS9879E,
MPDZ, CDK3, CD209L, SLC21A9, SHB, Rab11-FIP2, MAP4K5, DGKE, MTMR3,
KCNK5, CLCNKA, SGCE, FLJ10565, MCM7, AK5, NCR3, SERPINB4, TPST1,
alpha4GnT, NPEPL1, PRLR, MPHOSPH9, IL18RAP, PMSCL1, HS322B1A, TCF2,
TPD52, HIVEP2, KRTHB5, KRTAP1-1, DMD, C10ORF6, AGC1, FLJ23436,
PTK7, COL9A1, CGI-01, EPHB6, AVIL, LOC54550, NASP, OAZIN, SERPINA6,
GPR44, VCY, DIAPH2, 384D8-2, MAPK11, GALNT4, PTGES2, WNT2B, STX6,
STK17A, PPFIA1, CALCA, CCNA2, DOC2B, NID, BAZ2A, WNT10B, FBXW1B,
SPRR3, MINK, B3GNT4, CDK6, BHMT, SRPK2, PGCP, CNK, SSB, CDC6, GART,
DLX2, PLEK, PTPN7, UBQLN3, IFI44, TCOF1, FGF16, COPEB, SOCS4,
FLJ11222, MRPL12, WDR9, DKFZP434G2226, CLECSF9, NCR3, GPR49, EP400,
DKFZP586M0622, PCDHA9, C1QTNF3, STAB1, PRKDC, BEX1, FZD9, CAPN7,
BCR, FLJ11577, IGL@, ARR3, PTHLH, AP4S1, ABCG5, SNTG1, CRTAC1,
ZNF335, FLJ10979, HSU84971, POLI, KIAA0643, DKFZp434I1916, PPIG,
TRG@, MAPK12, ING1L, HIF3A, CDX4, CYHR1, TRAP100, UCHL5, CLOCK,
SLC17A7, HFL-EDDG1, ATF7, FLJ20105, HRH4, FALZ, SLC23A1, NRF1,
BTN2A2, FLJ20581, DKFZP761H1710, FLJ10376, GLRA3, C20orf30, C4orf6,
ELK4, PLCG1, CNR1, KNSL5, KIDINS220, ING4, PPFIBP1, SGSH, PRKAR1B,
UBE4B, INSL3, DKFZP434F1735, MTMR8, KRTHA2, MPHOSPH9, SQLE, OGG1,
OSMR, AFM, HSPBP1, VGF, HCGIX, U1SNRNPBP, FLJ23447, FLJ10057,
SPRR2B, GRIK3, MARK4, WIZ, CORT, MGEA6, BMP7, FLJ10648, BRAP,
DKFZP547E1010, C21orf59, STK6, KLK2, GRIN1, HOXB7, SMURF1, PCDH16,
BCL11A, SPPH1, FLJ12838, SSR3, KIAA0940, P2RY2, HSU84971, ZNF134,
CNTNAP2, ADAM23, MAGEA6, SPAG6, DKFZp761P1010, DTNB, CHAF1B, MLL,
DGCR8, MGC3101, SENP3, FLJ12331, LATS1, IPP, FXYD2, FLJ23360,
FLJ20898, LUC7A, NDRG4, LIN-28, CXorf15, FLJ13910, ELK1, MGC4294,
TBL1Y, FLJ12985, B7H2, FLJ13693, FLJ10945, FLJ20313, DKFZP566C0424,
IGHM, TPS1, GFAP, PEX1, NEU3, FLJ10719, NFIC, GTSE1, SIAT7D, PDYN,
SELPLG, B7H2, PIGO, SCNN1D, NMBR, NCAM2, YWHAE, SIP1, FLJ14084,
PROZ, ATF2, PPM1F, INSM1, CABP5, ZNF124, SP110, SPTA1, MGC2776,
BMP8, GAL, SCA7, FLJ11850, FCGR2B, PROSC, PDE4D, MGC11335, AKAP3,
CARF, DKKL1- pending, UGT1A1, SHANK2, LSS, GUCY2F, RANBP3, SLC16A7,
PIP5K1A, SCAMP-4, LOC92579, SLC7A8, CR2, FLJ20707, FLJ21106, MADH5,
CPS1, COL14A1, PROL3, CUL2, CHAF1A, OAS2, SOX10, MFAP4, TCFL4,
FLJ12618, SUSP1, MAGEA9, KIAA0322, SLC19A3, AKAP11, USP7, DC11,
KIAA0616, BC008967, OR7C2, CACNG3, PELI2,
FLJ14050, DMPK, FLJ23071, CCL14, IGHM, BM039, GASC1, BIRC4,
MGC5601, KCNK10, SLC22A8, MGC14817, GRCC8, LARGE, ZDHHC11, ANXA13,
FLJ14107, FLJ10246, C11orf5, POLA2, SILV, PARD3, LW-1, CCL13,
CLCA2, ME1, RAD51C, SSTR3, STK12, ADAMTS2, MRPS12, SMCY, TUBA4,
KIAA0794, CCL11, WFDC1, TRY6, MAP2K2, ACOX1, KIAA0874, C1orf16,
NRG1, RCN2, CLDN18, MYL3, FLJ13150, LNPEP, SLC25A21, PDE10A, STAG3,
TNNI3, CHC1, MAP3K7, OSRF, HMX1, HRG, FLJ11292, PAL, KIAA1659,
VARS2, HSRTSBETA, IL5RA, CYP3A4, FLJ23556, MAPK4, C16orf3, GPD2,
HOXA3, MMP7, FLJ10786, C6.1A, KIAA0892, PCDH11Y, TRB@, METL,
PRKAA2, ZNF76, FTSJ1, FLJ90130, FLT3, GNAO1, SCNN1G, TAF9L, PRV1,
SNX13, CENPJ, CNNM1, FTCD, NEK1, FLJ11336, FLJ14803, C9orf16, HIP1,
PPIF, GS3955, NFATC3, DOK1, ROPN1, MAGEC1, HGF, PRLR, CTSL2, NKTR,
SAA2, HOXD11, PROX1, MAP3K12, MORF, FLJ10619, SULT2A1, ERF,
DKFZP586A0522, KCNQ2, KIAA1387, DFFB, MGC4172, MOCS3, ITGB3,
PIB5PA, ZNF117, KCNA4, KIAA0999, HFE, CYP2A6, A2BP1, RASGRP2,
AMELY, GABRG3, ITGA8, DUSP3, PTGS1, KIAA0748, CACNA1G, CENPC1,
POT1, COL6A1, ST7, FLJ13052, MS4A12, DLG5, TECTA, ETV5, HEY1,
NECL1, DICER1, ALOX12P2, KIAA1025, FURIN, WISP2, CSDA, ALDH1A2,
USP19, TRG@, SFRS7, CDX2, MRPS31, NSAP1, CUL4B, ABCC2, IQGAP1,
WHSC1L1, ALCAM, SERPINB10, MDS028, KOC1, ELF2, DKFZP434A1022,
GPM6B, C2GNT3, CYLC1, FLJ11506, CEBPA, LIMK1, CPR2, CLTB, TNR,
PLA2G3, GPR30, APOL3, TSKS, HCGIV-6, KCNJ2, MGC5347, MAP1A, PPARD,
TMPO, LOC63923, CYP2E1, RYK, PRKAR1B, FLJ11336, FLJ10748, PRO2958,
CHN2, CELSR1, LCN1, SLC15A2, USP5, ZFR, CYB5-M, SLC27A5, MJD,
KIAA1096, HTR2C, NACA, APC, ELK4, JM1, KCNAB1, GDF2, ST7L, TGT,
AMY1A, ESR1, TLX1, TBX1, KIAA0967, KIAA0146, C1QR1, ARHGDIG,
KCNIP2, HDAC6, MTHFR, NTRK3, HAVCR1, FLJ22269, PLXNB1, CRACC, EGR4,
PMS2L6, POGZ, FLJ21148, FLJ20359, B4GALT1, KIAA1354, CSF3, SLC17A6,
PAK2, ZF, CLECSF6, FLJ21120, ZAP3, FLJ20127, VAMP1, DCLRE1C, DRIL2,
FLJ11608, SFTPC, GABPB2, ICAM1, PRO2405, TC10, XEDAR, CART, L3MBTL,
PMS2L3, R32184_3, TCL1A, MIP-T3, FLJ14639, PLGL, HPGD, MERTK,
EIF3S6, PPYR1, RPE, GLS, VAV2, TFAM, SLC6A1, RORA, PLVAP, PCDHB6,
HDAC7A, MGC10731, ARTN, HAO1, POU4F3, KCNJ4, ATP9B, F10, LSS, MPP6,
TGIF2, ITGA6, KIAA0682, NUDT13, MGC4293, DKFZP564O0523, PACRG,
ACLY, FLJ14627, OCM, SLC4A5, HNRPF, KRTHA1, FLJ21940, KIAA0632,
SSX3, TNFRSF9, C22orf19, SLC19A1, LSR7, ZFP36L1, SLIT3, DIP13B,
C20orf27, ARHGEF2, EST-YD1, PROL5, RAB3B, LAMB4, PPP2R5B, CRYGD,
TGM5, ADAM22, AGMAT, PKNOX1, DSC1, TOP1, TU3A, CACNA1G, IDUA,
LTBP4, MYRIP, ABLIM1, CALD1, ZNF46, CDKN2C, FLJ20958, RPS8, MAGEB1,
KIAA0683, RHAG, BLu, TFF2, XPNPEP2, TYR, FAP48, NCYM, HIF3A, MBNL,
LRP16, PLXNC1, LOC51145, C21orf2, ARHGAP8, FLJ32069, FGFR2, NICE-4,
PRKWNK1, LOC65243, DIO1, MDM2, PRDM13, CA-11, PSK, TNFSF15, OPRM1,
HSPC048, SPN, NBS1, BIRC4, CDC27, HRH2, TRIO, CACNA11, TFR2, HAN11,
NEUROD6, CADPS, MGC12386, ORC5L, TNXB, F2R, PRO2831, CDH18,
FLJ11106, DBP, PAX8, DLG1, CDC25A, CEGF3, FLJ10921, HRH4, FLJ20456,
IL12B, CACNA1F, E2F5, PRP17, LGALS8, MGC3771, SLC6A3, RAC2,
KIAA0286, MGC12488, NR0B1, AD7C-NTP, IGL@, TULP1, PSMD11, COL13A1,
UBE3B, FLJ20401, AKAP1, CRTL1, SPF45, FLJ10895, CCL13, COL16A1,
CHIA, RAMP2, SSTR1, FYB, TXNDC4, SCAM-1, DYRK1A, KIR3DL2, CNK2,
Di-Ras2, MCCC2, KRTAP2-4, KIAA0523, IGHM, ODF2, RXRA, GABRA2,
CLST11240, POLR2A, SRY, TAS2R7, BLR1, DKFZP586H2123, FLJ21007,
SPON1, ENIGMA, KIAA0140, RPL5, DESC1, DNAJC9, PTK9, MGC10715, SNCA,
CEZANNE, TBCE, HOOK1, COVA1, C21orf62, AGXT2L1, SLC24A1, SYCP2,
C17orf1A, OR5V1, HCN2, KLF12, AIM1L, LOC51336, PRC17, ITGB3,
PRO1992, POMC, PRO0149, B3GAT3, L3MBTL, APG-1, C12orf2, MOX2,
ARHGAP11A, ATP5G2, HLA-DOA, GPC4, LOC57406, COL2A1, GABPA, SCN4A,
RBP4, PHF7, GRID2, OSBPL7, MRPL9, MYH2, TFPI, FLJ10159, IPF1,
IL20RA, THRA, LOX, CMAH, KIAA0616, CYP1A1, MADH5, FLJ40021,
FLJ20069, FBXO22, GABRB3, CYP2D6, TNRC4, FLJ22582, NR2C1, PK428,
CBFA2T2, KCNK13, DCT, KCNG1, FLJ10648, CENTB1, ADAR3, HTN1, PDCD1,
TRIP, EFNB1, TFDP2, ATP2B2, TNFRSF7, MRPL4, PTP4A3, SIGLEC8,
PPP3CC, ENTPD5, BAG5, FLJ20047, GLI2, CCL21, EPN1, TONDU, RAP2B,
CGI-72, ZNF384, C20orf42, MEF2C, RAB28, TAF1C, USP18, GPR42, HTR2A,
PDE4DIP, DKFZP564C196, TXK, H2AFJ, FLJ20623, GPM6A, FOXJ1,
MGC29761, IGHM, RAI15, CSTF1, KIAA0800, CSH1, KRT20, RAD51, TAF7L,
FLJ10849, PTK9, RGS11, CDH20, FLJ20034, RFRP, FOXD2, HSA9761,
PQBP1, DGCR6L, FLJ11132, OR2W1, CRYBA1, LMOD1, PDPK1, GPR56,
KIAA0296, SERPINB13, KLHL5, ZNF79, BCDO1, PSORT, EPHA7,
DKFZP434J046, PRO0800, SV2B, C12orf3, SGCA, BMX, MHC2TA, RAD51L1,
CYB5-M, VIL2, FNBP2, LEC3, RBM9, BRAL1, NGFR, DDX34, MAPK8IP2,
ANKTM1, DDEF1, ARL7, STK18, AQP4, MDM2, SYNE-1, FOXO3A, TNNT2,
TITF1, ZIC3, PPBP, FLJ12542, SLC18A1, IGKC, HFE, PRO0038, NPPA,
IL-17RC, CXCR3, DOM3Z, GADD45A, GL012, CNOT2, TOB2, TFDP1,
FLJ21617, MTRF1, APBA2, TTS-2.2, CNOT4, F9, PRO2133, CRABP1,
CACNG1, IGFBP5, CTNND2, DKFZP564D166, MYT2, EVI5, HYA22, CHK,
HSPC073, RRBP1, FOSL2, FLJ21302, MGC2889, PRKCL1, TSPY, JAG1,
NDUFA5, IL1RN, CRH, CXCL11, MYH8, PURG, SLC7A1, KIAA0953, ELAVL2,
SP100, KIAA0675, MLLT4, ZNF198, CD38, BHLHB2, LLT1, FLJ10210,
PMS2L9, SOCS2, LIN7A, HOXA7, FLJ10661, ELAC2, CYP3A4, P2RX2,
MAPK8IP3, ADAM28, NPR3, DEF6, UTRN, PHC3, FBN1, DKFZP566K0524,
ZNF132, OR2J2, GJA8, PSIP2, ED1, PP2447, WSX1, LCP1, MAP2K3, KLF12,
TFPI, BTN3A1, GCM2, FMR2, DDX3, PRO1768, KIAA1641, HEMK, SLC8A1,
LALBA, RBAF600, FLJ10572, MSR1, KPNA4, CIAS1, MEP1B, NR4A2, PKNOX1,
GLP1R, FOXP3, dJ222E13.1, KIAA0471, KERA, COL4A3, NPTXR, KIAA0447,
ARHGDIA, ACACB, KIAA0847, CASP2, BRIP1, LRP8, IGL@, PCTK2, TFR2,
PLA2G5, HSPC056, IL16, FLJ12178, TBX1, KCNJ13, WT1, PRKACG,
DKFZp547G183, MYO3A, DSC2, ANAPC2, ALDH1B1, CD1B, MGC14433, GPHN,
IGHM, GUCY1A2, HPSE2, GHRH, BAGE, CYP2E1, GTSE1, MSCP, ADAM8,
PAPOLG, CGI- 14, SIRPB1, RGN, PGGT1B, ELL, RRP4, APOL2, POU3F1,
JAM1, SYP, SERPINI1, FLJ12595, NRG2, PDE3B, HIRA, DDX9, LTBP4,
FLJ11783, GABARAPL3, DRD3, XP5, FLJ20190, TRPC6, ADRA1A, DSPG3,
KIAA0564, KPNB2, DKFZP564O0523, UGT2B15, AP4E1, RGS7, ZNF10,
PIWIL2, HLF, CYP4F2, INVS, ITSN1, FCGR3B, ARF4L, REL, RGS20, EPOR,
FLJ21168, MSTP9, ULK1, NRF1, TIGD6, GPR88, DUOX2, GP5, SSB3,
FSHPRH1, RHOBTB3, C1QBP, CDSN, FSBP, CFDP1, ELK3, TUBD1, KIRREL,
BAAT, CEP2, GGA2, KIAA0874, CRB1, FLJ11726, P2Y10, PCDH11Y, GPM6B,
FLJ10715, TRIM9, FCAR, FGF22, FLJ13993, DIM1, GIPC2, KIAA0626,
SNIP1, Gene Symbol, LARS, C15orf15, KIAA0783, MGC2714, FLJ10036,
HSPC154, FLJ10486, FLJ30596, FKBP5, SERF1A, REC14, OCLN, FLJ21924,
LOC51249, FRSB, AD034, CCNB1, FAM3B, MLL3, IBA2, SEPP1, C14orf31,
HMGB1, C14orf35, MGC4308, FLJ10407, GRCC8, C20orf129, FLJ20060,
Spir-1, LANPL, RBBP7, KPNA4, FLJ10486, MKKS, SNX5, SART3, FLJ14494,
FLJ21087, HOXB9, NUCKS, PPP4R2, C14orf47, EHF, MGC14439, LOC55871,
AP1S2, TRNT1, FLJ25059, MGC10198, KIAA2024, KIAA1309, HSPC014,
LAPTM4A, GPR54, ARL6IP2, DNMT3A, DKFZP564B1023, KIAA0114, ATF7IP,
HSPCB, HDAC3, FLJ39370, FLJ20093, PP2447, LOC139231, MGC41917,
MGC20262, CSRP2BP, LOC51193, GRP58, HEY2, ANLN, UBL5, CDCA7,
KIAA1321, KIAA1323, UHRF1, HDAC3, KIAA1911, FLJ00166, KIAA1453,
DKFZP434A0131, NY-BR-1, 37865.00, Rpo1-2, MGC5306, BOC, FLJ25804,
FLJ14728, BDP1, PSCD3, AF15Q14, HDCMA18P, PRO2000, LOC152518, GART,
TRIPIN, DKFZp313A2432, PSA, PGGT1B, MGC4832, LOC85028, FIGNL1,
PECR, CBFA2T2, HOXC9, CPSF2, SLC25A19, C20orf45, FLJ32915, ZNF367,
PANK1, LOC131118, FLJ14909, MGEA5, TRIM46, Rpo1-2, DKFZP434C245,
AKAP10, CDCA1, H326, DKFZp761A078, FLJ20333, NEDD1, AUTL1, TRAP25,
KIAA1143, GPHN, LARS, DKFZP434D193, FANCD2, PRO2000, DKFZp313A2432,
FLJ12439, MKI67IP, LOC115004, FLJ11220, MCM10, MRPL1, NDUFS8,
PHF5A, OAZIN, LOC92345, KIAA1708, KIAA1982, MGC2628, PXMP4,
KIAA1804, ELYS, HNRPD, ZNF6, MRPL42, KIAA1287, TRUB1, TOMM22,
FLJ25070, SPPH1, ZIC2, C6.1A, CGI-77, MGC33864, MKI67IP, TUBE, VIK,
MGC14798, FLJ20354, KIAA0140, GTF2H3, FLJ12787, DLD, ARIH2,
KIAA2023, KIAA0864, CDC23, MGC13096, TRF4-2, OSBPL6, MNAB, ROD1,
USH1C, MGC16372, FLJ20333, FZD8, MCM10, FLJ23445, WDR4, OFD1, AK2,
REV1L, COQ3, ASCL2, EG1, TReP-132, CAB56184, FLJ13081, HELLS,
FLJ10378, C20orf161, EPHA8, DTNA, HSU53209, NAGS, LOC84524,
LOC91120, LZK1, DKFZP434I092, FLJ14431, FLJ20354, HS6ST2, FLJ20333,
KIAA0140, FLJ23476, C14orf31, LOC55871, C14orf75, C20orf42, TBX1,
CRMP5, Jade-1, CASPR4, FLJ11132, DKFZp547O146, MRPL50, LOC51193,
FUT10, FLJ30655, SELB, KIAA1524, FLJ14813, FLJ38608, TRIM7, SYT12,
FANCD2, FLJ25078, FLJ11294, KIAA1357, STRIN, pknbeta, NSD1,
DKFZP434B1727, BCRP2, FKSG14, EIF3S9, MGC2744, KIAA1595, C14orf106,
LOC144455, KLK12, KIAA1374, BCoR, GABRB3, TIMM22, FLJ25416,
BRUNOL5, MGC24665, ARX, DKFZP434K0427, KIAA1915, C7orf11, MtFMT,
FLJ21439, MAP2K7, DKFZp434H2111, ARFGEF2, PRO1489, PTPN1, MGC13204,
FLJ23322, MGC16386, MGC45866, FLJ30626, CML66, ZNF295, ARL8,
LOC115106, MGC12466, SNX5, FLJ22344, MGC10850, AKT2, NCOA5,
KIAA1713, MGA, FLJ20032, RNPC2, DKFZP434E2318, MLL3, SYNPR,
FLJ10989, C2orf7, LOC115827, LOC91862, MGC13016, USF1, DGKZ, LAMA3,
DKFZp564B0769, A2BP1, KIAA1560, LOC221002, BG1, ENT4, RNF3, CHAC,
ICAM2, FLJ10493, EIF3S6, TRA@, FLJ25604, TUBGCP6, GATA5, PGS1,
HT014, C20orf6, NAV2, KIAA1357, GABRB3, FLJ10378, HSPC150, ADCY3,
BIGM103, MGC3067, APC10, BOC, LOC120379, KPNA4, FKBP7, C14orf50,
FLJ22557, NUDT10, DDX17, FLJ22729, TA-NFKBH, FLJ10785, FLJ32745,
WHIP, CTLA4, MRPL30, MRPS25, FLJ10498, CDO1, FTCD, SPTB, KIAA1323,
DKFZp761F0118, MGC2452, AKAP13, LMLN, LOC112840, FUT10, TP73,
PDCD7, KIAA1274, Tenr, CRR9, KIS, SPG7, HSFY, LOC92691, POLH, SMC6,
MSCP, FLJ10378, DKFZp434F1819, CSTF3, CPNE4, HINT3, HSPCA,
KIAA0982, P53AIP1, ING5, DKFZp434D0513, STI2, SEC14L2, BCL11A,
EPI64, FLJ25530, GPR49, IRA1, ARHGEF7, USH1C, RBM6, DSCR8,
FLJ35863, NXPH1, MGC46719, MGC10981, ZNF398, CYBB, MGC4170,
KRTAP9-4, NCOA6IP, HCAP-G, DMRT2, CORO1A, C12orf22, MLL, KIAA1753,
DMRT3, KIAA1557, RAD18, FTCD, EIF2C2, KIF13A, DLL3, KRT19, TRA@,
SCAND2, FLJ25286, ZDHHC4, SEC13L, GPR92, ZNF207, FLJ14600, USP2,
HDAC9, PRKWNK3, DISPB, CENPH, MGC29667, LOC149420, PRPF18, CHD2,
KIAA0599, MGC16824, IRTA1, ZFP28, LOC112840, KIAA1411, LOC51194,
SLC4A5, LOC115098, KIAA1720, MGC40397, FLJ36874, NESH, TMF1, LGR6,
PF1, MGC16943, TUFM, HERC2, DKFZP434N1511, FLJ12697, NLN, FLJ32827,
CSRP2BP, RUFY2, RBM11, UBE2I, YAP, LRP15, CFLAR, OSBPL5, NPD007,
ZIC4, OR51E2, MGC17301, PAX6, FLJ12697, MGC35366, U2AF1, TU12B1-TY,
BAG2, SLA/LP, BICD2, KIAA1465, DKFZp434G0522, ZNF354B, FLJ10420,
DARS, KIAA1337, DKFZP434C0826, KIAA1712, CDGAP, FLJ10324, ARHGEF7,
DKFZp434G0625, HES6, MY050, CSNK2A1, MPHOSPH9, HDAC10, KCNJ16,
LOC135763, EKN1, ORAOV1, FLJ31528, POU4F1, MGC42174, SYNGAP1,
RRP40, MGC10744, FLJ12363, TTC7L1, DKFZP761N09121, ZDHHC11,
MGC8721, IRTA2, ODAG, TRPM7, KIAA1878, TM4-B, DKFZp761H039,
ADAMTS9, CGI-203, KIAA1881, FLJ20003, SPPL2B, FLJ13386, RPC5,
CTLA4, FLJ37034, DKFZP586N2124, DKFZP434D0127, KIAA1966, KIAA1946,
MGC20255, SPINO, FLJ90013, ALS2CR7, SH3GLB2, FLJ33962, FLJ23027,
PROK1, GABPB1, MIPOL1, MCM6, BAP29, VIT1, SYNGAP1, PELI1, FLJ25477,
WBP1, ROCK1, ABTB1, LGI4, WNT5B, CLDN6, FBXO2, C18orf2, GAJ, TRIM7,
FLJ13993, PEX5R, CECR6, PR, LOC151648, POSH, HRIHFB2072, SOX7,
LOC139231, DKFZP434K0410, SOX6, CHPT1, NUP133, PSG5, FLJ22688,
YME1L1, DKFZp313A2432, M11S1, FBXO5, KIAA1444, BCR, EPB41L5, RNPC2,
HTATIP2, KIAA0436, NS1-BP, LENG3, GLS, MIXL1, WDR9, DKFZP586M0122,
KNSL5, G3BP, KCNJ2, PTBP1, DKFZp434N1415, SEMA6D, LOC63929, PTER,
NAV1, FLJ39441, MIDORI, MGC14793, BAT4, FLJ12987, SEPP1, NYD-SP17,
ZnTL2, FLJ35725, C6orf12, GSBS, MGC40157, KIAA1458, AUTS2, FBXL12,
KIAA1453, C20orf44, MGC20533, PGS1, FLJ11053, MRPS10, EML4,
MGC14793, POLR3K, RINZF, MOBP, FLJ12298, PIST, DELGEF, MGC2629,
NPHP1, DKFZp434D1428, ARNTL2, NDUFB1, DKFZP667C165, FKSG42, HAL,
WBSCR22, MRPS25, DHCR24, LY6G6D, LCHN, DKFZp761A052, DKFZP434G156,
TBX3, FLJ21839, BRUNOL4, NYD-TSPG, KIAA1706, STYX, MMD, LOC113521,
TRIM35, ZNFN1A4, DKFZP586B0319, KIAA1798, FLJ30829, FLJ14281,
DKFZP586G1517, MGC2629, DDHD1, CRSP6, FLJ11252, TRB@, GNAS,
FLJ12975, KIAA1458, COL12A1, SPINO, KIAA0478, FLJ20085, SOX7, DRF1,
TBDN100, BHMT2, ZFP91, SRMS, MGC15523, KIAA1919, FLJ23816,
FLJ11125, C20orf151, STK31, RTBDN, FKSG83, GLI4, FLJ22548,
KIAA1912, C20orf42, TRIPIN, NDUFS7, HSPC135, MGC20460, YR-29,
SCDGF-B, KCNJ15, CLLD8, ZDHHC5, MGC10724, MGC33215, DKFZp547E052,
DEFB118, MGC24039, KIAA1046, FLJ10936, ACMSD, B2M, TGM7, MGC3165,
TRPM8, WHIP, LZK1, LOC90990, IRTA2, KIAA1560, NXF2, KIAA1317,
DXYS155E, FLJ31958, HSPC154, H19, BAP29, PRKRA, PLAC3, LOC58486,
FABP4, LOC130617, JAM3, LOC57019, TF, USP24, FLJ20222, FLJ20354,
KIAA1836, MGC3040, SAC2, BARHL1, DSCAML1, STK35, KIAA1337,
KIAA1276, LOC115557, FLJ14600, ROCK1, FLJ38359,
MGC33215, ATP9B, UBE3B, C7orf3, PRKWNK4, DKFZp434J0617, MAPK1,
PRKCE, KIAA2028, GBTS1, KIAA0716, DMRTC2, FLJ10998, FLJ32069,
LOC115330, FANCA, DGCR14, KIAA1337, FLJ23577, FLJ22761, FLJ35155,
FLJ22329, FLJ14427, FLJ20557, FLJ20321, ROCK1, PPP2R2C, BCoR,
FLJ00058, LAMA1, FLJ20898, FLJ31606, PCDHB4, DKFZp547M109, CLASP2,
KCNQ5, LOC51240, FKSG79, OAZIN, FLJ13576, MGC4473, LACRT, NAG73,
HSA251708, HSJ001348, TRA@, DKFZP434A236, MNAB, HAP1, MGC24995,
DKFZP566C134, KIAA1501, MGC13090, C8orf13, GGTL3, FLJ35757,
CRYPTIC, C14orf35, KIAA2015, FLJ12303, LOC92033, FLJ20171,
FLJ31340, TMPRSS2, RIP60, ZNF272, FLJ20641, RP4-622L5, CENTA2,
C20orf64, HHLA2, DPM1, PRKCL2, GNG2, and RTN4IP1.
[0174] TABLE-US-00004 TABLE 7A Genes Up Regulated in Un-Passaged
Tumorigenic vs. HSC KRT19, C3, GOLPH2, CRIP1, PTGIS, BF, RAI3,
CA12, S100A8, PPL, TUBB, CXADR, NNMT, ITGB5, COL3A1, FN1, C1S,
CD14, EFEMP1, COL1A2, GJA1, FLJ20151, LGALS3, TACSTD2, LGALS1, FN1,
MUC16, COL1A2, KRT7, RARRES1, DSP, ID4, HRASLS3, S100A11, CYR61,
SLPI, C4A, LGMN, S100A9, SERPINB2, MAFB, COBL, WT1, TGFBI, SPUVE,
CD24, DKFZp564A176, ANXA2P2, S100A10, ROR1, EGFL6, FN1, MUC1,
ALDH1A3, PARVA, CDH3, FN1, TIMP1, MGP, AGR2, KRT18, DC12, CHI3L1,
CD24, FLJ20273, ID3, H11, HLA-DQA1, ANXA2, SERPINA3, RAB31, ANXA2,
RAB31, EMS1, FER1L3, KIAA1199, CX3CR1, FLJ11619, KLK11, CD24,
TIMP2, CCND1, LOC51760, FLRT2, HP, GPRC5B, IL13RA2, APOE, GAS1,
PPIC, MAPK13, KIAA0882, APM2, PLAT, MYL9, MYO6, COL3A1, ANXA2,
RAB31, IGHG3, PMP22, FAT, S100A8, MARCO, PTPRK, PTPRF, CD163, DF,
C4B, COL1A1, IGKC, TFF1, TGM2, CTSL, ITGB5, GALNAC4S-6ST, IF,
RARRES2, ADAM9, VCAM1, CD9, ID4, APOC1, PDEF, VIL2, GRIA2, RIG,
MET, GNG12, CD163, FLJ22662, CAV1, PRG4, CDH11, IFI27, TM4SF1,
NNMT, DUSP4, THBS2, COL6A1, FGFR2, TNXB, A2M, UPK1B, BCHE, IFI30,
MAF, KIAA0752, TPD52L1, KRT8, FXYD3, CKAP4, ALDH1A2, ANXA8, BCMP1,
ALDH8A1, ASS, EFEMP1, LTF, FLJ20151, T1A-2, SELENBP1, CTSH, GPR64,
TJP1, RARRES1, SYN47, PDGFRA, PRSS11, AQP1, COL5A2, EPHA2, ITSN1,
SULF1, PTPN3, LGALS2, OGN, CTSB, IER3, FMO1, SNCAIP, PPAP2A,
MGC2376, GATA6, IL1R1, CD1C, MEIS2, TACC2, C1R, AQP3, LR8, SLC7A8,
S100A6, ATIP1, MIG2, TNXB, MAOB, DCAMKL1, DPP7, ANXA3, RBP4,
zizimin1, CHI3L1, FARP1, CLMN, BNC, HCA112, CSPG2, CD24, EMS1,
CEBPD, IL13RA1, RIL, COL4A5, KDELR3, CAP2, MAF, TFPI2, DOC1, CSPG2,
LGI2, Z39IG, CYP1B1, CAV1, ALP, ERBB2, LAMA4, CSPG2, LOC113146,
LAMP3, ARGBP2, MNDA, DKFZp564I1922, CAV2, MARCKS, TPM2, LOC92689,
GFPT1, N33, SECTM1, WFDC2, CLU, ROR1, TST, EFS2, GUK1, C1QB, CPE,
CRYAB, TSTA3, CALB2, EGFR-RS, PPAP2A, PTPRG, SAT, TFAP2C, C2, RCP,
SULF1, SFN, LAMB1, IL13RA1, PHT2, BMPR1A, LIM, FLNC, N33, ST5,
CSRP2, FLJ23091, PAPSS2, IGSF4, TNFRSF6, STEAP, BACE2, SERPINB7,
CALU, PDXK, PPIC, TACC2, CLDN4, GPNMB, RIN2, KIAA0599, LUM,
KIAA0790, CARD10, MVP, PDGFRL, RRAS2, KIAA1078, AKAP12, ARHE,
RNASE6, BLAME, TM4SF1, T1A-2, KIAA0869, MPZL1, NID2, DDR1, DUSP4,
LAMA5, SGCE, UBD, LGALS3BP, ENPP2, SGSH, COPE, KRT5, SEMA3C, IGKC,
COX5B, ELOVL1, S100A14, APEG1, ALOX5, TM4SF6, LMNA, DSTN, RAB20,
DNAJB2, TYROBP, UPK1B, KDR, P4HB, FLJ11856, C1orf34, ADM, NR2F2,
PLXNB2, ITPR3, S100B, SOX9, DCN, EPS8, EFA6R, ZFPM2, PPFIBP2,
SERPINF1, NQO1, NMA, AADAC, COL6A2, SERPINE1, MT1X, MGC3047,
NCKAP1, DDR1, TLE1, EPN3, TBX3, CDS1, HSPB1, DPP4, CTSB, NEO1,
TMEM8, NFIB, FKBP2, TNFRSF11B, FGR, FMOD, P4HA2, TNFRSF12A, ERBB3,
NQO1, LAMC1, PRO1489, IGFBP3, MYO1C, KIAA1026, SLC6A8, PDE4A, HML2,
FLJ21562, C8FW, MS4A6A, KCNK1, C3AR1, AK1, MT2A, KLK10, KIAA0429,
IGSF3, ARNT2, DCN, C12orf5, CD24, C4.4A, SFN, CRABP2, VIL2,
CLECSF6, HCK, SIX2, TSSC3, CCR7, GFPT2, TUBB-5, ENAH, SLC16A4,
C11orf9, FLJ20761, SAR1, GPC1, MYO1D, RGS16, DCN, MT1L, PCDHA12,
SGSH, RHBDL2, GLUL, CKMT1, NPAS2, EMP2, DAB2, DSCR1L1, MATN2,
BLVRB, PLAB, MT1G, WIT-1, OASIS, PPP1R3C, NQO1, AMOTL2, TNNT1,
AZGP1, PARG1, SLC7A7, COL5A2, NEDD4L, DCN, SERPINA1, DFNA5, SAMHD1,
IQGAP1, THBD, DPYS, ADAMTS5, MGC10848, NEBL, RAI2, TUFT1, KCNJ15,
LIF, CD151, DAF, IL1R2, NRXN3, HK3, FCN1, CXCL1, CALD1, PCDH7,
C1orf13, TRD@, NFIB, VEGFC, CCL22, CD63, CTSZ, KYNU, ADFP, HRH1,
CTGF, GRIK2, ANG, KIAA0790, SNK, CST3, SDR1, KIAA0703, MGC35048,
ANXA9, YAP1, ADH1B, CLDN1, TIP-1, COL18A1, DOK5, GPRC5C, IGSF4,
ABCA8, KDELR3, PPAP2C, KIAA0440, IGF2R, VLDLR, OSBPL10, SLC12A8,
NPD009, RPL37A, MAPT, FARP1, LAMP1, DAB2, KRT17, SSH-3, ABCA3,
PHLDA1, FBXL2, LOC114990, LOX, ALDH3B1, RIG, SDC4, CGI-38, ZFP36L1,
FOLR2, DLG5, PFC, BGN, DSC3, WARS, FLJ21610, MGC2494, PCOLCE,
FCER1G, FGF13, MD-2, UGCG, BAG3, MAOA, CAPN2, CCR1, TRIM2, CLU,
NR2F6, KIAA1598, GPR65, TRD@, PPARD, HSPA6, KIAA0436, DP1, GRN,
ABCA1, CD59, ITGA3, NT5E, SLIT3, CDC42BPB, ZNF144, LTBP2, FER1L3,
PCOLCE2, FST, CSTA, CLECSF6, HOMER-3, LDB2, SLC34A2, TEAD3, PMM1,
EFEMP2, HN1, FLJ20539, TPM1, CXCL6, MPZL1, DKFZP434B044, GS3955,
CHST6, RPL5, IL1RL1, RIS1, SN, CDKN1A, PIGPC1, SLC4A2, SMARCA1,
GBP2, RNASE4, EFNA1, MCP, DPP4, HSPA1A, LRP10, GRN, SLC39A1, PFN2,
BC-2, WNT2, FLJ23186, TPM1, SIAT4A, RNASE1, PLS3, TIMM17A, DDR1,
FLJ20366, EFNB2, PSPHL, MEOX2, KIAA0429, SDC2, MGC10796, SERPINB5,
CAST, MYO6, CRIM1, TFPI2, NCF2, FLJ22531, LISCH7, SLC7A11,
MGC11242, PKNOX2, RARRES1, FBP1, CLIC4, CAST, C5R1, SPR, BCL6,
RIPX, GRN, KIAA0934, HSPB2, SPARCL1, CTSB, S100A11P, IGF1, BCAR3,
ASTN, RRAS2, FLJ21562, KIAA0992, FHL2, HLA-DOB, LAMB1, MAP4K4,
EFEMP2, KIAA1029, PP1057, SLC7A8, TLR7, MMP15, WDR1, GHR, TJP1,
PCDHGC3, MMP19, ARHD, RIL, NOL3, WNT5A, RAB17, F-LAN-1, IGF1,
BMPR1A, TLR2, FTS, EPB41L1, TPM1, CD1D, YKT6, GRIM19, WARS, AXL,
MIF, CLIC3, MAPK13, SSB1, SEC61A1, PDGFRB, IL10RA, CLTB, PCNP,
SNAI2, SGCB, CYP39A1, FLJ90798, SBBI31, FZD2, AMMECR1, SOCS5,
KIF1C, S100A13, CLDN7, PBX1, TJP3, RGL, FKBP11, GRP58, EIF5,
IGFBP1, FLJ13612, G0S2, TNFAIP1, TIP-1, PSEN2, PPIB, DAG1, ARF4,
AHNAK, LOC115207, PCDHGA1, MST1R, SH3GLB1, SC65, MGST3, BMP2, CTSB,
TMSB10, TRIM38, ITSN1, MPZL1, ARHC, KIAA1078, PLTP, CRIM1,
C11orf24, KIAA0746, MGC2376, COLEC12, BBOX1, WNT2B, HUMPPA, PAM,
MAP4, FLJ21918, SLC2A6, MYO1B, NFE2L1, DXS9928E, SLC1A1, TUBGCP2,
SULT1A1, QSCN6, LOC51159, PSK-1, CYB5R2, RAI14, L1CAM, KCNMA1,
CD1E, HOXC6, THY1, PTOV1, EDG2, SUCLG2, AQP1, DDR1, TMEM4, EDG2,
FLJ22833, KCNK15, KIAA0417, TCF21, ASML3B, HSPC163, LAMA4, APOC1,
DKFZp761F2014, SLC21A11, CXCL14, FCGR2A, FLJ20967, MRPS12,
FLJ13110, KIAA0913, SHC1, DP1, TLE1, SLC2A10, PON2, SPAG4, ITSN1,
ACTL7A, RBP1, IL1RAP, C22orf2, ATP1A1, DES, MST1, PHLDA1, KIAA0934,
S100A2, ID4, ITGB4, CASK, SLC31A2, C21orf97, CD86, FBXO9, AP1M2,
D2S448, ADCY9, PALMD, PTPN21, TRA@, PPIB, EPB41L4B, PNMA2, RSN,
SYNGR2, SLI, FYCO1, CLTB, MGC16723, CKAP4, PLEC1, FLJ10521,
B4GALT4, ID1, CDA08, OPTN, PTHLH, MYO1B, LIM, TLR5, FLJ23516, CAST,
CTSL2, CSF2RA, C14orf58, SLC7A8, TREM2, CST6, ARHN, ST14, PTPN13,
SLC5A7, DUSP5, B4GALT4, DKFZp667G2110, TWIST, SC65, PPP2R1B, ITGB5,
KIAA1096, EVI5, RAB2, CTSD, SLIT3, KIAA0284, NPY1R, HERPUD1, PMM2,
HSD3B1, HPIP, UNC119, KDELR2, FLJ10199, PLOD, GTF2IRD1, SQSTM1,
BDKRB2, WSB2, DPP3, LOXL1, SEMA5A, TMP21, CLTB, DNALI1, CXCL13,
FZD1, CNN3, KDELR3, ADAMTS2, MD-1, TAT, FLJ20234, DKK1, FLJ10856,
TM4SF6, KIAA0152, FBXO2, CLECSF12, PRSS16, KIAA0103, UGDH, YIF1P,
P8, SNTB2, GOSR2, KDELR2, D4S234E, HABP4, ANKRD3, CCL18, TEGT,
EGFR, ATIP1, EPHB3, H_GS165L15.1, TCEB2, AGRN, NBL1, FLRT3, NPAS2,
SCO2, MAOA, NFE2L1, APLP2, MED8, LRP2, SMARCA1, TJP2, p47,
FLJ10055, EPS8R1, TGIF, AGRN, SEMACAP3, DSC2, FBLN2, ORMDL2,
ADAMTS3, PTGDS, CENTG2, MMP14, SNARK, PTGER3, DPH2L1, PTPN21,
DSCR1, PP1665, PTK9, AFFX- HSAC07/X00351_M_at, HAMP, TOB1, FACL3,
GMPPB, CSRP2, P4HB, NPC1L1, PIG7, VNN3, ARK5, PODXL, ACADVL, GNPI,
FLJ10261, UPLC1, SFN, PEA15, MLCB, SLC31A1, ICAM1, UP, SLC4A4,
C11orf17, PTGER3, ZFP103, CYP-M, HMOX1, SLC21A9, TCN1, SLC20A2,
RBSK, WNT4, CYBB, ANXA4, DNAJC3, MIRO-2, ARHGEF4, SULT1A3, GOLGA2,
PTPRF, NDUFB7, TBC1D2, MSR1, CORO1B, FADD, ATP6V1D, ALDOA, EPLIN,
MST1, TDO2, ETV2, CCR5, SERF2, GTPBP1, COL4A2, ASPH, ELMO3,
DKFZP564A2416, BAIAP3, APLP2, PDE8A, IFNGR1, GREB1, ANXA2P3, CAPG,
PTS, N33, MGC11256, PLA2G4C, HFE, FLJ90798, FLNA, LMNA, IRX5, SRPX,
LOC160313, SLC33A1, CSTB, FLJ20152, ATP6V0E, HSPA1A, KRT6A, SAR1,
POR, NDUFS8, CCL2, B4GALT1, TMSB4X, FLJ20701, ACTN1, IL4R, F5,
CD5L, IGFBP3, ALOX5, AUH, CKAP1, CCR1, KIAA0843, UGTREL1, GAS2L1,
AP1M2, RARRES3, PPGB, LY6E, GNB2, CTNND1, FPR1, ALDOA, PC326,
KIAA0980, PGM3, DHCR24, PTGDS, LAMB3, ALDH7A1, KIAA0716, TC10,
KIAA1096, IL1RN, C11orf24, FDXR, SERPINB3, COL6A1, FLJ20296, DTNA,
IGF2R, TRIM36, FLJ22593, IFITM2, ARHD, KIAA0220, OCRL, SDC2, KIF3B,
GALNT10, PRKAR1A, VTI1B, PSAP, PTPRO, FGF2, PCSK7, SUCLG2, ERP70,
FLJ20254, MLP, CORO2A, IL13RA1, RGS16, MEIS3, FOLR1, LGALS8, LAD1,
TGFBR3, NDUFA3, LANO, AFAP, SGPL1, UBXD2, GM2A, PCDHGA10, PACSIN3,
CFL1, PAM, GOLGA2, GSTM3, CREB3, C14orf92, IGL@, FLJ21313, SYNE-2,
EPHX1, MRPL17, PCDHGC3, MAP3K6, DNCH1, TM7SF1, LARGE, VRP, IL6,
KIAA1096, SARS, PSMD8, COX17, GPX4, SULF1, NEU1, ISGF3G, PLP2,
CYR61, ATP6V1D, EIF5, FLJ20847, DKFZp761K1423, FLJ11526, EHD1, KMO,
KIAA1735, RGS3, SDFR1, ASM3A, FGFR2, FCGR3B, TPM4, CPE, FLOT1,
CNGA1, SPHK2, FBXL7, SH3GLB1, LAMP2, EHD1, PLXNB1, VCP, SNCB,
ITGAV, FLJ21047, STAT3, PSMC4, CALD1, DES, ALDH3A2, VDR, PAPSS2,
MGC13523, ARF1, NDUFA2, PPAP2B, FUS1, ASNA1, TUBB4, MGC4504,
RGS19IP1, ATP5H, TSTA3, Cab45, RDH11, ECGF1, TMEM2, GALE, WSB2,
NSAP1, WFS1, HSPC003, GOLGA1, SH2D1A, FLJ20986, KRT17, UNC84A,
MYL6, LAMC2, FGF18, HS2ST1, RNPEP, TC10, FLJ14675, MGC3178, TM9SF1,
GALNS, SORT1, HSPC019, SULT1A3, ENC1, RAB9A, CED-6, C21orf97, HFE,
FUCA1, KIAA0674, EHD1, PLAUR, CETN2, TPBG, CYP27A1, MAN1C1,
PPP1R13B, ATP5J2, THBS3, FKBP10, YKT6, PIGO, CYP4F12, LRPAP1, ITCH,
MLF1, ACTN4, EIF2AK3, PDE4DIP, DZIP1, TUBB4, SEC24D, KIAA0143,
ITPK1, FLJ13110, AP2B1, IFITM2, SCN8A, STS, CDC42EP4, ARPC1A,
CD2BP2, CACNG4, SULT1A2, TAF10, BRD2, TRAM, HSF2BP, UBC, ADAMTS9,
AQP9, RALA, COL15A1, DYSF, LAMB2, RPL5, EHD1, CLCN3, ARF4L, HDLBP,
NPR2, HRB, SQRDL, MIG2, NAV2, TBC1D1, TPD52L1, VTN, ARL1, CYB5,
LGALS8, COPZ2, FLJ21916, FLJ20421, P4HA1, TBL1X, ANGPTL2, KIAA0992,
NRP1, SLC21A11, ICMT, STS, EIF5, PIP5K1C, RDS, PVRL3, PON2, HIG1,
DLAT, LOC64182, RNF3, ACAA1, UQCR, FLOT1, TC10, DSTN, TEAD4, RER1,
TREM1, IL17R, PLCE1, SLC6A8, HIMAP4, PILR(ALPHA), TRIM38, TXNDC4,
CTSK, DSS1, LPHH1, SGCD, PEN-2, KIAA0527, RRAS, CD3D, LANCL2,
P2RY6, TUBB, RAC1, AAK1, LOC51762, ALOX5AP, GNB1, FKBP11, RNASEH1,
EPB41L1, GPRK5, GPI, HMCS, PTGER3, SSR4, FKBP9, AK3, CBLC, SGPL1,
PLCD1, MED8, ALDH3A2, IGSF6, KCNN2, HS3ST3A1, MLCB, TRIM38, FCGR3A,
IFI35, ABCA1, DKFZp564A176, FSTL3, MAPKAP1, ENTPD3, FLJ23514,
HS3ST1, IGHM, PM5, NDUFB2, TOMM22, ANGPTL2, KRT7, SSH-3, ELOVL1,
NPEPL1, NEDD4L, PARVA, PTK2, SEMA3E, NCBP2, KMO, QP-C, ECM2, ATP9A,
HMOX2, SMAP, SLC9A3R1, ATP1B1, PCDH7, EDF1, OPCML, NEDD5, FLJ10466,
CBX6, CDH6, MAN2B1, CYB5, SLC38A6, FLJ12443, ASPH, MOB, HUMNPIIY20,
DC50, PSMD5, LRRFIP1, FLJ22160, PAFAH1B1, DKFZP586L151, BLAME, TAZ,
ATP6V0B, APBA2BP, RISC, ADRA1A, PIG3, TNFRSF21, CBFA2T1, EML1,
EPIM, APOE, WISP1, CA12, VIL2, RAI, FAAH, ATP6V0D1, CD97, JAG1,
STX4A, Cab45, NFE2L2, PPP1R12B, ZMPSTE24, KIAA0500, IL17BR, RRAD,
PGM1, CD59, ADAM19, NPEPPS, FJX1, GAA, SOX13, FLJ22638, BAIAP2,
DUOX1, TGFA, FLJ20719, LMCD1, BBS4, MARCKS, GM2A, FLJ11200, MAPK3,
WWP1, FLJ20152, SMARCA4, PSCA, MCJ, ARF4, SLC35A2, SKD3, CDC42EP4,
SLC22A1L, SSH-3, SMARCD3, PDLIM1, IL27w, CGI-135, COX5B, LOXL2,
CRK, GOLGB1, PSMD4, MAGED1, CDC42EP1, HSPC171, SEC13L1, KIAA0265,
PSEN2, XLKD1, STAB1, FLJ21079, FBLN1, INSM1, FLJ10252, MPDU1,
MGC3067, FLJ11181, TPARL, TULIP1, DUSP8, UBXD2, CPD, HSPA4,
FLJ11807, GPR1, CTNND1, TNFAIP2, MAGED1, MMP9, CKAP1, UGCGL1, SMP1,
FLJ22678, BZRP, COX8, BDKRB1, HOXC4,, H19, NMES1, SMOC2, PIGPC1,
TEM8, PTGFRN, FLJ23091, IGKC, ALS2CR9, IMUP, MIG-6, MAL2, SPUVE,
YAP1, CXCL16, MYO5B, KIAA1244, PARVA, SYNE-1, FGG, AGR2, KIAA1500,
RERG, NTN4, TMPRSS3, ARHU, RHPN2, GLIS2, UGCG, SULF2., BOK, OGN,
CLDN1, DKFZp434G171, FAD104, KIAA1165, ShrmL, PTGFRN, AD037, OSAP,
LOC51760, MS4A6A, FLJ20273, MS4A6A, FLJ23153, NAP1L, LRG, LOC55971,
MGC14839, FLJ30532, UNC5H2, FLJ14299, TCEA3, CTL2, ORF1-FL49,
LOC155465, ENAH, OSR-1, SBBI31, DAG1, EDG3, PSK-1, MGC2615,
ALS2CR9, DKFZP761L0424, TBX3, FZD4, FLJ20171, DKFZp761P0423, NGEF,
TOB1, C1QG, DNALI1, MGC35048, GUK1, DKFZp586C1021, KIAA1500,
LOC83468, p25, CCL26, GNG12, SAMHD1, ID4, B4GALT1, DKFZp434D0215,
GJB2, FLJ14957, PRO2605, MGC13040, CHDH, ALDOA, FST, TEAD2,
KIAA2028, FLRT3, FLJ31842, CDKN2B, MGC16028, IRX3, TEAD1, MGC33662,
MS4A6A, SEMA6D, DKFZp434E2321, PKIB, PKIB, KIAA1671, FLJ22174,
LOC128153, COTL1, SAMHD1, MGC24103, UACA, SELM, CGI-85, NAP1L,
CAMK2D, C4orf7, BOC, MGC11034, DKFZP564J0863, DKFZP434H0820, PARVA,
SPP2, FLJ40432, STEAP2, PDGFA, BACE2, FLJ14834, LOC55971, ANGPTL1,
MFI2, KIAA1337, WNT7B, IPP, DKFZp547D065, MGC39325, CTL2, SAMHD1,
LNX, MGC26963, KIAA1324, MGC16212, KIAA1921, ALS2CR9, CXCL14,
SPPL2A, FLJ14525, ENPP5, MGC29643, TCF21, ECGF1, PCDHB14, CFL2,
GRP58, TGFBR3, DKFZp434F2322, FLJ22474, RCP,
KIAA1866, MGC10974, PHLDA1, MGC12335, SYTL2, LOC51242, PCDHA10,
KIAA1145, KLF15, TMEPAI, GRIA2, LOC92689, SIPL, H19, FAD104,
C11orf15, MGC39329, MAFB, BCAR1, RDHL, C14orf50, DRAPC1, RORC,
MYEOV, GPR92, DUSP16, GFRA3, ZD52F10, FLJ14735, LOC113026,
FLJ20048, CLDN11, CDH24, TLR8, FLJ31052, C(27)-3BETA- HSD, YAP1,
EMS1, GATA5, FLJ23420, FLJ10035, IL28RA, MAF, HMT-1, DERMO1, DIRC2,
HSPC163, ARHU, LOC114990, MSTP043, CGN, DUSP16, ODZ2, INMT, GPR,
CRBPIV, FLJ22558, KIAA1145, TCEB2, LOC55829, SEMA4B, COL12A1,
MGC11034, KIAA1576, MTA3, ATP1B1, C20orf155, SDCCAG28, MGC16028,
CXADR, CTSB, KIAA0146, MGC33602, CLDN12, RAB23, DKFZp434F2322,
PRO2714, BTBD6, MRPS10, SNX9, IL4I1, DKFZP434I1735, LOC91523,
AFFX-HSAC07/X00351_M_at, RERG, FLJ14642, FLJ22833, MYO5B, SDCCAG28,
RAB10, LBP-32, C14orf31, DLG5, FLJ22415, PCDHB16, MGC10204,
C21orf63, DKFZP434K0427, NRP2, KIAA1870, TEAD2, SPTB, FLJ33516,
SURF4, NPD007, PCDH20, MGC19825, MGC26818, MGC4604, KIAA1337, ESDN,
FLJ23091, MacGAP, CGI-85, C8orf13, FLJ40021, MS4A7, LTB4DH,
PLEKHA1, SORCS2, CRIM1, FLJ11200, HS6ST2, FLJ10697, WW45,
LOC132671, DCAL1, SNX9, DKFZp761K2222, IGSF9, LOC57168, LOC90701,
GPCR1, AK2, FLJ31564, KIAA0599, ANGPTL1, FBXO25, KCNK6, MRPL41,
FZD8, UGCGL1, COPZ1, RBMS1, C20orf23, Cab45, TRIM7, OAZIN,
FLJ10210, SYTL2, FLJ20442, C20orf139, KIAA1394, C20orf110, MGC1314,
C20orf52, CNN3, MacGAP, CAC-1, MAP1B, FLJ40021, PRIC285, RAP2B,
TMPIT, KIF1B, GFRA1, DKFZp762A217, XPR1, EMILIN-2, FLJ32069, SMUG1,
ARF1, NDUFB10, EHF, NT5E, CORTBP2, FLJ32194, FLJ90440, LOC147700,
MGC21874, KRT19, PCDHA10, DTNA, RGC32, ULBP2, H2AFJ, CFL1, MGC2601,
DKFZP566F084, SLC26A9, KIAA1404, PX19, APOA1BP, WASL, TLR7,
FLJ20739, FLJ25157, FLJ22833, MGC14353, DKFZP566J2046, SNX8,
BHLHB5, TAF10, FLJ14594, MRAS, FLJ14511, UBXD1, AMID, ANKRD9,
ACTR3, TMEM9, DKFZp761N0624, FLJ20748, ROR2, LOC91461, TLE1,
SEC14L2, BAT5, SSB1, E2IG5, KIAA1357, MBC3205, FLJ11046, FLJ14681,
HSPC242, DKFZp547A023, CED-6, KIAA1715, TNKS1BP1, ATP11A, EHD4,
INADL, FLJ11011, KIF3B, DKFZP434K0427, FLJ32069, CSEN,
DKFZp761D0614, MRPL41, PXMP4, LOC84518, LOC115265, LOC51255,
ATP6V0B, N4WBP5, GGTL3, MAGI-3, MLLT4, LUC7L, ERO1L, MGC13114,
MGC39807, CAPNS1, TRIM47, GPR34, KIAA1200, N33, PSCD3, NSE1, BAL,
C20orf24, MGC22805, KIAA1337, CDH11, LOC51248, KIAA1126, FLJ90119,
PVRL2, ARHC, SSBP4, DNAJC1, E2IG5, FLJ10702, NUMBL, SET7, BRI3,
FLJ32069, FLJ20097, KIAA1870, C14orf31, TP53INP1, NCAG1, GSH-2,
FLJ21963, KIAA0599, MPP5, SCDGF-B, AXIN2, CGI-149, CGI-97,
MGC19825, DNAJA4, SMOC2, MRPL27, KIAA1542, ARHGEF5, CAMK2D,
SLC21A11, FLJ37318, C20orf64, D1S155E, UNC84B, MGC26963, dJ55C23.6,
GK001, CPNE4, MGC16491, FHOD2, HTPAP, KIAA2002, PRDM6, FGFR1,
DKFZP564B1162, HLA-C, PRDX5, FLJ20623, FLJ20719, C14orf47, MYBBP1A,
RDH13, DPP3, PCDHB18, NOL6, JAM1, LOC54516, FLJ10210, NRXN3,
MRPL53, KIAA1643, MGC15523, LOC115704, BR13, GTAR, KIAA1434,
MGC33510, FRABIN, UBQLN1, MGC3195, FBXO32, SMP1, FLJ10902, C1orf13,
CGI-72, MGC45474, TRIM8, HM13, NFKBIE, FLJ22004, AD-003, MMP24,
RBM8A, DNAJC5, C20orf169, NOR1, METL, MGC2747, FLJ14251,
DKFZp451G182, KIAA1363, FLJ23393, RNF19, STK35, AMID, MGC4604,
FLII, DKFZP566J2046, SNAP29, DKFZp547A023, DKFZp434F2322, SLC17A5,
FLJ14117, MGC4342, SLC31A1, MGC2555, KLF2, NKD2, SEC61A1, LOC91012,
MSTP028, FLJ20421, MGC40555, KIAA1554, AD-003, SURF4, GALK1, FACL6,
DKFZP434D146, GPT2, BRPF3, KIAA1165, SLC30A1, FLJ20542, KIAA1255,
JUB, SYNPO2, SURF4, MGC2550, LOC90507, SYNPO2, ARFGAP1, KIAA0599,
DNAJB11, UBE2H, C20orf149, PHP14, FLJ23577, FLJ23654, LOC51290,
DJ667H12.2, FLJ23277, LOC115098, DKFZp547O146, LACTB, FLJ90575,
NEK6, Cab45, MGC13045, SRA1, DPP9, SFRP2, LOC113179, KIAA1784,
C20orf149, CGI-09, GBP2, PDK4, HRMT1L1, MGC33993, MESDC2, IDS,
RDGBB, RPL17, TEAD2, SEI1, C20orf58, HSPC210, KIAA1163, KIAA1223,
RAB18, NFKBIA, SEPP1, B7-H3, MGC33607, CAB56184, SDCBP2, PCDH18,
SPEC1, RAB18, SH120, MGC11102, MGC19825, LMLN, REN, CALM2,
PPP1R14A, NDUFB9, KIAA1026, MGC20486, FLJ30803, AKIP, LTB4DH,
DKFZp547A023, C20orf167, FLJ31937, FLJ20186, APXL2, CFL2, CGI- 20,
KIAA1437, PVRL2, KIAA1295, KIAA1912, DC-TM4F2, CDW92, RPS27L,
CAMK2D, RAB18, FLJ21415, MGC10999, KIAA1896, KIAA1337, CGI-69, and
STC1.
[0175] TABLE-US-00005 TABLE 7B Genes Down Regulated in Un-passaged
Tumorigenic vs. HSC HSPC053, HOXA9, SPINK2, HOXA9, MPL, KIAA0125,
BEX1, FLJ14054, CD69, ANGPT1, AKR1C3, LAGY, TNFSF4, HLA-DQB1,
ITM2A, KIT, GUCY1B3, PLAG1, PROML1, MYCN, MLC1, LYL1, MPO, HOXA10,
PCDH9,, PLCL2, HLF, SV2, LOC81691, DLK1, HLF, ERG, SOCS2, MYB,
PPM1F, PRSS2, BAALC, NPR3, EREG, MMRN, IQGAP2, C17, MPHOSPH9,
LOC51659, SELL, MEF2C, TEK, RAB38, FLJ10178, TRY6, NINJ2, FLJ22746,
BM046, ICAM2, MLLT3, BCL11A, HMMR, NAP1L3, MPO, AREG, SATB1, LGN,
FLJ10713, ERG, PADI5, IGHM, HLA-DQA1, SCHIP1, ARHGEF6, GUCY1A3,
TMSNB, TYMS, TAL1, MS4A3, GMFG, FLI1, LPIN1, 6-Sep, C20orf42,
TACC3, LOC81558, MCM5, TRAITS, IL8, CXCR4, KIAA0186, RetSDR2, RAMP,
MGC2306, LGN, CDW52, HMGA2, PTGER4, NUDT11, ZNF198, PCDH9,
FLJ10468, PSIP2, CRHBP, ICAM3, IL12RB2, KIF4A, DKFZp761P1010,
FLJ12428, GPR56, CXCL2, PRIM1, BIRC5, PLAC8, TFPI, H3F3B, HBB,
NEFH, LMO2, SV2B, ITM2A, BRRN1, MCM2, MLLT3, H2BFQ, DOCK2,
UBCE7IP4, ZNFN1A1, BCL11A, DDO, NRIP1, TARBP1, HBB, KIAA1750,
F2RL1, NRIP1, FLJ10719, CDC25A, VRK1, DUT, PIP5K1B, NR4A2, BCL11A,
BM039, HSPC022, 6-Sep, TOP2A, PDE4B, GIT2, JAM2, KIAA1939, MAP4K1,
RUNX3, SELP, ANKT, B4GALT6, BCE-1, HBD, PECAM1, E2F3, FLT3, PIR51,
TRAP-1, TFR2, P311, HSU79274, CLDN10, DNMT3B, CDC45L, CDW52, PELI2,
MGC861, C1orf29, BRCA1, HHEX, LBR, TOX, ITGA2B, FLJ11712, LOC81691,
PPM1F, STAC, CRYGD, MAD2L1, KIAA0379, ITGA4, PLAGL1, TAL1, PF4,
ELMO1, ITPR1, RNU2, SNTB1, RAD54L, HCGIV.9, LRMP, BRDG1, ZNF22,
CABC1, TEC, NR4A1, FLJ20898, FLJ21276, FLJ10038, ITGA2B, ADA,
SSBP2, RRM2, STMN1, PSIP2, DSIPI, NR3C1, RAD51, SCML2, STK17B,
LCP2, MCM7, NT5M, FANCG, NR4A2, SCGF, KIAA0916, PRKCB1, STK18,
PRSS21, SEMA4D, KIAA0101, DLG7, FLJ10493, KOC1, PDZ-GEF1, ASB9,
SCN9A, KIAA0820, FLJ23468, PTGS2, HIS1, GABPB2, KLHL3, PRKCB1,
H1FX, PDZ-GEF1, TKT, AKAP7, MST4, PER1, CKAP2, GSTM5, KIAA0582,
PRKCH, AMD1, AD024, CD34, SLC27A2, FOXM1, RAGD, MEF2C, LOC51334,
EDG6, HMGB2, FLJ22690, CPA3, ANP32B, GNA15, PRC1, CXCL3, SAH,
CENPF, PRKACB, KIAA0092, RFC5, MAP4K1, SPN, SORL1, RPS21, ALDH1A1,
VRP, TFEC, KIAA0769, SERPINB1, CTSW, KNSL1, CBFA2T3, RNF2,
KIAA0711, MSH5, CCNB2, PTPN7, FLJ22794, NASP, WBSCR5, RUNX3, CDC42,
NR4A2, MCM6, FLJ10719, HLA-DQB1, C11orf8, BIRC5, NSBP1, PECAM1,
WSX1, CCND2, E2F1, UPF3B, LOC129080, STAT5A, KIAA0471, SCARF1,
KIAA0239, CASP2, PPBP, SFRS5, MCM5, SERPINB1, HSPC157,
DKFZp564B0769, PFAS, C4S-2, BANK, H2BFA, HNRPA1, MPHOSPH9, SMCY,
NUDT1, KIAA0841, MFNG, HEC, VWF, TUCAN, RAB33A, FLJ13949, HMMR,
SRISNF2L, GNAI1, H4FG, RTP801, DACH, KIAA0918, SYK, CKS2, SLA,
HNRPDL, EHD3, SPN, TNFAIP3, MDM1, DJ434O14.3, NASP, PMSCL1, PLAGL1,
RPIA, FLJ13912, FLJ20005, HERC1, CDC2, DC11, ACYP1, TALDO1, MYB,
TIF1, DKFZP564D0462, IL1B, ING3, AMT, FLJ20047, GGH, PLAGL1, PRKG2,
DHFR, AND-1, ATP6V0A2, CDH7, RACGAP1, ITGB3BP, RPS14, TK1, POLA,
FLJ20456, 6-Sep, SMC4L1, RYBP, CHAF1A, HCAP-G, EZH2, POLE2, USF2,
PRO2198, BCL2, NUP98, ATP2A3, FLJ10604, AMD1, SMARCF1, IL3RA,
RUNX1, FLJ12673, KIAA0084, KIAA1157, HMGA1, COX11, HDGFRP3, SS-56,
POLQ, GRB10, MSH5, DDX28, RRM1, CEB1, AS3, DNMT1, TCF8, C4ST, LSM5,
TRIM22, KEO4, NR2C1, KIAA0092, KIAA0332, KIAA0308, PSIP1, RNF8,
NR3C1, TAF5, TTK, RBM8A, MGC12760, KIAA0056, DHFR, ZFP36L2,
RASGRP2, HEI10, NAB1, KIAA0170, NAP1L2, KIAA0286, ABCF2, HYA22,
PRKACB, LAIR1, 24432, DCK, TFDP2, MGC2217, HOXA10, KIAA1028, DKC1,
C11orf2, C11orf21, SKP2, USP1, FUS2, DNAJC9, KIAA1110, GAB2, ZNEU1,
M6A, DLEU1, MAC30, DUT, HNRPD, SIAH1, FLJ14280, KIAA0179, TRIP-Br2,
DKFZp564B0769, TIEG, PTTG1, FANCA, ESPL1, ING1, BIN2, KIAA0721,
HYAL3, CENPA, LRBA, MUTYH, CAPRI, PSMD11, FLJ11222, PDE4D, AKR1C2,
BZW2, SLC27A2, ALDH5A1, BIN1, SLK, NFATC1, TFAM, MAPRE2, ABCC4,
CA1, RBM15, PRSS3, PRV1, FEN1, PCNA, LOC58504, OIP5, SMC2L1, ITSN2,
TOP3A, FLJ23053, TIMM8A, APOBEC3G, TRIM9, RPA1, KNSL7, C5orf6,
RBM12, MAC30, UBCE7IP5, CUGBP2, ARHGDIG, NRGN, SHCBP1, CGI-30,
CDT1, DGKZ, RAC2, FLJ20272, C20orf42, SLA, MPP1, KIAA0682,
DKFZP547E2110, ARHH, KIAA1172, KIAA0265, SOS2, HNRPA0, GIPC2,
WASF1, MGC14258, HPRT1, KIAA0443, CD164, KIAA1466, FLJ23151,
FLJ10450, DKFZP586A011, BUB1B, C20orf59, TFPI, KIAA0841, DATF1,
SLC18A2, MGC14258, CBFB, UBE1L, SNRK, MGC26766, RAD52, SNCA, CHES1,
KHK, LRBA, CG018, MBNL, VAV1, BIN1, HIC2, FLJ23018, HSU53209, ELA2,
PTGER2, KIAA0555, CYFIP2, MBNL, CLC, AMPD2, CENTB1, PEPP2, ZFP36L2,
CENPF, LEPR, C5, FLJ12888, IGLL1, TLK1, AKR1C1, IAPP, TIMELESS,
DNAJC6, PRO1331, TIF1, SF3B3, RES4-25, FLJ20641, TPST2, CENTB1,
DUT, CD244, EP400, ZWINT, SNCA, GJA4, AVP, MRPL16, MAN2A2, HADHSC,
6-Sep, MAPK14, TAF1C, LY75, MELK, GMNN, NSMAF, BUB1, HGF, PRTN3,
AK2, FLJ10335, SFRS5, ZNF215, FLJ12735, MGC5528, GABPB1, GP1BB,
MYOZ3, RAB6KIFL, RFC3, OXT, SMC1L1, Nup43, PDGFC, RRP4, HTR1F,
HPS4, ICAM4, STRIN, 384D8-2, ANKRD6, ING4, JJAZ1, KIAA0916, FXYD6,
KIAA0981, HSPC056, FLJ11294, SPAG5, HSPC047, WFDC1, ORC6L, ZAP,
GAPCENA, LMNB2, MGC2603, POLQ, SFRS7, MYOM2, FLJ10156, WEE1,
DPH2L1, MIRO-1, POLG2, CHEK1, SRPR, ST7, NEK9, ITM2C, JIK, PAICS,
KPNB1, CGI-32, FLJ20105, PTEN, CDC7L1, FLJ13262, ATPAF2, FGFR4,
STAG2, UBE1L, FLJ14007, KIAA0308, H2AFY, KIAA0451, FLJ21478, NFE2,
GTL3, KATNB1, RIN3, ICAM2, CREB1, ABCB1, MGC4701, ATF1, LOC90355,
FLJ10290, FLJ23392, FNBP1, SMARCE1, CES1, KIAA0419, FLJ20035,
LOC51320, PRDM2, TIMM9, RAD51, PPM1B, HELLS, CHD4, MORF, TRIP13,
NTSR1, LPIN1, MAPRE2, ZNF278, HYA22, CG005, NPAT, MONDOA, LAPTM4B,
RRM2, C20orf1, FLJ20010, PRKRIR, SFRS3, DKFZp547I014, MCM3, PCNT2,
NAP1L1, FLJ23476, MYBPC2, PA26, C6orf32, MGC13024, OPA1, RBBP4,
BIN1, CAMLG, cig5, PLA2G3, KIAA0592, FLJ20094, HNRPH3, GEMIN4,
FLJ13386, TKT, DKFZP434B168, PMS1, FMR2, C21orf66, C19orf2, TFPI,
DKFZP564O0523, LRMP, PPP2R2B, ZNF135, ZNF198, FBL, SCGF, CEL,
LRPPRC, FLJ12903, FLJ10858, KIAA1041, KIAA0800, PCDHA10, JRKL,
SUPT3H, ITPR1, POT1, C16orf5, CGI-48, FLJ22002, SFRS11, SYPL, MSH6,
ZNF85, DLEU2, LIPT1, RFC4, FLJ10539, LZTFL1, BMI1, CSF1, COX11,
UBE2C, LOC93349, ATP2A3, GPC5, F2R, RPL28, TGT, TCERG1, DDX34,
LAMP2, CCNF, M96, CDC25C, LANPL, ADCYAP1R1, SUV39H1, FLJ14213,
DKFZP434L0718, FLJ21269, PRAX-1, ANP32A, SRRM1, CDC6, FANCE, H2AV,
C6orf48, TSN, FBXW3, CEP1, ZNF161, SF3B3, CDC23, SFRS11, CYLN2,
IMPDH2, PIGL, H2AFJ, KL, TNFAIP3, MGC2306, Jade-1, CDKN3, FLJ10287,
CSNK2A2, OPA1, TRAF5, RPP40, HTATIP2, ANP32A, WTAP, ESRRB,
LOC51185, MRE11A, H4FJ, KIAA0097, WAS, HMGB3, MCM10, NBR2, RPL3L,
LAPTM4B, FLJ23277, HSA250839, C19orf7, MGC19570, C6orf32, APEX1,
KIAA1387, FHL3, CGI-49, TMPO, CGI-127, TBC1D5, RBMX, SF3A3,
FLJ10379, HADHSC, IGHG3, LOC254531, SFPQ, FLJ10154, DKFZP434H132,
KPNB1, WHSC1, PRSS3, CCNB1, CYP3A7, FLJ20244, RAB6IP1, SNRPA,
LOC115648, BLM, FLJ20136, SYT11, CAT, USP15, PRPS2, UBE2D2, CENTB2,
SRP72, TOPBP1, SIL, MAP2K5, SPG4, RENT2, SCAP1, GP1BA, DNAJC9, TPO,
ZNF261, TOP2B, PDCD1, IPW, SNX26, PTTG3, ENO2, CNR1, DDX11, CRLF3,
KIAA0092, KIAA0433, NBS1, C20orf67, GP5, KIAA0101, BTBD3, GPRK6,
TLK2, FLJ20856, PKD1-like, RECQL5, ARHGEF9, FLJ11210, DKFZP564I052,
PLCG2, BITE, HYPH, HNRPA1, ATP11B, LIG1, KIAA1473, PTER, PPP1R16B,
FLJ10597, KCND1, FLJ22474, MTMR4, SMC5, FLJ20288, MED6, ULK1, DNM2,
ZFHX1B, LRP16, FLJ11184, RNF38, LOH11CR2A, NEDD4, AND-1, ITGA9,
CDK2, PGDS, FLJ11896, FLJ13449, LOC93081, MRPS14, ANP32B, FLJ21272,
KIAA0555, CDCA4, KIAA1966, FADS1, PRKCN, OGT, TRIP-Br2, KCNE1L,
UQCRB, HIF1, SCA7, RAD51C, HDGFRP3, FLJ10565, HINT1, AKR1C1, PTBP2,
TCF12, CG005, MPHOSPH9, KIAA0953, OSRF, C14orf94, PNN, NGLY1,
LILRA2, CD79B, LANCL1, C20orf16, CCNE2, MTCP1, PPAT, KIAA0800,
KIAA1039, MGC5149, FLJ22843, FLJ12610, MRPS31, C14orf2, RUFY2,
NCOA6IP, FBXO4, PRKAR2B, TOX, HBOA, PMPCB, LOC51275, GFI1,
MGC21654, TGIF2, LARS, DKFZp547P234, NR4A1, KIAA0036, PHKA2, MYST1,
HSA9761, AIP1, TFAM, CDC20, CLNS1A, THY28, ZNF145, FLJ20509,
FLJ10890, MAX, FLJ20312, ZNF305, C21orf45, ESPL1, ZNF292, VIP,
FLJ13902, HA-1, ARTS-1, AS3, H4FI, THEA, FRAG1, DNA2L, KIAA0240,
OIP2, ZNF16, GOLGIN-67, GPR44, MTHFD1, IMPA1, GNB2L1, CNGB1, SYPL,
PASK, PTDSS1, FLJ11342, MRPS31, CBX8, TTF2, DYRK1A, CR2, RANBP2,
FLJ20003, APOBEC3B, BCMSUNL, KIAA0725, PDE4D, PRH1, XPO1, CML2,
HYA22, IDN3, KIAA0261, ZNF175, YARS, CDC6, MOAP1, GLRX, ATP2B2,
PPAT, FLJ20530, ZFR, COIL, KIAA1100, PER1, PSTPIP2, TXNDC, PP2447,
FLJ13197, CIAS1, JMJ, SYT11, H2AV, SPS, CUL3, FLJ23306, SNRPD1,
FLJ10876, NBR2, DKFZP434F0318, SP100, NIP30, BANP, SMC2L1, GPR21,
CSTF2T, HSA9761, SFPQ, EFNA2, GRB10, RPS20, KCNAB1, FLJ32069, PUM2,
RPL17, FLJ20499, HGF, CCND3, CTSG, ABCC1, PIAS1, PPARBP, DC13,
SPHAR, SUSP1, C14orf10, NPFF, PFKFB1, PAPOLB, H2AFY, SPRR2C, STAG3,
C11orf8, D6S2654E, INVS, ANAPC1, GPHN, DKFZP564O043, TM7SF3,
UBE2E1, NAP1L4, RASA1, MGC12909, DIAPH2, FAIM, UCHL1, C10orf2,
NUMA1, FLJ10706, SSH3BP1, FLJ23560, ZNF137, MTMR2, ZFD25, PIGN,
KIAA0252, MEIS1, SSRP1, ZNF363, NUP50, FLJ10315, UNG, COL6A1,
ZNF10, ILF3, DDX28, MGC4170, TSC22, MATR3, ARHGAP11A, LAG3,
LOC51231, C21orf33, KIAA0376, ZNF42, RERE, GalNac-T10, NSBP1,
CLEC2, RNPS1, MAP4K1, ADSL, SYNGR1, RPL22, FLJ10716, LHX6,
FLJ10546, XRCC5, SP192, JJAZ1, INPP5D, HPIP, LOC57019,
DKFZp434N062, DEK, EIF4ENIF1, ZFP36L2, FLJ13920, MDS1, KIAA0404,
HMGB1, ILF3, SYNGR1, SIAH1, FADS2, KIAA1074, FLJ12788, TAF7, KCNA3,
CL640, KHDRBS1, FLJ12377, ED1, MTCP1, FNBP1, EPS15, BHC80, CHD1L,
DKFZP434L187, FLJ20477, SCOP, KIAA0470, ME3, QKI, SALL2, SON,
CSF3R, HDGFRP3, EIF2C1, P53AIP1, PCTK2, PAI-RBP1, ATRX, HTR2C,
CHAF1B, NXT2, Nbak2, CDC14B, CCBL1, GTF3C3, DNMT2, SLC24A1, AND-1,
FLJ13373, SET, USP4, CRSP2, NFRKB, P2RX1, SE70-2, CALCRL,
DKFZP434D1335, OSBPL3, TUBA1, DKFZp434N062, DNAJC8, ALOX12, RTN3,
KIAA0543, DNAJC8, AFFX-r2-Bs-phe-M_at, AXOT, PSMAL/GCP III, WHSC2,
DMRT1, TIC, AF311304, NPR3, C14orf93, FLJ10483, IMPACT, TGIF2, TNS,
CAPN3, ZNF292, FLJ22557, KIAA0036, CGI-79, H4FA, TFDP2, UBL3,
SLC22A6, CGBP, SNRPD1, SCGF, MRPS27, ZNF335, RBBP9, STK12, MAT2A,
FLJ11175, KIAA0528, MXD3, CPSF4, HINT1, PPIH, GNAO1, BRD1,
KIAA0368, AP1S2, NAP1L1, ST3GALVI, ZNF287, CYP2C8, ZNF291,
KIAA0582, GART, EPM2A,,, LOC51194, FLJ21269, EMCN, MGC41924, USP2,
HEMGN, MGC24665, ZNFN1A1, CDCA7, SHANK3, Evi1, CDH26, FLJ20171,
C4ST3, MGC21854, ST6GalII, CT2, WHIP, MGC16386, FLJ33957, BCL11A,
FLJ33069, DKFZp762L0311, ZNF6, DACH, CENPH, EHZF, NIN283, FLJ39957,
DKFZP566N034, PTGS1, DKFZP586D0824, KIAA1218, MMP28, NID67, CYYR1,
5'OY11.1, BIC, CDT1, FLJ14503, B3GNT5, SDPR, ITGA4, MGC16179,
HOXA7, ROBO4, GNAI1, DJ79P11.1, C1QTNF4, RAD52B, KIAA1726,
FLJ30046, ARHGAP9, PRDM16, FANCD2, C21orf91, UHRF1, OAZIN, FKSG14,
NIN283, EPB41L5, RAB39B, TFDP2, FLJ12994, PRKACB, FLJ32009, KLHL6,
FLJ10493, KIAA0748, FLJ21986, NOG, GPR27, EPC1, STIP-1, CGI-105,
MGC12935, FLJ20093, HSAJ1454, EVIN2, KIAA1554, MGC20262, FLJ20354,
MGC8721, EKI1, MAML3, SEPP1, TRB@, CHD2, MSI2, DKFZP434A0131,
KIAA1554, MGC20262, KIAA1798, TMPO, SYTL4, EHZF, KIAA1337, HNRPD,
Rgr, FLJ00026, IRF5, MGC4832, MGC34827, PRAM-1, GAB3, ING3,
MGC7036, Ells1, DKFZP761M1511, PRO1635, ZNF367, MYNN, SH2D3C,
FLJ11220, HHGP, MCM10, GNG2, FLJ20280, FLJ11252, RPL13, YR-29,
KIAA1805, FLJ14642, FLJ12892, CGI-67, OSM, EIF3S6, DKFZp761D221,
PAPOLA, MCLC, LOC159090, FLJ20280, KLF12, LOC144455, ALS2, WHSC1,
STRIN, UCC1, FANCA, PTPN22, KIAA1677, FLJ23563, MDS006, HMGB1,
MGC10744, TIGA1, IL17D, SNURF, LOC221002, CED-6, 1-Sep, CGI-105,
LOC134147, FLJ39370, DRLM, LOC85028, P66, CASP2, SLC25A21,
MGC10966, FLJ32234, DCLRE1B, CSTF3, ATPAF1, FLJ00026, C6orf33,
NY-REN-58, MGC35274, DKFZp571K0837, BRD7, MGC27085, KIAA1084,
DKFZp434G0920, MGC45962, MLL, CYYR1, KIAA1387, FLJ23306, AF15Q14,
RAMP, CCNB1, HSPC063, FLJ11220, C6orf33, NHP2L1, DKFZp761N1114,
CGGBP1, USP16, KIAA1789, DKFZp434C1714, FLJ32194, TIGD3, FLJ32549,
MGC20496, LCX, ARHGAP9, STN2, MCM10, GPR114, PPIL3, MJD, UBE3B,
WHSC1, LOC51234, CLLD8, C15orf15, TTC7L1, PRO2000, HEMGN, ELAVL4,
KIAA1635, CLYBL, NLK, CLLD8, MDM4, MSI2, ASE-1, LSR7, LOC146853,
TIGD7, HELLS, LOC159090, TAF9L, DKFZp762O076, FLJ32370, WDR9, HRB2,
TIGD2, GAJ, LOC51193, FLJ13614, BAALC, KCNK17, DKFZp313A2432,
ARRB1, DKFZp762N0610, DKFZp564B0769, MGC45866, CGI-30, FLJ23277,
ROCK1, TRA@, ARRB1, CUL5, DKFZP727C091, FLJ34817, FKBP5, FLJ00058,
FLJ90013, FLJ11275, KIAA1211, FLJ13215, HSA9761, EVIN2,
DKFZP434C245, MGC16824, HSPC126, HSP70-4, LOC119392, FLJ35382,
MMP28, ARIH2, SUV39H2, DKFZp761F0118, FLJ10997, NDUFB1, MNAB, MU,
FRSB, KIAA1871, RARA, FLJ11712, MGC5306, FLJ30525, FLJ00005,
LOC115330, AMBP, FLJ32942, LOC91768, PECI, KIAA1959, MGC10744,
FLJ90013,
5'OY11.1, LOC116349, TSGA14, KIAA1954, HSPC129, KIAA1194, KIAA1238,
KHDRBS1, SNRPE, SGKL, FLJ31818, CNOT6L, KIAA0853, MGC39650,
FLJ22955, C11ORF30, CKLFSF7, CGI-30, GRCC8, AP3M1, MGC10946, CRSP6,
AGS3, DKFZp564B0769, LOC81023, STAF65(gamma), ZRF1, LOC63929, HYPC,
LOC90507, bioref, FLJ21438, MGC22679, HP1- BP74, Jade-1, RGM, CYCS,
EG1, C20orf92, TPC2, AUTS2, FLJ21918, ZNFN1A1, MAIL, DC6, AUTL1,
TAGAP, STARD4, TBRG1, FLJ20354, LSR7, RARA, FLJ14936, FLJ12975,
KIAA0379, RIG-1, PPP2CA, MGC15548, HNRPC, ZNF265, TRAP25,
DKFZp564D177, MGC33864, HSPC129, PPHLN1, HSPC195, FLJ32020, WWP1,
AKIP, TADA2L, DKFZP564I1171, FIGNL1, GRP58, KIAA0141, LOC151648,
FLJ20095, FLJ10997, KIAA1545, TIGD7, PRKRA, FLJ20060, DKFZP434G156,
FLJ14775, NAV1, RPLP1, B3GNT1, C21orf45, KIAA1586, ELD/OSA1,
LOC51249, KIAA1982, FLJ23309, ANAPC1, HINT1, MGC17919, TSGA14,
DRLM, MCM6, KIAA1238, KPNA4, AFFX-r2-Bs-thr-3_s_at, IGHG3, YARS,
FLJ20309, LU, FLJ10407, MGC14797, KIAA1554, LOC115827, NRM, DNMT3A,
MGC4308, KIAA1554, MGC41917, ATE1, TUFM, ROCK1, MATR3, KIAA1311,
FGD3, FLJ10876, KIAA1337, ZNFN1A4, PRO2000, SCAP2, FBXO4, CNTN1,
MYH11, TRNT1, TCF7L2, CDK5RAP2, DKFZp313A2432, GTF2H3, MGC14439,
MGC4730, MGC19570, EIF2S3, RNF3, MGC13204, CHES1, CNNM3, SFRS3,
SMBP, TMF1, CSTF3, HBOA, CDCA1, FLJ32745, SPIN, WHSC1L1,
DKFZP566I1024, FLJ14906, C20orf24, OSBPL7, NAALADASEL, HSA251708,
KIAA0254, LOC144402, FLJ34231, KIAA1228, C20orf72, RANBP2, and
NIP30.
[0176] TABLE-US-00006 TABLE 7C Genes Up Regulated in Passaged
Tumorigenic vs. HSC FN1, FN1, RAI3, KRT19, FN1, FN1, ITGB5, S100A8,
S100P, CA12, TACSTD2, AGR2, S100A2, DC12, DSP, DUSP4, FLJ20151,
IGFBP3, S100A9, CXADR, CYR61, BIK, PTPRK, SERPINA3, zizimin1, CD24,
SYN47, HRASLS3, LGALS3, FLJ11619, LCN2, RARRES1, GOLPH2, HRY, TFF1,
EFEMP1, STHM, IFI27, SFN, MGC4309, ABCC3, DKFZp564A176, CD24, MYO6,
KRT7, MUC1, IER3, CTSL2, S100A11, MET, PRO1489, C8orf4, PPL, CD24,
GPRC5B, S100A8, COBL, CDS1, TACSTD1, TACC2, KRT18, IL1R2, SOX9,
SPUVE, CAV2, TSSC3, C3, CYP1B1, ITGB5, CD9, KRT6A, MAPK13, ARHGAP8,
CDKN2A, S100A10, SFN, RDHL, SOX9, CEACAM6, FLJ20273, MGP, CAV1, F3,
TGFBI, LGALS1, MYO10, S100A14, INHBA, TM4SF1, CXCL1, TUBB, PPIC,
FLJ10052, IL1RN, DPP7, FXYD3, GALNT3, KRT6A, ANXA2, ANXA2, FER1L3,
ANXA9, TPD52L1, HRY, PTPN3, EFNA1, C8FW, CDH1, EPS8, CLDN4, PTPRF,
CCND1, CALU, GALNAC4S- 6ST, DKFZp564I1922, ASS, CAP2, FARP1, CRIP1,
LOC51760, HOXA1, MIG2, ANXA2P2, TGM2, MUC16, PAPSS2, SNK, RAI14,
CAV1, COL4A5, C4.4A, PTGIS, KIAA1078, SLPI, SAR1, RARRES1, DUSP4,
ANXA2, FLJ10901, CD24, KRT6B, EPN3, ADAM9, EPHA2, TFAP2C, BMPR1A,
PARVA, SERPINB5, ENAH, MARCKS, FAT, BF, TACC2, FLJ20171, NCKAP1,
TONDU, PIGPC1, PARG1, EMS1, CTSL, LIF, EPB41L1, ISG20, ITPR3,
LOC90957, CXCL5, PACE4, PHLDA1, HN1, CXCL6, VIL2, C1orf34, GNG12,
ALDH1A3, TJP1, TM4SF6, ROR1, FLJ20151, LGMN, DUSP5, IRS1, GFPT1,
CD24, ADM, GATA6, LAMC1, NRCAM, CRABP2, ARHE, MCP, YAP1, ADFP,
CARD10, COL4A2, EDG2, PTGES, OSBPL10, IGFBP3, KCNK1, RAB20, RIL,
NFIB, EFEMP1, CTSH, PDXK, SGK, DEFB1, KRT17, RAB25, HUMPPA,
C12orf5, DLG5, KIAA0869, SLC1A1, PPP1R14B, KDELR3, RAB31, DDR1,
TSTA3, CDH3, TFPI2, PPAP2C, SLC12A8, TM4SF1, FLJ22662, DDR1,
S100A6, DD96, KIAA1078, VEGF, ARHGAP8, ELF3, RAB31, RIG, MAL,
COL4A1, HBP17, LOC113146, ERBB3, RHCG, NR2F6, EMS1, MUC4, PLAB,
STEAP, S100A7, NET1, FLJ11856, MGC5395, GPR48, DLAT, RIN2, NFIB,
CEACAM6, CORO2A, TIMM17A, CLMN, FLJ13593, FARP1, E2IG4, IL1RL1,
DSTN, CYB5R2, TIMP2, KRT8, GFPT2, POLR2J, SLC6A14, ANXA3, LAMB1,
FLJ21918, MGC10796, EPB41L4B, G0S2, SDC4, CCL20, TLE1, LAMC2, NMU,
SPAG4, TRIM2, RAB31, EGFR, ZNF339, MGC35048, PLAT, PITX1, ZFP36L1,
GMFB, PHLDA1, BNC, SLC11A2, LAMB3, TFPI2, FLJ22408, SAT, LAMP1,
POR, TGFA, MYO6, KCNMA1, TPM2, TUFT1, GPR87, BZW1, KDELR3, ANKRD3,
EGFR-RS, AKR1B10, RBP1, CDKN2A, CLDN1, AKAP12, SLC7A5, SEMA3C,
ERBB2, GPR64, PLXNB1, COX5B, MGC11242, FACL3, PPARD, PPAP2A, EMP2,
CASK, MT1H, TMPRSS4, PDEF, KDELR2, FLJ21610, TMEM8, GSTT1, KREMEN2,
ECT2, PFN2, MT1X, MT2A, HAIK1, CNN3, PTK2, IL1A, S100A13, NDRG1,
MID1, TNFRSF11B, SOCS5, MATN2, ME1, SEMA3F, ARHD, PP35, ZNF144,
MLPH, PDZK1, SCD, CRYAB, HSPC163, RRAD, IGSF3, PCBD, ITSN1,
IL13RA1, UGCG, EDG2, ANXA8, SSSCA1, LAMA5, KIAA0436, KIAA0599,
ENDOG, SLC6A8, CALD1, FLJ11183, MGC3101, UMPK, EFA6R, NQO1, PTK9,
MT1L, ELF3, CST6, ST5, NETO2, KIAA0802, MYO1B, NOTCH3, PTK6,
KIAA1416, MYO1C, SUCLG2, KRT17, RHBDL2, AMOTL2, COL7A1, IL20RA,
CD14, CEBPD, SMARCA1, ESDN, TNFRSF6, FLJ20591, PEG10, FOXA1,
KIAA1026, FLJ21870, PBEF, TOB1, AQP3, LISCH7, TGIF, MYO1B, MPZL1,
DDR1, CP, IQGAP1, P4HA2, BMPR1A, NEBL, PLEK2, EPHB4, AK3, BHLHB3,
IL6, TAZ, PLS3, OSR2, SH3YL1, NQO1, PPAP2A, UP, SBBI31, KDELR2,
KIAA0790, FLJ10292, SLC2A1, AQP6, P2RY2, MTAP, FLJ10718, DAF, MOB,
MKLN1, TM4SF6, SQSTM1, OCRL, C21orf97, NMB, FLJ23186, SDC1, RIS1,
PTPRF, KLK10, SCEL, MGST3, CSTB, HOMER-3, PON2, CASK, SSH-3, DPP4,
HSPB1, MGC2376, LOC92689, RARRES1, LTBP2, BNIP3, HMCS, TGM2, TNC,
ITCH, MRPS12, CTSB, SUCLG2, PPIC, SLC31A1, MGC14480, KIAA0440,
EGFR, AK3, SRD5A1, FBP1, FLJ13984, UBE2H, H2BFL, MGC3103, NPD009,
FCGBP, CDK5, ANG, TEAD3, DPP4, PRRG1, NQO1, KIAA0429, SUCLG2, IF2,
ERO1L, CLDN3, SERPINE1, SFN, FHL2, HS3ST1, PDE8A, CLDN8, BAP29,
RRAS2, RPL5, PIG11, PPFIBP2, DNAJB2, RRAS2, NID2, TOPK, MRPL19,
NT5E, FN1, KIAA0103, CED-6, MAP4K4, PRSS8, COL13A1, G1P2, ROR1,
UGCG, BCAR3, ISG20, CYP24, LIM, LOC57228, SERPINE1, SLC7A8, TJP3,
ESR1, NPAS2, CKAP4, CLDN7, UCHL3, KIAA0143, RBSK, FJX1, NOL3,
SLC39A4, FLJ12910, BNIP3, PLP2, FLJ22531, FLJ22028, JAM1, LMNA,
KIAA0644, CUGBP1, VNN3, LAMC1, CX3CL1, THBS1, NUP50, SLC31A2, NNMT,
THBS1, AMMECR1, KMO, MAPK13, KIAA1695, RCP, GTF2IRD1, ARPC1A, MMP7,
DKFZP434E2135, IF2, GLDC, PRSS11, TJP1, ATF3, PAX8, IL13RA1,
ATP6V1C1, TST, SHANK2, ANK1, CRIP2, ChGn, GAS2L1, EPHB3, N33, CD59,
GEM, EIF5, CENTG2, OAZ3, ASPH, SRPK2, B3GNT3, EDNRA, HSPC159,
BACE2, ATP6V1C1, DP1, EHD1, DNAJB1, YKT6, KLF8, DDEF2, SRD5A1,
RALA, CYP1B1, GPNMB, DKFZP564A022, FGFR3, ACP1, FLJ20366, TLR5,
SCD, KIAA0882, KIAA1028, SC4MOL, MPZL1, RALGPS1A, SAR1, PTCH, SDR1,
PDE4A, CELSR1, F12, FGF2, GCNT3, SNCAIP, DDR1, PBEF, MMP14, EGLN1,
ELOVL1, ADCY9, FST, KIAA0716, HSPA1A, CNGA1, HNMT, KIAA0984,
SIRPB2, HRH1, ITGA3, FASTK, LDLR, RGS20, MRPS17, ELMO3, AP1M2,
TEGT, SH3GLB1, SMARCA1, UNC84A, GJB3, CAST, DKFZP564F0522, SLC19A2,
HK2, ID1, ARNTL2, EVI5, KLK11, KIAA0703, NPAS2, MEIS2, CRIM1, GCLM,
PARD3, EML1, RAD23B, AP1M2, S100A11P, YWHAZ, PON2, MTCH2, FLJ23153,
TUBB-5, CDH6, SCD, KRT5, RNASEH1, LHX1, UBE2D1, TMEFF1, MGC4171,
PGM3, KLC2, TNF, HSKM-B, IDH3A, KIAA0874, FLJ11773, PSMD5, HGD,
PPP1R13B, TNFRSF12A, FLJ13841, MBLL39, SH3BP5, FLJ22418, CETN2,
CAST, IF2, LLGL2, SPATA2, SYNGR2, SLC16A1, FBXO26, C1orf27, ITGB5,
LOC113251, KIAA1029, FLJ20623, SELENBP1, PCDH1, DAG1, TMSB10, SUDD,
STK17A, LAD1, SQSTM1, THBS1, ARNT2, CGI-115, TRIP13, DSTN, CTNND1,
SOX13, SFTPA2, SLC2A10, CGI-141, MT1G, COL4A6, CTNNAL1, RIL,
IL1RAP, SNRPD3, MAOB, G1P3, PIK3R3, FLJ21511, NAV2, CLDN3, VEGF,
KIAA1609, MEF2A, SCARA3, CPD, FER1L3, KMO, NY-REN-45, JAG2, OSBPL2,
YIF1P, FLJ10055, PSMD12, GRIT, LOC113251, FBXL2, PRSS16, PTPRG,
FOXE1, EML1, GUK1, RHO6, TPBG, HRB, H_GS165L15.1, FLJ12571,
MGC29643, SBBI26, MARCKS, PSMB3, SLC11A2, FZD2, KIAA0220, TMEPAI,
MTRR, HMGE, BCL6, STK39, CELSR2, KIAA0895, ACP1, E2IG5, KDELR3,
CYP-M, ANXA10, ANK3, CLIC4, KRTHB6, TSTA3, MLF1, TES, ASPH, PAPSS2,
SLC20A2, RGS19IP1, NFIB, NPD009, HOXB7, FLJ10134, APOE, KIAA1219,
KIAA0173, PODXL, IGFBP1, HSPCA, MAK, C11orf5, HIG2, CRIM1, FKBP2,
HSPA1B, FLJ20624, CPD, ITCH, ENSA, UNC84A, KIAA0062, EPPB9,
FLJ10851, STK6, PSCA, PTP4A1, DNAJC3, FLJ13782, CKTSF1B1, UAP1,
KRT15, AXL, HMGCS1, GNPI, PRKCI, MGC5509, MAGED2, CD63, FLJ11856,
ADAM10, KIAA0934, DXS9928E, SYNE-2, IFNGR1, SLC7A11, RIG, PP1057,
LOXL2, SPOCK, PTPRF, PACSIN3, ATP11A, STK24, CAPN2, C4BPA,
FLJ11149, TMP21, CYP2E1, COL4A1, PTP4A1, KIAA0937, PKP2, ARF4,
KLF5, HSPA4, NPC1L1, ATP5J2, MSLN, TLE1, ARK5, SS18, SNARK,
LOC56902, KIAA1630, JAG1, KIAA0843, CIS, MAP4K3, TAZ, PTHLH, RHEB2,
NEDD5, HOXB7, MGC24447, EIF2AK3, UGTREL1, MIG2, ADK, GAL, FTH1,
FTS, PEN-2, TNFRSF11B, CGI-148, MGC11061, LAMP1, MGC39851, CPD,
MGC11061, NCOA3, CDC42BPB, C11orf24, MAP3K8, MGC3038, TRA@, IRS3L,
CLTB, SC65, KIAA0471, PTS, POLR2K, CED-6, BLZF1, TRIM36, SPR,
AP1S1, EVA1, LIMK1, TIMP1, KIAA0923, NDUFS8, EMP1, BFSP1, JAG1,
GOCAP1, BID, RIL, CGI-90, CLTB, RIG-I, ANGPTL4, ATP11A, ITGAV,
IL1RAP, SH2D1A, FLJ22693, INSIG1, FKBP10, FLJ20847, DUSP14, VDR,
IFRD1, TOMM22, POLR2K, IGFBP4, HSD11B2, PTHR2, PREI3, FLJ10769,
AFAP, ENC1, MFN1, CD24, H2BFT, TRIM2, HIP2, JAG2, DAF, FLJ10099,
CRK, YES1, DLG5, RARRES2, LIPG, APXL, FLJ20113, CYP51, CALM1,
MKI67, PLS1, VIP32, WARS, ABCA1, RASAL1, CDC42EP4, MYO1D, CRA,
H2BFB, KIAA0790, BOP1, TACSTD2, KPNA2, SGSH, RPP20, LAMP2, GRSF1,
CBLC, ZNF165, SCAMP1, PLOD2, GSTM3, CLTB, C2orf6, MST1R, GSPT1,
CLCA2, SGCE, CHST3, CDC42EP4, NPC1, TPM4, HEBP2, WBSCR21, HMGCR,
ARL7, FLJ20623, DHFR, FLJ23548, IL8, DKFZP564F013, SECTM1, RAD23B,
CFLAR, POU2F3, ITPK1, IGSF4, CBX3, RHOBTB3, PDP, HSPA4, WFDC2,
TRIM16, ARHD, KIAA0632, TCN1, ITGB4, KIF5B, SGPL1, RAD1, EIF2S2,
CYC1, IL1R1, HARC, KIAA0779, SLC25A13, PPARG, RAB17, PLEC1,
DKFZP564A2416, C20orf97, DDX26, ALDH3A2, CGI-12, BAG3, EPB41L1,
GS3955, FLJ20986, C14orf92, PP35, BTF, KRT7, FLJ20457, G10, EPS8R2,
LOC160313, MGC2376, KIAA0429, GOLGA2, GOSR2, COX17, FLJ21313,
FLJ10300, EIF5, SKD3, ADK, NPEPL1, SLC35A3, FLJ20186, YWHAZ, UBE2A,
CYB561, NR2F2, ELK1, FLJ13397, LAMP2, SGSH, FDPS, FLJ10534, PIK3R3,
SPINT1, FLJ11619, FLJ20989, ATIP1, SORD, PP, HCCS, SLC1A1,
FLJ20739, SLC6A8, RBBP8, GRIK3, CALU, KIAA0644, SAA2, KIAA0934,
USP18, TXNL2, FLJ10521, FBXO3, SSBP1, MGC3067, CGI-100, MRPL13,
PIG7, KIF3B, KIAA1735, DAAM1, ADAM17, IL5RA, TPD52L1, PPP2R3A,
RAB9A, PAWR, HIPK3, PPP3CB, EPHA1, GFPT1, KIAA0431, C7orf14, BNIP1,
LMCD1, ATP6V1G1, COPB2, KIAA0265, RPL5, FLJ20234, OBP2B, MIR16,
CTNND1, ATP6V0E, DHCR24, FRK, MGC5178, IQGAP1, HFE, DKFZP434J214,
ACTL7A, APBB2, LANO, PMM2, HMGE, ARHGEF4, NPTX1, CTSB, RPA3, NET-7,
ARHGAP6, FLJ20637, FLRT3, FLJ10407, RTP801, NR6A1, NR5A2, PTPN12,
ZNF217, TEB4, CALD1, HSPC111, DP1, SNAI2, STS, ANXA4, BRIX,
MGC16723, MCP, FLJ22055, C1orf28, ACTN1, TMEM4, FLJ20401, SE57-1,
SH3GLB1, CDYL, OAZIN, PRO1855, H41, RAB22A, FLJ10326, PEX13,
SH3BP5, MIF, SOAT1, MRS2L, CDC6, PEPP3, FLJ14675, TPD52, CTBP2,
SPINK1, PPP2R1B, SELT, TNFAIP1, IFRD1, SORT1, ATP1B1, QSCN6, PDK1,
SNX16, VIL2, PMM1, CIB1, FLJ22195, SLC27A5, PCNP, TNFRSF10B, CDR2,
FLJ21657, MTX1, SLC38A1, BC-2, PEX3, CIAO1, PLXNB2, ROD1, RPL39L,
TAF1B, ZF, C12orf22, DDX26, ME1, NPEPPS, DNAJB1, SLC39A1, ATIP1,
MGC2742, BBOX1, FAM3C, FBXL11, EGR1, LIN7C, UBE2G1, MCP, TMPRSS3,
MARCKS, LOC56902, GRAF, ALS2CR3, KIAA0680, FZD6, SPON1, HSPC111,
CCNB1, P2RX5, B4GALT4, GOLGA2, p47, KOC1, RAB2, TM4SF9, MGAT4A,
HS2ST1, CD44, FLJ20315, TCFL4, PCMT1, BHLHB2, VRP, RBSK, FLJ10829,
HES2, EKI1, ZRF1, C2orf6, TUBGCP2, PFTK1, BZW1, CYR61, NOL3, PTGES,
CGI-100, BM039, SCRIB, DDX3, SVIL, SMC6, NET-6, KIAA1023, ATOX1,
IER5, IL1R2, STX6, PKP3, PITX1, ETV2, MCCC2, MRPL33, MGC2494, BPGM,
C22orf2, ACTR2, BCL10, TRAM, B7, FLJ12439, DKFZp564A176, PHKA1,
SLC33A1, TGOLN2, HRC, LGALS8, FLJ22940, OBP2A, STOML2, IFNGR1,
POLR2J2, DKFZP586B0923, SLC2A4RG, NDUFA8, KIAA0964, FLJ11269,
TMPRSS2, PLEKHA1, UGT2B28, ARL1, PFDN2, IGLJ3, FLJ23516, KIAA1609,
WSB2, KIAA1598, YES1, KIAA0284, ATP6V1D, VMP1, C22orf5, HSPA6,
MUC1, MAPK9, PARD3, APG12L, RAB5C, PAK6, LSM1, INSIG1, NDUFS6,
ALDH3B2, TNFSF10, FLJ20275, CHML, UBE2V1, IGF2R, ITGB5, SEC61G,
LOC55831, OPTN, ORMDL2, GABRP, DPP3, FLJ20967, POP3, GPC1, ANXA2P3,
PRDX4, CHPPR, DKFZp434G2311, LGALS3BP, UEV3, KRAS2, TM4SF11,
FLJ10116, CTBP2, CALU, USP3, P4HA1, SLC22A1L, FER, SLC1A7, PCDHA12,
ENC1, FLJ14251, PPP2R3A, FLJ20069, DDXx, STK6, PLA2G5, ZYG, PPFIA1,
AFFX-HUMGAPDH/M33197_5_at, AK1, GNA11, WWP1, HRY, SMURF1, FOP,
DHCR7, GCSH, HDGF, NCBP1, ETEA, KIAA1096, GMPS, TGFBR3, HSF2BP,
ZFP103, CD44, C20orf24, PSEN2, PEX7, TNFRSF21, ARHGEF7, CD2AP,
ARF4, CHD1L, MGC8974, ZMPSTE24, PSMB5, ACR, GSK3B, NEDD4L, KPNA4,
VIL2, CDC42EP2, UNC119, EPS8R1, KIAA0143, FLJ22709, LOC55862,
YWHAE, BAZ1A, WIT-1, IL13RA1, ITGB8, OS4, LRP3, DRIL1, FASN, TXN,
RASAL2, NCOA3, JUP, AUH, NEK2, GEMIN6, PSMD11, RECQL, MAP7, SNX4,
TPD52, KLK8, INPP5E, KIF1C, ORC5L, CDA, C20orf35, FLJ13189,
B4GALT4, CDK5R1, C1orf16, ATP6V1D, KIF5B, CTNND2, CGGBP1, SQLE,
PTP4A1, CSNK2A1, LIFR, PLSCR1, SRI, CDC20, PSMB7, C20orf18, NAT1,
KLK5, KPNA1, PELI1, TRIM29, YWHAZ, KLF4, FLJ21916, LTF, DAPK2,
DHCR7, RNMT, RXRA, SPAG1, DDX21, CKTSF1B1, OXTR, KIAA1096, COL16A1,
CELSR2, KIAA0111, TPARL, MLCB, STS, DKFZP586C1619, TPSB2, MEIS3,
APBB2, HSPC121, ASK, ABCB6, RBMS2, DKFZp762N1910, CCNE1, FLJ22347,
TEAD4, PPIB, NDUFS8, TMG4, BUB1, RRAS2, NOC4, SSH-3, TAX1BP1, EPN2,
ISGF3G, MRPL17, AHNAK, TBL1X, EKI1, B4GALT1, SPHK1, PPIF, TXNDC4,
DSC2, KIAA1096, SSR1, ATP9A, OSBPL1A, COX8, EIF2S1, SIP1, ACPP,
FLJ20085, SMARCA4, SSTR1, UNG2, C1GALT1, PRKCL2, CABYR, FLJ10232,
SLC4A7, ARHGEF5, GLUD1, MED8, MAP2K1, PPM1B, NET1, PPP2R3A, RHEB2,
PME-1, FLJ20591, FLJ22595, SPS, CPSF5, MGC5466, SLC35A2, PLOD2,
DKFZP434B103, APPBP2, TFIP11, FLJ10252, MRPS16, KCNK1, GOLGA5,
PAIP1, CHPPR, PA200, APP, FLJ23338, FLJ13852, RHEB2, PK428, BAIAP2,
LAMC2, C7orf10, LANCL2, ITGB1, HCCS, TPM1, FACL3, MRPS15, EPPB9,
ITGB1, FLJ10199, CSPG6, COPS7A, KRTHA6, SGPL1, EML4, AHCYL1, TPD52,
SHC1, EPLIN, TUBB1, GAS2L1, MPZL1, IDH3A, CYP4B1, CGI-96, TM9SF2,
FER1L4, C10orf3, FLJ23537, LGALS8, P2RY6, ALDOA, PEX7, EBNA1BP2,
DKFZP566C134, NPEPPS, PDE4DIP, GSG1, FLJ20485, MTIF2, PCTAIRE2BP,
FLJ23510, LAMP1, KIAA0020, GMFB, ACTR2, HLCS, P4HB, CYCS, PSMD8,
TIMM17A, MFTC, TXNL2, PNAS-4, CGI-60, PMP22, TONDU, GGPS1,
FLJ20604, TAT, FLJ10803, CLN5, NRP2, RPN1, KIAA1718, CALM1, NOV,
MAOA, TPS1, FLJ20555, KIAA0649, TSLL2, OSBPL11,
TPM2, MRPL40, TCF-3, H2BFT, SLC4A7, SURF2, LZ16, KIAA0471, DPM1,
DNAJA2, COG5, DKFZP434G2226, DC50, TCEB1, ACLY, DUSP3, ROD1, NCOA3,
NFATC4, GAN, UNC84A, UCHL5, FLJ11850, RPP38, MYCBP, PDEF,
DKFZP586N0721, KLK6, TPI1, PSMC2, SLC16A1, TEAD1, VEGF, NDUFS1,
BS69, MAGEA3, TLE2, HSPC051, FN1, BAZ1A, FLJ22584, SEC23B,,,,
NMES1, MAL2, PIGPC1, LOC55971, FLJ20171, ShrmL, LOC91523, FLJ22474,
H19, RHPN2, MIG-6, NGEF, KIAA1165, YAP1, MGC4309, SYNE-1, CDKN2B,
ENAH, CTL2, ALS2CR9, TMEPAI, IMUP, DKFZP564J0863, UGCG, MGC12335,
ITGB6, CYP4X1, GLIS2, FLJ20273, FLJ31842, LOC55971, TMEPAI, SYT13,
SPUVE, KIAA1244, HSJ001348, MGC29643, BOK, TEM8, FLJ30532, LBP-32,
DKFZP761L0424, FLJ23153, EDG3, IL20RA, MYO5B, GJB2, MYEOV, PTK2,
KIAA2028, SBBI31, FLJ10052, AGR2, FGG, FAD104, LOC120224, CLDN1,
LOC51760, IRX3, C20orf100, CLDN12, MGC4734, ERO1L, FLJ40432,
MGC33630, NTN4, KIAA1522, SLC4A11, ESDN, DKFZp434C0328, PTGFRN,
EHF, MFI2, PRO1489, TCEA3, GNG12, TMPRSS3, TEAD2, GJB6, ALS2CR9,
DDEF1, CFL2, LOC116238, KIAA1671, SDCCAG43, MGC35048, TOB1, LRG,
DKFZp761P0423, C20orf129, SMOC2, FZD4, RDHL, WNT7B, MGC14839,
DJ667H12.2, TEAD1, RDHL, FLJ14957, ZIC2, HSPC163, DLG5, FLJ14735,
FLJ20048, WW45, FLJ90440, LOC92689, DAG1, LOC55971, B4GALT1, HAS3,
PIGR, SNX9, AK2, PRO2605, UGCGL2, CDH24, GFRA3, FLJ13593, CP,
CRBPIV, FHOD2, MGC26963, LOC129642, UACA, YAP1, FLJ23420, IL28RA,
PSA, DKFZp434D0215, PPP1R14C, PTGFRN, E2IG5, C14orf31, FLJ10052,
BCAR1, MGC22805, DKFZp434G171, MGC11034, KIAA1870, FLJ22415,
FLJ34633, GPR54, CHDH, FST, KIAA1708, UBE2H, DDEF1, WASL, FLJ14408,
CXCL16, PARVA, DKFZP434H0820, CASPR3, RAB10, PDP, ANLN, FLJ25157,
NETO2, OLD35, UBQLN1, LOC58489, FLJ23867, E2IG5, ATP11A, CD44,
DNAH5, LOC128153, PHLDA1, IPP, DUSP16, COL12A1, MGST1, PLEKHA1,
KIAA2025, LTB4DH, FLJ20739, FLJ22174, MGC24180, DKFZp761N0624,
IRAK2, ALS2CR9, MGC39329, AKAP2, C14orf50, MGST1, UGCGL1, KLK7,
FLJ31937, DIRC2, FLJ10035, MGC11034, SOX7, PARVA, LOC139231, GPCR1,
SDCCAG28, GPR92, LOC147184, LOC113026, MGC14798, LOC147700,
DKFZP434A1315, FLJ10702, LTB4DH, PYPAF3, RBMS1, SLC30A1, MTA3,
ARL8, KIAA1688, RASAL2, PDK1, XPR1, SULF2., STEAP2, H41, METL,
FBXO32, TLE1, DDEF1, GPT2, MRPL30, FLJ14117, DKFZp434E2321,
MGC26963, SAT, ORF1-FL49, GRP58, MGC33662, NT5E, FLJ31052, RNAC,
CGI-85, CTL2, STC1, SCD, DKFZP434K0427, SCARA3, MGC14128, BCCIP,
MGC3195, TGFBR3, PXMP4, KIAA1500, Spir-1, ARHGEF12, DKFZP434A0225,
LOC55829, C20orf24, HSPC242, CAMK2D, FAD104, ZD52F10, HS6ST2, HLCS,
FLRT3, SDCCAG28, KLF15, C20orf139, FLJ39155, MGC1314, C20orf24,
FLJ14511, CGI-20, EDG8, MGC10765, C7orf3, MGC14801, FLJ10697,
ATP1B1, EHF, JUB, FLJ11200, MacGAP, H4FH, MGC11102, RORC, COL12A1,
PRO1853, MGC13096, SPTB, FLJ32115, DKFZP566F084, SEMA4B,
DKFZP434A0225, BTC, PCDHB14, CGI-09, EMS1, PCDHB16, KIAA1384, SCEL,
GRP58, KIAA1357, CAC-1, SURF4, FLJ11011, LMLN, ARL6IP2, OCLN,
C17orf28, INPP4B, C14orf31, FLJ22558, FLJ10116, KIAA1363, DAB2IP,
MGC35352, GK001, PDGFA, SNX8, MGC22805, LOC114990, ELP2, CXADR,
LOC120224, ST6GalNAcI, MGC35403, MGC39350, KPNB2, DSCR1L2,
FLJ20333, PPP1R1B, EIF2C2, PX19, BPNT1, AD-003, LACTB, FLJ36445,
ULBP2, GUK1, KIAA1321, SPP2, CRB3, FLJ90586, NDUFB9, PDK4,
FLJ30973, HSPC228, MacGAP, DEFB118, DKFZp761K2222, ASPH, MGC45474,
UBQLN1, TRAF4, DKFZp761K2222, DJ667H12.2, AFFX-
HUMGAPDH/M33197_5_at, C12orf22, RHOBTB3, MGC33974, KPNB2, C9orf5,
FLJ32421, FLJ25604, COQ4, FLJ20281, FLJ13391, TEAD2, ELL2, RPS3A,
FLJ33516, ESPN, DKFZP434A0225, KIAA1684, TRA@, SEC61A1,
DKFZP434K0427, PRIC285, KIAA1870, AMN, LOC151242, FLJ20686,
FLJ10210, FLJ22415, MGC19764, CGI-97, CDW92, NAT5, KIAA1126, CLMN,
RAB18, MRPS15, JAM1, TEAD2, ENAH, KIAA1228, ACTR3, PCDHA10, ATP5A1,
GNPNAT1, CL25084, LOC51260, CNN3, TFDP1, FLJ31528, KIAA1434,
FLJ10902, MGC14289, GGTL3, SYTL2, MGC21874, TIM50L, PHCA, PSCD3,
KIAA1026, INADL, DNAJC5, AD037, FLJ11046, KIAA1804, KIAA1337,
PPARD, KIF1B, MIR16, ROD1, SLC2A13, CFL2, GDF1, MRPL36, SLC26A9,
LOC51290, CABYR, HSPC159, SPPL2A, ABCC3, BTBD6, SMURF2, STK35,
CGI-85, ZAK, DKFZp434B1231, KCNK6, PCDHB2, Spir-1, KIAA0146,
ZNF265, COPZ1, FLJ20421, C11orf15, DKFZp761D0614, KRT19, RAB23,
MGC16491, FLJ40432, MGC10981, C20orf45, CTEN, MGC30022, NUCKS,
MGC13251, MRPL27, FLJ90586, MGC16028, FLJ90165, SHMT1, FLJ14525,
BACE2, ABLIM2, FLJ20719, SCGB3A1, MGC2477, FLJ20038, MGC29643,
FLJ30829, C20orf155, PGK1, FLJ37440, RBM8A, FBXO22, KIAA1219,
KIAA1200, KIF3B, MGC19825, AK5, C22orf20, FLJ10378, INADL, HSPCA,
EIF5A2, RAB18, BCL2L13, MBC3205, UBE2H, FLJ20354, SLC5A7, FLJ30532,
C14orf47, TMPIT, EHD4, FLJ13089, MGC17299, IDS, CED-6, MGC27277,
LOC137392, FXYD6, MGC22825, CPM, SNX9, MGC19764, TLR7, FENS-1,
SDCBP2, NUDT5, MGC11102, SEC24A, CGI-141, NKD2, EFG1, ANAPC11,
MYO5B, MGC14833, LOC85865, EPB41L4B, FLJ21415, KCNC4, GSBS, TEAD2,
LOC115548, MAGI-3, C9orf5, CLONE24922, MRPS15, RGNEF, CORTBP2,
FLJ20354, HSPC121, NOC4, KIAA1673, MGC14595, MGC2560, MGC2408,
MRPL14, APOA1BP, FLJ14681, MGC13102, KIAA1437, KIAA1126, MGC13034,
CSEN, SH120, VIP, PRO2000, SLC31A1, AD-003, CALM2, HT002, RAP2A,
EML4, WDR5, MPP5, LOC90990, MGC2560, FLJ14431, ARHGEF5, HCC8,
TCEB2, FLJ13187, FLJ90575, FLJ10525, FLJ23393, HOXB9, LOC84661,
dJ55C23.6, HFE, MGC13040, WDR20, MRPL4, FLJ25604, DKFZP566C134,
LOC55871, CGI-09, MRPS23, MRPL47, MGC13045, ERK8, KIAA1500, HPS3,
CRYPTIC, SBBI31, MGC14353, CGI-20, FHOD2, PPP1R14A, REPS1, MAPKAP1,
V-1, FBXO25, BNIP-S, MGC13114, EKN1, GPR24, RCP, FLJ12806, MGC2747,
OBP2A, HM13, C21orf97, FLJ14909, C9orf10, STYX, THOC3, RDGBB,
PFKFB4, FLJ21924, KIAA1295, ZDHHC9, STXBP5, RPE, UBE2H, PCDHB18,
FLJ20303, NPD007, N4WBP5, FLJ20333, FLJ12747, SURF4, C20orf45,
FLJ12787, LOC90507, FLJ10839, EPB41L4B, FLJ37953, BAP29, MRPL50,
MGC10999, C9orf5, TBDN100, STK35, FRABIN, JUB, PRO2714, MLLT4,
MGC40214, CPNE4, FLJ22233, MIZIP, MGC14859, MRPS24, HPS3, FLJ23841,
FLJ23577, HSPCA, MRPS10, FLJ14251, SSR3, MGC13186, KIAA1453, HN1,
HOOK3, ATP1B3, MRPL50, MAP4K1, LOC90120, D1S155E, DKFZP564O0463,
FLJ23816, CFTR, MGC40555, MGC20781, FLJ20085, NOPE, FLJ14825, MSP,
LMO7, C7orf2, MRPL32, FLJ10074, MAK3P, KRT6IRS, DKFZp547A023,
SAMHD1, HSPC043, FLJ10597, FACL6, LGR6, SORCS2, MGC4840, RAB35,
MGC10911, and MLL3.
[0177] TABLE-US-00007 TABLE 7D Genes Down Regulated in Passaged
Tumorigenic vs. HSC MEF2C, HSPC053, HOXA9, PRG1, RetSDR2, GMFG,
AIF1, AIF1, HLA-DPB1, PLCL2, ICAM2, HLA-DPA1, PTPRC, SPINK2, SPARC,
CUGBP2, PTGER4, CECR1, CDW52, CCND2, LYZ, SELL, CD69, HOXA9, ITM2A,
HLA-DQB1, ITM2B, LYL1, KIAA0125, LMO2, ARHGEF6, KIAA0084, MPL,
RGS2, LAGY, QKI, EVI2B, ZNFN1A1, DOCK2, HLA-DRB3, NAP1L3, HLA-DPA1,
KIT, HF1, HLF, LST1, ANGPT1, CD53, LST1, FLJ14054, SELPLG, LST1,
BM046, TUBA3, HLA- DQA1, BCE-1, CDW52, FLJ10178, PRKACB, PRKCB1,
IQGAP2, CHES1, GUCY1B3, PSCDBP, HLA-DRA, LAPTM5, PRG1, MEF2C,
SLC2A5, LST1, FHL1, MAP4K1, TNFSF4, PLAC8, HLA-DQB1, IGFBP7, PCDH9,
MAP4K1, EVI2A, SATB1, MLC1, SSBP2, FLI1, CLIC2, CLECSF2, LY75, NDN,
HLA-DRB1, FLJ21276, DLK1, GLUL, NUDT11, BEX1, SH3BGRL, PRKCB1,
MPHOSPH9, LST1, HLA-DQB1, FLJ22690, UQCRH, FLJ22746, HLA-DRB3,
SLC2A3, NPIP, BCL11A, MPO, RUNX3, ERG, SV2, HLF, MMRN, CYFIP2,
HLA-DRB4, PECAM1, CORO1A, MOX2, SEPP1, BAALC, 6- Sep, ITM2B, LCP2,
PELI2, C17, IGHM, LRMP, PPP1R16B, HLA-DRB5, HBB, DJ971N18.2,
LOC51186, SCGF, ERG, LAPTM5, P311, SAMSN1, ITGA4, DJ434O14.3,
IGFBP7, TFEC, HA-1, MAGED1, HSPC022, FNBP1, TCF8, ELMO1, CUGBP2,
NGFRAP1, PIP5K1B, DDO, MLLT3, ALCAM, NPR3, CMRF-35H, DPYD, PLAG1,
BIN2, ITM2A, MYCN, GSPT2, LXN, ALEX1, PIK3CD, ADAM28, PLAGL1, FLT3,
WBSCR5, C6orf37, GUCY1A3, CD74, KIAA0053, TRAITS, HLA-DQB1,
MGC2306, ICAM3, PTGS2, H3F3B, TCF4, SNCA, FLJ10713, PROML1, TEK,
APOBEC3G, PRO1635, HLA-E, JAM3, UBE1L, BCL11A, GNAI1, LHFP, LST1,
CDH2, MYB, FLJ10462, ZFHX1B, CBFA2T3, TMSNB, HLA-DMA, PLCB1, SOCS2,
CG018, PDE4B, MHC2TA, PADI5, USF2, CUGBP2, VIM, HLA-DRB6, TFPI,
BIRC1, PTGS1, HFL2, SCDGF-B, LSP1, NRLN1, MPO, KIAA1939, PTGS1,
MS4A3, HPIP, FLJ20220, HLA-DPA1, NCF4, MAPRE2, ZFP, BANK, TOX,
CXCR4, IGHM, RUNX3, HCLS1, LOC81558, ARHGDIB, TRO, SCHIP1, CRHBP,
KIAA1750, BCL2, FLJ20950, FLJ10097, DAB2, BASP1, JAM2, FLJ21616,
HHEX, ITM2C, SPRY1, SERPING1, SLA, EBI2, ZNF42, DSIPI, FLJ10038,
PECAM1, 6- Sep, CASP1, RB1, TACC3, 13CDNA73, 6-Sep, MAPRE2, FCER1A,
BTK, LOH11CR2A, LRMP, PLAGL1, MICAL, TCF4, CLGN, H1FX, WASPIP,
LAIR1, ZNF175, INSR, FLJ20456, C11orf8, KIAA0443, AKAP7, TAL1,
HLA-DRA, HRB2, PLEK, RAGD, PLAGL1, ALDH1A1, B4GALT6, GLIPR1, GAB2,
KIAA1157, PPM1F, WAS, SETBP1, MUF1, C6orf32, MYOZ3, TUCAN, RNU2,
KLHL3, TSC, PKIA, MLLT3, NEFH, DKFZp564B0769, PPM1F, SNTB1, PCDH9,
CRYGD, MPP1, ABCB1, KIAA1110, ALEX3, ATP2A3, KIAA0308, MAGEH1,
BIMLEC, CTSW, SORL1, FLJ20898, MCM5, CD244, PPP1R16B, MAGED1, ASC,
GIPC2, RASSF2, LOC81691, SCGF, PTEN, 24432, STAT5A, 6-Sep, SLC24A1,
UBE1L, CD83, TAHCCP1, GNA15, NR3C2, KIAA0053, INPP5D, CPA3, GYPC,
SYK, PRKACB, RUNX1, RIN3, TRB@, NPIP, CABC1, HLA-B, PGDS, CD34,
SPN, LOC58504, MAGEL2, TBXAS1, MFNG, LOC91316, TRAP-1, RECK, TCEA2,
FLJ20136, ARHGAP6, AMT, CAT, ADARB1, PTEN, LCP1, CCL3, SCN9A,
RASGRP2, DKFZP586I2223, SS-56, SLA, C4S-2, PDGFC, LILRA2, RAGD,
HNRPDL, ZNF288, ITGA2B, LOC81691, HBD, SELP, C6orf32, PDZ-GEF1,
CPT1A, KLF2, ZNF198, TACC1, HBB, B1, CIAS1, HNRPA0, HLA-DQA1,
KIAA0308, MYO1F, PRO1331, RAB33A, TNS, NAP1L2, CERK, MGC4170, ADA,
RNASE3, NFE2, ANKRD6, AKR1C3, CDC42, HIS1, TRIM22, BIN1, ICAM4,
IL12RB2, CSF2RB, EPB41L3, BRDG1, TNRC5, CIRBP, RPLP2, AMPD2, SFRS7,
EDG6, BRCA1, MSN, HLA-DQB1, C5orf5, GSTM5, ITPR1, IL16, AIF1,
NFATC1, LILRB2, FGF23, STAC, RPL22, PTEN, LRBA, PFAS, CGI-116,
DKFZP586A0522, MGC13024, GALC, ABCG1, MGC45806, ELF1, SAP18,
ALDH5A1, ELA2, GATM, CHC1L, KIAA0918, LOC51334, FOSB, PRO2198, TEC,
SLC1A4, CAD, KIAA1028, VAV1, LOC57100, C11orf21, SLC1A4, TRPV2,
EPB41L2, FBN1, CD48, GIT2, CSF3R, DNAJC6, BIN1, KIAA0582, ARL4,
SH3BGRL, GLS, FXYD6, PF4, SCGF, NEK9, PKD2, MATK, BIN1, NSBP1,
MSH5, PRKG2, NT5M, PML, CD37, SF3A2, PLSCR4, CSK, HA-1, NUDT1,
SIAH1, MEIS1, IGLJ3, HLX1, SV2B, DKFZP586I2223, KEO4, ENPP2, CTSF,
IL1B, PSMB10, IL1B, ZFP36L2, SFPQ, FLJ11175, ATP2A3, STK10,
FLJ22021, MYOM2, PTENP1, MGC861, HERC1, Jade-1, BTEB1, KIAA11102,
NPTX2, UCHL1, LYN, COL5A1, ZNF215, MGC2217, SRISNF2L, LOH11CR2A,
RERE, COL5A1, RAP1B, CLDN15, VWF, HHEX, SMARCA2, SMCY, UBCE7IP4,
LOC115207, KPNB1, ZNF22, STOM, C16orf5, ICAM2, KIAA1102, CENTB1,
DKFZP434C171, ITGAM, TFPI, CASP1, CLN2, TAL1, AASS, SAH, FLJ11712,
FXYD5, KIAA0303, FBXL5, SFRS5, FNBP1, FLJ11749, MAGE-E1, SNRK, SPN,
CTSS, SIAT1, SCARF1, HSPC047, CD38, VAMP5, SF3B3, FLJ10374, FHL1,
PTPRCAP, LRBA, DUSP6, PTPRC, KIAA0092, PLA2G4A, RBM5, FLJ21478,
PLCB2, GOLGIN-67, RBM8A, OXCT, HEM1, DUSP6, CRI1, RAB6IP1, IMPDH2,
C21orf33, LOC93349, EMP3, NASP, MGC40204, PTGER2, COL5A1, SPARC,
NISCH, SIGLEC5, CSTF2T, HGF, SNX10, DACH, NINJ2, MGC12760,
KIAA1332, NPIP, KIAA0379, LYN, H2AFY, PACAP, PLCG2, PDE4D,
LOC129080, FLJ11753, KIAA0447, BCL2A1, FUS2, PTPN7, WASF1, ZNF42,
C18orf1, UROD, KIAA0303, NRGN, RNASE2, FLJ23056, FYN, DEFCAP,
PTPN22, MAPKAPK3, ZFP36L2, AF1Q, NCF4, CDH7, DJ971N18.2, PA26,
ANXA6, PHGDH, MCL1, LEPROTL1, HUMMHCW1A, TNFRSF14, STK17B, CGI-49,
MGC14258, PSIP2, CRI1, FLJ35827, CCRL2, PTPRN2, CES1, SCA1,
FLJ21865, KIAA0798, BIA2, HLA-DQB1, UCP2, DPYSL2, FLJ11259,
FLJ20312, KIAA0240, GTL3, C6orf48, AK2, TFR2, FLJ13949, MAX, CHKL,
FLJ12668, ALDH2, NUCB2, HPIP, RNF8, C1orf21, AS3, ZNEU1, FLJ11323,
FLJ23506, LOC115648, KCND1, STMN1, BTN3A3, MAP4K1, ALG12, ATP5G2,
PET112L, TIAF1, KIAA1043, TRPC1, THY28, SYT11, HSU79274, PRPF8,
CLC, PCNT2, H2AFY, DAPK1, CCL4, RPL28, IFRG28, CCND3, C14orf94,
MGC3035, 6-Sep, GNB5, KIAA0916, EIF3S7, LENG4, FACL5, AP1S2, MCM5,
DKFZp434N062, AIP1, PROS1, CIRBP, REC8, SLK, C11orf2, dJ222E13.1,
H2AV, NEK1, BNIP2, FLJ13197, ITGA4, FLJ21269, KIAA0708, IMPA1,
FLJ12750, SLC18A2, EMR1, KIAA0239, RPS9, ARHH, MCJ, ALTE, KCNE1L,
ABCB1, RPL22, KIAA0841, LOC58486, SNX26, ADAMTS1, USP4, STXBP1,
ITGA2B, C5orf6, RBM10, FLJ21439, KHK, OS4, MAPK14, NIP30, KIAA0471,
SLC16A7, RIN3, DDX28, HPIP, RNASE6, ADSL, ARHG, GNG7, HLA-C,
RHOBTB1, CACNB2, DATF1, PDZ-GEF1, RPL13, TALDO1, DGKG, FLJ22794,
PTPN6, SYT11, C5, FLJ22349, FGFR4, CGBP, PROL2, LARS, RPL3, JIK,
MGC45806, MGC2488, MGC2752, TYMS, PECAM1, NSMAF, ABCC1, LEPR, MYB,
LAIR1, LOC57209, EP400, ALCAM, ZNF187, FLJ13386, KPNB1, LTA4H, HGF,
PP1628, NRIP1, GNAO1, IL3RA, CD79B, CENTB1, ZNF261, ST18, FGF9,
CDK10, RAI17, STARD5, OXT, PML, KATNB1, ASMTL, NEDD4, ACTA2, MBNL,
FLJ31821, PER1, MOAP1, DCK, DXS1283E, SNCA, AD7C-NTP, MYBPC2, STX8,
ATPAF2, ACYP1, RAD51L1, CLIPR-59, FACL4, AASS, RAC2, MGC2306,
SLC27A2, FLJ23018, RGS1, NAP1L1, ELAC2, LOC51185, SGKL, PCDH16,
TRAF5, KIAA0682, DGKZ, FLJ10539, PIGN, FLJ10647, NCOA1, LBR, GFI1,
MAN2A2, KRTAP2-4, HLA-C, FLJ35827, PCDHA10, HLA-A, APLP2, SFRS5,
FLJ13262, WTAP, EFNA2, C12orf8, CCND2, PTPRC, MPPE1, HMGA2, CLK2,
SWAP70, PRO1843, FLJ14280, FLJ23277, KIAA1172, PRCP, MADD, SMARCA2,
WASF2, MGC5149, CDC42, PLEK, SMARCF1, RCD-8, ATP9B, IHPK2, IGHG3,
DHRS4, EEF2, QARS, KIAA0841, ADRA2A, RPL29, GCNT1, UBL3, GRB10,
IMP-2, ABCA5, HSPC157, TNFRSF5, H2AV, JM4, TBXA2R, SLC1A4, RPS6KA5,
IGLL1, MGC8721, PEPP2, USP7, PSMB8, ARHGDIG, HLA-A, RBM10, NAP1L1,
KIAA1393, AVP, KIAA1018, RPL28, RES4-22, NAP1L1, ST13, KIAA0186,
MBNL, HEXA, KIAA0555, FLJ20189, MN1, TSPYL, USF2, APLP2, ZNF135,
HPS1, RPS21, MAP2K5, HSD17B8, PROSC, NAP1L1, DUT, KIAA0170, TPK1,
NY-REN-34, RBIG1, IL16, AKR7A2, STK10, PRP17, WWP2, PTD015, CAPRI,
ARHGAP8, FLJ20856, APPBP2, LRRN1, MDM1, HLA-DMB, CGI-30, COX11,
DDX28, ACK1, TM7SF3, FLJ23554, SDCCAG8, FLJ20094, MMP28, MUTYH,
CA1, AKR7A2, WDR6, DYRK1A, DPH2L1, RBPMS, FLJ20005, MAP2K5, C4ST,
FLJ22059, FLJ20202, H2BFQ, CAMLG, CHAF1A, ABLIM1, MAPK11, RAP140,
DUT, ITSN2, EHHADH, DKFZP547E2110, H2AFJ, MGC4659, RPL13, KCNA3,
BC008967, CASP1, NMI, NBEA, NUMA1, DEF6, PRAX-1, TBC1D5, KIAA0332,
NEW1CP, KIAA0769, CENTB2, CKIP-1, EIF4A2, OAZ, ARH, KIAA0467,
C19orf7, KCNAB2, TTLL1, FLJ10597, SF3A2, FLJ11222, PSTPIP2, BCL11A,
SPHAR, GLIPR1, KIAA0555, MMP2, EIF4A1, STOM, ALOX12, FLJ11588,
RBAF600, PROSC, CG005, VILL, FLJ12707, M6A, TCIRG1, HTR1F, RICH1,
F13A1, CACNA2D3, RRP4, TAF7, ZNF134, HSU53209, LZTFL1, TKT, LILRA2,
ZNF302, FLJ13114, ZNF177, PURA, DKFZp547I014, TXN2, TLR3, BHC80,
MGC5139, PTPNS1, ZNF145, THTPA, BTBD3, MDS010, KIAA0924, ZNF292,
ITGB2, TJP4, GPRK6, CYLN2, ENPP4, ALB, RPS20, FOXO1A, ADH5, CTSS,
FLJ23221, C11orf8, TNFSF13, TOLLIP, KIAA1449, HINT1, GLTSCR2,
KIAA1052, FLJ10260, RAB3GAP, HINT1, TAPBP, CHD5, LOC57406, TP53TG1,
SRP46, MS4A4A, NUP62, PIM1, ZNF42, COG4, ADPRTL1, ZNF289, CATSPER2,
TXNIP, PDE4DIP, HSA250839, FUT4, HSPA1L, GALT, MGC4278, APEX1, FN5,
STRIN, USP11, SPP1, NPFF, CEP1, GAPCENA, HLA-E, SCAND2, CG005, VRP,
BRAP, GPR56, MLH1, GPR105, OGT, C1R, BTN3A1, FLJ14107, PACS1,
MGC26766, FLJ22378, APOBEC3C, CG005, CA11, QDPR, DUT, ALDH6A1,
FLJ10450, BST1, NGLY1, FLJ12057, FECH, ZNF137, SERPINB1, EZH1,
CASP1, MGC3265, CXorf9, TRG@, DKFZp564B0769, KIAA0616, D1S155E,
MN7, C18orf1, NSBP1, NXF1, FHL1, TOP3A, TARBP1, KIAA0766, RRAS,
SEMA4D, CEBPA, TIP120A, IL15, HADHSC, HIRIP3, CTBP1, DVL2, RBM12,
RAD54L, NYD-SP15, PHC1, KIAA1042, IGL@, NPR3, HRMT1L1, FLJ20551,
MYST1, LOC51231, TCF12, KIAA0543, MKPX, LOC51157, SYNGR1, AKR1A1,
SCOP, LRRN1, FY, AMY1A, PHEMX, KIAA0930, MAP3K3, FLJ10631, ZNF85,
APOL3, MAPK12, TRG@, POLD1, LDOC1, POLA, TPST2, WASF3, RPL11, MKL1,
FLJ22242, PTPRM, AMHR2, FLJ20288, TERF2, DOK4, KCNAB1, DISC1,
FLJ22494, LOC91316, VIP, POLR2A, RGS19, C12orf6, RPS9, LIG1, NASP,
ARHGEF9, MANBA, SARM, SRPR, CDH9, MRPL16, FLJ20509, SNRPN, HLA-E,
NTS, ZNF232, FLJ12903, PHKA2, MSH5, PURA, ATP9B, TRIM28, FLJ12768,
ME2, IDS, MPHOSPH9, DIA1, ADAM8, HADHSC, STX12, COX15, RPA2,
SHANK1, GGA1, LANCL1, UBE3A, SOX11, LAT, BCL7A, DKFZp434K1210,
BRAP, SMARCC2, DKFZP434H132, NHP2L1, FLJ11294, FLJ12270, KIAA1649,
SRP46, PSMB9, GGA1, MGC4368, TOP2B, PTK2B, FLJ13912, EZH1, THRA,
BAX, NAG, MERTK, HADHA, SRRM2, HNRPH3, GNG7, HSPC018, FLJ22573,
HPCAL4, MBC2, MAPK4, FLJ10716, ITGAL, NFRKB, MRP63, DKFZP434L187,
GABARAP, CHD4, DKFZP564D172, FGL2, LOC57019, KIAA0478, NTSR1,
LPIN1, USP4, KIAA0391, ASGR1, KIAA0174, TBXA2R, TRAP95, FLJ22649,
NEK3, ZNF271, SIL1, 76P, CYLD, CD164, TINF2, ZNF220, DAB2,
HRIHFB2206, SF3A3, TRO, FLJ13373, UBE4B, GC20, ADAM28, PHKB, BCAS3,
MGC14258, RAD52, HLA-F, KIAA0721, MRC1, CHD1L, LMOD1, FLJ10315,
CHRNA7, NAP1L1, PIB5PA, GADD45A, RPL35A, LPIN1, TFPI, FLJ14213,
KIAA0746, KIAA0981, C22orf4, PP1044, ABCF2, FLJ10379, RASSF1,
FLJ23392, RPS8, DAB2, FLJ14011, CDC2L2, GAD1, MGC17330, FLJ23342,
HEI10, NPDC1, KIAA0710, BIRC1, KIAA0349, SF3B3, MST4, IRAK3, CD81,
LOC57406, FLJ12610, SF1, SLC27A2, KIAA0804, KIAA1055, GTF2F1,
SEPX1, SCAMP2, PPP3CB, U5-200KD, HMGN2, F2, PCBP3, FLJ20721, ING4,
HADHSC, KIAA0286, TREX1, ATP11B, RUFY2, SUPT3H, SFRS11, PIAS1,
HBOA, HAS1, HYMAI, NUP210, TGT, FLJ11896, CIDEB, TRHDE, FLJ90524,
TOX, KIAA0261, GSTM2, GAS7, MBD1, KIAA1305, PPP2R2B, CDT1,
FLJ11164, TMPRSS2, TYROBP, G6PT1, PRIM1, GP5, DKFZP566H073, RPS14,
CCNG1, FANCG, CMAH, SORBS1, KIAA0800, C1QTNF3, UBCE7IP5, FXR1,
ZNF334, CNN2, RFC5, ACAA2, GNB1, FLJ22757, CDKN1C, UROD, KIAA1028,
HD, CTSG, CLNS1A, P2RX1, TACC1, ADH5, RPL13A, ZNF363, PRKCH,
AF020591, LOC51659, PER1, TFPI, TSN, BMI1, KIAA0625, MLLT2, TAF1C,
DHFR, SLC23A1, HAGE, NAP1L4, EGFL3, SCA2, FLJ20489, SNAP25, USF2,
CRYL1, GG2-1, EDN3, TRPC1, AP1S2, ERCC1, KIAA0582, RPL15, LOC54103,
FLJ22557, CGI- 127, CSNK2A2, ZNF278, EDG5, IPW, RASGRP2, SAE1,
KIAA0725, RTN2, CTNS, FLJ20274, FLJ10276, LTBP4, FLJ10539, HYAL3,
MTL5, MGEA6, BNIP3L, PARVB, MGC15523, KCNK7, IGHM, PASK, KIDINS220,
PCM1, KIAA0092, ASB9, MAP3K4, CD1B, COL6A1, HCA127, ZNF262, GG2-1,
CAPN3, SAP18, EIF3S5, ZNF337, EIF4A1, DBT, CROT, FLJ10474,
FLJ10483, CBX8, DKFZP586M1523, CCRL1AP, FLJ14153, KIAA0397, COL2A1,
CD164, TLE4, PRO2730, ATM, RFX5, KIAA0515, FLJ20542, HYPH, ERG-1,
DBH, SCML2, GNAO1, WDR13, GCA, FLJ23323, FLJ11362, CGBP, MGAT1,
HMGB2, NDUFA6, KIAA0515, KIF13A, OPA1, BRD1, ATP2B4, PSME1,
KIAA0931, HPS4, KIAA1966, DKFZP564J0123, DBY, HUMNPIIY20, MAT2A,
DFFB, FLJ20294, ADSL, CSTF2T,, ZNFN1A1, LOC51194, FLJ21269,
DJ79P11.1, BCAT1, MGC21854, DKFZP586D0824, EMCN, C21orf91, SDPR,
PRO1635, ITGA4, FLJ20171, ROBO4, ZNF6, DRLM, TAGAP, PRDM16,
ST6Ga1II, GNAI1, EHZF, MGC10966, ARHGAP9, HEMGN, GNG2, LOC83690,
PTGS1, MGC41924, USP2, FLJ33069, CT2, C4ST3, PRAM-1, FLJ32122,
SLC11A3, BIC, TNFSF13B, FLJ37080, FLJ35564, KIAA1913, CDH26,
BCL11A, FLJ30046, MGC7036, DKFZP566N034, RARA, C1orf21, PAG,
SH2D3C, FLJ00026, STIP-1, FLJ39957, KLHL6, VIK, FLJ34922, SHANK3,
FLJ00026, PTPN22, HRB2, ZDHHC2, DKFZP566K1924, SYTL4, DACH,
FLJ21986, EVIN2,
GAB3, CYYR1, MMP28, EHZF, FLJ00058, LOC93589, KLF12, CLLD8,
KIAA1218, MGC16179, HS3ST3B1, ARHGAP9, LOC144402, LOC114928,
FLJ39370, PRKACB, MGC13105, Ells1, CGI-145, EPB41L5, RAB39B,
LOC145553, HRB2, SDCCAG33, ARRB1, EEF1A1, MGC12992, BBX, DAP10,
CMG2, GPR27, GBP5, FLJ20202, UCC1, RAD52B, KIAA1554, AKNA, TBXAS1,
a1/3GTP, JAK3, B2M, MGC20496, CLLD8, ALEX3, FLJ21438, MJD,
FLJ22570, AP1S2, TFDP2, P5CR2, C1orf21, KIAA1554, Evil, MGC8721,
FACL5, CYSLTR1, CTSS, Rgr, NID67, FLJ32194, MGC45400, KIAA1789,
DCP1B, MGC4251, CPXM, SMBP, PARVG, ESRRBL1, C6orf33, MGC20262,
C6orf33, MGC27027, LOC51234, ZNF33A, RGS18, KIAA1607, TIGA1, HOXA7,
NAALADASEL, ATP8B2, CLYBL, DKFZP727G051, KIAA1214, WHIP, IRF5,
UBL5, KIAA1946, GLTSCR2, CMG2, OSM, KIAA0748, FLJ11113, FLJ12994,
EROI-L(BETA), NUCB2, KIAA1337, DEF6, POLH, FLJ11712, LOC91526,
TTYH2, ACRBP, MAML3, FLJ00012, C6orf37, MYH11, C9orf24, HNRPD,
CCNDBP1, DKFZP434L0117, GPR114, ANKH, MGC13170, NOG, CXorf10,
C1QTNF4, NAV1, RPIB9, DKFZp571K0837, SFXN1, KIAA1497, PHACS,
PAPOLA, ELAC1, MDS006, FLJ14167, LOC136895, CGGBP1, MGC45962,
CGI-85, AUTS2, FXYD5, FLJ32009, FGD3, HSAJ1454, GRP58, KIAA1954,
ELD/OSA1, PRex1, MGC11324, FLJ90013, NIN283, HCA127, DKFZP564D1378,
HMGB1, TRB@, MGC4796, ASE-1, YR-29, FLJ25476, CGI-67, STK33,
SLC25A21, ZNFN1A1, DRLM, PP2135, STMN3, CAMK2G, MGC16169, DC6,
GCNT1, PRO1635, STRIN, DLC1, DKFZp761D221, FLJ10656, ZNFN1A4,
SENP7, MGC34827, MGC15619, FLJ32942, RPL28, FLJ00005, FLJ23462,
DKFZp762L0311, FLJ30726, MGC3200, ARRB1, EIF3S7, HSA9761, FLJ11896,
MGC10744, KIAA1309, WDR9, KIAA1587, MIR, FLJ12953, MGC12921,
LOC130617, NAV1, HPSE, FLJ20085, KIAA1982, KCNK17, KIAA1495,
LOC64744, AUTL1, LOC91689, SEPP1, PPP2CA, KHDRBS1, DREV1, MGC35274,
SNRPE, LOC91689, KIAA0853, FLJ13215, TACC1, MGC20262, MGC17515,
MGC40157, DKFZP572C163, PRPF8, HINT1, FUSIP1, MEF2D, C20orf24,
TADA2L, NIN283, FS, HSPC063, ALS2, NHP2L1, LGALS12, MGC10986,
KIAA1871, DKFZP434A0131, KIAA1949, DTNBP1, GPHN, SUV39H2, BRD7,
FLJ32001, HYPC, EEF2K, ESRRB, ZNF226, IL18BP, CSRP2BP, HEMGN,
FOXP1, SGKL, FLJ11220, TRIM4, FLJ21918, KIAA1545, MGC2474, CDCA7,
HSPC002, LOC115294, LOC119710, GTF3A, TAGAP, TCF7L2, FLJ22690,
OAZIN, TRAP1, MGC42174, MGC9850, KIAA1632, HSU53209, BIVM, BAALC,
WHSC1, C16orf5, KIAA1238, MRS2L, CGI-105, ZDHHC2, LOC143903,
DKFZp762N0610, NSE1, OSBPL7, HAVCR2, ASAHL, KIAA1798, TLR4,
MGC10946, PRex1, FLJ31340, TAHCCP1, C20orf141, FLJ20313, TAF9L,
FRSB, PRKRA, P66, KIAA0141, RARA, BANP, FLJ00007, DTNBP1, LRP5,
KIAA1337, MGC29667, WHSC1, MMP28, EVIN2, Cab45, CED-6, PTER,
ZNFN2A1, NDP52, CHES1, KIAA1635, NFAT5, FLJ32332, HTRA3, MAP4K1,
KIAA1337, AP1S2, FLJ23306, HP1-BP74, KIAA1218, BTBD4,
DKFZp761F0118, MGC16703, BAZ2B, MU, FLJ13614, MYO15B, OAZIN,
LOC92799, CANX, SUFU, KIAA1954, AGS3, LAPTM4A, HP1-BP74, FLJ23467,
FLJ12892, MGC40042, KIAA1143, RPL11, LSR7, CENPJ, NY-REN-58, NRM,
FLJ23563, WASF2, AMBP, NIP30, EIF2AK4, MGC15429, TTC7L1, NICN1,
FXC1, FLJ20793, SOC, RPL13, HYPC, CLONE24945, MGC24663, TEM7R,
FLJ14768, DKFZp667M2411, STARD9, FOXP1, ELP3, KIAA1337, CDA017,
PPP6C, PAK1, FLJ10876, EPC1, ZNF397, C21orf63, KIAA1805, MIR,
CYYR1, DKFZp564B0769, EPSTI1, MDM4, MGC23947, MGC14421, SDCCAG33,
DKFZp762O076, LOC93109, STN2, HSMPP8, FLJ20265, LOC85028, MGC15435,
1-Sep, MGC41917, MSI2, Jade-1, IL17D, MGC2752, MATR3, PRKRA,
DKFZp434C1714, MGC4415, DKFZP727C091, MY038, FLJ35453, FLJ30794,
DJ462O23.2, FLJ90130, FLJ22283, EEF2, LOC155066, ATPAF1, FLJ23499,
STAM2, LOC85028, FLJ21709, LOC51279, TRA@, JAM3, SIAT6, KIAA1453,
EIF2S3, LSR7, ROCK1, DKFZP566I1024, FANCD2, MEF-2, MGC2664,
MGC15548, ZNF75A, HSPC126, EIF3S5, RBM7, FLJ20280, GSTA4, SEPP1,
TIGD3, DKFZP434A1319, MCLC, MGC14136, DKFZP762N2316, LOC115330,
D4ST-1, UCP4, PRMT6, LAK, NIN, FLJ10997, RAB4B, LMO4, RRN3, CENPH,
FLJ23277, GBTS1, FLJ90013, LOC115509, PP2135, FLJ36175, SPINO,
PAIP2, DKFZp761G0122, ATF7IP, WBP1, MGC29937, MGC9564, CASP2,
TIGD7, C4S-2, MGC25181, LOC89887, KIAA1387, FLJ22283, GIT2, MIR,
SSBP3, LOC159090, U5-200KD, FLJ10997, ZNF295, PGBD1, HEL308, POLH,
AP3M1, NORE1, SEMA6D, PPID, CUL5, LOC91663, FLJ13171, BAT4, RPLP1,
KIAA1630, CT2, HSPC182, HMGB1, FLJ20280, FKBP5, EIF3S6, C15orf15,
TRPC7, FLJ31153, TA-KRP, MGC17919, AP2A1, C20orf132, SECP43, PPIL2,
FLJ14494, YARS, MGC10974, CLN6, C20orf81, U2AF1, KIAA1238,
FLJ23861, LOC144455, DKFZp564D177, NIP30, TBC1D1, ZNF265, and
PPP4R2.
[0178] TABLE-US-00008 TABLE 8 Some Solid Tumor Stem Cell Cancer
Markers Bmi-1, eed, easyh1, easyh2, rnf2, yy1, smarcA3, smarckA5,
smarcD3, smarcE1, mllt3, frizzled 2, frizzled 6, frizzled 7, mf2,
Frizzled 1, Frizzled2, Frizzled4, Frizzled10, Frizzled6, FZD1,
FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9, FZD10, WNT2, WNT2B, WNT3,
WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC, (TCF4),, SLC7A8, IL1RAP,
TEM8, TMPRSS4, MUC16, GPRC5B, SLC6A14, SLC4A11, PPAP2C, CAV1, CAV2,
PTPN3, EPHA1, SLC1A1, CX3CL1, ADORA2A, MPZL1, FLJ10052, C4.4A,
EDG3, RARRES1, TMEPAI, PTS, CEACAM6,, NID2, STEAP, ABCA3, CRIM1,
IL1R1, OPN3, DAF, MUC1, MCP, CPD, NMA, ADAM9, GJA1, CD14, SLC19A2,
ABCA1, PCDH7, ADCY9, SLC39A1, NPC1, ENPP1, N33, GPNMB, LY6E,
CELSR1, LRP3, C20orf52, TMEPAI, FLVCR, PCDHA10, GPR54, TGFBR3,
SEMA4B, and PCDHB2.
[0179] TABLE-US-00009 TABLE 9 The Alpha-catenin and E-cadherin
Cancer Stem Cell Gene Signatures Cancer stem cell gene Low to
undetectable signatures expression Elevated expression CTNNA1
CTNNA1, LNX, ARMCX3, CAV1, CAV2, IGFBP3, S100A2, Signature 1
D2S448, TUSC1, GLUL, RB1, CXCL5, MET, FOXQ1, CDKN2A, BEX2, SLC12A2,
GALC, MFHAS1, IL27RA, KLRF1, NGFRAP1, FGF13, KIAA1102, PKCA, UPP1,
SLC7A5, ARNTL2, SLC1A4, DNAJD1 PRSS1 /// PRSS2 /// PRSS3, PRSS3,
VNN1, RAB38, ZBED2, MYEOV, MAL, IMP-3, DHRS9 CTNNA1 CTNNA1, NCSTN,
LNX, EDG2, CAV1, CAV2, DCBLD2, Signature 2 ARMCX3, D2S448, TUSC1,
IGFBP3, S100A2, CXCL5, MET, GLUL, RB1, BEX2, SLC12A2, FOXQ1,
CDKN2A, MFHAS1, GALC, NGFRAP1, FGF13, IL27RA, KLRF1, PKCA, UPP1,
KIAA1102, SLC1A4, DNAJD1 CTSL2, SLC7A5, ARNTL2,
PRSS1///PRSS2///PRSS3, PRSS3, VNN1, RAB38, ZBED2, MYEOV, MAL,
IMP-3, DHRS9 CTNNA1 CTNNA1, NCSTN, LNX, EDG2, CAV1, CAV2, DCBLD2,
Signature 3 ARMCX3, D2S448, GLUL, RB1 IGFBP3, S100A2, CXCL5, MET,
FOXQ1, CDKN2A, MFHAS1, CTSL2 CTNNA1 CTNNA1, NCSTN, TUSC1, EDG2,
CAV1, CAV2, DCBLD2, Profile 4 GLUL, FGF13, SLC12A2, GALC, CDKN2A,
FOXQ1, IGFBP3, (295 array) SLC1A4, DNAJD1, RB1, S100A2, MFHAS1,
IL27RA, ARMCX3, NGFRAP1, KIAA1102 CTSL2, MET, PKCA, UPP1, ARNTL2,
PRSS3, VNN1, RAB38, MAL, ZBED2, MYEOV, IMP-3, KLRF1, SLC7A5, DHRS9
CTNNA1 CTNNA1, NCSTN, D2S448, EDG2, CAV1, CAV2, CDKN2A, Profile 5
GLUL, FGF13, GALC, SLC1A4, IGFBP3, S100A2, MFHAS1, (286 array)
DNAJD1, RB1, ARMCX3, IL27RA, CTSL2, MET, PKCA, NGFRAP1, KIAA1102
UPP1, PRSS1///PRSS2///PRSS3, PRSS3, VNN1, RAB38, MAL, ZBED2, IMP-3,
KLRF1, SLC7A5, CXCL5, DHRS9 CDH1 CDH1, MMP7, Nov, FOSL1, FLJ20152,
ARNT, CYFIP2, Signature 1 IL1R2, SFRP1, KRT6B, G0S2, C17orf27,
TAP1, RNASEL, IL8, B3GNT5, FGFBP1 LOC57168 CDH1 CDH1, MMP7, Nov,
FOSL1, SHC1, FLJ20152, ARNT, CYFIP2, Signature 2 IL1R2, SFRP1,
KRT6B, G0S2, C17orf27, TAP1, RNASEL, IL8, B3GNT5, FGFBP1 LOC57168
CDH1 CDH1, MMP7, Nov, FOSL1, SHC1, FLJ20152 Signature 3 IL1R2 CDH1
CDH1, MMP7, Nov, FOSL1, SHC1, FLJ20152, ARNT, CYFIP2, Profile 4
IL1R2, SFRP1, KRT6B, IL8, C17orf27, TAP1, RNASEL, (295 array)
B3GNT5, FGFBP1 LOC57168 CDH1 CDH1, MMP7, Nov, FOSL1, SHC1,
FLJ20152, CYFIP2, TAP1 Profile 5 IL1R2, SFRP1, KRT6B, G0S2, (286
array) IL8, FGFBP1
[0180] Table 9 shows alpha-catenin and E-cadherin cancer stem cell
gene signatures as distinct, yet both reveal the loss, as compared
to normal human breast epithelium, of essential components of
cell-cell contacts known as adherens junctions. Cancer stem cells
that possess signature 1 gene expression display undetectable or
low levels of alpha-catenin (CTNNA1) expression, and cancer stem
cells that possess signature 2 gene expression display undetectable
or low levels of e-cadherin (CDH1) expression. E-cadherin is a
cell-surface receptor involved in homophilic cell-cell adhesion and
epithelial polarity. E-cadherin interacts directly with
beta-catenin, which in addition to its function at cell junctions,
is an essential component of the Wnt signaling pathway.
Beta-catenin in turn interacts with alpha-catenin, and
alpha-catenin binds to polymerized actin to anchor cell junctions
to the cell cytoskeleton (Bienz, 2004, Cur. Biol. 15:R64; Kobielak
& Fuchs, 2004, Nat. Rev. Mol. Cell Biol. 5:614). Reduced levels
of either alpha-catenin or e-cadherin protein can disrupt cell-cell
adhesion, and genetic deletions of alpha-catenin in mice reveals
epithelial polarity defects and epidermal hyperplasia that are
accompanied by epithelial invaginations resembling precancerous
lesions. Both mutations and decreased expression levels of
alpha-catenin and e-cadherin characterize many different human
cancers, including tumors of the breast and colon. Reduced
expression of e-cadherin or alpha-catenin often correlates with
metastasis. Furthermore, levels of e-cadherin influence signaling
by beta-catenin, and loss of e-cadherin expression might allow for
sustained activation of Wnt signaling, which itself is well-known
to be involved in certain human cancers as described herein
(Kobielak & Fuchs, 2004, Nat. Rev. Mol. Cell Biol. 5:614; Hazan
et al., 2004, Annals NY Acad. Science 1014:155-163; Mohammad, 2005,
J. Pathol. 205:130-144).
The Alpha-Catenin Cancer Stem Cell Gene Signature.
[0181] In addition to the undetectable or low levels of
alpha-catenin expression in cancer stem cells the present invention
further identifies the increased and decreased expression as
compared to normal breast epithelium of a diverse group of genes
that have various physiological functions and that are implicated
to varying degrees in the development, maintenance, and/or
progression of human cancers. In some embodiments of the present
invention the undetectable or low levels of alpha-catenin
expression is accompanied by undetectable or low level expression
of one or more of a distinct set of genes comprising: nicastrin
(NCSTN); ligand of numb-protein X (LNX); armadillo repeat
containing, X-linked 3 (ARMCX3); melanoma associated gene (D2S448);
tumor suppressor candidate 1 (TUSC1); glutamine synthase (GLUL);
retinoblastoma 1 (RB1), brain expressed X-linked 2 (BEX2); solute
carrier family 12, member 2 (SLC12A2); galactosylceramidase (GALC);
nerve growth factor receptor associated protein I (NGFRAP1);
fibroblast growth factor 13 (FGF13); KIAA1102; solute carrier
family 1, member 4 (SLC1A4); and DnaJ homolog, subfamily D, member
1 (DNAJD1) and elevated expression of one or more of a distinct set
of genes comprising: endothelial differentiation, lysophosphatidic
acid G-protein coupled receptor 2 (EDG2); caveolin 1 (CAV1);
caveolin 2 (CAV2); discoidin, CUB and LCCL domain containing 2
(DCBLD2); insulin-like growth factor binding protein 3 (IGFBP3);
S100A2; CXCL5; c-Met (MET); forkhead box Q1 (FOXQ1);
cyclin-dependent kinase inhibitor 2A (CDKN2A); malignant fibrous
histiocytoma amplified sequence 1 (MFHAS1); interleukin 27
receptor, alpha (IL27RA); killer cell lectin-like receptor
subfamily F, member 1 (KLRF1); protein kinase C, alpha (PKCA);
uridine phosphorylase 1 (UPP1); cathepsin L2 (CTSL2); solute
carrier family 7, member 5 (SLC7A5); aryl hydrocarbon receptor
nuclear translocator-like 2 (ARNTL2); protease, serine, 1, 2, and 3
(PRSS1, PRSS2, PRSS3); vanin 1 (VNN1); RAB38; zinc finger, BED
domain containing 2 (ZBED2); myeloma overexpressed gene (MYEOV);
MAL; IGF-II mRNA-binding protein 3 (IMP-3); and
dehydrogenase/reductase SDR family, member 9 (DHRS9). In another
embodiment the undetectable or low levels of alpha-catenin
expression further comprises undetectable or low level expression
of one or more of the genes: NCSTN; LNX; ARMCX3; D2S448; TUSC1;
GLUL; RB1; BEX2; SLC12A2; GALC; NGFRAP1; FGF13; KIAA1102; SLC1A4;
and DNAJD1. In another embodiment the undetectable or low levels of
alpha-catenin is accompanied by the elevated expression of one or
more of the genes: EDG2; CAV1; CAV2; DCBLD2; IGFBP3; S100A2; CXCL5;
MET; FOXQ1; CDKN2A; MFHAS1; IL27RA; KLRF1; PKCA; UPP1; CTSL2;
SLC7A5; ARNTL2; PRSS1; PRSS2; PRSS3; VNN1; RAB38; ZBED2; MYEOV;
MAL; IMP-3; and DHRS9. In further embodiments of the present
invention signature 1 cancer stem cells display undetectable or low
level expression of one or more of the genes: alpha-catenin; NCSTN;
LNX; ARMCX3; D2S448; TUSC1; GLUL; RB1; BEX2; SLC12A2; GALC;
NGFRAP1; FGF13; KIAA1102; SLC1A4; and DNAJD1 and increased
expression of one or more of the genes: EDG2; CAV1; CAV2; DCBLD2;
IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A; MFHAS1; IL27RA; KLRF1;
PKCA; UPP1; CTSL2; SLC7A5; ARNTL2; PRSS1; PRSS2; PRSS3; VNN1;
RAB38; ZBED2; MYEOV; MAL; IMP-3; and DHRS9. Alternatively,
signature 1 cancer stem cells comprises: 1) undetectable or low
level expression of two or more of the genes: alpha-catenin; NCSTN;
LNX; ARMCX3; D2S448; TUSC1; GLUL; RB1; BEX2; SLC12A2; GALC;
NGFRAP1; FGF13; KIAA1102; SLC1A4; and DNAJD1 or 2) elevated
expression of two or more of the genes: EDG2; CAV1; CAV2; DCBLD2;
IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A; MFHAS1; IL27RA; KLRF1;
PKCA; UPP1; CTSL2; SLC7A5; ARNTL2; PRSS1; PRSS2; PRSS3; VNN1;
RAB38; ZBED2; MYEOV; MAL; IMP-3; and DHRS9.
[0182] In some embodiments of the present invention the
undetectable or low levels of alpha-catenin expression is
accompanied by undetectable or low level expression of one or more
of a distinct set of genes comprising: nicastrin (NCSTN); ligand of
numb-protein X (LNX); armadillo repeat containing, X-linked 3
(ARMCX3); melanoma associated gene (D2S448); glutamine synthase
(GLUL); and retinoblastoma 1 (RB1), and elevated expression of one
or more of a distinct set of genes comprising: endothelial
differentiation, lysophosphatidic acid G-protein coupled receptor 2
(EDG2); caveolin 1 (CAV1); caveolin 2 (CAV2); discoidin, CUB and
LCCL domain containing 2 (DCBLD2); insulin-like growth factor
binding protein 3 (IGFBP3); S100A2; CXCL5; c-Met (MET); forkhead
box Q1 (FOXQ1); cyclin-dependent kinase inhibitor 2A (CDKN2A);
cathepsin L2 (CTSL2); and malignant fibrous histiocytoma amplified
sequence 1 (MFHAS1). In another some embodiment the undetectable or
low levels of alpha-catenin expression is accompanied by
undetectable or low level expression of one or more of the genes:
NCSTN; LNX; ARMCX3; D2S448; GLUL; and RB1. In another some
embodiment the undetectable or low levels of alpha-catenin is
accompanied by the elevated expression of one or more of the genes:
EDG2; CAV1; CAV2; DCBLD2; IGFBP3; S100A2; CXCL5; MET; FOXQ1;
CDKN2A; CTSL2; and MFHAS1. In further some embodiments of the
present invention signature 1 cancer stem cells display
undetectable or low level expression of one or more of the genes:
alpha-catenin; NCSTN; LNX; ARMCX3; D2S448; GLUL; and RB1 and
increased expression of one or more of the genes: EDG2; CAV1; CAV2;
DCBLD2; IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A; CTSL2; and
MFHAS1. Alternatively, signature 1 cancer stem cells display: 1)
undetectable or low level expression of two or more of the genes:
alpha-catenin; NCSTN; LNX; ARMCX3; D2S448; GLUL; and RB1 or 2)
elevated expression of one or more of the genes: EDG2; CAV1; CAV2;
DCBLD2; IGFBP3; S100A2; CXCL5; MET; FOXQ1; CDKN2A; CTSL2; and
MFHAS1.
[0183] Signature 1 cancer stem cell gene expression can encompass
decreased expression of Nicastrin (NCSTN). Nicastrin is an
essential component of the multimeric gamma-secretase complex that
includes presenilins as its catalytic subunit. Intramembrane
proteolysis by gamma-secretase is required for the normal
processing of many receptor-like proteins including: Notch, where
it leads to intracellular signaling during tissue development and
renewal; beta-amyloid precursor protein (APP), where it contributes
to the generation of amyloid beta peptides that accumulate in
Alzheimer's disease; and E-cadherin, where both interactions with
and cleavage by the gamma-secretase complex regulate the stability
of adherens junctions. Nicastrin is involved in stabilizing
presenilin and is thus required for gamma-secretase activity (Baki
et al., 2001, PNAS 98:2381; Marambaud et al., EMBO J. 21:1948; Yan
et al., 2004, J. Neurosci. 24:2942. However, Nicastrin can also
play an inhibitory role as fibroblasts from heterozygous nicastrin
mice unexpectedly display increased gamma-secretase activity
compared to the complete absence of activity in the knock out mice
(Li et al., 2003, J. Biol. Chem.278:33445). Thus decreased
expression of Nicastrin can first increase gamma-secretase
activity, increasing proliferative signaling via Notch and
decreasing cellular adhesion via cleavage of E-cadherin, suggesting
that further decreases in expression of nicastrin or
gamma-secretase inhibitors can slow tumor growth and inhibit
metastasis.
[0184] Signature 1 cancer stem cell gene expression can also
include decreased expression of Ligand of numb-protein X (LNX). LNX
is a RING finger-type E3 ubiquitin ligase that targets the cell
fate determinant Numb for ubiquitylation and proteasomal
degradation. During cell division Numb controls cell fate by its
asymmetric localization to a single daughter cell and subsequent
regulation of Notch signaling. Decreased degradation of Numb is
proposed to disrupt this asymmetric localization (Nie et al., 2002,
EMBO J. 21:93; Nie et al., 2004, J. Biol. Chem. 279:20807). Thus
the decreased expression of LNX in cancer stem cells can contribute
to the self-renewal of tumorigenic stem cells over the generation
of non-tumorigenic daughter cells.
[0185] Signature 1 cancer stem cell gene expression further
comprises decreased expression of ARMCX3, a member of the armadillo
repeat (arm) family of proteins implicated in embryogenesis, tissue
maintenance, and cancer. Expression of arm family members is
significantly reduced in various human carcinomas suggesting a role
in suppressing tumors of epithelial origin (Kurochkin et al., 2001,
Biochem. Biophys. Res. Commun. 280:340).
[0186] Signature 1 cancer stem cell gene expression further
comprises decreased expression of Melanoma associated gene (MG50).
MG50 is a melanoma antigen which encodes epitopes recognized by
human cytolytic T lymphocytes and is a possible IL-1 receptor
antagonist (Mitchell et al., 2000, Cancer Res. 60:6448).
[0187] Signature 1 cancer stem cell gene expression further
comprises decreased expression of Glutamine synthase (GLUL). GLUL
catalyzes the ATP-dependent conversion of glutamate and ammonia to
glutamine, an abundant amino acid essential for cellular growth.
Although highly expressed in a subset of cells, such as astrocytes
and pericentrally located hepatocytes, involved in controlling
levels of potentially toxic glutamate and ammonia, the majority of
cells express low levels of GLUL for the production of glutamine.
GLUL is over-expressed in liver tumors with beta-catenin mutations,
suggesting regulation by the Wnt signaling pathway. GLUL is,
however, considered a dispensable enzyme for tumors though its
induction and could help provide glutamine for quickly
proliferating tumor cells and enhance tumor growth rates (Medina et
al., 2001, Am. Soc. Nut. 131:2539S; Leoppen et al., 2002, Cancer
Res. 62:5685).
[0188] Signature 1 cancer stem cell gene expression also comprises
decreased expression of Retinoblastoma1 (RB1), a well-characterized
tumor suppressor that is mutated in inherited retinoblastoma and
functionally inactivated in a large number of cancers. RB1 acts as
a critical transcriptional regulator of cell cycle progression and
differentiation, and its loss can contribute to uncontrolled cancer
stem cell proliferation (Yamasaki & Pagano, 2004, Curr. Opin.
Cell Biol. 16:623).
[0189] The alpha-catenin gene expression signature further
comprises the decreased expression of brain expressed X-linked 2
(BEX2); solute carrier family 12, member 2 (SLC12A2);
galactosylceramidase (GALC); nerve growth factor receptor
associated protein 1 (NGFRAP1); fibroblast growth factor 13
(FGF13); KIAA1102; solute carrier family 1, member 4 (SLC1A4); DnaJ
homolog, subfamily D, member 1 (DNAJD1) and tumor suppressor
candidate 1 (TUSC1). BEX2 (also designated as p75NTR-associated
cell death executor 5; NADE5) and NGFRAP1 (also designated as NADE
and BEX3) are adaptor proteins for p75 neurotrophin receptor
signaling and promote the induction of apoptosis (Mukai et al.,
2000, J. Biol. Chem. 275:17566-70; Mukai et al., 2003, Vitam. Horm.
66:385-402; Roux & Barker, 2002, Prog. Neurobiol. 67:203-33).
SLC12A2 is an ubiquitously expressed sodium-potassium-chloride
co-transporter with an important role in epithelial salt secretion,
cell volume regulation, and neuronal membrane potential (Hebert et
al., 2004, Pflugers Arch. 447:580-93) and is one of several genes
whose loss-of-function causes antenatal and classic Bartter
syndrome (Hebert, 2003, Curr. Opin. Nephrol. Hypertens. 12:527-32).
GALC encodes a beta-galactocerebrosidase that catalyzes the
lysosomal hydrolysis of specific galactolipids including
galatosylceramide, one of the major glycosphingolipids of myelin.
GALC is defective in Krabbe disease (globoid-cell leukodystrophy;
GLD) in which 90% of patients are infants with fatal cerebral
demyelination (Rafi et al., 1995, Hum. Mol. Genet. 4:1285-9; Boggs
et al., 2004, Glycoconj. J. 21:97-110). FGF13 is a member of the
fibroblast growth factor family implicated in a diverse array of
cellular processes including proliferation, apoptosis, cell
survival, chemotaxis, cell adhesion, differentiation, and migration
(Bottcher & Niehrs, 2005, Endocr. Rev. 26:63-77; Greene et al.,
1998, Eur. J. Neurosci. 10:1911-25). KIAA1102 a hypothetical human
protein at LOC22998. SLCIA4 is a ubiquitous neutral amino acid
transporter (Zerangue & Kavanaugh, 1996, J. Biol. Chem.
271:27991-4). And lastely, DNAJD1 is a heat shock protein 40
homolog molecular chaperone. DNAJD1 expression is lost in many
primary ovarian tumors, conferring of them resistance to
chemotherapeutic agents (Shridhar et al., 2001, Cancer Res.
61:4258-65).
[0190] Signature 1 cancer stem cell gene expression comprises
increased expression of Endothelial differentiation gene 2 (EDG2).
EDG2 belongs to a family of G-protein coupled receptors with high
affinity for lysophosphatidic acid (LPA), a bioactive phospholipid
that stimulates cell proliferation over differentiation,
morphological changes, and tumor cell invasion. LPA promotes growth
of ovarian tumors and is found at high concentrations in patients
with ovarian carcinomas, suggestive of an important role in ovarian
cancers. Elevated levels of LPA have also been detected in patients
with endometrial and cervical cancers (Mills and Moolenaar, 2003,
Nat. Rev. Cancer 3:582). Increased expression of EDG2 in a
population of cancer stem cells can implicate responsiveness to LPA
more broadly in initiating tumorigenesis. However, increased
expression level of EDG2 is associated with decreased cell growth
rates via LPA-independent induction of apoptosis (Fang et al.,
2000, Annals NY Acad. Science 188) suggesting that antagonizing
LPA-dependent signaling but enhancing LPA-independent apoptosis
must be balanced to counter tumor cell growth.
[0191] Signature 1 cancer stem cell gene expression further
comprises increased expression of both caveolin-1 (CAV1) and
caveolin-2 (CAV2). The caveolins are integral membrane proteins
that serve both structural and regulatory roles at plasmalemmal
invaginations called caveolae. Caveolae have been implicated in a
range of cellular functions including vesicular transport,
cholesterol homeostasis, and compartmentalization of signal
transduction. Caveolin-1 has tumor suppressor properties and is
mutated or lost in some breast cancers. Conversely caveolin-1 is
up-regulated in gastrointestinal and prostate cancers and is
associated with metastasis in the latter. The recent identification
of a secreted form of caveolin with the ability to stimulate cell
viability and clonal growth can help explain these contradictory
results (Cohn et al., 2004, Physiol. Rev. 84:1341; Williams &
Lisanti, 2005, Am. J. Physiol Cell Physiol. 288:C494-C506.) Thus
targeting extracellular forms of caveolin can inhibit proliferation
of cancer stem cells with increased expression of these
proteins.
[0192] Signature 1 cancer stem cell gene expression additionally
comprises increased expression of Discoidin, CUB and LCCL domain
containing 2 (DCBLD2), a type-I transmembrane protein structurally
similar to the neurophilins, cell surface receptors for VEGF and
semaphorins. Increased expression of DCBLD2 is found in lung cancer
cells upon acquisition of a metastatic phenotype and in lung
cancers that have a high frequency of metastatic lesions (Kobuke et
al., 2001, J. Biol. Chem. 276:34105; Koshikawa et al., 2002,
21:2822-8). Thus increased expression of DCBLD2 in type 1 tumor
stem cells can indicate an increased metastatic potential.
[0193] Signature 1 cancer stem cell gene expression further
comprises increased expression of Insulin-like growth factor
binding protein 3 (IGFBP3). IGFBP3 is the main binding partner for
insulin-like growth factor (IGF)-I, which regulates cell
proliferation and survival. IGFBP-3 both directly counteracts the
mitogenic effects of IGF and mediates growth inhibition and
apoptosis by other growth factors and hormones. And in vitro
IGFBP-3 alone can stimulate cell proliferation through its
interactions with the EGF receptor and mitogen-activated protein
kinase (MAPK) signaling. High levels of circulating IGFBP-3 are
associated with an increased risk of premenopausal breast cancer,
however, to date most evidence points to IGFBP-3 playing a
protective role against various cancers (Schedlich & Graham,
2002, 59:12-22; Ali et al., 2003, Horm. Metab. Res. 35:726-33;
Renehan et al., 2004, 363:1346; Vestey et al., 2005, Breast Cancer
Res. 7:R119).
[0194] Signature 1 cancer stem cell gene expression also comprises
increased expression of S100A2. The S100 family of Ca2+ binding
proteins is implicated in various cellular functions including Ca2+
homeostasis and cell growth. Furthermore, the expression of many
S100 proteins is altered in human cancers. Expression of S100A2 is
increased in several cancers including non-small cell lung
carcinoma (NSCLC), where it is often associated with DeltaNp63 and
can be linked to metastatic potential. The role and importance of
the S100 proteins in cancer, however, is not yet clear (Diederichs
et al., 2004, Cancer Res. 64:6654-9; Emberley et al., 2004,
Biochem. Cell Biol. 82:508-15; Smith et al., 2004, Br. J. Cancer
91:1515-24).
[0195] Signature 1 cancer stem cell gene expression further
comprises increased expression of CXCL5, a
lipopolysaccharide-inducible chemokine that recruits neutrophils of
the immune system and is pro-angiogenic. Over-expression of CXCL5
has been linked to the growth of human adrenocortical carcinomas
and can contribute to the self-renewal of hematopoietic stem cells
(Keane et al., 2001, Am. J. Respir. Crit. Care Med. 164:2239;
Schteingart et al., 2001, J. Clin. Endocrinol. Metab. 86:3968;
Choong et al., 2004, Cytokine 25:239-45; Pold et al., 2004, Cancer
Res. 64:1853). Thus increased expression of CXCL5 by cancer stem
cells can contribute to stem cell self-renewal and/or help maintain
tumors via angiogenesis.
[0196] Signature 1 cancer stem cell gene expression comprises
increased expression of c-Met, a receptor tyrosine kinase activated
by the secreted hepatocyte growth factor/scatter factor (HGF/SF).
c-Met controls cell proliferation, dissociation, and migration
during embryogenesis and aberrant activation of these processes in
human cancer contributes to tumor growth and metastasis. Met
activation phosphorylates beta-catenin, a modification that
promotes loss of beta-catenin association with alpha-catenin at
cell junctions decreasing cellular adhesion and making beta-catenin
available for Wnt mediated signaling (Tokunou et al., 2001, Am. J.
Pathol. 158:1451; Birchmeier et al., 2003, Nat. Rev. Mol. Cell
Biol. 4:915; Biez, 2004, Curr. Biol. 15:R64; Boccaccio et al.,
2005, Nature 434:396; and Ma et al., 2005, Cancer Res.
65:1479).
[0197] Signature 1 cancer stem cell gene expression additionally
comprises increased expression of forkhead box Q1 (FOXQ1). The
forkhead family is a diverse group of winged helix transcription
factors involved in numerous aspects of development, and their
deregulation contributes to human cancer. FOXQ1 is required for
proper differentiation of epidermal hair shafts in mice and is
overexpressed in colorectal adenocarcinoma and lung carcinoma cell
lines as well as pancreatic cancers. The role overexpression of
FOXQ1 plays in carcinogenesis is as yet unclear (Bieller et al.,
2001, DNA Cell Biol. 20:555-61; Hong et al., 2001, Genesis
29:163-71; Cao et al., 2004, Cancer Biol. Ther. 3:1081-9).
[0198] Signature 1 cancer stem cell gene expression also comprises
increased expression of cyclin-dependent kinase inhibitor 2A
(p16INK4). p16INK4 is an inhibitor of activated cyclin-Cdk
complexes that control the G.sub.1 checkpoint of the mammalian cell
cycle, and has been identified as a potent inhibitor of
cdk4-mediated phosphorylation of the tumor suppressor protein
retinoblastoma (Rb). p16INK4 is a tumor suppressor that is
inactivated in a number of human cancers (Okamoto et al., 1994,
PNAS 91:11045; Kim et al., 2005, Int. J. Oncol. 26:1217-26).
[0199] Signature 1 cancer stem cell gene expression further
comprises increased expression of Malignant fibrous histiocytoma
amplified sequence 1 (MRHAS1). MRHAS1 is located on chromosome
8p23.1, a region that is amplified in some solid tumors and that is
translocated in hematological malignancies and head and neck
squamous carcinomas. MRHAS1 itself is translocated in a B-cell
lymphoma cell line, and both wild-type and chimeric MRHAS1 possess
tumorigenic properties in a nude mouse model (Tagawa et al., 2005,
Oncogene 23:2576-81).
[0200] Signature 1 cancer stem cell gene expression further
comprises increased expression of cathepsin L2 (CTSL2). CTSL2 is a
thymus and testis-specific lysosomal cyteine proteinase member of
the peptidase C1 family and is misexpressed in colorectal, breast,
ovarian, and renal carcinomas (Santamaria et al., 1998, Cancer Res.
58:1624-30).
[0201] The alpha-catenin gene expression signature further
comprises the elevated expression of interleukin 27 receptor, alpha
(IL27RA); killer cell lectin-like receptor subfamily F, member 1
(KLRF1); protein kinase C, alpha (PKCA); uridine phosphorylase 1
(UPP1); solute carrier family 7, member 5 (SLC7A5); aryl
hydrocarbon receptor nuclear translocator-like 2 (ARNTL2);
protease, serine, 1, 2, and 3 (PRSS1, PRSS2, PRSS3); vanin 1
(VNN1); RAB38; zinc finger, BED domain containing 2 (ZBED2);
myeloma overexpressed gene (MYEOV); MAL; IGF-II mRNA-binding
protein 3 (IMP-3); and dehydrogenase/reductase SDR family, member 9
(DHRS9). IL27RA is a class I cytokine receptor involved in
regulating adaptive immunity and critical to the generation of a
Th1 response (Chen et al., 2000, Nature 407:916-20; Robinson &
O'Garra, Immunity 16:755-8). KLRF1 is a type II transmembrane
glycoproteins with a single extracellular C-type lectin-like
domain. KLRF1 is expressed by natural killer (NK) cells and other
hematopoietic cells that bind MHC class I molecules to distinguish
tumor or virus-infected cells from normal host cells (Roda-Navarro
et al., 2001, Biochim. Biophys. Acta. 1520:141-6; Natarajan et al.,
2002, Annu. Rev. Immunol. 20:853-5). PKCA is a member of a family
of serine- and threonine-specific protein kinases activated by
calcium and diacylglycerol that phosphoylate a wide range of
protein targets involved in numerous cellular signaling pathways.
Several PKC isoforms are upregulated in human cancers (Shen, 2003,
Curr. Drug Targets Cardiovasc. Haematol. Disord. 3:301-7; Lahn et
al., 2004, Oncol. 67: 1-10). Uridine phosphorlyase (UPP1) is a
critical enzyme in the pyrimidine salvage pathway catalyzing the
reversible phosphorolysis of uridine to uracil. UPP1 is
overexpressed in several tumor cell lines and in primary tumors
associated with metastases (Watanabe & Uchida, 1995, Biochem.
Biophys. Res. Commun. 2:265-72; Miyashita et al., 2002, Cancer
94:2959-66; Sahin et al., 2005, Pancreas 30:158-67). SLC7A5 is a
cationic amino acid transporter (Closs et al., 1993, J. Biol. Chem.
268:7538-44). ARNTL2 is a member of the basic helix-loop-helix
PER-ARNT-SIM family of transcription factors that control diverse
physiological processes including circadian rhythms and cell
proliferation (Schoenhard et al., 2002, Am. J. Physiol. Cell
Physiol. 283:C103-14; Yeh et al., 2003, Oncogene 22:5306-14).
PRSS1, PRSS2, and PRSS3 are serine proteases secreted by the
pancreas of which PRSS1 is mutated in 80% of patients with
symptomatic hereditary pancreastitis (Szmola et al., 2003, J. Biol.
Chem. 278:48580-9; Howes et al., 2005, Clin. Lab Med. 25:39-59).
VNN1 is an epithelial ectoenzyme member of the vanin family of
proteins and plays a role in the glutathione-dependent response to
oxidative-stress (Martin et al., 2001, Immunogenet. 53:296-306;
Berruyer et al., 2004, Mol. Cell Biol. 24:7214-24). RAB38 is a
small GTP binding protein member of the RAS oncogene family that
regulates intracellular vesicle trafficking. A point mutation in
the GTP binding domain of RAB38 in melanocytes produces the
oculocutaneous albinism of chocolate mice (Loftus et al., 2002,
PNAS99:4471-6; Osanai et al., 2005, Biol. Chem 286:143-53). ZBED2
is a zinc finger protein containing a BED finger domain, a domain
proposed to play a role in altering local chromatin architecture
(Mahajan et al., 2002, Mol. Cell Biol. 22:6883-94). MAL is a
hydrophobic integral membrane protein of the MAL family of
proteolipids and is involved in the formation, maintenance, and
function of glycosphingolipid-enriched myelin and membrane
microdomains (Frank, 2000, Prog. Neurobiol. 60:531-44). IMP-3 is
localized to the nucleolus where it binds to and represses
translation of the 5' UTR of the insulin-like growth factor II
leader 3 mRNA during late mammalian development. Furthermore, IMP-3
is a sensitive and specific marker for carcinomas and high-grade
dysplastic lesions of the pancreatic ductal epithelium (Nielsen et
al., 1999, Mol. Cell Biol. 19:1262-70; Yantiss et al., 2005, Am. J.
Surg. Pathol. 29:188-95). DHRS9 is a retinol
dehydrogenase/reductase of the SDR superfamily that converts
retinol to retinaldehyde, the first of two reactions in the
formation of all-trans retinoic acid, which mediates the various
biological functions of vitamin A including visual transduction,
cell growth, and embryonic development. Expression of DHRS9 is
reduced in colon adenomas, carcinomas, and in seven carcinoma cell
lines and appears to be regulated by APC (Markova et al., 2003, Mol
Genet. Metab. 78:119-35; Jette et al., 2004, J. Biol. Chem.
279:34397-405).
[0202] It should be understood the signatures described above are
optimized and some signatures of the present invention. The present
invention is not limited to the use of these particular signatures.
Any combination of one or more markers that provides useful
information can be used in the methods of the present invention.
For example, it should be understood that one or more markers can
be added or substracted from the above signatures, while
maintaining the ability of the signatures to yield useful
information (e.g., more information than would be obtained in the
absence of testing).
The E-Cadherin Cancer Stem Cell Gene Signature.
[0203] In addition to the undetectable or low levels of E-cadherin
expression in cancer stem cells the present invention further
identifies the increased and decreased expression as compared to
normal breast epithelium of a diverse set of genes with a range of
physiological functions that are implicated in the development,
maintenance, and/or progression of human cancers. In some
embodiments of the present invention the undetectable or low levels
of E-cadherin expression further comprises undetectable or low
level expression of one or more of of the following genes: matrix
metalloproteinase 7 (MMP7); nephroblastoma overexpressed gene
(Nov); FOS-like antigen 1 (FOSL1); interleukin 1 receptor, type II
(IL1R2), secreted frizzled-related protein 1 (SFRP1); keratin 6B
(KRT6B); putative lymphocyte G0/G1 switch gene (G0S2); interleukin
8 (IL8); UDP-GIcNAc:betaGal
beta-1,3-N-acetylglucosaminyltransferase 5 (B3GNT5); and fibroblast
growth factor binding protein 1 (FGFBP1) and elevated expression of
one or more of the genes comprising: SHC (Src homology 2 domain
containing) transforming protein 1 (SHC1); FLJ20152; aryl
hydrocarbon receptor nuclear translocator (ARNT); cytoplasmic FMR1
interacting protein 2 (CYFIP2); chromosome 17 open reading frame 27
(C7orf27); transporter 1, ATP-binding cassette, sub-family B
(TAP1); RNASEL; and similar to aspartate beta hydroxylase
(LOC57168). In another embodiment the undetectable or low levels of
E-cadherin expression further comprises undetectable or low level
expression of one or more of the genes: MMP7; Nov; FOSL1; IL1R2;
SFRP1; KRT6B; G0S2; IL8; B3GNT5; and FGFBP1. In another embodiment
the undetectable or low levels of E-cadherin expression further
comprises elevated expression of one or more of the genes: SHC1;
FLJ20152; ARNT; CYFIP2; C17orf27; TAP1; RNASEL; and LOC57168. In
further embodiments of the present invention signature 2 cancer
stem cells comprise undetectable or low level expression of one or
more of the genes: E-cadherin; MMP7; Nov; FOSL1; IL1R2; SFRP1;
KRT6B; G0S2; IL8; B3GNT5; and, FGFBP1 and further comprises
elevated expression of one or both of the genes: SHC1; FLJ20152;
ARNT; CYFIP2; C17orf27; TAP1; RNASEL; and LOC57168. Alternatively
signature 2 cancer stem cells comprise 1) undetectable or low level
expression of one or more of the genes: E-cadherin; MMP7; Nov;
FOSL1; IL1R2; SFRP1; KRT6B; G0S2; IL8; B3GNT5; and FGFBP1 or 2)
elevated expression of one or more of the genes: SHC1; FLJ20152;
ARNT; CYFIP2; C17orf27; TAP1; RNASEL; and LOC57168.
[0204] In some embodiments of the present invention the
undetectable or low levels of E-cadherin expression further
comprises undetectable or low level expression of one or more of
the genes: matrix metalloproteinase 7 (MMP7); nephroblastoma
overexpressed gene (Nov); FOS-like antigen 1 (FOSL1); and
interleukin 1 receptor, type II (IL1R2), and elevated expression of
one or more of the genes comprising: SHC (Src homology 2 domain
containing) transforming protein 1 (SHC1) and FLJ20152. In another
more some embodiment the undetectable or low levels of E-cadherin
expression further comprises undetectable or low level expression
of one or more of the genes: MMP7; Nov; FOSL1; and IL1R2. In
another embodiment the undetectable or low levels of E-cadherin
expression further comprises elevated expression of one or both of
the genes: SHC1 and FLJ20152. In further some embodiments of the
present invention signature 2 cancer stem cells comprise
undetectable or low level expression of one or more of the genes:
E-cadherin; MMP7; Nov; FOSL1; and IL1R2, and further comprises
elevated expression of one or both of the genes: SHC1 and FLJ20152.
Alternatively signature 2 cancer stem cells comprise 1)
undetectable or low level expression of one or more of the genes:
E-cadherin; MMP7; Nov; FOSL1; and IL1R2 or 2) elevated expression
of one or more of the genes: SHC1 and FLJ20152.
[0205] Signature 2 cancer stem cell gene expression comprises the
decreased expression of matrix metalloproteinase 7 (MMP7). Matrix
metalloproteinases (MMPs) are secreted proteolytic enzymes involved
in the turnover of the extracellular matrix during tissue formation
and remodeling. Overexpression and secretion of MMPs by tumor cells
is thought to contribute to inappropriate degradation of both the
extracellular matrix and basement membranes, liberating bioactive
molecules that can stimulate cellular growth and aiding tumor cell
invasion and metastasis (Hamacher et al., 2004, Dtsch. Med.
Wocherschr. 129:1976-80; Mott & Werb, 2004, Curr. Opin Cell
Biol. 16:558-64).
[0206] Signature 2 cancer stem cell gene expression further
comprises the decreased expression of nephroblastoma overexpressed
gene (Nov). Nov was identified as the insertion site of the
myelobastosis-associated virus 1-N in avian nephroblastoma and
belongs to a family of secreted proteins associated with the
extracellular matrix that play various biological roles including
cell proliferation, chemotaxis, and cellular adhesion. Nov has been
implicated in cell cycle control and slowing cell growth.
Consistent with this notion, high levels of Nov expression are
associated with less aggressive brain tumors, and levels of Nov
decrease with progression of adrenocortical tumors to a malignant
state (Martinerie et al., 2001, J. Clin. Endocrinol. Metab.
86:3929-40; Gellhaus et al., 2004, J. Biol. Chem. 279:36931).
[0207] Signature 2 cancer stem cell gene expression additionally
comprises the decreased expression of FOS-like antigen 1 (FOSL1).
Dimers of Jun and Fos proteins, including FOSL1, make up the
transcription factor activator protein-1 (AP-1). AP-1 is linked to
a large number of often competing cellular functions including cell
transformation, proliferation, differentiation, and apoptosis that
are determined by a complex network of extracellular and
intracellular signaling pathways. FOSL1 differs from c-Fos in not
contain transactivation domains essential for cellular
transformation induced by AP-1 (Matsuo et al., 2000, Nat. Genet.
24:184-7; Ameyar et al., 2003, Biochimie 85:747-52).
[0208] Signature 2 cancer stem cell gene expression also comprises
the decreased expression of interleukin 1 receptor, type II
(IL1R2), a non-signaling decoy receptor for IL-I with both secreted
and membrane bound forms. IL-I is a potent pro-inflammatory
cytokine that can stimulate the production of pro-tumorigenic
cytokines such as the angiogenic and mitogenic cytokine IL-8
(Bourke et al., 2003, J. Immunol. 170:5999; Cui et al., 2003, J.
Immunol. 171:6814; Pantschenko et al., 2003, Int. J. Oncol.
23:269-84). Thus restoration of IL1R2 expression levels in this
population of cancer stem cells can help to counteract both
inflammation and tumor growth.
[0209] The E-cadherin gene expression signature further comprises
decreased expression of secreted frizzled-related protein 1
(SFRP1); keratin 6B (KRT6B); putative lymphocyte G0/G1 switch gene
(G0S2); interleukin 8 (IL8); UDP-GIcNAc:betaGal
beta-1,3-N-acetylglucosaminyltransferase 5 (B3GNT5); and fibroblast
growth factor binding protein 1 (FGFBP1). SFRP1 is a secreted
frizzled-related protein that binds to Wnt proteins and modulates
signaling (Uren et al., 2000, J. Biol. Chem. 275:4374-82). SFRP1
can promote apoptosis and is downregulated or hypermethylated in
various carcinomas (reviewed in Kawano & Kypta, 2003,
116:2527-34). KRT6B is a member of the keratin gene family
expressed in epithelial cells and strongly induced in stratified
epithelia undergoing excessive cell proliferation or abnormal
differentiation (Takahashi et al., 1995, J. Biol. Chem.
270:18581-92). G0S2 encodes a small basic phosphoprotein that plays
a role in the commitment of cells to enter the G1 phase of the cell
cycle (Cristillo et al., 1997, DNA Cell Biol. 16:1449-58). IL8 is a
potent pro-inflammatory, chemoattractant, and pro-angiogenic CXC
chemokine (Dumitrascu, 1996, Rom J. Intern. Med. 34:159-72;
Rosenkilde & Schwartz, 2004, APMIS112:481-95). B3GNT5 encodes a
type II membrane enzyme of the
beta-1,3-N-acetylglucosaminyltransferase family that transfers
GlcNAc to glycolipid substrates (Togayachi et al., 2001, J. Biol.
Chem. 276:22032-40) and is strongly linked to tumor invasion and
metastasis (Chakraborty & Pawelek, 2003, 20:365-73). FGFBP1
binds and activates both acidic and basic members of the fibroblast
growth factor family, which have been implicated in a diverse array
of cellular processes including proliferation, apoptosis, cell
survival, chemotaxis, cell adhesion, differentiation, and migration
(Bottcher & Niehrs, 2005, Endocr. Rev. 26:63-77).
[0210] Signature 2 cancer stem cell gene expression further
comprises the increased expression of SHC (Src homology 2 domain
containing) transforming protein 1 (SHC1). SHC1 is an adaptor
protein that is a key mediator of the insulin-like growth factor
(IGF-1) and epithelial growth factor (EGF) pathways that regulates
cell proliferation, differentiation, and apoptosis. Three isoforms
of SHC1 are expressed from the same gene, p46 Shc, p52 Shc, and p66
Shc, and whereas the p46 and p52 isoforms are overexpressed in
gastric cancers (Yukimasa et al., 2005, Int. J. Oncol. 26:905-11) a
variant allele of p66 Shc can decrease the risk of breast cancer
(Wagner et al., 2004, Carcinogenesis 25:2473).
[0211] Signature 2 cancer stem cell gene expression further
comprises the increased expression of FLJ20152 a hypothetical human
protein at LOC54463.
[0212] The E-cadherin gene expression signature further comprises
elevated expression of aryl hydrocarbon receptor nuclear
translocator (ARNT); cytoplasmic FMR1 interacting protein 2
(CYFIP2); chromosome 17 open reading frame 27 (C17orf27);
transporter 1, ATP-binding cassette, sub-family B (TAP1); RNASEL;
and similar to aspartate beta hydroxylase (LOC57168). The aryl
hydrocarbon (Ah) receptor, a member of the basic helix-loop-helix
PER-ARNT-SIM transcription factor family, binds environmental
pollutants, including polycyclic aromatic hydrocarbons, and
regulates expression of genes involved in xenobiotic metabolism
through interaction with specific xenobiotic response elements
(XREs; Reyes et al., 1992, Science 256:1193-5). CYFIP2 interacts
with the fragile X mental retardation protein (FMRP), an
RNA-binding protein associated with polysomes, and acts as an
effector of Rac1, a small GTP-binding protein cytoskeletal
regulator, to antagonize FMRP function (Schenck et al., 2003,
Neuron 38:843-5; Schenck et al., 2001, PNAS 98:8844-9). TAP1 is a
member of the ATP-binding cassette (ABC) transporter superfamily.
TAP1 is localized to the endoplasmic reticulum and cis-golgi and is
involved in the presentation of degraded cytoplasmic protein
peptides to the MHC class I molecule of the cellular immune system
(Townsend & Trowsdale, 1993, 4:53-61). RNASEL is an
endoribonuclease induced by interferon and activated by
5'phosphorylated, 2',5'-linked oligoadenylates that is implicated
in both the actions of interferon as well as basic homeostatic RNA
stability in mammalian cells (Zhou et al., 1993, Cell72:753-65).
Mutations in RNASEL can increase the risk of prostate cancer
(Silverman, 2003, Biochem. 42:1805-12).
[0213] It should be understood the signatures described above are
optimized and represent some signatures of the present invention.
The present invention is not limited to the use of these particular
signatures. Any combination of one or more markers that provides
useful information can be used in the methods of the present
invention. For example, it should be understood that one or more
markers can be added or substracted from the above signatures,
while maintaining the ability of the signatures to yield useful
information (e.g., more information than would be obtained in the
absence of testing).
[0214] Additional solid tumor stem cells cancer markers can be
identified, for example, using the methods described in Example 4
below.
[0215] Another aspect of the present invention is the means and
methods for classifying tumors based upon the profiling of solid
tumor samples by comparing a gene expression pattern of a cancer
sample to a cancer stem cell gene expression signature. This
invention for the first time has discovered tumor stem cell gene
expression signatures that are predictors of distant metastases and
death. The microarray data of the present invention identifies
cancer stem cell markers likely to play a role in breast or colon
cancer development, progression, and/or maintenance while also
identifying individual predictor genes and gene signatures useful
in classifying tumors, such as breast and colon tumors, into low
and high risk of, for example, metastasis and death. Classification
based on the detection of differentially expressed polynucleotides
and/or proteins that comprise a cancer gene profile when compared
to a cancer stem cell gene signature can be used to predict
clinical course, predict sensitivity to chemotherapeutic agents,
guide selection of appropriate therapy, and monitor treatment
response. Furthermore, following the development of therapeutics
targeting such cancer stem cell markers, detection of the cancer
gene signatures described in detail herein will allow the
identification of patients likely to benefit from such
therapeutics.
[0216] As described herein, the invention employs methods for
clustering genes into gene expression profiles by determining their
expression levels in two different cell or tissue samples. The
invention further envisions using these gene profiles as compared
to a cancer stem cell gene signature to predict clinical outcome
including, for example, metastasis and death. The microarray data
of the present invention identifies gene profiles comprising
similarly and differentially expressed genes contained on the
Affymetrix HG-U133 array between two tissue samples including
between tumor stem cells and normal breast epithelium,
non-tumorigenic tumor cells and normal breast epithelium, and tumor
stem cells and non-tumorigenic tumor cells. These broad gene
expression profiles can then be further refined, filtered, and
subdivided into gene signatures based on various different criteria
including, but not limited to, fold expression change, statistical
analyses (e.g. t-test P value from multiple compared samples),
correlation with expression of other genes, biological function
(e.g. cell cycle regulators, transcription factors, proteases,
etc.), some therapeutic targets (e.g. genes encoding extracellular
membrane associated proteins suitable for antibody based
therapeutics), identified expression in additional patient samples,
and ability to predict clinical outcome.
[0217] Thus in some embodiments of the present invention the genes
differentially expressed in tumor stem cells versus normal breast
epithelium are subdivided into different cancer stem cell gene
signatures based on their fold expression change. For example genes
with from 2 to 2.5 fold elevated (or reduced, or both elevated and
reduced) expression in tumor stem cells comprise a cancer stem cell
gene signature, genes with from 2.5 to 3 fold elevated (or reduced,
or both) expression comprise another cancer stem cell gene
signature. Alternatively, all genes above a certain fold expression
change are included in a cancer stem cell gene signature. For
example, all genes with a 2 fold or more reduced (or elevated, or
both) expression in tumor stem cells can comprise one cancer stem
cell gene signature, all genes with a 3 fold or more reduced (or
elevated, or both) expression in tumor stem cells can comprise
another cancer stem cell gene signature, and so on. In other
embodiments, the genes differentially expressed in tumor stem cells
versus normal breast epithelium are filtered by using statistical
analysis. For example, all genes with elevated (or reduced, or
both) expression with a t-test P value across samples from 0.01 and
0.005 can comprise one cancer stem cell gene signature, all genes
with elevated (or reduced, or both) expression with a t-test P
value across samples of 0.005 and 0.001 can comprise another cancer
stem cell gene signature, and so on. Furthermore, gene expression
analysis of independent patient samples or different cell lines can
be compared to any cancer stem cell gene signature generated as
described above. A cancer stem cell gene signature can be modified,
for example, by calculating individual phenotype association
indices as described (Glinsky et al., 2004, Clin. Cancer Res.
10:2272) to increase or maintain the predictive power of a given
cancer stem cell gene signature. In addition a cancer stem cell
gene signature can be further narrowed or expanded gene by gene by
excluding or including genes based on various criteria (e.g.
inclusion of a some therapeutic target or exclusion based of a
biologically unrelated target).
[0218] In yet further embodiments, a broad gene expression profile
such as those generated by the Affymetrix HG-U133 array analyses of
the present invention can be further refined, filtered, subdivided,
etc. into gene signatures based on two or more different criteria.
In some embodiments of the present invention the genes
differentially expressed in tumor stem cells versus normal breast
epithelium are subdivided into different cancer stem cell gene
signatures based on their fold expression change as well as their
biological function. For example, all genes involved in cell cycle
regulation with 3 to 3.5 fold elevated (or reduced, or both)
expression in tumor stem cells versus normal breast epithelium can
comprise one cancer stem cell gene signature, all genes involved in
cell cycle regulation with 3.5 to 4 fold elevated (or reduced, or
both) expression in tumor stem cells versus normal breast
epithelium can comprise another cancer stem cell gene signature,
all genes encoding extracellular membrane associated proteins with
4 fold or more elevated (or reduced, or both) expression in tumor
stem cells versus normal breast epithelium can comprise another
cancer stem cell gene signature, all genes encoding extracellular
membrane associated proteins with 5 fold or more elevated (or
reduced, or both) expression in tumor stem cells versus normal
breast epithelium can comprise yet another cancer stem cell gene
signature.
[0219] In some embodiments, the genes differentially expressed in
tumor stem cells are divided into cancer stem cell gene signatures
based on the correlation of their expression with a chosen gene in
combination with their fold or percentage expression change.
Specifically, in some embodiments the microarray analysis of the
invention was used to identify a solid tumor stem cell signature,
the alpha-catenin gene signature, based on genes with expression
levels that correlate with alpha-catenin expression and display a
fold or percentage expression change in tumor stem cells with
undetectable or low levels of alpha-catenin compared to normal
breast tissue and alpha-catenin non-deficient tumor stem cells.
Genes with undetectable to low expression in tumor stem cells
comprising low to undetectable alpha-catenin expression were
identified as having a positive correlation, from 0.9 to1, with
alpha-catenin expression in all tumor stem cells as well as
expression levels lower by 90% or more in tumor stem cells
comprising low to undectable alpha-catenin compared to normal
breast tissue and alpha-catenin non-deficient tumor stem cells.
Genes with elevated expression in tumor stem cells comprising low
to undetectable alpha-catenin expression were identified as having
a negative correlation, from -0.9 to -1, with alpha-catenin
expression in all tumor stem cells as well as expression levels in
tumor stem cells comprising low to undectable alpha-catenin that
are 9 fold or more than in normal breast tissue and alpha-catenin
non-deficient tumor stem cells. Together these genes comprise the
alpha-catenin signature 1 (Table 9). A second alpha-catenin
signature (alpha-catenin signature 2) was then generated by further
including genes that slightly violated the fold or expression
change criteria described above but were subjectively determined to
be therapeutically and/or biologically related genes: one gene with
undetetable to low expression and three genes with elevated
expression (underlined in Table 9). A third alpha-catenin signature
(alpha-catenin signature 3) was then generated by excluding genes
from alpha-catenin signature 2: nine genes with undetectable to low
expression and fifteen genes with elevated expression (Table 9).
The alpha-catenin signature 2 was compared against gene expression
analysis from the two independent cancer patient populations: 295
consecutive early breast cancer patients from the Netherlands
Cancer Institute and 286 lymph node negative breast cancer patients
from the Erasmus Medical Center producing alpha-catenin profile 4
and alpha-catenin profile 5, respectively (Table 9).
[0220] In other embodiments the microarray analysis of the
invention was used to identify a solid tumor stem cell signature,
the E-cadherin gene signature, based on genes with expression
levels that correlate with E-cadherin expression and display a fold
or percentage expression change in tumor stem cells with
undetectable or low levels of E-cadherin compared to normal breast
tissue and E-cadherin non-deficient cells. Genes with undetectable
to low expression in tumor stem cells comprising low to
undetectable E-cadherin expression were identified as having a
positive correlation, from 0.9 to1, with E-cadherin expression in
all tumor stem cells as well as expression levels lower by 85% or
more in tumor stem cells comprising low to undectable E-cadherin
compared to normal breast tissue and E-cadherin non-deficient tumor
stem cells. Genes with elevated expression in tumor stem cells
comprising low to undetectable E-cadherin expression were
identified as having a negative correlation, from -0.9 to -1, with
E-cadherin expression in all tumor stem cells as well as expression
levels in tumor stem cells comprising low to undectable E-cadherin
expression that are 2.5 fold or more than in normal breast tissue
and E-cadherin non-deficient tumor stem cells. Together these genes
comprise the E-cadherin signature 1. A second E-cadherin signature
(E-cadherin signature 2) was then generated by further including
genes that slightly violated the fold or expression change criteria
described above but were subjectively determined to be
therapeutically and/or biologically interesting genes: one gene
with elevated expression (underlined in Table 9). A third
E-cadherin signature (E-cadherin signature 3) was then generated by
excluding genes from E-cadherin signature 2 that were subjectively
determined not to be therapeutically and/or biologically
interesting genes: six genes with undetectable to low expression
and six genes with elevated expression (Table 9). The E-cadherin
signature 2 was then compared against gene expression analysis from
the two independent cancer patient populations: 295 consecutive
early breast cancer patients from the Netherlands Cancer Institute
and 286 lymph node negative breast cancer patients from the Erasmus
Medical Center producing E-cadherin profile 4 and E-cadherin
profile 5, respectively (Table 9).
[0221] The invention further embodies the use of these cancer stem
cell gene signatures to predict clinical outcome including, but not
limited to, metastasis and death. Any independent patient
population that includes gene expression analysis (e.g microarray
analysis, immunohistochemical analysis, etc) or tumor samples
suitable for gene expression analysis (e.g. frozen tissue biopsies,
paraffin embedded tumor tissue samples, etc) along with determined
clinical parameters or ongoing monitoring of clinical parameters
including, for example, lymph node status, metastasis, death, etc.
can be used to assess the ability of a cancer stem cell gene
signature to predict clinical outcomes. In some embodiments the
invention tests the ability of the alpha-catenin and E-cadherin
tumor stem cell gene signatures to predict metastasis and death in
two independent cancer patient populations: 295 consecutive early
breast cancer patients from the Netherlands Cancer Institute (van
de Vijver et al., 2002, N. Eng. J. Med. 347:1999) and 286 lymph
node negative breast cancer patients from the Erasmus Medical
Center (Wang et al., 2005, Lancet 365:671). Many statistical
analyses can be used to determine predictive ability. These
include, for example, Kaplan-Meier survival analysis, Cox
proportional hazard survival analysis, chi-square analysis, and
multivariate analysis. In some embodiments of the present
invention, Cox proportional hazard survival analysis of the 295
consecutive early breast cancer patients from the Netherlands
Cancer Institute and chi-square analysis of the 286 patients from
the Erasmus Medical Center were used to identify cancer stem cell
gene signatures significantly predictive of clinical outcome.
[0222] Correlation and Cox proportional hazard survival analysis of
microarray data from 295 consecutive early breast cancer patients
from the Netherlands Cancer Institute (van de Vijver et al., 2002,
N. Eng. J. Med. 347:1999) identified 125 patient tumors with a gene
expression profile (alpha-catenin profile 4) that positively
correlated with the alpha-catenin signature 2, and showed
alpha-catenin signature 2 as significantly predictive of metastasis
with a univariate hazard ratio of 1.15 per 0.1 correlation
(P=5.9.times.10.sup.-4) and significantly predictive of death with
a univariate hazard ratio of 1.24 per 0.1 correlation
(P=3.7.times.10.sup.-7). Furthermore, correlation and chi-square
analysis of the microarray data from 286 lymph-node negative breast
cancer patients from the Erasmus Medical Center (Wang et al., 2005,
Lancet 365:671) revealed that patient tumors with a gene expression
profile (alpha-catenin profile 5) that correlated with the
alpha-catenin signature 2 (n=77) had an increased risk of
metastasis (P=0.67). Thus a tumor stem cell gene signature, such as
the alpha-catenin expression signature 2 provides a gene signature
for tumors with high risk of metastasis and death, and is thus a
gene signature that predicts a poor prognosis. Although any
particular gene of the alpha-catenin expression signature 2 can or
can not have either reduced expression or elevated expression in a
tumor sample, the expression level and its relationship with the
other genes in the signature creates a unique solid tumor stem cell
signature that can be used to classify a tumor sample.
[0223] A similar comparison using the E-cadherin gene expression
signature described above was again used to assess clinical outcome
as summarized in Table 10. Correlation and Cox proportional hazard
survival analysis of microarray data from 295 consecutive early
breast cancer patients from the Netherlands Cancer Institute
identified 240 patient tumors with a gene expression profile
(E-cadherin profile 4) that positively correlated with the
E-cadherin signature 2, and showed E-cadherin signature 2 as
predictive of metastasis with a univariate hazard ratio for
metastasis of 0.981 per 0.1 correlation (P=0.59) and predictive of
death with a univariate hazard ratio of 0.938 per 0.1 correlation
(P=0.1). Combining the alpha-catenin and E-cadherin gene expression
signatures was also predictive of metastasis in patients
(univariate hazard ratio for metastasis of 1.28 per 0.1 correlation
(P =4.2.times.10.sup.-4)). In addition, correlation and chi-square
analysis of microarray data from 286 lymph-node negative breast
cancer patients from the Erasmus Medical Center (Wang et al., 2005,
Lancet 365:671) showed that patient tumors with a gene expression
profile (E-cadherin profile 5) that correlated with the E-cadherin
gene signature 2 (n=198) had an increased risk of metastasis
(P=0.57). TABLE-US-00010 TABLE 10 Statistical Analysis of
Metastasis and Death Prediction by the Alpha-Catenin and E-Cadherin
Gene Signatures Death Metastasis 295 patients 295 patients
(Netherlands (Netherlands Metastasis Cancer Institute) Cancer
Institute) 286 patients Gene Hazard Hazard (Erasmus expression
ratio ratio Medical Center) signature P value (per 0.1) P value
(per 0.1) P value CDH1 0.1 0.938 0.59 0.981 0.57 CTNNA1 3.7e-7 1.24
0.00059 1.15 0.67 CDH1 + 6.6e-5 1.37 0.00042 1.28 CTNNA1
[0224] The invention for the first time identifies the
alpha-catenin gene signature as a predictor of poor clinical
outcome. In certain embodiments of the present invention the
alpha-catenin signature is used clinically to classify tumors as
low or high risk and to assign a tumor to a low or high-risk
category. The alpha-catenin signature can further be used to
provide a diagnosis, prognosis, and/or select a therapy based on
the classification of a tumor as low or high risk as well as to
monitor a diagnosis, prognosis, and/or therapy over time. If it is
known that a patient has a tumor that expresses the genes
comprising the alpha-catenin signature and thus has a poor
prognosis, a more aggressive approach to therapy can be warranted
than in tumors not falling within the alpha-catenin subclass. For
example, in patients where there is no evidence of disease in lymph
nodes (node-negative patients), a decision must be made regarding
whether to administer chemotherapy (adjuvant therapy) following
surgical removal of the tumor. While some patients are likely to
benefit from such treatment, it has significant side effects and
can be avoided by patients with low risk tumors. Presently it is
difficult or impossible to predict which patients would benefit.
Knowing that a patient falls into a poor prognosis category can
help in this decision. Furthermore, detecting expression of an
alpha-catenin gene profile that is highly correlated with the
alpha-catenin signature of the present invention can provide
information related to tumor progression. It is well known that as
tumors progress, their phenotypic characteristics can change. The
invention thus contemplates the possibility that breast tumors can
evolve from expressing an alpha-catenin gene profile that is highly
correlated with a cancer stem cell gene signature to not (or vice
versa) either in response to therapy or in response to lack of
therapy. Thus detection of an alpha-catenin gene profile that
either correlates with or fails to correlate with an alpha-catenin
gene signature can be used to detect such progression and alter
therapy accordingly.
[0225] It is well known in the art that some tumors respond to
certain therapies while others do not. At present there is very
little information that can be used to determine, prior to
treatment, the likelihood that a specific tumor will respond to a
given therapeutic agent. Many compounds have been tested for
anti-tumor activity and appear to be effective in only a small
percentage of tumors. Due to the current inability to predict which
tumors will respond to a given agent, these compounds have not been
developed into marketed therapeutics. This problem reflects the
fact that current methods of classifying tumors are limited.
However, the present invention offers the possibility of
identifying tumor subgroups and characterizing tumors by a
significant likelihood of response to a given agent. Tumor sample
archives containing tissue samples obtained from patients that have
undergone therapy with various agents are available along with
information regarding the results of such therapy. In general such
archives consist of tumor samples embedded in paraffin blocks.
These tumor samples can be analyzed for their expression of
polypeptides that are then compared to the polypeptides encoded by
the genes comprising an alpha-catenin signature of the present
invention. For example, immunohistochemistry can be performed using
antibodies that bind to the polypeptides. Alternatively these tumor
samples can be analyzed by their expression of polynucleotides that
are then compared to the polynucleotides comprising an
alpha-catenin signature of the present invention. For example, RNA
can be extracted from the tumor sample and RT-PCR used to
quantitatively amplify mRNAs that are then compared to the
polynucleotides comprising an alpha-catenin signature. Tumors
belonging to an alpha-catenin subclass can then be identified on
the basis of this information. It is then possible to correlate the
expression of an alpha-catenin profile with an alpha-catenin
signature predicted response of the tumor to therapy, thereby
identifying particular compounds that show a superior efficacy
against tumors of this subclass as compared with their efficacy
agaisnt tumors overall or against tumors not falling within the
alpha-catenin subclass. Once such compounds are identified it will
be possible to select patients whose tumors fall into an
alpha-catenin subclass for additional clinical trials using these
compounds. Such clinical trials, performed on a selected group of
patients, are more likely to demonstrate efficacy. The reagents
provided herein, therefore, are valuable both for retrospective and
prospective trials.
[0226] In the case of prospective trials, detection of expression
of one or more of the genes or encoded polypeptides in a cancer
stem cell profile, such as an alpha-catenin profile, that
correlates with a cancer stem cell signature, such as an
alpha-catenin signature, can be used to stratify patients prior to
their entry into the trial or while they are enrolled in the trial.
In clinical research, stratification is the process or result of
describing or separating a patient population into more homogeneous
subpopulations according to specified criteria. Stratifying
patients initially rather than after the trial is frequently some
(including by regulatory agencies such as the U.S. Food and Drug
Administration involved in the approval process for a medication),
and stratification is frequently useful in performing statistical
analysis of the results of a trial. In some cases stratification
can be required by the study design. Various stratification
criteria can be employed in conjunction with detection of
expression of one or more cancer stem cell gene profiles that
correlate with a cancer stem cell signature, such as an
alpha-catenin gene signature. Commonly used criteria include age,
family history, lymph node status, tumor size, tumor grade, etc.
Other criteria that can be used include, but are not limited to,
tumor aggressiveness, prior therapy received by the patient,
estrogen receptor (ER) and/or progesterone (PR) positivity,
Her2/neu status,or p53 status. Ultimately, once compounds that
exhibit superior efficacy against cancer gene profile tumors that
are highly correlated with a cancer stem cell gene signature, such
as the alpha-catenin signature, are identified, reagents for
detecting expression of the gene profile can be used to guide the
selection of appropriate therapy for additional patients. Thus, by
providing reagents and methods for classifying tumors based on
their expression of a cancer gene profile that is compared to a
cancer stem cell gene signature, the present invention provides a
means to identify a patient population that can benefit from
potentially promising therapies that have been abandoned due to
inability to benefit broader or more heterogenous patient
populations and further offers a means to individualize cancer
therapy.
[0227] Information regarding the expression of cancer stem cell
signature genes, such as the alpha-catenin signature genes, is thus
useful even in the absence of specific information regarding their
biological function or role in tumor development, progression, and
maintenance. Although the reagents disclosed herein find particular
application with respect to breast cancer, the invention also
contemplates their use to provide diagnostic and/or prognostic
information for other cancer types including but not limited to:
biliary tract cancer; bladder cancer; brain cancer including
glioblastomas and medulloblastomas; cervical cancer;
choriocarcinoma; colon cancer; ondometial cancer; esophageal
cancer; gastric cancer; hematological neoplasms including acute
lymphocytic and myelogenous leukemia; multiple myeloma;
AIDS-associated leukemias and adult T-cell leukemia lymphoma;
intraepithelial neoplasms including Bowen's disease and Paget's
disease; liver cancer; lung cancer; lymphomas including Hodgkin's
disease and lymnphocytic lymphomas; neuroblastomas; oral cancer
including squamous cell carcinoma; ovarian cancer including those
arising from epithelial cells, stromal cells, germ cells and
mesenchymal cells; pancreatic cancer; prostate cancer; rectal
cancer; sarcomas including leiomyosarcoma, rhabdomyosarcoma,
liposarcoma, fibrosarcoma, and osteosarcoma; skin cancer including
melanoma, Kaposi's sarcoma, basocellular cancer, and squamous cell
cancer; testicular cancer including germinal tumors such as
seminoma, non-seminoma (teratomas, choriocarcinomas), stromal
tumors, and germ cell tumors; thyroid cancer including thyroid
adenocarcinoma and modullar carcinoma; and renal cancer including
adenocarcinoma and Wilms tumor.
[0228] In other embodiments of the present invention, a cancer stem
cell gene signature, such as an alpha-catenin signature, can be
used experimentally to test and assess lead compounds including,
for example, small molecules, siRNAs, and antibodies for the
treatment of cancer. For example tumor cells from a patient can be
screened for expression of a particular solid tumor stem cell gene
signature, such as the alpha-catenin gene signature, and then
transplanted into the xenograft model described herein and the
effect of test compounds, such as for example antibodies against
one or more cancer stem cell markers described herein, tested for
effects on tumor growth and survival. Furthermore a cancer gene
profile can be determined following treatment and the cancer gene
profile compared to a cancer stem cell gene signature to assess the
effectiveness of the therapy and in turn guide a future treatment
regimen. In addition the efficacy of test compounds can be assessed
against different tumor subclasses. For example test compounds can
be used in xenografts of tumors that express a cancer gene profile
that is highly correlated with a cancer stem cell signature, such
as the alpha-catenin gene signature, versus tumors having a gene
profile that does not correlate with a cancer stem cell gene
signature, or that express another gene signature such as, for
example, an E-cadherin gene signature. Any differences in response
of the different tumor subclasses to the test compound are
determined and used to optimize treatment for particular classes of
tumors.
[0229] The cancer stem cell gene signatures, such as the
alpha-catenin gene signatures, were identified from genes that are
expressed at decreased or at, elevated levels in tumor stem cells
compared to normal breast epithelium. Thus in certain embodiments
expression levels of mRNA, or amplified or cloned version thereof,
are determined from a tumor sample by hybridization to
polynucleotides that represent each particular gene comprising a
cancer stem cell gene signature. Some polynucleotides of this type
contain at least about 20 to at least about 32 consecutive
basepairs of a gene sequence that is not found in other gene
sequences. Even more some are polynucleotides of at least about 50
to at least about 400 basepairs of a gene sequence that is not
found in other gene sequences. Such polynucleotides are also
referred to as polynucleotide probes in that they are capable of
hybridizing to sequences of the genes, or unique portions thereof,
described herein. The sequences can be those of mRNA encoded by the
genes, the corresponding cDNA to such mRNAs, and/or amplified
versions of such sequences. In one some embodiment of the invention
a cancer stem cell gene profile is detected by polynucleotide
probes that comprise a cancer stem cell gene signature, such as an
alpha-catenin signature, immobilized on an array (such as a cDNA
microarray).
[0230] In another some embodiment of the invention, all or part of
the disclosed polynucleotides of a cancer stem cell gene signature,
such as an alpha-catenin gene signature, can be amplified and
detected by methods such as the polymerase chain reaction (PCR) and
variations thereof, such as, but not limited to, quantitative PCR
(Q-PCR), reverse transcription PCR (RT-PCR), and real-time PCR
(including means of measuring the initial amounts of mRNA copies
for each sequence in a sample). Real-time RT-PCR or real-time Q-PCR
can be used. Such methods utilize one or two primers that are
complementary and hybridize to portions of a disclosed sequence,
where the primers are used to prime nucleic acid synthesis. The
newly synthesized nucleic acids are optionally labeled and can be
detected directly or by hybridization to a polynucleotide of the
invention. Additional methods to detect expressed nucleic acids
include RNAse protection assays, including liquid phase
hybridizations, and in situ hybridization of cells or tissue
samples.
[0231] In yet other embodiments of the invention, gene expression
can be determined by analysis of protein expression. Protein
expression can be detected by use of one or more antibodies
specific for one or more epitopes of individual gene products
(proteins), or proteolytic fragments thereof, of a cancer stem cell
gene signature, such as an alpha-catenin signature, in a tumor
sample. Detection methodologies suitable for use in the practice of
the invention include, but are not limited to, immunohistochemistry
of cells in a tumor sample, enzyme linked immunosorbent assays
(ELISAs) including antibody sandwich assays of cells in a tumor
sample, mass spectroscopy, immuno-PCR, FACS, and protein
microarrays.
[0232] It is envisioned that any patient tumor sample can be
analysed, a tumor profile determined and then compared to a cancer
stem cell gene signature. The alpha-catenin gene expression
signature, an example of a solid tumor stem cell gene signature,
was discovered from a comparison of gene expression of cancer stem
cells against a non-tumorigenic tissue, such as, for example,
normal breast tissue, and its prognostic ability was identified
from microarray analysis of unfractionated, and thus heterogenous,
breast tumor samples normalized against a reference set of tumor
samples (van't Veer et al., 2002, Nature 415:530; van de Vijver et
al., 2002, N. Eng. J. Med. 347:1999) or to a target intensity (Wang
et al., 2005, Lancet 365:671). Thus unfractioned tumor samples,
including but not limited to a solid tissue biopsy, fine needle
aspiration, or pleural effusion can be analysed for generating a
cancer gene profile in a tumor sample and comparing the profile to
a cancer stem cell gene signature. More selective samples that are
isolated from a heterogenous patient sample such as, for example,
by isolating tumorigenic cancer cells or by laser capture
microdissections can also be used. Alternatively the sample can
permit the collection of cancer cells as well as normal cells for
analysis so that the gene expression patterns for each sample can
be determined and compared to a cancer stem cell signature.
[0233] In addition to the solid tumor stem cell gene signatures,
one or more individual genes that comprise the signatures are
significantly predictive of metastasis and death in the 295
patients from the Netherlands Cancer Institute suggesting that one
or more of these genes can be used in place of an entire solid
tumor stem cell gene signature as described above. In the case of
the alpha-catenin gene signature it was discovered that the
following genes GALC, CTSL2, FOXQ1, MYEOV, RB1, and SLC7A5 were
significantly predictive of metastases and death. Expression of low
to undetectable levels of GALC compared to a reference set of
expression across all tumor samples (described in van't Veer et
al., 2002, Nature 415:530 and van de Vijver et al., 2002, N. Eng.
J. Med. 347:1999) was significantly predictive of metastasis with a
univariate hazard ratio of 0.632 per 0.1 correlation
(P=8.1.times.10.sup.-3) and significantly predictive of death with
a univariate hazard ratio of 0.583 per 0.1 correlation
(P=5.4.times.10.sup.-3). Expression of elevated levels of CTSL2
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.52 per 0.1
correlation (P=1.7.times.10.sup.-6) and significantly predictive of
death with a univariate hazard ratio of 1.86 per 0.1 correlation
(P=4.0.times.10.sup.-11). Expression of elevated levels of FOXQ1
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.44 per 0.1
correlation (P=1.7.times.10.sup.-3) and significantly predictive of
death with a univariate hazard ratio of 1.73 per 0.1 correlation
(P=1.6.times.10.sup.-5). Expression of elevated levels of MYEOV
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.76 per 0.1
correlation (P=2.2.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 2.09 per 0.1 correlation
(P=5.9.times.10.sup.-3). Expression of elevated levels of RB1
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 0.72 per 0.1
correlation (P=1.6.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 0.664 per 0.1 correlation
(P=6.8.times.10.sup.-3). Expression of elevated levels of SCL7A5
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 3 per 0.1 correlation
(P=2.6.times.10.sup.-4) and significantly predictive of death with
a univariate hazard ratio of 3.52 per 0.1 correlation
(P=1.1.times.10.sup.-4).
[0234] In addition, several of the genes comprising the E-cadherin
gene expression signature were predictive alone including some with
low to undetectable expression: IL8 and KRT6B and some with
elevated expression: RNASEL and C17orf27. Expression of low to
undectable levels of IL8 compared to the reference set was
significantly predictive of metastasis with a univariate hazard
ratio of 1.17 per 0.1 correlation (P=5.2.times.10.sup.-2) and
significantly predictive of death with a univariate hazard ratio of
1.3 per 0.1 correlation (P=3.0.times.10.sup.-3). Expression of low
to undetectable levels of KRT6B compared to the reference set was
significantly predictive of metastasis univariate hazard ratio of
1.35 per 0.1 correlation (P=3.9.times.10.sup.-2) and significant
predictive of death with aunivariate hazard ratio of 1.54 per 0.1
correlation (P=4.7.times.10.sup.-3). Expression of elevated levels
of RNASEL compared to the reference set was significantly
predictive of metastasis with a univariate hazard ratio of 0.655
per 0.1 correlation (P=3.7.times.10.sup.-2) and significantly
predictive of death with a univariate hazard ratio of 0.498 per 0.1
correlation (P=1.4.times.10.sup.-3). Elevated expression levels of
C17orf27 compared to the reference set was significantly predictive
of metastasis with a univariate hazard ratio of 2.35 per 0.1
correlation (P=1.5.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 3.19 per 0.1 correlation
(P=3.1.times.10.sup.-3).
IV. Detection of Solid Tumor Stem Cell Cancer Markers
[0235] In some embodiments, the present invention provides methods
for detection of expression of stem cell cancer markers (e.g.,
breast cancer stem cell cancer markers). In some embodiments,
expression is measured directly (e.g., at the RNA or protein
level). In some embodiments, expression is detected in tissue
samples (e.g., biopsy tissue). In other embodiments, expression is
detected in bodily fluids (e.g., including but not limited to,
plasma, serum, whole blood, mucus, and urine). The present
invention further provides panels and kits for the detection of
markers. In some embodiments, the presence of a stem cell cancer
marker is used to provide a prognosis to a subject. The information
provided is also used to direct the course of treatment. For
example, if a subject is found to have a marker indicative of a
solid tumor stem cell (see, e.g. Tables 4-9), additional therapies
(e.g., hormonal or radiation therapies) can be started at an
earlier point when they are more likely to be effective (e.g.,
before metastasis). In addition, if a subject is found to have a
tumor that is not responsive to hormonal therapy, the expense and
inconvenience of such therapies can be avoided.
[0236] The present invention is not limited to the markers
described above. Any suitable marker that correlates with cancer or
the progression of cancer can be utilized. Additional markers are
also contemplated to be within the scope of the present invention.
Any suitable method can be utilized to identify and characterize
cancer markers suitable for use in the methods of the present
invention, including but not limited to, those described in
illustrative Example 4 below. For example, in some embodiments,
markers identified as being up or down-regulated in solid tumor
stem cells using the gene expression microarray methods of the
present invention are further characterized using tissue
microarray, immunohistochemistry, Northern blot analysis, siRNA or
antisense RNA inhibition, mutation analysis, investigation of
expression with clinical outcome, as well as other methods
disclosed herein.
[0237] In some embodiments, the present invention provides a panel
for the analysis of a plurality of markers. The panel allows for
the simultaneous analysis of multiple markers correlating with
carcinogenesis and/or metastasis. Depending on the subject, panels
can be analyzed alone or in combination in order to provide the
best possible diagnosis and prognosis. Markers for inclusion on a
panel are selected by screening for their predictive value using
any suitable method, including but not limited to, those described
in the illustrative examples below.
[0238] 1. Detection of RNA
[0239] In some some embodiments, detection of solid tumor stem cell
cancer markers (e.g., including but not limited to, those disclosed
in Tables 4-9) are detected by measuring the expression of
corresponding mRNA in a tissue sample (e.g., breast cancer tissue).
mRNA expression can be measured by any suitable method, including
but not limited to, those disclosed below.
[0240] In some embodiments, RNA is detection by Northern blot
analysis. Northern blot analysis involves the separation of RNA and
hybridization of a complementary labeled probe.
[0241] In still further embodiments, RNA (or corresponding cDNA) is
detected by hybridization to an oligonucleotide probe). A variety
of hybridization assays using a variety of technologies for
hybridization and detection are available. For example, in some
embodiments, TaqMan assay (PE Biosystems, Foster City, Calif.; See
e.g., U.S. Pat. Nos. 5,962,233 and 5,538,848, each of which is
herein incorporated by reference) is utilized. The assay is
performed during a PCR reaction. The TaqMan assay exploits the
5'-3' exonuclease activity of the AMPLITAQ GOLD DNA polymerase. A
probe consisting of an oligonucleotide with a5'-reporter dye (e.g.,
a fluorescent dye) and a3'-quencher dye is included in the PCR
reaction. During PCR, if the probe is bound to its target, the
5'-3' nucleolytic activity of the AMPLITAQ GOLD polymerase cleaves
the probe between the reporter and the quencher dye. The separation
of the reporter dye from the quencher dye results in an increase of
fluorescence. The signal accumulates with each cycle of PCR and can
be monitored with a fluorimeter.
[0242] In yet other embodiments, reverse-transcriptase PCR (RT-PCR)
is used to detect the expression of RNA. In RT-PCR, RNA is
enzymatically converted to complementary DNA or "cDNA" using a
reverse transcriptase enzyme. The cDNA is then used as a template
for a PCR reaction. PCR products can be detected by any suitable
method, including but not limited to, gel electrophoresis and
staining with a DNA specific stain or hybridization to a labeled
probe. In some embodiments, the quantitative reverse transcriptase
PCR with standardized mixtures of competitive templates method
described in U.S. Pat. Nos. 5,639,606, 5,643,765, and 5,876,978
(each of which is herein incorporated by reference) is
utilized.
[0243] 2. Detection of Protein
[0244] In other embodiments, gene expression of stem cell cancer
markers is detected by measuring the expression of the
corresponding protein or polypeptide. Protein expression can be
detected by any suitable method. In some embodiments, proteins are
detected by immunohistochemistry. In other embodiments, proteins
are detected by their binding to an antibody raised against the
protein. The generation of antibodies is described below.
[0245] Antibody binding is detected by techniques known in the art
(e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay),
"sandwich" immunoassays, immunoradiometric assays, gel diffusion
precipitation reactions, immunodiffusion assays, in situ
immunoassays (e.g., using colloidal gold, enzyme or radioisotope
labels, for example), Western blots, precipitation reactions,
agglutination assays (e.g., gel agglutination assays,
hemagglutination assays, etc.), complement fixation assays,
immunofluorescence assays, protein A assays, and
immunoelectrophoresis assays, etc.
[0246] In some embodiments, antibody binding is detected by
detecting a label on the primary antibody. In another embodiment,
the primary antibody is detected by detecting binding of a
secondary antibody or reagent to the primary antibody. In a further
embodiment, the secondary antibody is labeled. Many methods are
known in the art for detecting binding in an immunoassay and are
within the scope of the present invention.
[0247] In some embodiments, an automated detection assay is
utilized. Methods for the automation of immunoassays include those
described in U.S. Pat. Nos. 5,885,530, 4,981,785, 6,159,750, and
5,358,691, each of which is herein incorporated by reference. In
some embodiments, the analysis and presentation of results is also
automated. For example, in some embodiments, software that
generates a prognosis based on the presence or absence of a series
of proteins corresponding to cancer markers is utilized.
[0248] In other embodiments, the immunoassay described in U.S. Pat.
Nos. 5,599,677 and 5,672,480; each of which is herein incorporated
by reference.
[0249] 3. cDNA Microarray Technology
[0250] cDNA microarrays consist of multiple (usually thousands) of
different cDNAs spotted (usually using a robotic spotting device)
onto known locations on a solid support, such as a glass microscope
slide. The cDNAs are typically obtained by PCR amplification of
plasmid library inserts using primers complementary to the vector
backbone portion of the plasmid or to the gene itself for genes
where sequence is known. PCR products suitable for production of
microarrays are typically from 0.5 and 2.5 kB in length. Full
length cDNAs, expressed sequence tags (ESTs), or randomly chosen
cDNAs from any library of interest can be chosen. ESTs are
partially sequenced cDNAs as described, for example, in Hillier, et
al., 1996, 6:807-828. Although some ESTs correspond to known genes,
frequently very little or no information regarding any particular
EST is available except for a small amount of 3' and/or 5' sequence
and, possibly, the tissue of origin of the mRNA from which the EST
was derived. As will be appreciated by one of ordinary skill in the
art, in general the cDNAs contain sufficient sequence information
to uniquely identify a gene within the human genome. Furthermore,
in general the cDNAs are of sufficient length to hybridize,
selectively, specifically or uniquely, to cDNA obtained from mRNA
derived from a single gene under the hybridization conditions of
the experiment.
[0251] In a typical microarray experiment, a microarray is
hybridized with differentially labeled RNA, DNA, or cDNA
populations derived from two different samples. Most commonly RNA
(either total RNA or poly A+RNA) is isolated from cells or tissues
of interest and is reverse transcribed to yield cDNA. Labeling is
usually performed during reverse transcription by incorporating a
labeled nucleotide in the reaction mixture. Although various labels
can be used, most commonly the nucleotide is conjugated with the
fluorescent dyes Cy3 or Cy5. For example, Cy5-dUTP and Cy3-dUTP can
be used. cDNA derived from one sample (representing, for example, a
particular cell type, tissue type or growth condition) is labeled
with one fluorophore while cDNA derived from a second sample
(representing, for example, a different cell type, tissue type, or
growth condition) is labeled with the second fluorophore. Similar
amounts of labeled material from the two samples are cohybridized
to the microarray. In the case of a microarray experiment in which
the samples are labeled with Cy5 (which fluoresces red) and Cy3
(which fluoresces green), the primary data (obtained by scanning
the microarray using a detector capable of quantitatively detecting
fluorescence intensity) are ratios of fluorescence intensity
(red/green, R/G). These ratios represent the relative
concentrations of cDNA molecules that hybridized to the cDNAs
represented on the microarray and thus reflect the relative
expression levels of the mRNA corresponding to each cDNA/gene
represented on the microarray.
[0252] Each microarray experiment can provide tens of thousands of
data points, each representing the relative expression of a
particular gene in the two samples. Appropriate organization and
analysis of the data is of key importance, and various computer
programs that incorporate standard statistical tools have been
developed to facilitate data analysis. One basis for organizing
gene expression data is to group genes with similar expression
patterns together into clusters. A method for performing
hierarchical cluster analysis and display of data derived from
microarray experiments is described in Eisen et al., 1998, PNAS
95:14863-14868. As described therein, clustering can be combined
with a graphical representation of the primary data in which each
data point is represented with a color that quantitatively and
qualitatively represents that data point. By converting the data
from a large table of numbers into a visual format, this process
facilitates an intuitive analysis of the data. Additional
information and details regarding the mathematical tools and/or the
clustering approach itself can be found, for example, in Sokal
& Sneath, Principles of numerical taxonomy, xvi, 359, W. H.
Freeman, San Francisco, 1963; Hartigan, Clustering algorithms,
xiii, 351, Wiley, New York, 1975; Paull et al., 1989, J. Natl.
Cancer Inst. 81:1088-92; Weinstein et al. 1992, Science 258:447-51;
van Osdol et al., 1994, J. Natl. Cancer Inst. 86:1853-9; and
Weinstein et al., 1997, Science, 275:343-9.
[0253] Further details of the experimental methods used in the
present invention are found in the Examples. Additional information
describing methods for fabricating and using microarrays is found
in U.S. Pat. No. 5,807,522, which is herein incorporated by
reference. Instructions for constructing microarray hardware (e.g.,
arrayers and scanners) using commercially available parts can be
found at "http://" followed by "cmgm.stanford.edu/pbr-own/" and in
Cheung et al., 1999, Nat. Genet. Supplement 21:15-19, which are
herein incorporated by reference. Additional discussions of
microarray technology and protocols for preparing samples and
performing microrarray experiments are found in, for example, DNA
arrays for analysis of gene expression, Methods Enzymol,
303:179-205, 1999; Fluorescence-based expression monitoring using
microarrays, Methods Enzymol, 306: 3-18, 1999; and M. Schena (ed.),
DNA Microarrays: A Practical Approach, Oxford University Press,
Oxford, UK, 1999. Descriptions of how to use an arrayer and the
associated software are found at "http://" followed by
"cmgm.stanford.edu/pbrown/mguide/a-rrayerHTML/ArrayerDocs.html",
which is herein incorporated by reference.
[0254] 4. Data Analysis
[0255] In some embodiments, a computer-based analysis program is
used to translate the raw data generated by the detection assay
(e.g., the presence, absence, or amount of a given marker or
markers) into data of predictive value for a clinician. The
clinician can access the predictive data using any suitable means.
Thus, in some some embodiments, the present invention provides the
further benefit that the clinician, who is not likely to be trained
in genetics or molecular biology, need not understand the raw data.
The data is presented directly to the clinician in its most useful
form. The clinician is then able to immediately utilize the
information in order to optimize the care of the subject.
[0256] The present invention contemplates any method capable of
receiving, processing, and transmitting the information to and from
laboratories conducting the assays, information provides, medical
personal, and subjects. For example, in some embodiments of the
present invention, a sample (e.g., a biopsy or a serum or urine
sample) is obtained from a subject and submitted to a profiling
service (e.g., clinical lab at a medical facility, genomic
profiling business, etc.), located in any part of the world (e.g.,
in a country different than the country where the subject resides
or where the information is ultimately used) to generate raw data.
Where the sample comprises a tissue or other biological sample, the
subject can visit a medical center to have the sample obtained and
sent to the profiling center, or subjects can collect the sample
themselves and directly send it to a profiling center. Where the
sample comprises previously determined biological information, the
information can be directly sent to the profiling service by the
subject (e.g., an information card containing the information can
be scanned by a computer and the data transmitted to a computer of
the profiling center using an electronic communication system).
Once received by the profiling service, the sample is processed and
a profile is produced (e.g., expression data), specific for the
diagnostic or prognostic information desired for the subject.
[0257] The profile data is then prepared in a format suitable for
interpretation by a treating clinician. For example, rather than
providing raw expression data (e.g. examining a number of the
markers described in Tables 4-9), the prepared format can represent
a diagnosis or risk assessment for the subject, along with
recommendations for particular treatment options. The data can be
displayed to the clinician by any suitable method. For example, in
some embodiments, the profiling service generates a report that can
be printed for the clinician (e.g., at the point of care) or
displayed to the clinician on a computer monitor.
[0258] In some embodiments, the information is first analyzed at
the point of care or at a regional facility. The raw data is then
sent to a central processing facility for further analysis and/or
to convert the raw data to information useful for a clinician or
patient. The central processing facility provides the advantage of
privacy (all data is stored in a central facility with uniform
security protocols), speed, and uniformity of data analysis. The
central processing facility can then control the fate of the data
following treatment of the subject. For example, using an
electronic communication system, the central facility can provide
data to the clinician, the subject, or researchers.
[0259] In some embodiments, the subject is able to directly access
the data using the electronic communication system. The subject can
chose further intervention or counseling based on the results. In
some embodiments, the data is used for research use. For example,
the data can be used to further optimize the inclusion or
elimination of markers as useful indicators of a particular
condition or stage of disease.
[0260] 5. Kits
[0261] In yet other embodiments, the present invention provides
kits for the detection and characterization of cancer (e.g. for
detecting one or more of the markers shown in Tables 4-9, or for
modulating the activity of a peptide expressed by one or more of
markers shown in Tables 4-9). In some embodiments, the kits contain
antibodies specific for a cancer marker, in addition to detection
reagents and buffers. In other embodiments, the kits contain
reagents specific for the detection of mRNA or cDNA (e.g.,
oligonucleotide probes or primers). In some embodiments, the kits
contain all of the components necessary and/or sufficient to
perform a detection assay, including all controls, directions for
performing assays, and any necessary software for analysis and
presentation of results.
[0262] Another embodiment of the present invention comprises a kit
to test for the presence of the polynucleotides or proteins, e.g.
in a tissue sample or in a body fluid, of a solid tumor stem cell
gene signature, such as the alpha-catenin signature. The kit can
comprise, for example, an antibody for detection of a polypeptide
or a probe for detection of a polynucleotide. In addition, the kit
can comprise a reference or control sample; instructions for
processing samples, performing the test and interpreting the
results; and buffers and other reagents necessary for performing
the test. In certain embodiments the kit comprises a panel of
antibodies for detecting expression of one or more of the proteins
encoded by the genes of the alpha-catenin signature. In other
embodiments the kit comprises pairs of primers for detecting
expression of one or more of the genes of the solid tumor stem cell
gene signature signature. In other embodiments the kit comprises a
cDNA or oligonucleotide array for detecting expression of one or
more of the genes of the solid tumor stem cell gene signature.
[0263] 6. In Vivo Imaging
[0264] In some embodiments, in vivo imaging techniques are used to
visualize the expression of cancer markers in an animal (e.g., a
human or non-human mammal). For example, in some embodiments,
cancer marker mRNA or protein is labeled using a labeled antibody
specific for the cancer marker. A specifically bound and labeled
antibody can be detected in an individual using an in vivo imaging
method, including, but not limited to, radionuclide imaging,
positron emission tomography, computerized axial tomography, X-ray
or magnetic resonance imaging method, fluorescence detection, and
chemiluminescent detection. Methods for generating antibodies to
the cancer markers of the present invention are described
below.
[0265] The in vivo imaging methods of the present invention are
useful in the diagnosis of cancers that express the solid tumor
stem cell cancer markers of the present invention (e.g., in breast
cancer). In vivo imaging is used to visualize the presence of a
marker indicative of the cancer. Such techniques allow for
diagnosis without the use of an unpleasant biopsy. The in vivo
imaging methods of the present invention are also useful for
providing prognoses to cancer patients. For example, the presence
of a marker indicative of cancer stem cells can be detected. The in
vivo imaging methods of the present invention can further be used
to detect metastatic cancers in other parts of the body.
[0266] In some embodiments, reagents (e.g., antibodies) specific
for the cancer markers of the present invention are fluorescently
labeled. The labeled antibodies are introduced into a subject
(e.g., orally or parenterally). Fluorescently labeled antibodies
are detected using any suitable method (e.g., using the apparatus
described in U.S. Pat. No. 6,198,107, herein incorporated by
reference).
[0267] In other embodiments, antibodies are radioactively labeled.
The use of antibodies for in vivo diagnosis is well known in the
art. Sumerdon et al., (Nucl. Med. Biol 17:247-254 [1990] have
described an optimized antibody-chelator for the
radioimmunoscintographic imaging of tumors using Indium-111 as the
label. Griffin et al., (J Clin Onc 9:631-640 [1991]) have described
the use of this agent in detecting tumors in patients suspected of
having recurrent colorectal cancer. The use of similar agents with
paramagnetic ions as labels for magnetic resonance imaging is known
in the art (Lauffer, Magnetic Resonance in Medicine 22:339-342
[1991]). The label used will depend on the imaging modality chosen.
Radioactive labels such as Indium-111, Technetium-99m, or
Iodine-131 can be used for planar scans or single photon emission
computed tomography (SPECT). Positron emitting labels such as
Fluorine-19 can also be used for positron emission tomography
(PET). For MRI, paramagnetic ions such as Gadolinium (III) or
Manganese (II) can be used.
[0268] Radioactive metals with half-lives ranging from 1 hour to
3.5 days are available for conjugation to antibodies, such as
scandium-47 (3.5 days) gallium-67 (2.8 days), gallium-68 (68
minutes), technetiium-99m (6 hours), and indium-111 (3.2 days), of
which gallium-67, technetium-99m, and indium-111 are preferable for
gamma camera imaging, and gallium-68 is preferable for positron
emission tomography.
[0269] A useful method of labeling antibodies with such radiometals
is by means of a bifunctional chelating agent, such as
diethylenetriaminepentaacetic acid (DTPA), as described, for
example, by Khaw et al. (Science 209:295 [1980]) for In-111 and
Tc-99m, and by Scheinberg et al. (Science 215:1511 [1982]). Other
chelating agents can also be used, but the
1-(p-carboxymethoxybenzyl)EDTA and the carboxycarbonic anhydride of
DTPA are advantageous because their use permits conjugation without
affecting the antibody's immunoreactivity substantially.
[0270] Another method for coupling DPTA to proteins is by use of
the cyclic anhydride of DTPA, as described by Hnatowich et al.
(Int. J. Appl. Radiat. Isot. 33:327 [1982]) for labeling of albumin
with In-111, but which can be adapted for labeling of antibodies. A
suitable method of labeling antibodies with Tc-99m which does not
use chelation with DPTA is the pretinning method of Crockford et
al., (U.S. Pat. No. 4,323,546, herein incorporated by
reference).
[0271] A some method of labeling immunoglobulins with Tc-99m is
that described by Wong et al. (Int. J. Appl. Radiat. Isot., 29:251
[1978]) for plasma protein, and recently applied successfully by
Wong et al. (J. Nucl. Med., 23:229 [1981]) for labeling
antibodies.
[0272] In the case of the radiometals conjugated to the specific
antibody, it is likewise desirable to introduce as high a
proportion of the radiolabel as possible into the antibody molecule
without destroying its immunospecificity. A further improvement can
be achieved by effecting radiolabeling in the presence of the
specific stem cell cancer marker of the present invention, to
insure that the antigen binding site on the antibody will be
protected.
[0273] In still further embodiments, in vivo biophotonic imaging
(Xenogen, Almeda, Calif.) is utilized for in vivo imaging. This
real-time in vivo imaging utilizes luciferase. The luciferase gene
is incorporated into cells, microorganisms, and animals (e.g., as a
fusion protein with a cancer marker of the present invention). When
active, it leads to a reaction that emits light. A CCD camera and
software is used to capture the image and analyze it.
V. Antibodies and Antibody Fragments
[0274] The present invention provides isolated antibodies and
antibody fragments (e.g, Fabs). In some embodiments, the present
invention provides monoclonal antibodies or antibody fragments that
specifically bind to an isolated polypeptide comprised of at least
five, or at least 15 amino acid residues of the stem cell cancer
markers described herein (e.g., as shown in Tables 4-9). These
antibodies or antibody fragments find use in the diagnostic, drug
screening, and therapeutic methods described herein (e.g. to detect
or modulate the activity of a stem cell cancer marker peptide).
[0275] An antibody, or antibody fragment, against a protein of the
present invention can be any monoclonal or polyclonal antibody, as
long as it can recognize the protein. Antibodies can be produced by
using a protein of the present invention as the antigen according
to a conventional antibody or antiserum preparation process.
[0276] The present invention contemplates the use of both
monoclonal and polyclonal antibodies. Any suitable method can be
used to generate the antibodies used in the methods and
compositions of the present invention, including but not limited
to, those disclosed herein. For example, for preparation of a
monoclonal antibody, protein, as such, or together with a suitable
carrier or diluent is administered to an animal (e.g., a mammal)
under conditions that permit the production of antibodies. For
enhancing the antibody production capability, complete or
incomplete Freund's adjuvant can be administered. Normally, the
protein is administered once every 2 weeks to 6 weeks, in total,
about 2 times to about 10 times. Animals suitable for use in such
methods include, but are not limited to, primates, rabbits, dogs,
guinea pigs, mice, rats, sheep, goats, etc.
[0277] For preparing monoclonal antibody-producing cells, an
individual animal whose antibody titer has been confirmed (e.g., a
mouse) is selected, and 2 days to 5 days after the final
immunization, its spleen or lymph node is harvested and
antibody-producing cells contained therein are fused with myeloma
cells to prepare the desired monoclonal antibody producer
hybridoma. Measurement of the antibody titer in antiserum can be
carried out, for example, by reacting the labeled protein, as
described hereinafter and antiserum and then measuring the activity
of the labeling agent bound to the antibody. The cell fusion can be
carried out according to known methods, for example, the method
described by Koehler and Milstein (Nature 256:495 [1975]). As a
fusion promoter, for example, polyethylene glycol (PEG) or Sendai
virus (HVJ), can be used.
[0278] Examples of myeloma cells include NS-1, P3U1, SP2/0, AP-1
and the like. The proportion of the number of antibody producer
cells (spleen cells) and the number of myeloma cells to be used can
be about 1:1 to about 20:1. PEG (e.g., PEG 1000-PEG 6000) can be
added in concentration of about 10% to about 80%. Cell fusion can
be carried out efficiently by incubating a mixture of both cells at
about 20.degree. C. to about 40.degree. C., or about 30.degree. C.
to about 37.degree. C. for about 1 minute to 10 minutes.
[0279] Various methods can be used for screening for a hybridoma
producing the antibody (e.g., against a tumor antigen or
autoantibody of the present invention). For example, where a
supernatant of the hybridoma is added to a solid phase (e.g.,
microplate) to which antibody is adsorbed directly or together with
a carrier and then an anti-immunoglobulin antibody (if mouse cells
are used in cell fusion, anti-mouse immunoglobulin antibody is
used) or Protein A labeled with a radioactive substance or an
enzyme is added to detect the monoclonal antibody against the
protein bound to the solid phase. Alternately, a supernatant of the
hybridoma is added to a solid phase to which an anti-immunoglobulin
antibody or Protein A is adsorbed and then the protein labeled with
a radioactive substance or an enzyme is added to detect the
monoclonal antibody against the protein bound to the solid
phase.
[0280] Selection of the monoclonal antibody can be carried out
according to any known method or its modification. Normally, a
medium for animal cells to which HAT (hypoxanthine, aminopterin,
thymidine) are added is employed. Any selection and growth medium
can be employed as long as the hybridoma can grow. For example,
RPMI 1640 medium containing 1% to 20% or 10% to 20% fetal bovine
serum, GIT medium containing 1% to 10% fetal bovine serum, a serum
free medium for cultivation of a hybridoma (SFM-101, Nissui
Seiyaku) and the like can be used. Normally, the cultivation is
carried out at 20.degree. C. to 40.degree. C., e.g., 37.degree. C.,
for about 5 days to 3 weeks, e.g., 1 week to 2 weeks under about 5%
CO.sub.2 gas. The antibody titer of the supernatant of a hybridoma
culture can be measured according to the same manner as described
above with respect to the antibody titer of the anti-protein in the
antiserum.
[0281] Separation and purification of a monoclonal antibody (e.g.,
against a cancer marker of the present invention) can be carried
out according to the same manner as those of conventional
polyclonal antibodies such as separation and purification of
immunoglobulins, for example, salting-out, alcoholic precipitation,
isoelectric point precipitation, electrophoresis, adsorption and
desorption with ion exchangers (e.g., DEAE), ultracentrifugation,
gel filtration, or a specific purification method wherein only an
antibody is collected with an active adsorbent such as an
antigen-binding solid phase, Protein A or Protein G and
dissociating the binding to obtain the antibody.
[0282] Polyclonal antibodies can be prepared by any known method or
modifications of these methods including obtaining antibodies from
patients. For example, a complex of an immunogen (an antigen
against the protein) and a carrier protein is prepared and an
animal is immunized by the complex according to the same manner as
that described with respect to the above monoclonal antibody
preparation. A material containing the antibody against is
recovered from the immunized animal and the antibody is separated
and purified.
[0283] As to the complex of the immunogen and the carrier protein
to be used for immunization of an animal, any carrier protein and
any mixing proportion of the carrier and a hapten can be employed
as long as an antibody against the hapten, which is crosslinked on
the carrier and used for immunization, is produced efficiently. For
example, bovine serum albumin, bovine cycloglobulin, keyhole limpet
hemocyanin, etc. can be coupled to a hapten in a weight ratio of
about 0.1 parts to about 20 parts, about 1 part to about 5 parts
per 1 part of the hapten.
[0284] In addition, various condensing agents can be used for
coupling of a hapten and a carrier. For example, glutaraldehyde,
carbodiimide, maleimide activated ester, activated ester reagents
containing thiol group or dithiopyridyl group, and the like find
use with the present invention. The condensation product as such or
together with a suitable carrier or diluent is administered to a
site of an animal that permits the antibody production. For
enhancing the antibody production capability, complete or
incomplete Freund's adjuvant can be administered. Normally, the
protein is administered once every 2 weeks to 6 weeks, in total,
about 3 times to about 10 times.
[0285] The polyclonal antibody is recovered from blood, ascites and
the like, of an animal immunized by the above method. The antibody
titer in the antiserum can be measured according to the same manner
as that described above with respect to the supernatant of the
hybridoma culture. Separation and purification of the antibody can
be carried out according to the same separation and purification
method of immunoglobulin as that described with respect to the
above monoclonal antibody.
[0286] The protein used herein as the immunogen is not limited to
any particular type of immunogen. For example, a stem cell cancer
marker of the present invention (further including a gene having a
nucleotide sequence partly altered) can be used as the immunogen.
Further, fragments of the protein can be used. Fragments can be
obtained by any methods including, but not limited to expressing a
fragment of the gene, enzymatic processing of the protein, chemical
synthesis, and the like. The antibodies and antibody fragments can
also be conjugated to therapeutic (e.g. cancer cell killing
compounds). In this regard, the antibody directed toward one of the
stem cell cancer markers is used to specifically deliver a
therapeutic agent to a solid tumor cancer cell (e.g. to inhibit the
proliferation of such sell or kill such a cell).
VI. Drug Screening
[0287] In some embodiments, the present invention provides drug
screening assays (e.g., to screen for anticancer drugs). The
screening methods of the present invention utilize stem cell cancer
markers identified using the methods of the present invention
(e.g., including but not limited to, the stem cell cancer markers
shown in Tables 4-9). For example, in some embodiments, the present
invention provides methods of screening for compound that alter
(e.g., increase or decrease) the expression of stem cell cancer
marker genes. In some embodiments, candidate compounds are
antisense agents or siRNA agents (e.g., oligonucleotides) directed
against cancer markers. In other embodiments, candidate compounds
are antibodies that specifically bind to a stem cell cancer marker
of the present invention. In certain embodiments, libraries of
compounds of small molecules are screened using the methods
described herein.
[0288] In one screening method, candidate compounds are evaluated
for their ability to alter stem cell cancer marker expression by
contacting a compound with a cell expressing a stem cell cancer
marker and then assaying for the effect of the candidate compounds
on expression. In some embodiments, the effect of candidate
compounds on expression of a cancer marker gene is assayed by
detecting the level of cancer marker mRNA expressed by the cell.
mRNA expression can be detected by any suitable method. In other
embodiments, the effect of candidate compounds on expression of
cancer marker genes is assayed by measuring the level of
polypeptide encoded by the cancer markers. The level of polypeptide
expressed can be measured using any suitable method, including but
not limited to, those disclosed herein. In some embodiments, other
changes in cell biology (e.g., apoptosis) are detected.
[0289] Specifically, the present invention provides screening
methods for identifying modulators, i.e., candidate or test
compounds or agents (e.g., proteins, peptides, peptidomimetics,
peptoids, small molecules or other drugs) which bind to, or alter
the signaling or function associated with the cancer markers of the
present invention, have an inhibitory (or stimulatory) effect on,
for example, stem cell cancer marker expression or cancer markers
activity, or have a stimulatory or inhibitory effect on, for
example, the expression or activity of a cancer marker substrate.
Compounds thus identified can be used to modulate the activity of
target gene products (e.g., stem cell cancer marker genes) either
directly or indirectly in a therapeutic protocol, to elaborate the
biological function of the target gene product, or to identify
compounds that disrupt normal target gene interactions. Compounds
which inhibit the activity or expression of cancer markers are
useful in the treatment of proliferative disorders, e.g., cancer,
particularly metastatic cancer or eliminating or controlling tumor
stem cells to prevent or reduce the risk of cancer.
[0290] The invention provides assays for screening candidate or
test compounds that are substrates of a cancer markers protein or
polypeptide or a biologically active portion thereof. In another
embodiment, the invention provides assays for screening candidate
or test compounds that bind to or modulate the activity of a cancer
marker protein or polypeptide or a biologically active portion
thereof.
[0291] The test compounds of the present invention can be obtained
using any of the numerous approaches in combinatorial library
methods known in the art, including biological libraries; peptoid
libraries (libraries of molecules having the functionalities of
peptides, but with a novel, non-peptide backbone, which are
resistant to enzymatic degradation but which nevertheless remain
bioactive; see, e.g., Zuckennann et al., J. Med. Chem. 37: 2678-85
[1994]); spatially addressable parallel solid phase or solution
phase libraries; synthetic library methods requiring deconvolution;
the `one-bead one-compound` library method; and synthetic library
methods using affinity chromatography selection. The biological
library and peptoid library approaches are some for use with
peptide libraries, while the other four approaches are applicable
to peptide, non-peptide oligomer or small molecule libraries of
compounds (Lam (1997) Anticancer Drug Des. 12:145).
[0292] Examples of methods for the synthesis of molecular libraries
can be found in the art, for example in: DeWitt et al., Proc. Natl.
Acad. Sci. U.S.A. 90:6909 [1993]; Erb et al., Proc. Nad. Acad. Sci.
USA 91:11422 [1994]; Zuckermann et al., J. Med. Chem. 37:2678
[1994]; Cho et al., Science 261:1303 [1993]; Carrell et al., Angew.
Chem. Int. Ed. Engl. 33.2059 [1994]; Carell et al., Angew. Chem.
Int. Ed. Engl. 33:2061 [1994]; and Gallop et al., J. Med. Chem.
37:1233 [1994].
[0293] Libraries of compounds can be presented in solution (e.g.,
Houghten, Biotechniques 13:412-421 [1992]), or on beads (Lam,
Nature 354:82-84 [1991]), chips (Fodor, Nature 364:555-556 [1993]),
bacteria or spores (U.S. Pat. No. 5,223,409; herein incorporated by
reference), plasmids (Cull et al., Proc. Nad. Acad. Sci. USA
89:18651869 [1992]) or on phage (Scott and Smith, Science
249:386-390 [1990]; Devlin Science 249:404-406 [1990]; Cwirla et
al., Proc. Natl. Acad. Sci. 87:6378-6382 [1990]; Felici, J. Mol.
Biol. 222:301 [1991]).
[0294] In some embodiments, an assay is a cell-based assay in which
a cell that expresses a stem cell cancer marker protein or
biologically active portion thereof is contacted with a test
compound, and the ability of the test compound to the modulate
cancer marker's activity is determined. Determining the ability of
the test compound to modulate stem cell cancer marker activity can
be accomplished by monitoring, for example, changes in enzymatic
activity. The cell, for example, can be of mammalian origin.
[0295] The ability of the test compound to modulate cancer marker
binding to a compound, e.g., a stem cell cancer marker substrate,
can also be evaluated. This can be accomplished, for example, by
coupling the compound, e.g., the substrate, with a radioisotope or
enzymatic label such that binding of the compound, e.g., the
substrate, to a cancer marker can be determined by detecting the
labeled compound, e.g., substrate, in a complex.
[0296] Alternatively, the stem cell cancer marker is coupled with a
radioisotope or enzymatic label to monitor the ability of a test
compound to modulate cancer marker binding to a cancer markers
substrate in a complex. For example, compounds (e.g., substrates)
can be labeled with .sup.125I, .sup.35S .sup.14C or .sup.3H, either
directly or indirectly, and the radioisotope detected by direct
counting of radioemmission or by scintillation counting.
Alternatively, compounds can be enzymatically labeled with, for
example, horseradish peroxidase, alkaline phosphatase, or
luciferase, and the enzymatic label detected by determination of
conversion of an appropriate substrate to product.
[0297] The ability of a compound (e.g., a stem cell cancer marker
substrate) to interact with a stem cell cancer marker with or
without the labeling of any of the interactants can be evaluated.
For example, a microphysiorneter can be used to detect the
interaction of a compound with a cancer marker without the labeling
of either the compound or the cancer marker (McConnell et al.
Science 257:1906-1912 [1992]). As used herein, a "microphysiometer"
(e.g., Cytosensor) is an analytical instrument that measures the
rate at which a cell acidifies its environment using a
light-addressable potentiometric sensor (LAPS). Changes in this
acidification rate can be used as an indicator of the interaction
between a compound and cancer markers.
[0298] In yet another embodiment, a cell-free assay is provided in
which a cancer marker protein or biologically active portion
thereof is contacted with a test compound and the ability of the
test compound to bind to the stem cell cancer marker protein or
biologically active portion thereof is evaluated. Some biologically
active portions of the cancer markers proteins to be used in assays
of the present invention include fragments that participate in
interactions with substrates or other proteins, e.g., fragments
with high surface probability scores.
[0299] Cell-free assays involve preparing a reaction mixture of the
target gene protein and the test compound under conditions and for
a time sufficient to allow the two components to interact and bind,
thus forming a complex that can be removed and/or detected.
[0300] The interaction between two molecules can also be detected,
e.g., using fluorescence energy transfer (FRET) (see, for example,
Lakowicz et al., U.S. Pat. No. 5,631,169; Stavrianopoulos et al.,
U.S. Pat. No. 4,968,103; each of which is herein incorporated by
reference). A fluorophore label is selected such that a first donor
molecule's emitted fluorescent energy will be absorbed by a
fluorescent label on a second, `acceptor` molecule, which in turn
is able to fluoresce due to the absorbed energy.
[0301] Alternately, the `donor` protein molecule can simply utilize
the natural fluorescent energy of tryptophan residues. Labels are
chosen that emit different wavelengths of light, such that the
`acceptor` molecule label can be differentiated from that of the
`donor`. Since the efficiency of energy transfer between the labels
is related to the distance separating the molecules, the spatial
relationship between the molecules can be assessed. In a situation
in which binding occurs between the molecules, the fluorescent
emission of the `acceptor` molecule label in 15 the assay should be
maximal. An FRET binding event can be conveniently measured through
standard fluorometric detection means well known in the art (e.g.,
using a fluorimeter).
[0302] In another embodiment, determining the ability of the stem
cell cancer markers protein to bind to a target molecule can be
accomplished using real-time Biomolecular Interaction Analysis
(BIA) (see, e.g., Sjolander and Urbaniczky, Anal. Chem.
63:2338-2345 [1991] and Szabo et al. Curr. Opin. Struct. Biol.
5:699-705 [1995]). "Surface plasmon resonance" or "BIA" detects
biospecific interactions in real time, without labeling any of the
interactants (e.g., BIAcore). Changes in the mass at the binding
surface (indicative of a binding event) result in alterations of
the refractive index of light near the surface (the optical
phenomenon of surface plasmon resonance (SPR)), resulting in a
detectable signal that can be used as an indication of real-time
reactions between biological molecules.
[0303] In some embodiments, the target gene product or the test
substance is anchored onto a solid phase. The target gene
product/test compound complexes anchored on the solid phase can be
detected at the end of the reaction. The target gene product can be
anchored onto a solid surface, and the test compound, (which is not
anchored), can be labeled, either directly or indirectly, with
detectable labels discussed herein.
[0304] It can be desirable to immobilize stem cell cancer markers,
an anti-cancer marker antibody or its target molecule to facilitate
separation of complexed from non-complexed forms of one or both of
the proteins, as well as to accommodate automation of the assay.
Binding of a test compound to a stem cell cancer marker protein, or
interaction of a cancer marker protein with a target molecule in
the presence and absence of a candidate compound, can be
accomplished in any vessel suitable for containing the reactants.
Examples of such vessels include microtiter plates, test tubes, and
micro-centrifuge tubes. In some embodiments, a fusion protein can
be provided which adds a domain that allows one or both of the
proteins to be bound to a matrix. For example,
glutathione-S-transferase-cancer marker fusion proteins or
glutathione-S-transferase/target fusion proteins can be adsorbed
onto glutathione Sepharose beads (Sigma Chemical, St. Louis, Mo.)
or glutathione-derivatized microtiter plates, which are then
combined with the test compound or the test compound and either the
non-adsorbed target protein or cancer marker protein, and the
mixture incubated under conditions conducive for complex formation
(e.g., at physiological conditions for salt and pH). Following
incubation, the beads or microtiter plate wells are washed to
remove any unbound components, the matrix immobilized in the case
of beads, complex determined either directly or indirectly, for
example, as described above.
[0305] Alternatively, the complexes can be dissociated from the
matrix, and the level of cancer markers binding or activity
determined using standard techniques. Other techniques for
immobilizing either cancer markers protein or a target molecule on
matrices include using conjugation of biotin and streptavidin.
Biotinylated cancer marker protein or target molecules can be
prepared from biotin-NHS (N-hydroxy-succinimide) using techniques
known in the art (e.g., biotinylation kit, Pierce Chemicals,
Rockford, EL), and immobilized in the wells of streptavidin-coated
96 well plates (Pierce Chemical).
[0306] In order to conduct the assay, the non-immobilized component
is added to the coated surface containing the anchored component.
After the reaction is complete, unreacted components are removed
(e.g., by washing) under conditions such that any complexes formed
will remain immobilized on the solid surface. The detection of
complexes anchored on the solid surface can be accomplished in a
number of ways. Where the previously non-immobilized component is
pre-labeled, the detection of label immobilized on the surface
indicates that complexes were formed. Where the previously
non-immobilized component is not pre-labeled, an indirect label can
be used to detect complexes anchored on the surface; e.g., using a
labeled antibody specific for the immobilized component (the
antibody, in turn, can be directly labeled or indirectly labeled
with, e.g., a labeled anti-IgG antibody).
[0307] This assay is performed utilizing antibodies reactive with
stem cell cancer marker protein or target molecules but which do
not interfere with binding of the stem cell cancer markers protein
to its target molecule. Such antibodies can be derivatized to the
wells of the plate, and unbound target or cancer markers protein
trapped in the wells by antibody conjugation. Methods for detecting
such complexes, in addition to those described above for the
GST-immobilized complexes, include immunodetection of complexes
using antibodies reactive with the cancer marker protein or target
molecule, as well as enzyme-linked assays which rely on detecting
an enzymatic activity associated with the cancer marker protein or
target molecule.
[0308] Alternatively, cell free assays can be conducted in a liquid
phase. In such an assay, the reaction products are separated from
unreacted components, by any of a number of standard techniques,
including, but not limited to: differential centrifugation (see,
for example, Rivas and Minton, Trends Biochem Sci 18:284-7 [1993]);
chromatography (gel filtration chromatography, ion-exchange
chromatography); electrophoresis (see, e.g., Ausubel et al., eds.
Current Protocols in Molecular Biology 1999, J. Wiley: New York.);
and immunoprecipitation (see, for example, Ausubel et al., eds.
Current Protocols in Molecular Biology 1999, J. Wiley: New York).
Such resins and chromatographic techniques are known to one skilled
in the art (See e.g., Heegaard J. Mol. Recognit 11:141-8 [1998];
Hageand Tweed J. Chromatogr. Biomed. Sci. Appl 699:499-525 [1997]).
Further, fluorescence energy transfer can also be conveniently
utilized, as described herein, to detect binding without further
purification of the complex from solution.
[0309] The assay can include contacting the stem cell cancer
markers protein or biologically active portion thereof with a known
compound that binds the cancer marker to form an assay mixture,
contacting the assay mixture with a test compound, and determining
the ability of the test compound to interact with a cancer marker
protein, wherein determining the ability of the test compound to
interact with a cancer marker protein includes determining the
ability of the test compound to preferentially bind to cancer
markers or biologically active portion thereof, or to modulate the
activity of a target molecule, as compared to the known
compound.
[0310] To the extent that stem cell cancer markers can, in vivo,
interact with one or more cellular or extracellular macromolecules,
such as proteins, inhibitors of such an interaction are useful. A
homogeneous assay can be used can be used to identify
inhibitors.
[0311] For example, a preformed complex of the target gene product
and the interactive cellular or extracellular binding partner
product is prepared such that either the target gene products or
their binding partners are labeled, but the signal generated by the
label is quenched due to complex formation (see, e.g., U.S. Pat.
No. 4,109,496, herein incorporated by reference, that utilizes this
approach for immunoassays). The addition of a test substance that
competes with and displaces one of the species from the preformed
complex will result in the generation of a signal above background.
In this way, test substances that disrupt target gene
product-binding partner interaction can be identified.
Alternatively, cancer markers protein can be used as a "bait
protein" in a two-hybrid assay or three-hybrid assay (see, e.g.,
U.S. Pat. No. 5,283,317; Zervos et al., Cell 72:223-232 [1993];
Madura et al., J. Biol. Chem. 268.12046-12054 [1993]; Bartel et
al., Biotechniques 14:920-924 [1993]; Iwabuchi et al., Oncogene
8:1693-1696 [1993]; and Brent WO 94/10300; each of which is herein
incorporated by reference), to identify other proteins, that bind
to or interact with cancer markers ("cancer marker-binding
proteins" or "cancer marker-bp") and are involved in cancer marker
activity. Such cancer marker-bps can be activators or inhibitors of
signals by the cancer marker proteins or targets as, for example,
downstream elements of a cancer markers-mediated signaling
pathway.
[0312] Modulators of cancer markers expression can also be
identified. For example, a cell or cell free mixture is contacted
with a candidate compound and the expression of cancer marker mRNA
or protein evaluated relative to the level of expression of stem
cell cancer marker mRNA or protein in the absence of the candidate
compound. When expression of cancer marker mRNA or protein is
greater in the presence of the candidate compound than in its
absence, the candidate compound is identified as a stimulator of
cancer marker mRNA or protein expression. Alternatively, when
expression of cancer marker mRNA or protein is less (i.e.,
statistically significantly less) in the presence of the candidate
compound than in its absence, the candidate compound is identified
as an inhibitor of cancer marker mRNA or protein expression. The
level of cancer markers mRNA or protein expression can be
determined by methods described herein for detecting cancer markers
mRNA or protein.
[0313] A modulating agent can be identified using a cell-based or a
cell free assay, and the ability of the agent to modulate the
activity of a cancer markers protein can be confirmed in vivo,
e.g., in an animal such as an animal model for a disease (e.g., an
animal with prostate cancer or metastatic prostate cancer; or an
animal harboring a xenograft of a prostate cancer from an animal
(e.g., human) or cells from a cancer resulting from metastasis of a
prostate cancer (e.g., to a lymph node, bone, or liver), or cells
from a prostate cancer cell line.
[0314] This invention further pertains to novel agents identified
by the above-described screening assays (See e.g., below
description of cancer therapies). Accordingly, it is within the
scope of this invention to further use an agent identified as
described herein (e.g., a cancer marker modulating agent, an
antisense cancer marker nucleic acid molecule, a siRNA molecule, a
cancer marker specific antibody, or a cancer marker-binding
partner) in an appropriate animal model (such as those described
herein) to determine the efficacy, toxicity, side effects, or
mechanism of action, of treatment with such an agent. Furthermore,
novel agents identified by the above-described screening assays can
be, e.g., used for treatments as described herein (e.g. to treat a
human patient who has cancer).
VII. Cancer Therapies
[0315] In some embodiments, the present invention provides
therapies for cancer (e.g., breast cancer). In some embodiments,
therapies target cancer markers (e.g., including but not limited
to, those shown in Tables 4-9).
[0316] A. Antisense Therapies
[0317] Candidate therapeutic agents also find use in drug screening
and research applications. In some embodiments, the present
invention targets the expression of stem cell cancer markers. For
example, in some embodiments, the present invention employs
compositions comprising oligomeric antisense compounds,
particularly oligonucleotides (e.g., those identified in the drug
screening methods described above), for use in modulating the
function of nucleic acid molecules encoding stem cell cancer
markers of the present invention, ultimately modulating the amount
of cancer marker expressed. This is accomplished by providing
antisense compounds that specifically hybridize with one or more
nucleic acids encoding cancer markers of the present invention. The
specific hybridization of an oligomeric compound with its target
nucleic acid interferes with the normal function of the nucleic
acid. This modulation of function of a target nucleic acid by
compounds that specifically hybridize to it is generally referred
to as "antisense." The functions of DNA to be interfered with
include replication and transcription. The functions of RNA to be
interfered with include all vital functions such as, for example,
translocation of the RNA to the site of protein translation,
translation of protein from the RNA, splicing of the RNA to yield
one or more mRNA species, and catalytic activity that can be
engaged in or facilitated by the RNA. The overall effect of such
interference with target nucleic acid function is modulation of the
expression of cancer markers of the present invention. In the
context of the present invention, "modulation" means either an
increase (stimulation) or a decrease (inhibition) in the expression
of a gene. For example, expression can be inhibited to potentially
prevent tumor proliferation.
[0318] It is some to target specific nucleic acids for antisense.
"Targeting" an antisense compound to a particular nucleic acid, in
the context of the present invention, is a multistep process. The
process usually begins with the identification of a nucleic acid
sequence whose function is to be modulated. This can be, for
example, a cellular gene (or mRNA transcribed from the gene) whose
expression is associated with a particular disorder or disease
state, or a nucleic acid molecule from an infectious agent. In the
present invention, the target is a nucleic acid molecule encoding a
stem cell cancer marker of the present invention. The targeting
process also includes determination of a site or sites within this
gene for the antisense interaction to occur such that the desired
effect, e.g., detection or modulation of expression of the protein,
will result. Within the context of the present invention, a some
intragenic site is the region encompassing the translation
initiation or termination codon of the open reading frame (ORF) of
the gene. Since the translation initiation codon is typically
5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding
DNA molecule), the translation initiation codon is also referred to
as the "AUG codon," the "start codon" or the "AUG start codon". A
minority of genes have a translation initiation codon having the
RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and
5'-CUG have been shown to function in vivo. Thus, the terms
"translation initiation codon" and "start codon" can encompass many
codon sequences, even though the initiator amino acid in each
instance is typically methionine (in eukaryotes) or
formylmethionine (in prokaryotes). Eukaryotic and prokaryotic genes
can have two or more alternative start codons, any one of which can
be preferentially utilized for translation initiation in a
particular cell type or tissue, or under a particular set of
conditions. In the context of the present invention, "start codon"
and "translation initiation codon" refer to the codon or codons
that are used in vivo to initiate translation of an mRNA molecule
transcribed from a gene encoding a tumor antigen of the present
invention, regardless of the sequence(s) of such codons.
[0319] Translation termination codon (or "stop codon") of a gene
can have one of three sequences (i.e., 5'-UAA, 5'-UAG and 5'-UGA;
the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA,
respectively). The terms "start codon region" and "translation
initiation codon region" refer to a portion of such an mRNA or gene
that encompasses from about 25 to about 50 contiguous nucleotides
in either direction (i.e., 5' or 3') from a translation initiation
codon. Similarly, the terms "stop codon region" and "translation
termination codon region" refer to a portion of such an mRNA or
gene that encompasses from about 25 to about 50 contiguous
nucleotides in either direction (i.e., 5' or 3') from a translation
termination codon.
[0320] The open reading frame (ORF) or "coding region," which
refers to the region between the translation initiation codon and
the translation termination codon, is also a region that can be
targeted effectively. Other target regions include the 5'
untranslated region (5' UTR), referring to the portion of an mRNA
in the 5' direction from the translation initiation codon, and thus
including nucleotides between the 5' cap site and the translation
initiation codon of an mRNA or corresponding nucleotides on the
gene, and the 3' untranslated region (3' UTR), referring to the
portion of an mRNA in the 3' direction from the translation
termination codon, and thus including nucleotides between the
translation termination codon and 3' end of an mRNA or
corresponding nucleotides on the gene. The 5' cap of an mRNA
comprises an N7-methylated guanosine residue joined to the 5'-most
residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap
region of an mRNA is considered to include the 5' cap structure
itself as well as the first 50 nucleotides adjacent to the cap. The
cap region can also be a some target region.
[0321] Although some eukaryotic mRNA transcripts are directly
translated, many contain one or more regions, known as "introns,"
that are excised from a transcript before it is translated. The
remaining (and therefore translated) regions are known as "exons"
and are spliced together to form a continuous mRNA sequence. mRNA
splice sites (i.e., intron-exon junctions) can also be some target
regions, and are particularly useful in situations where aberrant
splicing is implicated in disease, or where an overproduction of a
particular mRNA splice product is implicated in disease. Aberrant
fusion junctions due to rearrangements or deletions are also some
targets. It has also been found that introns can also be effective,
and therefore some, target regions for antisense compounds
targeted, for example, to DNA or pre-mRNA.
[0322] In some embodiments, target sites for antisense inhibition
are identified using commercially available software programs
(e.g., Biognostik, Gottingen, Germany; SysArris Software,
Bangalore, India; Antisense Research Group, University of
Liverpool, Liverpool, England; GeneTrove, Carlsbad, Calif.). In
other embodiments, target sites for antisense inhibition are
identified using the accessible site method described in U.S.
Patent WO0198537A2, herein incorporated by reference.
[0323] Once one or more target sites have been identified,
oligonucleotides are chosen that are sufficiently complementary to
the target (i.e., hybridize sufficiently well and with sufficient
specificity) to give the desired effect. For example, in some
embodiments of the present invention, antisense oligonucleotides
are targeted to or near the start codon.
[0324] In the context of this invention, "hybridization," with
respect to antisense compositions and methods, means hydrogen
bonding, which can be Watson-Crick, Hoogsteen or reversed Hoogsteen
hydrogen bonding, between complementary nucleoside or nucleotide
bases. For example, adenine and thymine are complementary
nucleobases that pair through the formation of hydrogen bonds. It
is understood that the sequence of an antisense compound need not
be 100% complementary to that of its target nucleic acid to be
specifically hybridizable. An antisense compound is specifically
hybridizable when binding of the compound to the target DNA or RNA
molecule interferes with the normal function of the target DNA or
RNA to cause a loss of utility, and there is a sufficient degree of
complementarity to avoid non-specific binding of the antisense
compound to non-target sequences under conditions in which specific
binding is desired (i.e., under physiological conditions in the
case of in vivo assays or therapeutic treatment, and in the case of
in vitro assays, under conditions in which the assays are
performed).
[0325] Antisense compounds are commonly used as research reagents
and diagnostics. For example, antisense oligonucleotides, which are
able to inhibit gene expression with specificity, can be used to
elucidate the function of particular genes. Antisense compounds are
also used, for example, to distinguish between functions of various
members of a biological pathway.
[0326] The specificity and sensitivity of antisense is also applied
for therapeutic uses. For example, antisense oligonucleotides have
been employed as therapeutic moieties in the treatment of disease
states in animals and man. Antisense oligonucleotides have been
safely and effectively administered to humans and numerous clinical
trials are presently underway. It is thus established that
oligonucleotides are useful therapeutic modalities that can be
configured to be useful in treatment regimes for treatment of
cells, tissues, and animals, especially humans.
[0327] While antisense oligonucleotides are a some form of
antisense compound, the present invention comprehends other
oligomeric antisense compounds, including but not limited to
oligonucleotide mimetics such as are described below. The antisense
compounds in accordance with this invention can comprise from about
8 to about 30 nucleobases (i.e., from about 8 to about 30 linked
bases), although both longer and shorter sequences can find use
with the present invention. Particularly some antisense compounds
are antisense oligonucleotides, e.g., those comprising from about
12 to about 25 nucleobases.
[0328] Specific examples of some antisense compounds useful with
the present invention include oligonucleotides containing modified
backbones or non-natural internucleoside linkages. As defined in
this specification, oligonucleotides having modified backbones
include those that retain a phosphorus atom in the backbone and
those that do not have a phosphorus atom in the backbone. For the
purposes of this specification, modified oligonucleotides that do
not have a phosphorus atom in their internucleoside backbone can
also be considered to be oligonucleosides.
[0329] Some modified oligonucleotide backbones include, for
example, phosphorothioates, chiral phosphorothioates,
phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters,
methyl and other alkyl phosphonates including 3'-alkylene
phosphonates and chiral phosphonates, phosphinates,
phosphoramidates including 3'-amino phosphoramidate and
aminoalkylphosphoramidates, thionophosphoramidates,
thionoalkylphosphonates, thionoalkylphosphotriesters, and
boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs
of these, and those having inverted polarity wherein the adjacent
pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to
5'-2'. Various salts, mixed salts and free acid forms are also
included.
[0330] Some modified oligonucleotide backbones that do not include
a phosphorus atom therein have backbones that are formed by short
chain alkyl or cycloalkyl internucleoside linkages, mixed
heteroatom and alkyl or cycloalkyl internucleoside linkages, or one
or more short chain heteroatomic or heterocyclic internucleoside
linkages. These include those having morpholino linkages (formed in
part from the sugar portion of a nucleoside); siloxane backbones;
sulfide, sulfoxide and sulfone backbones; formacetyl and
thioformacetyl backbones; methylene formacetyl and thioformacetyl
backbones; alkene containing backbones; sulfamate backbones;
methyleneimino and methylenehydrazino backbones; sulfonate and
sulfonamide backbones; amide backbones; and others having mixed N,
O, S and CH.sub.2 component parts.
[0331] In other some oligonucleotide mimetics, both the sugar and
the internucleoside linkage (i.e., the backbone) of the nucleotide
units are replaced with novel groups. The base units are maintained
for hybridization with an appropriate nucleic acid target compound.
One such oligomeric compound, an oligonucleotide mimetic that has
been shown to have excellent hybridization properties, is referred
to as a peptide nucleic acid (PNA). In PNA compounds, the
sugar-backbone of an oligonucleotide is replaced with an amide
containing backbone, in particular an aminoethylglycine backbone.
The nucleobases are retained and are bound directly or indirectly
to aza nitrogen atoms of the amide portion of the backbone.
Representative United States patents that teach the preparation of
PNA compounds include, but are not limited to, U.S. Pat. Nos.:
5,539,082; 5,714,331; and 5,719,262, each of which is herein
incorporated by reference. Further teaching of PNA compounds can be
found in Nielsen et al., Science 254:1497 (1991).
[0332] In some embodiments, the oligonucleotides have
phosphorothioate backbones and oligonucleosides with heteroatom
backbones, and in particular --CH.sub.2, --NH--O--CH.sub.2--,
--CH.sub.2--N(CH.sub.3)--O--CH.sub.2-- [known as a methylene
(methylimino) or MMI backbone],
--CH.sub.2--O--N(CH.sub.3)--CH.sub.2--,
--CH.sub.2--N(CH.sub.3)--N(CH.sub.3)--CH.sub.2--, and
--O--N(CH.sub.3)--CH.sub.2--CH.sub.2-- [wherein the native
phosphodiester backbone is represented as --O--P--O--CH.sub.2--] of
the above referenced U.S. Pat. No. 5,489,677, and the amide
backbones of the above referenced U.S. Pat. No. 5,602,240. Also
some oligonucleotides have morpholino backbone structures of the
above-referenced U.S. Pat. No. 5,034,506.
[0333] Modified oligonucleotides can also contain one or more
substituted sugar moieties. Some oligonucleotides comprise one of
the following at the 2' position: OH; F; O--, S--, or N-alkyl; O--,
S--, or N-alkenyl; O--, S-- or N-alkynyl; or O-alkyl-O-alkyl,
wherein the alkyl, alkenyl and alkynyl can be substituted or
unsubstituted C.sub.1 to C.sub.10 alkyl or C.sub.2 to C.sub.10
alkenyl and alkynyl. Particularly some are
O[(CH.sub.2).sub.nO].sub.mCH.sub.3, O(CH.sub.2).sub.nOCH.sub.3,
O(CH.sub.2).sub.nNH.sub.2, O(CH.sub.2).sub.nCH.sub.3,
O(CH.sub.2).sub.nONH.sub.2, and
O(CH.sub.2).sub.nON[(CH.sub.2).sub.nCH.sub.3)].sub.2, where n and m
are from 1 to about 10. Other some oligonucleotides comprise one of
the following at the 2' position: C.sub.1 to C.sub.10 lower alkyl,
substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl,
SH, SCH.sub.3, OCN, Cl, Br, CN, CF.sub.3, OCF.sub.3, SOCH.sub.3,
SO.sub.2CH.sub.3, ONO.sub.2, NO.sub.2, N.sub.3, NH.sub.2,
heterocycloalkyl, heterocycloalkaryl, aminoalkylamino,
polyalkylamino, substituted silyl, an RNA cleaving group, a
reporter group, an intercalator, a group for improving the
pharmacokinetic properties of an oligonucleotide, or a group for
improving the pharmacodynamic properties of an oligonucleotide, and
other substituents having similar properties. A some modification
includes 2'-methoxyethoxy (2'-O--CH.sub.2CH.sub.2OCH.sub.3, also
known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv.
Chim. Acta 78:486 [1995]) i.e., an alkoxyalkoxy group. A further
some modification includes 2'-dimethylaminooxyethoxy (i.e., a
O(CH.sub.2).sub.2ON(CH.sub.3).sub.2 group), also known as 2'-DMAOE,
and 2'-dimethylaminoethoxyethoxy (also known in the art as
2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e.,
2'-O--CH.sub.2--O--CH.sub.2--N(CH.sub.2).sub.2.
[0334] Other some modifications include 2'-methoxy(2'-O--CH.sub.3),
2'-aminopropoxy(2'-OCH.sub.2CH.sub.2CH.sub.2NH.sub.2) and 2'-fluoro
(2'-F). Similar modifications can also be made at other positions
on the oligonucleotide, particularly the 3' position of the sugar
on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides
and the 5' position of 5' terminal nucleotide. Oligonucleotides can
also have sugar mimetics such as cyclobutyl moieties in place of
the pentofuranosyl sugar.
[0335] Oligonucleotides can also include nucleobase (often referred
to in the art simply as "base") modifications or substitutions. As
used herein, "unmodified" or "natural" nucleobases include the
purine bases adenine (A) and guanine (G), and the pyrimidine bases
thymine (T), cytosine (C) and uracil (U). Modified nucleobases
include other synthetic and natural nucleobases such as
5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine,
hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives
of adenine and guanine, 2-propyl and other alkyl derivatives of
adenine and guanine, 2-thiouracil, 2-thiothymine and
2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and
cytosine, 6-azo uracil, cytosine and thymine, 5-uracil
(pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol,
8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and
guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other
5-substituted uracils and cytosines, 7-methylguanine and
7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and
7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further
nucleobases include those disclosed in U.S. Pat. No. 3,687,808.
Certain of these nucleobases are particularly useful for increasing
the binding affinity of the oligomeric compounds of the invention.
These include 5-substituted pyrimidines, 6-azapyrimidines and N-2,
N-6 and O-6 substituted purines, including 2-aminopropyladenine,
5-propynyluracil and 5-propynylcytosine. 5-methylcytosine
substitutions have been shown to increase nucleic acid duplex
stability by 0.6-1.2.degree. C. and are presently some base
substitutions, even more particularly when combined with
2'-O-methoxyethyl sugar modifications.
[0336] Another modification of the oligonucleotides of the present
invention involves chemically linking to the oligonucleotide one or
more moieties or conjugates that enhance the activity, cellular
distribution or cellular uptake of the oligonucleotide. Such
moieties include but are not limited to lipid moieties such as a
cholesterol moiety, cholic acid, a thioether, (e.g.,
hexyl-S-tritylthiol), a thiocholesterol, an aliphatic chain, (e.g.,
dodecandiol or undecyl residues), a phospholipid, (e.g.,
di-hexadecyl-rac-glycerol or triethylammonium
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate), a polyamine or a
polyethylene glycol chain or adamantane acetic acid, a palmityl
moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol
moiety.
[0337] One skilled in the relevant art knows well how to generate
oligonucleotides containing the above-described modifications. The
present invention is not limited to the antisense oligonucleotides
described above. Any suitable modification or substitution can be
utilized.
[0338] It is not necessary for all positions in a given compound to
be uniformnly modified, and in fact more than one of the
aforementioned modifications can be incorporated in a single
compound or even at a single nucleoside within an oligonucleotide.
The present invention also includes antisense compounds that are
chimeric compounds. "Chimeric" antisense compounds or "chimeras,"
in the context of the present invention, are antisense compounds,
particularly oligonucleotides, which contain two or more chemically
distinct regions, each made up of at least one monomer unit, i.e.,
a nucleotide in the case of an oligonucleotide compound. These
oligonucleotides typically contain at least one region wherein the
oligonucleotide is modified so as to confer upon the
oligonucleotide increased resistance to nuclease degradation,
increased cellular uptake, and/or increased binding affinity for
the target nucleic acid. An additional region of the
oligonucleotide can serve as a substrate for enzymes capable of
cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNaseH is a
cellular endonuclease that cleaves the RNA strand of an RNA:DNA
duplex. Activation of RNaseH, therefore, results in cleavage of the
RNA target, thereby greatly enhancing the efficiency of
oligonucleotide inhibition of gene expression. Consequently,
comparable results can often be obtained with shorter
oligonucleotides when chimeric oligonucleotides are used, compared
to phosphorothioate deoxyoligonucleotides hybridizing to the same
target region. Cleavage of the RNA target can be routinely detected
by gel electrophoresis and, if necessary, associated nucleic acid
hybridization techniques known in the art.
[0339] Chimeric antisense compounds of the present invention can be
formed as composite structures of two or more oligonucleotides,
modified oligonucleotides, oligonucleosides and/or oligonucleotide
mimetics as described above.
[0340] The present invention also includes pharmaceutical
compositions and formulations that include the antisense compounds
of the present invention as described below.
[0341] B. Genetic Therapies
[0342] The present invention contemplates the use of any genetic
manipulation for use in modulating the expression of stem cell
cancer markers of the present invention. Examples of genetic
manipulation include, but are not limited to, gene knockout (e.g.,
removing the cancer marker gene from the chromosome using, for
example, recombination), expression of antisense constructs with or
without inducible promoters, addition of a heterologous gene (e.g.
controlled by an inducible promoter), and the like. Delivery of
nucleic acid construct to cells in vitro or in vivo can be
conducted using any suitable method. A suitable method is one that
introduces the nucleic acid construct into the cell such that the
desired event occurs (e.g., expression of an antisense
construct).
[0343] Introduction of molecules carrying genetic information into
cells is achieved by any of various methods including, but not
limited to, directed injection of naked DNA constructs, bombardment
with gold particles loaded with said constructs, and macromolecule
mediated gene transfer using, for example, liposomes, biopolymers,
and the like. Some methods use gene delivery vehicles derived from
viruses, including, but not limited to, adenoviruses, retroviruses,
vaccinia viruses, and adeno-associated viruses. Because of the
higher efficiency as compared to retroviruses, vectors derived from
adenoviruses are the some gene delivery vehicles for transferring
nucleic acid molecules into host cells in vivo. Adenoviral vectors
have been shown to provide very efficient in vivo gene transfer
into a variety of solid tumors in animal models and into human
solid tumor xenografts in immune-deficient mice. Examples of
adenoviral vectors and methods for gene transfer are described in
WO 00/12738 and WO 00/09675 and U.S. Pat. Nos. 6,033,908,
6,019,978, 6,001,557, 5,994,132, 5,994,128, 5,994,106, 5,981,225,
5,885,808, 5,872,154, 5,830,730, and 5,824,544, each of which is
herein incorporated by reference in its entirety.
[0344] Vectors can be administered to a subject in a variety of
ways. For example, in some embodiments of the present invention,
vectors are administered into tumors or tissue associated with
tumors using direct injection. In other embodiments, administration
is via the blood or lymphatic circulation (See e.g., PCT
publication 99/02685 herein incorporated by reference in its
entirety). Exemplary dose levels of adenoviral vector can be, e.g.,
10.sup.8 to 10.sup.11 vector particles added to the perfusate.
[0345] C. Antibody Therapy
[0346] In some embodiments, the present invention provides
antibodies that target tumors that express a stem cell cancer
marker of the present invention (e.g., those shown in Tables 4-9).
Any suitable antibody (e.g., monoclonal, polyclonal, or synthetic)
can be utilized in the therapeutic methods disclosed herein. In
some embodiments, the antibodies used for cancer therapy are
humanized antibodies. Methods for humanizing antibodies are well
known in the art (See e.g., U.S. Pat. Nos. 6,180,370, 5,585,089,
6,054,297, and 5,565,332; each of which is herein incorporated by
reference).
[0347] In some embodiments, the therapeutic antibodies comprise an
antibody generated against a stem cell cancer marker of the present
invention, wherein the antibody is conjugated to a cytotoxic agent.
In such embodiments, a tumor specific therapeutic agent is
generated that does not target normal cells, thus reducing many of
the detrimental side effects of traditional chemotherapy. For
certain applications, it is envisioned that the therapeutic agents
will be pharmacologic agents that will serve as useful agents for
attachment to antibodies, particularly cytotoxic or otherwise
anticellular agents having the ability to kill or suppress the
growth or cell division of endothelial cells. The present invention
contemplates the use of any pharmacologic agent that can be
conjugated to an antibody, and delivered in active form. Exemplary
anticellular agents include chemotherapeutic agents, radioisotopes,
and cytotoxins. The therapeutic antibodies of the present invention
can include a variety of cytotoxic moieties, including but not
limited to, radioactive isotopes (e.g., iodine-131, iodine-123,
technicium-99m, indium-111, rhenium-188, rhenium-186, gallium-67,
copper-67, yttrium-90, iodine-125 or astatine-211), hormones such
as a steroid, antimetabolites such as cytosines (e.g., arabinoside,
fluorouracil, methotrexate or aminopterin; an anthracycline;
mitomycin C), vinca alkaloids (e.g., demecolcine; etoposide;
mithramycin), and antitumor alkylating agent such as chlorambucil
or melphalan. Other embodiments can include agents such as a
coagulant, a cytokine, growth factor, bacterial endotoxin or the
lipid A moiety of bacterial endotoxin. For example, in some
embodiments, therapeutic agents will include plant-, fungus- or
bacteria-derived toxin, such as an A chain toxins, a ribosome
inactivating protein, .alpha.-sarcin, aspergillin, restrictocin, a
ribonuclease, diphtheria toxin or pseudomonas exotoxin, to mention
just a few examples. In some some embodiments, deglycosylated ricin
A chain is utilized.
[0348] In any event, it is proposed that agents such as these can,
if desired, be successfully conjugated to an antibody, in a manner
that will allow their targeting, internalization, release or
presentation to blood components at the site of the targeted tumor
cells as required using known conjugation technology (See, e.g.,
Ghose et al., Methods Enzymol., 93:280 [1983]).
[0349] For example, in some embodiments the present invention
provides immunotoxins targeted a stem cell cancer marker of the
present invention. Immunotoxins are conjugates of a specific
targeting agent typically a tumor-directed antibody or fragment,
with a cytotoxic agent, such as a toxin moiety. The targeting agent
directs the toxin to, and thereby selectively kills, cells carrying
the targeted antigen. In some embodiments, therapeutic antibodies
employ crosslinkers that provide high in vivo stability (Thorpe et
al., Cancer Res., 48:6396 [1988]).
[0350] In other embodiments, particularly those involving treatment
of solid tumors, antibodies are designed to have a cytotoxic or
otherwise anticellular effect against the tumor vasculature, by
suppressing the growth or cell division of the vascular endothelial
cells. This attack is intended to lead to a tumor-localized
vascular collapse, depriving the tumor cells, particularly those
tumor cells distal of the vasculature, of oxygen and nutrients,
ultimately leading to cell death and tumor necrosis.
[0351] In some embodiments, antibody based therapeutics are
formulated as pharmaceutical compositions as described below. In
some embodiments, administration of an antibody composition of the
present invention results in a measurable decrease in cancer (e.g.,
decrease or elimination of tumor).
[0352] D. RNAi Therapies
[0353] In other embodiments, RNAi is used to regulate expression of
the stem cell cancer markers of the present invention (e.g. those
shown in Tables 4-9). RNAi represents an evolutionary conserved
cellular defense for controlling the expression of foreign genes in
most eukaryotes, including humans. RNAi is triggered by
double-stranded RNA (dsRNA) and causes sequence-specific mRNA
degradation of single-stranded target RNAs homologous in response
to dsRNA. The mediators of mRNA degradation are small interfering
RNA duplexes (siRNAs), which are normally produced from long dsRNA
by enzymatic cleavage in the cell. siRNAs are generally
approximately twenty-one nucleotides in length (e.g. 21-23
nucleotides in length), and have a base-paired structure
characterized by two nucleotide 3'-overhangs. Following the
introduction of a small RNA, or RNAi, into the cell, it is believed
the sequence is delivered to an enzyme complex called RISC
(RNA-induced silencing complex). RISC recognizes the target and
cleaves it with an endonuclease. It is noted that if larger RNA
sequences are delivered to a cell, RNase III enzyme (Dicer)
converts longer dsRNA into 21-23 nt ds siRNA fragments.
[0354] Chemically synthesized siRNAs have become powerful reagents
for genome-wide analysis of mammalian gene function in cultured
somatic cells. Beyond their value for validation of gene function,
siRNAs also hold great potential as gene-specific therapeutic
agents (Tuschl and Borkhardt, Molecular Intervent. 2002; 2(3):
158-67, herein incorporated by reference).
[0355] The transfection of siRNAs into animal cells results in the
potent, long-lasting post-transcriptional silencing of specific
genes (Caplen et al, Proc Natl Acad Sci U.S.A. 2001; 98: 9742-7;
Elbashir et al., Nature. 2001; 411:494-8; Elbashir et al., Genes
Dev. 2001; 15: 188-200; and Elbashir et al., EMBO J. 2001; 20:
6877-88, all of which are herein incorporated by reference).
Methods and compositions for performing RNAi with siRNAs are
described, for example, in U.S. Pat. No. 6,506,559, herein
incorporated by reference.
[0356] siRNAs are extraordinarily effective at lowering the amounts
of targeted RNA, and by extension proteins, frequently to
undetectable levels. The silencing effect can last several months,
and is extraordinarily specific, because one nucleotide mismatch
between the target RNA and the central region of the siRNA is
frequently sufficient to prevent silencing Brummelkamp et al,
Science 2002; 296:550-3; and Holen et al, Nucleic Acids Res. 2002;
30:1757-66, both of which are herein incorporated by reference.
[0357] E. Pharmaceutical Compositions
[0358] The present invention further provides pharmaceutical
compositions (e.g., comprising a small molecule, antisense,
antibody, or siRNA that targets the stem cell cancer markers of the
present invention). The pharmaceutical compositions of the present
invention can be administered in a number of ways depending upon
whether local or systemic treatment is desired and upon the area to
be treated. Administration can be topical (including ophthalmic and
to mucous membranes including vaginal and rectal delivery),
pulmonary (e.g., by inhalation or insufflation of powders or
aerosols, including by nebulizer; intratracheal, intranasal,
epidermal and transdermal), oral or parenteral. Parenteral
administration includes intravenous, intraarterial, subcutaneous,
intraperitoneal or intramuscular injection or infusion; or
intracranial, e.g., intrathecal or intraventricular,
administration.
[0359] Pharmaceutical compositions and formulations for topical
administration can include transdermal patches, ointments, lotions,
creams, gels, drops, suppositories, sprays, liquids and powders.
Conventional pharmaceutical carriers, aqueous, powder or oily
bases, thickeners and the like can be necessary or desirable.
[0360] Compositions and formulations for oral administration
include powders or granules, suspensions or solutions in water or
non-aqueous media, capsules, sachets or tablets. Thickeners,
flavoring agents, diluents, emulsifiers, dispersing aids or binders
can be desirable.
[0361] Compositions and formulations for parenteral, intrathecal or
intraventricular administration can include sterile aqueous
solutions that can also contain buffers, diluents and other
suitable additives such as, but not limited to, penetration
enhancers, carrier compounds and other pharmaceutically acceptable
carriers or excipients.
[0362] Pharmaceutical compositions of the present invention
include, but are not limited to, solutions, emulsions, and
liposome-containing formulations. These compositions can be
generated from a variety of components that include, but are not
limited to, preformed liquids, self-emulsifying solids and
self-emulsifying semisolids.
[0363] The pharmaceutical formulations of the present invention,
which can conveniently be presented in unit dosage form, can be
prepared according to conventional techniques well known in the
pharmaceutical industry. Such techniques include bringing into
association the active ingredients with the pharmaceutical
carrier(s) or excipient(s). In general the formulations are
prepared by uniformly and intimately bringing into association the
active ingredients with liquid carriers or finely divided solid
carriers or both, and then, if necessary, shaping the product.
[0364] The compositions of the present invention can be formulated
into any of many possible dosage forms such as, but not limited to,
tablets, capsules, liquid syrups, soft gels, suppositories, and
enemas. The compositions of the present invention can also be
formulated as suspensions in aqueous, non-aqueous or mixed media.
Aqueous suspensions can further contain substances that increase
the viscosity of the suspension including, for example, sodium
carboxymethylcellulose, sorbitol and/or dextran. The suspension can
also contain stabilizers.
[0365] In some embodiments of the present invention the
pharmaceutical compositions can be formulated and used as foams.
Pharmaceutical foams include formulations such as, but not limited
to, emulsions, microemulsions, creams, jellies and liposomes. While
basically similar in nature these formulations vary in the
components and the consistency of the final product.
[0366] Agents that enhance uptake of oligonucleotides at the
cellular level can also be added to the pharmaceutical and other
compositions of the present invention. For example, cationic
lipids, such as lipofectin (U.S. Pat. No. 5,705,188), cationic
glycerol derivatives, and polycationic molecules, such as
polylysine (WO 97/30731), also enhance the cellular uptake of
oligonucleotides.
[0367] The compositions of the present invention can additionally
contain other adjunct components conventionally found in
pharmaceutical compositions. Thus, for example, the compositions
can contain additional, compatible, pharmaceutically-active
materials such as, for example, antipruritics, astringents, local
anesthetics or anti-inflammatory agents, or can contain additional
materials useful in physically formulating various dosage forms of
the compositions of the present invention, such as dyes, flavoring
agents, preservatives, antioxidants, opacifiers, thickening agents
and stabilizers. However, such materials, when added, should not
unduly interfere with the biological activities of the components
of the compositions of the present invention. The formulations can
be sterilized and, if desired, mixed with auxiliary agents, e.g.,
lubricants, preservatives, stabilizers, wetting agents,
emulsifiers, salts for influencing osmotic pressure, buffers,
colorings, flavorings and/or aromatic substances and the like which
do not deleteriously interact with the nucleic acid(s) of the
formulation.
[0368] Certain embodiments of the invention provide pharmaceutical
compositions containing (a) one or more compounds that modulate the
activity of a stem cell caner marker (e.g. antibody, small
molecule, siRNA, anti-sense, etc.) and (b) one or more other
chemotherapeutic agents. Examples of such chemotherapeutic agents
include, but are not limited to, anticancer drugs such as
daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin,
nitrogen mustard, chlorambucil, melphalan, cyclophosphamide,
6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil
(5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine,
vincristine, vinblastine, etoposide, teniposide, cisplatin and
diethylstilbestrol (DES). Anti-inflammatory drugs, including but
not limited to nonsteroidal anti-inflammatory drugs and
corticosteroids, and antiviral drugs, including but not limited to
ribivirin, vidarabine, acyclovir and ganciclovir, can also be
combined in compositions of the invention. Other chemotherapeutic
agents are also within the scope of this invention. Two or more
combined compounds can be used together or sequentially.
[0369] Dosing is dependent on severity and responsiveness of the
disease state to be treated, with the course of treatment lasting
from several days to several months, or until a cure is effected or
a diminution of the disease state is achieved (e.g. reduction in
tumor size). Optimal dosing schedules can be calculated from
measurements of drug accumulation in the body of the patient. The
administering physician can easily determine optimum dosages,
dosing methodologies and repetition rates. Optimum dosages can vary
depending on the relative potency of individual oligonucleotides,
and can generally be estimated based on EC.sub.50s found to be
effective in in vitro and in vivo animal models or based on the
examples described herein. In general, dosage is from 0.01 .mu.g to
100 g per kg of body weight, and can be given once or more daily,
weekly, monthly or yearly. The treating physician can estimate
repetition rates for dosing based on measured residence times and
concentrations of the drug in bodily fluids or tissues. Following
successful treatment, it can be desirable to have the subject
undergo maintenance therapy to prevent the recurrence of the
disease state, wherein the oligonucleotide is administered in
maintenance doses, ranging from 0.01 .mu.g to 100 g per kg of body
weight, once or more daily, to once every 20 years.
VIII. Transgenic Animals Expressing Cancer Marker Genes
[0370] The present invention contemplates the generation of
transgenic animals comprising an exogenous cancer marker gene of
the present invention or mutants and variants thereof (e.g.,
truncations or single nucleotide polymorphisms) or knock-outs
thereof. In some embodiments, the transgenic animal displays an
altered phenotype (e.g., increased or decreased presence of
markers) as compared to wild-type animals. Methods for analyzing
the presence or absence of such phenotypes include but are not
limited to, those disclosed herein. In some some embodiments, the
transgenic animals further display an increased or decreased growth
of tumors or evidence of cancer.
[0371] The transgenic animals of the present invention find use in
drug (e.g., cancer therapy) screens. In some embodiments, test
compounds (e.g., a drug that is suspected of being useful to treat
cancer) and control compounds (e.g., a placebo) are administered to
the transgenic animals and the control animals and the effects
evaluated.
[0372] The transgenic animals can be generated via a variety of
methods. In some embodiments, embryonal cells at various
developmental stages are used to introduce transgenes for the
production of transgenic animals. Different methods are used
depending on the stage of development of the embryonal cell. The
zygote is the best target for micro-injection. In the mouse, the
male pronucleus reaches the size of approximately 20 micrometers in
diameter that allows reproducible injection of 1-2 picoliters (pl)
of DNA solution. The use of zygotes as a target for gene transfer
has a major advantage in that in most cases the injected DNA will
be incorporated into the host genome before the first cleavage
(Brinster et al., 1985, PNAS 82:4438-4442). As a consequence, all
cells of the transgenic non-human animal will carry the
incorporated transgene. This will in general also be reflected in
the efficient transmission of the transgene to offspring of the
founder since 50% of the germ cells will harbor the transgene. U.S.
Pat. No. 4,873,191 describes a method for the micro-injection of
zygotes; the disclosure of this patent is incorporated herein in
its entirety.
[0373] In other embodiments, retroviral infection is used to
introduce transgenes into a non-human animal. In some embodiments,
the retroviral vector is utilized to transfect oocytes by injecting
the retroviral vector into the perivitelline space of the oocyte
(U.S. Pat. No. 6,080,912, incorporated herein by reference). In
other embodiments, the developing non-human embryo can be cultured
in vitro to the blastocyst stage. During this time, the blastomeres
can be targets for retroviral infection (Janenich, 1976, PNAS
73:1260). Efficient infection of the blastomeres is obtained by
enzymatic treatment to remove the zona pellucida (Hogan et al., in
Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, N.Y. [1986]). The viral vector system used to
introduce the transgene is typically a replication-defective
retrovirus carrying the transgene (Jahner et al., 1985, PNAS
82:6927). Transfection is easily and efficiently obtained by
culturing the blastomeres on a monolayer of virus-producing cells
(Stewart, et al., 1987, EMBO J., 6:383).
[0374] Alternatively, infection can be performed at a later stage.
Virus or virus-producing cells can be injected into the blastocoele
(Jahner et al., 1982, Nature 298:623). Most of the founders will be
mosaic for the transgene since incorporation occurs only in a
subset of cells that form the transgenic animal. Further, the
founder can contain various retroviral insertions of the transgene
at different positions in the genome that generally will segregate
in the offspring. In addition, it is also possible to introduce
transgenes into the germline, albeit with low efficiency, by
intrauterine retroviral infection of the midgestation embryo
(Jahner et al., supra [1982]). Additional means of using
retroviruses or retroviral vectors to create transgenic animals
known to the art involve the micro-injection of retroviral
particles or mitomycin C-treated cells producing retrovirus into
the perivitelline space of fertilized eggs or early embryos (PCT
International Application WO 90/08832 [1990], and Haskell and
Bowen, 1995, Mol. Reprod. Dev., 40:386).
[0375] In other embodiments, the transgene is introduced into
embryonic stem cells and the transfected stem cells are utilized to
form an embryo. ES cells are obtained by culturing pre-implantation
embryos in vitro under appropriate conditions (Evans et al., 1981,
Nature 292:154; Bradley et al., 1984, Nature 309:255; Gossler et
al., 1986, PNAS 83:9065; and Robertson et al., 1986, Nature
322:445). Transgenes can be efficiently introduced into the ES
cells by DNA transfection by a variety of methods known to the art
including calcium phosphate co-precipitation, protoplast or
spheroplast fusion, lipofection and DEAE-dextran-mediated
transfection. Transgenes can also be introduced into ES cells by
retrovirus-mediated transduction or by micro-injection. Such
transfected ES cells can thereafter colonize an embryo following
their introduction into the blastocoel of a blastocyst-stage embryo
and contribute to the germ line of the resulting chimeric animal
(for review, See, Jaenisch, Science, 1988, 240:1468). Prior to the
introduction of transfected ES cells into the blastocoel, the
transfected ES cells can be subjected to various selection
protocols to enrich for ES cells which have integrated the
transgene assuming that the transgene provides a means for such
selection. Alternatively, the polymerase chain reaction can be used
to screen for ES cells that have integrated the transgene. This
technique obviates the need for growth of the transfected ES cells
under appropriate selective conditions prior to transfer into the
blastocoel.
[0376] In still other embodiments, homologous recombination is
utilized to knock-out gene function or create deletion mutants
(e.g., truncation mutants). Methods for homologous recombination
are described in U.S. Pat. No. 5,614,396, incorporated herein by
reference.
Experimental
[0377] The following examples are provided in order to demonstrate
and further illustrate certain some embodiments and aspects of the
present invention and are not to be construed as limiting the scope
thereof.
[0378] In the experimental disclosure which follows, the following
abbreviations apply: N (normal); M (molar); mM (millimolar); .mu.M
(micromolar); mol (moles); mmol (millimoles); .mu.mol (micromoles);
nmol (nanomoles); pmol (picomoles); g (grams); mg (milligrams);
.mu.g (micrograms); ng (nanograms); l or L (liters); ml
(milliliters); .mu.l (microliters); cm (centimeters); mm
(millimeters); Jim (micrometers); nm (nanometers); and .degree. C.
(degrees Centigrade).
EXAMPLE 1
Establishing and Analyzing a Solid Tumor Cell Xenograft Model
[0379] This example describes the generation of tumors in mice
using human solid tumor cells from humans and the analysis of these
tumors.
[0380] Materials and Methods
[0381] Mouse preparation. 8-week old female NOD-SCID mice were
anesthetized by an intra-peritoneal injection of 0.2 ml
Ketamine/Xylazine (300 mg Ketamine combined with 20 mg Xylazine in
a 4 ml volume. 0.02 ml of the solution was used per 20 g mouse).
Dilution to 200 .mu.l was done using HBSS. Mice were then treated
with VP-16 (etoposide) via an intra-peritoneal injection (30 mg
etoposide dose per 1 kg mouse, diluted in serum-free HBSS for a
final injection volume of 200 .mu.l). At the same time, estrogen
pellets were placed subcutaneously on the back of the mouse's neck
using a trocar. All tumor injections/implants were done 5 days
after this procedure. In the following procedures, mice were
anesthetized as described above.
[0382] Primary tumor specimen implantations. For the implantation
of fresh specimens, samples of human breast tumors were received
within an hour after surgery. The tumors were cut up with scissors
into small pieces, and the pieces were then minced with a blade to
yield 2.times.2 mm-size pieces. Mincing was done in sterile RPMI
1640 medium supplemented with 20% Fetal Bovine Serum (FBS) under
sterile conditions on ice. The tumor pieces were washed with
serum-free HBSS before implantation. A 2-mm incision was then made
in the mid abdomen area, and using a trocar, one to two small tumor
pieces were implanted in the region of the upper right and upper
left mammary fat pats (right below the second nipple on both
sides). A 6-0 suture was wrapped twice around the MFP-Nipple
allowing it to hold the implanted pieces in place. Sutures were
removed after 5 days. Nexaban was used to seal the incision and
mice were monitored weekly for tumor growth.
[0383] Pleural effusions injections. For the injection of the
pleural effusions, cells were received shortly after thorocentesis
and washed with serum-free HBSS. Cells were then suspended in serum
free-RPMI/Matrigel mixture (1:1 volume) and then injected into the
upper right and left mammary pads using an 18 G needed. 0.2 ml
containing 1-2 million cells were typically injected. The site of
the needle injection was sealed with Nexaban to prevent any cell
leakage.
[0384] Preparation of single cell suspensions of tumor cells. Prior
to digestion with collagenase, Xenograft tumors or primary human
tumors were cut up into small pieces and then minced completely
using sterile blades. To obtain single cell suspensions, either
pleural effusion cells or the resulting tumor pieces were then
mixed with ultra-pure Collagenase III in HBSS solution (200-250 U
Collagenase per ml) and allowed to incubate at 37.degree. C. for
3-4 hours. Pipetting with a 10 ml pipette was done every 15-20
minutes. At the end of the incubation, cells were filtered through
a 45 .mu.l nylon mesh and washed with RPMI-20% FBS, then washed
twice with HBSS. Cells to be injected were then suspended in
HBSS/Matrigel mix (1:1 volume) and injected into the area of the
mammary fat pad as described above. Nexaban was used to seal the
injection site.
[0385] Cell staining for flow-cytometry. Cells were counted and
then transferred to a 5 ml tube, washed twice with HBSS with 2%
Heat-inactivated calf serum (HICS) (5 min@1000 rpm), then
re-suspended in 100 .mu.l (per 10.sup.6 cells) of HBSS with 2%
HICS. 5 ml of Sandoglobin solution (1 mg/ml) was then added and
incubated on ice for 10 minutes, after which the sample was washed
twice with HBSS 2% HICS and re-suspended in 100 ml (per 10.sup.6
cells) of HBSS 2% HICS. Antibodies (using appropriate dilution per
antibody) were then added and incubated for 20 minutes on ice, and
then washed twice with HBSS 2% HICS. When needed, a secondary
antibody addition was conducted by re-suspending in 100 ul (per
10.sup.6 cells) of HBSS 2% HICS, and then adding 1-4 ml of
secondary antibody (depending on the secondary antibody and its
concentration), followed by a 20 minute incubation. When
streptavidin was used, cells were re-suspended in 100 ul (per
10.sup.6 cells) of HBSS 2% HICS and then 1 ul of strepavidin
conjugated with the indicated fluorescent dye was added, followed
by a 20 minute incubation. The cells were washed twice with HBSS 2%
heat-inactivated fetal calf serum (HICS) and re-suspended in 0.5 ml
(per million cells) of HBSS 2% HICS that contained 7AAD (1 mg/ml
final concentration).
[0386] Flow-cytometry. The antibodies used were anti-CD44 (APC, PE
or Biotin), anti-CD24 (PE or FITC), anti-B38.1 (APC), anti-ESA-FITC
(Biomeda, CA), anti-H2Kd, (Santa Cruz Products, Santa Cruz,
Calif.). Lineage marker antibodies were anti-CD2, -CD3 - CD10,
-CD16, -CD18, -CD31, -CD64 and -CD140b. Unless noted, antibodies
were purchased from Pharmingen (San Diego, Calif.). Antibodies were
directly conjugated to various fluorochromes depending on the
tests. In all tests, mouse cells and/or Lineage.sup.+ cells were
eliminated by discarding H2K.sup.d+ (class I MHC) cells or
Lineage.sup.+ cells during flow-cytometry. Dead cells were
eliminated using the viability dye 7-AAD. Flow-cytometry was
performed on a FACSVantage (Becton Dickinson, San Jose, Calif.).
Side scatter and forward scatter profiles were used to eliminate
cell doublets. Cells were routinely sorted twice and the cells were
re-analyzed for purity, which typically was greater than 95%.
[0387] In solid tumors, it has been demonstrated that only a small
proportion of the tumor cells are able to form colonies in an in
vitro clonogenic assay.sup.21-24,101-103 (Southam & Brunschwig,
1961, Cancer 14:971-8; Wodinsky et al., 1967, Cancer Chemother.
Rep. 51:415-21; Bergsagel & Valeriote, 1968, Cancer Res
28:2187-96; Fialkow, 1976, Birth Defects Orig. Artic Ser.
12:123-32; Hamburger & Salmon, 1977, Science 197:461-3;
Heppner, 1984, Cancer Res. 44:2259-65; Weisenthal & Lippman,
1985, Cancer Treat. Report 69:615-48). Furthermore, large numbers
of cells must typically be transplanted to form tumors in xenograft
models. One possible explanation for these observations is that
every cell within a tumor has the ability to proliferate and form
new tumors but that the probability of an individual cell
completing the necessary steps in these assays is small. An
alternative explanation is that only a rare, phenotypically
distinct subset of cells has the capacity to significantly
proliferate and form new tumors, but that cells within this subset
do so very efficiently (Reya et al., 2001, Nature 414:105-11). To
distinguish between these possibilities it is necessary to identify
the clonogenic cells in these tumors with markers that distinguish
these cells from other non-tumorigenic cells. This has been
accomplished in acute myelogenous leukemia (AML), where it was
demonstrated that a specific subpopulation of leukemia cells (that
expressed markers similar to normal hematopoietic stem cells) was
consistently enriched for clonogenic activity in NOD/SCID
immunocompromised mice while other cancer cells were depleted of
clonogenic activity (Lapidot et al., 1994, Nature 17:645-8;
Larochelle et al., 1996, Nat. Med. 2:1329-37; Bonnet & Dick,
1997, Nat. Med. 3:730-7). Such tests have not been reported in
solid cancers.
[0388] To investigate the mechanisms of solid tumor heterogeneity,
a mouse model was developed that was a modification of the NOD/SCID
immunodeficient mouse model in which human breast cancers were
efficiently propagated in the mouse mammary fat pad (Sakakibara et
al., 1996, Cancer J. Si. Am. 2:291-300). In the present
application, it was shown that solid tumors contain a distinct
population of cells with the exclusive ability to form tumors in
mice. These cells are referred to as tumorigenic cells or cancer
initiating cells since they consistently formed tumors while other
cancer cell populations were depleted of cells capable of tumor
formation. Cell surface markers were identified which can
distinguish between these cell populations. These findings provide
a new model of breast tumor biology in which a defined subset of
cells drives tumorigenesis, as well as generating tumor cell
heterogeneity. The prospective identification of this tumorigenic
population of cancer cells allows for the identification of
molecules expressed in these cells that can then serve as targets
to eliminate this critical population of cancer cells.
[0389] Tumor specimens and engraftment rate. Human breast cancer
specimens obtained from primary or metastatic sites in 9 different
patients (designated tumors 1-9; T1-T9) all engrafted in the
NOD/SCID mice. (Table 1). In one case, the cancer cells were
obtained from a primary breast tumor (T2) while in other cases the
cells were obtained from metastatic pleural effusions (T1, T3-T9).
Some tests were conducted on cells after they had been passaged
once or twice in mice (designated Passage 1 & 2) while other
tests were conducted on unpassaged fresh or frozen tumor samples
obtained directly from patients. When using human cancer cells from
tumors passaged in mice, contaminating mouse cells were removed by
eliminating H2K.sup.+ cells [mouse histocompatability class I
(MHC)]. TABLE-US-00011 TABLE 1 Formation Passage Tumor Origin In
mice In mice Diagnosis 1 Metastasis Yes Yes Infiltrating ductal
carcinoma T2 Breast Yes Yes Adenocarcinoma Primary T3 Metastasis
Yes Yes Invasive lobular carcinoma T4 Metastasis Yes No Invasive
lobular carcinoma T5 Metastasis Yes Yes Invasive lobular carcinoma
T6 Metastasis Yes Yes Inflammatory breast carcinoma T7 Metastasis
Yes Yes Invasive lobular carcinoma T8 Metastasis Yes Yes
Inflammatory breast carcinoma T9 Metastasis Yes Yes
Adenocarcinoma
Table 1 presented the results of engraftment of human breast
cancers into NOD/SCID mice. Mice were injected with unsorted T1 and
T3 cells, and a 2 mm piece of T2. Cells from T4-T9 were isolated by
flow cytometry as described in FIG. 1. All 9 tumors tested
engrafted in the NOD/SCID mouse model. Except for T2 which was a
primary breast tumor, all other tumors were metastases. All of the
tumors were passaged serially in mice except for T4.
[0390] Identification of tumorigenicity markers. Breast cancer
cells were heterogeneous with respect to expression of a variety of
cell surface-markers including CD44, CD24, and B38.1. CD24 and CD44
are adhesion molecules, while B38.1 has been described as a
breast/ovarian cancer-specific marker (Kufe et al., 1983, Cancer
Res. 43:851-7; Uchida et al., 2000, PNAS 97:14720-5; Ahrens et al.,
2001, Oncogene 20). To determine whether these markers could
distinguish tumorigenic from non-tumorigenic cells, flow-cytometry
was used to isolate cells that were positive or negative for each
marker from first passage T1 or T2 cells. When
2.times.10.sup.5-8.times.10.sup.5 cells of each population were
injected, all injections of CD44.sup.+ cells (8/8), B38.1.sup.+
cells (8/8), or CD24.sup.-/low cells (12/12) gave rise to visible
tumors within 12 weeks of injection, but none of the CD44.sup.-
cell (0/8), or B38.1.sup.- cell (0/8) injections formed detectable
tumors (Table 2). Although no tumors could be detected by palpation
in the locations injected with CD24.sup.+ cells, 2 of 12 mice
injected with CD24.sup.+ cells did contain small growths at the
injection site that were detected upon necropsy. These growths most
likely arose from the 1-3% of CD24.sup.- cells that invariably
contaminate the sorted CD24.sup.+ cells, or alternatively from
CD24.sup.+ cells with reduced proliferative capacity (Table 2).
Because the CD44.sup.+ cells were exclusively B38.1.sup.+, we
focused on the CD44 and CD24 markers in subsequent tests.
[0391] Several antigens associated with normal cell types (Lineage
markers; CD2, CD3, CD10, CD16, CD18, CD31, CD64, and CD140b) were
found not to be expressed by the cancer cells based on analyses of
tumors that had been passaged multiple times in mice. By
eliminating Lineage.sup.+ cells from unpassaged or early passage
tumor cells, normal human leukocytes, endothelial cells,
mesothelial cells and fibroblasts were eliminated. By microscopic
examination, the Lineage.sup.- tumor cells had the appearance of
neoplastic cells (FIG. 6). TABLE-US-00012 TABLE 2 Tumors/Injections
Cells/Injection 8 .times. 10.sup.5 5 .times. 10.sup.5 2 .times.
10.sup.5 Passsaged T1 CD44- 0/2 0/2 -- CD44+ 2/2 2/2 -- B38.1- 0/2
0/2 -- B38.1+ 2/2 2/2 -- CD24+ -- -- 1/6 CD24- -- -- 6/6 Passaged
T2 CD44- 0/2 0/2 -- CD44+ 2/2 2/2 -- B38.1- 0/2 0/2 -- B38.1+ 2/2
2/2 -- CD24+ -- -- 1/6 CD24- -- -- 6/6
[0392] Table 2 shows the results of cells isolated by flow
cytometry as described in FIG. 1 based upon expression of the
indicated marker and assayed for the ability to form tumors after
injection into the mammary fat pads of NOD/SCID mice. For 12 weeks,
mice were examined weekly for tumors by observation and palpation,
then all mice were necropsied to look for growths at injection
sites that were too small to palpate. The number of tumors that
formed/the number of injections that were performed is indicated
for each population. All tumors were readily apparent by visual
inspection and palpation except for tumors from the CD24+
population that were only detected upon necropsy.
[0393] Depending on the tumor, 11% to 35% of the Lineage.sup.-
cancer cells in tumors or pleural effusions were
CD44.sup.+CD24.sup.-/low (FIG. 4a-1f).
CD44.sup.+CD24.sup.-/lowLineage.sup.- cells or other populations of
Lineage.sup.- cancer cells that had been isolated from nine
patients were injected into the mammary fat pads of mice (Table 3).
When injecting unsorted, passaged T1 or T2 cells, 5.times.10.sup.4
cells consistently gave rise to tumors, but 10.sup.4 cells gave
rise to tumors in only a minority of cases. In contrast, as few as
10.sup.3 T1 or T2 CD44.sup.+CD24.sup.-/lowLineage.sup.- cells gave
rise to tumors in all cases (Table 3). In T1 and T2, up to
2.times.10.sup.4 cells that were CD44.sup.+Lineage.sup.- but
CD24.sup.+ failed to form tumors. These data suggest that the
CD44.sup.+CD24.sup.-/lowLineage.sup.- population is 10-50 fold
enriched for the ability to form tumors in NOD/SCID mice relative
to unfractionated tumor cells. Whether the
CD44.sup.+CD24.sup.-/lowLineage.sup.- cells were isolated from
passaged tumors (T1, T2, T3) or from unpassaged cancer cells
obtained directly from patients (T1, T4-T6, T8, T9), they were
enriched for tumorigenic activity. Note that T7 was the only one of
9 cancers studied that did not fit this pattern (FIG. 4f). Other
than T7, CD24.sup.+Lineage.sup.- cancer cells in both unpassaged
and passaged tumors were unable to form new tumors (Table 3).
Therefore, the xenograft and unpassaged patient tumors were
composed of similar populations of phenotypically diverse cancer
cell types, and in both cases only the
CD44.sup.+CD24.sup.-/lowLineage.sup.-cells had the capacity to
proliferate to form new tumors (p<0.001). TABLE-US-00013 TABLE 3
# of cells per injection 5 .times. 10.sup.5 10.sup.5 5 .times.
10.sup.4 2 .times. 10.sup.4 10.sup.4 5 .times. 10.sup.3 10.sup.3
500 200 100 Mouse passage 1 Unsorted 8/8 8/8 10/10 3/12 0/12
CD44.sup.+CD24.sup.+ 0/10 0/10 0/14 0/10 CD44.sup.+CD24.sup.-/low
10/10 10/10 14/14 10/10 CD44.sup.+CD24.sup.-/low 10/10* 4/4 4/4 1/6
ESA.sup.+ CD44.sup.+CD24.sup.-/low 0/10* 0/4 0/4 0/6 ESA.sup.-
Mouse passage 2 CD44.sup.+CD24.sup.+ 0/9 CD44.sup.+CD24.sup.-/low
9/9 Patients' tumor cells CD44.sup.+CD24.sup.+ 0/3 0/4 0/8 1/13 0/2
CD44.sup.+CD24.sup.-/low 3/3 4/4 11/13 1/1 CD44.sup.+CD24.sup.-/low
2/2 2/2 ESA.sup.+ CD44.sup.+CD24.sup.-/low .sup. 2/2.sup.# 0/2
ESA.sup.-
[0394] As shown in Table 3, tumorigenic breast cancer cells were
highly enriched in the ESA+CD44+CD24-/low population. Cells were
isolated from first passage (designated Mouse Passage 1) Tumor
1,Tumor 2 and Tumor 3, second passage Tumor 3 (designated mouse
Passage 2), unpassaged cells obtained from 6 different patients,
T1, T4, T5, T6, T8 and T9, (designated Patients' tumor cells).
[0395] CD44+CD24+Lineage- populations and CD44+CD24-/lowLineage-
cells were isolated by flow-cytometry as described in FIG. 1. The
indicated number of cells of each phenotype was injected into the
breast of NOD/SCID mice. The frequency of tumorigenic cells
calculated by the modified maximum likelihood analysis method is
.about.5/10.sup.5 if single tumorigenic cells were capable of
forming tumors, and every transplanted tumorigenic cell gave rise
to a tumor (Porter & Berry, 1964, Br. J. Cancer 17). Therefore,
this calculation can underestimate the frequency of the tumorigenic
cells since it does not take into account cell-cell interactions
and local environment factors that can influence engraftment. In
addition to the markers that are shown, all sorted cells in all
tests were Lineage-, and the tumorigenic cells from T1, T2, and T3
were further selected as B38.1+. The mice were observed weekly for
4-61/2 months, or until the mice became sick from the tumors.
#Tumor formation by T5 ESA-CD44+CD24-/lowLINEAGE- cells was delayed
by 2-4 weeks. *2,000 cells were injected in these tests.
[0396] FIG. 1 shows isolation of tumorigenic cells. Flow cytometry
was used to isolate subpopulations of Tumor 1 (a, b), Tumor 3 (c),
Tumor 5 (d), Tumor 6 (e) and Tumor 7 cells (f) that were tested for
tumorigenicity in NOD/SCID mice. T1 (b) and T3 (c) had been
passaged (P) once in NOD/SCID mice while the rest of the cells were
frozen or unfrozen samples obtained directly after removal from a
patient (UP). Cells were stained with antibodies against CD44,
CD24, Lineage markers, and mouse-H2K (for passaged tumors obtained
from mice), and 7AAD. Dead cells (7AAD+), mouse cells (H2K+) and
Lineage+ normal cells were eliminated from all analyses. Each plot
in FIG. 1 depicts the CD24 and CD44 staining patterns of live human
Lineage- cancer cells, and the frequency of the boxed tumorigenic
cancer population as a percentage of cancer cells/all cells in each
specimen is shown.
[0397] In three of the tumors, further enrichment of tumorigenic
activity was possible by isolating the ESA.sup.+ subset of the
CD44.sup.+CD24.sup.-/low population. ESA (Epithelial Specific
Antigen, Ep-CAM) has been used in the past to distinguish
epithelial cancer cells from benign reactive mesothelial cells
(Packeisen et al., 1999, Hybridoma 18:37-40). When
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- cells were isolated
from passaged T1, as few as 200 cells consistently formed tumors of
approximately 1 cm about 5-6 months after injection whereas 2000
ESA.sup.-CD44.sup.+CD24.sup.-/lowLineage.sup.- cells or 20,000
CD44.sup.+CD24.sup.+ cells always failed to form tumors (Table 3).
Ten thousand unsorted cells formed tumors in only 3 of 12 mice.
This suggests that the
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- population was more
than 50 fold enriched for the ability to form tumors relative to
unfractionated tumor cells (Table 3). The
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- population accounted
for 2-4% of first passage T1 cells (2.5-5% of cancer cells). The
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- population (0.6% of
cancer cells) from unpassaged T5 cells was also enriched for
tumorigenic activity compared to
ESA.sup.-CD44.sup.+CD24.sup.-/lowLineage.sup.- cells, but both the
ESA.sup.+and ESA.sup.- fractions had some tumorigenic activity
(Table 3). Among unpassaged T5 cells, as few as 1000
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.-cells consistently
formed tumors.
[0398] In order to determine whether the difference in
tumorigenicity of the cell populations was due to differences in
cell cycle, populations were analyzed by flow-cytometry. Comparison
of the cell cycle status of tumorigenic and non-tumorigenic cancer
cells from T1 revealed that both exhibited a similar cell cycle
distribution (FIG. 2a, 2b). Therefore, neither population was
enriched for cells at a particular stage of the cell-cycle, and the
non-tumorigenic cells were able to undergo at least a limited
number of divisions in the xenograft model.
[0399] FIG. 2 shows the DNA content of tumorigenic and
non-tumorigenic breast cancer cells. The cell cycle status of the
ESA+CD44+CD24-/lowLineage- tumorigenic cells (a) and the remaining
Lineage- non-tumorigenic cancer cells (b) isolated from T1 were
determined by hoechst 33342 staining of DNA content (20). The
tumorigenic and non-tumorigenic cell populations exhibited similar
cell cycle distributions
[0400] Six months after inoculation, the injection sites of 20,000
tumorigenic CD44.sup.+CD24.sup.-/lowLineage.sup.-cells and 20,000
CD44.sup.+CD24.sup.+Lineage.sup.- cells were examined by histology.
The CD44.sup.+CD24.sup.-/lowLineage.sup.- injection sites contained
tumors approximately 1 cm in diameter while the
CD44.sup.+CD24.sup.+Lineage.sup.- injection sites contained no
detectable tumors (FIG. 6c). Only normal mouse mammary tissue was
seen by histology at the sites of the
CD44.sup.+CD24.sup.+Lineage.sup.- injections (FIG. 3a), whereas the
tumors formed the CD44.sup.+CD24.sup.-/lowLineage.sup.- cells
contained malignant cells as judged by hematoxylin and eosin
stained sections (FIG. 3b). Even when
CD.sup.44.sup.+CD24.sup.+Lineage.sup.- injection sites from 58
mice, each administered 1,000-50,000 cells, were examined after
16-29 weeks, no tumors were detected. Furthermore, the tumorigenic
and non-tumorigenic populations were indistinguishable
morphologically. Both the tumorigenic and non-tumorigenic subsets
of Lineage- cells from passaged and unpassaged tumors contained
>95% cancer cells as judged by Wright staining or Papanicolaou
staining and microscopic analysis. By histology, the
CD44.sup.+CD24.sup.-/lowLineage.sup.- cells and the rest of the
Lineage- cells had the appearances of epithelial cancer cells (FIG.
3d, 3e).
[0401] FIG. 3 shows histology from the CD24.sup.+ injection site
(a), (20.times. objective magnification) revealed only normal mouse
tissue while the CD24.sup.-/low injection site (b), (40.times.
objective magnification) contained malignant cells. (c) A
representative tumor in a mouse at the
CD44.sup.+CD24.sup.-/lowLineage.sup.- injection site, but not at
the CD44.sup.+CD24.sup.+Lineage.sup.- injection site. T3 cells were
stained with Papanicolaou stain and examined microscopically
(100.times. objective). Both the non-tumorigenic (c) and
tumorigenic (d) populations contained cells with a neoplastic
appearance, with large nuclei and prominent nucleoli.
[0402] The tumorigenic population is capable of generating the
phenotypic heterogeneity found in the initial tumor. The ability of
small numbers of CD44.sup.+CD24.sup.-/lowLineage.sup.- tumorigenic
cells to give rise to new tumors was reminiscent of the organogenic
capacity of normal stem cells. Normal stem cells self-renew and
give rise to phenotypically diverse cells with reduced
proliferative potential. To test whether tumorigenic breast cancer
cells also exhibit these properties, tumors arising from 200
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- T1 or 1,000
CD44.sup.+CD24.sup.-/lowLineage.sup.- T2 cells were dissociated and
analyzed by flow-cytometry. The heterogeneous expression patterns
of ESA, CD44 or CD24 in the secondary tumors resembled the
phenotypic complexity of the tumors from which they were derived
(FIG. 7a,7b vs 7e,7f). Within these secondary tumors, the
CD44.sup.+CD24.sup.-/lowLineage.sup.- cells remained tumorigenic,
while other populations of Lineage.sup.- cancer cells remained
non-tumorigenic (Table 3). Thus tumorigenic cells gave rise to both
additional CD44.sup.+CD24.sup.-/lowLineage.sup.- tumorigenic cells
as well as to phenotypically diverse non-tumorigenic cells that
recapitulated the complexity of the primary tumors from which the
tumorigenic cells had been derived. These
CD44.sup.+CD24.sup.-/lowLineage.sup.- tumorigenic cells from T1, T2
and T3 have now been serially passaged through four rounds of tumor
formation in mice, yielding similar results in each passage with no
evidence of decreased tumorigenicity. These observations suggest
that CD44.sup.+CD24.sup.-/lowLineage.sup.- tumorigenic cancer cells
undergo processes analogous to the self-renewal and differentiation
of normal stem cells.
[0403] FIG. 4 shows the phenotypic diversity in tumors arising from
CD44+CD24-/lowLineage- cells. The plots depict the CD24 and CD44 or
ESA staining patterns of live human Lineage- cancer cells from
Tumor 1 (a, c and e) or Tumor 2 (b, d and f). T1 CD44+Lineage-
cells (a) or T2 Lineage- cells (b) were obtained from tumors that
had been passaged once in NOD/SCID mice. ESA+CD44+CD24-/lowLineage-
tumorigenic cells from T1 (c) or CD44+CD24-/lowLineage- tumorigenic
cells from T2 (d) were isolated and injected into the breasts of
NOD/SCID mice. Panels (e) and (f) depict analyses of the tumors
that arose from these cells. In both cases, the tumorigenic cells
formed tumors that contained phenotypically diverse cells similar
to those observed in the original tumor.
[0404] Expression of Wnt pathway genes in subpopulations of breast
cancer tumor cells. The Frizzled proteins are receptors for the
growth/survival factors of the Wnt family. In some normal stem
cells, Wnt is known to play a role in proliferation, survival and
differentiation. In certain situations, stimulation of Wnt can
promote stem cell self-renewal. Upon activation, Wnt induces the
stabilization of .beta.-catenin. Flow cytometry using an antibody
against .beta.-catenin demonstrates that Tumor 1 cells express this
protein (FIG. 5). Immunohistochemistry shows that the
.beta.-catenin is located in the cytoplasm and the nucleus,
indicating that the protein is active (data not shown). Different
Wnt proteins specifically activate different frizzled receptors
(Taipale & Beachy, 2001, Nature, 411:349). Since the Wnt
signaling pathway appears to play a critical role in proliferation
of both normal and breast cancer cell proliferation, the expression
of Wnt pathway genes in Tumor 1 tumorigenic cells and
non-tumorigenic cells was examined (FIG. 5). To do this, one
hundred ESA.sup.+B38.1.sup.+CD24.sup.-/loLINEAGE.sup.-
(tumorigenic) or non-tumorigenic tumor cells were isolated. RT-PCR
using nested primers for each of the frizzled proteins was done.
These results demonstrate that the tumorigenic cells expressed
frizzled 2 and 6, while the non-tumorigenic cells expressed
frizzled 2 and 7 (FIG. 5). These tests have been repeated twice
with identical results. Next, members of the Wnt family expressed
by the breast cancer cells were identified. RNA was isolated from
10,000 stem and non-tumorigenic cells. There are more than 20 known
members of the Wnt family, making it difficult to analyze
expression of particular Wnts in breast cancer tumors. Therefore
RT-PCR was performed using degenerate primers that recognize all
known Wnt genes and cloned and sequenced the resultant cDNA.
Surprisingly, we were able to detect expression of cDNA only by the
non-tumorigenic cells (FIG. 5). This was confirmed doing RT-PCR at
the ten-cell level. Frizzled 6 expression was detected in nine of
ten tumorigenic samples, and only one of ten non-tumorigenic cell
samples. The cDNA was cloned, and sequencing revealed that these
cells expressed Wnt 3A, 4, 7A, 7B, 10B, and 11. Wnt signals have
been implicated in the growth of both breast cancer cells and
normal endothelial cells. While not necessary to understand to
practice the present invention, this suggests that the
non-tumorigenic cells promote tumor formation both by stimulation
of breast cancer stem cells and vessel formation via the Wnt
pathway. This model fits very well with known observations that it
is much easier to grow breast cancers using pieces of tissue as
opposed to individual cells (Bergsagel & Valeriote, 1968,
Cancer Res. 28:2187-96).
[0405] FIG. 5 shows the expression of Wnt (left panel) and Frizzled
(right panel). In regard to the left panel, RT-PCR was done using
degenerate Wnt primers with RNA isolated from 10,000 cells of the
indicated type. + or - indicates whether RT was used. Right panel.
RNA was isolated from one hundred breast cancer cells or breast
cancer stem cells isolated by flow cytometry as described in FIG.
1. RT-PCR was done using nested primers to detect the indicated
mRNA. Control RT-PCR reactions omitting RT were negative.
[0406] To confirm the RT-PCR results for the expression of frizzled
proteins, an Affymetrix microarray was probed with cDNA made from
Tumor 1, Tumor 2 and Tumor 3 cancer stem cells. All three tumors
expressed Frizzled 2 & 6. In addition, Tumors 2 & 3
appeared to express frizzled 4.
[0407] Isolation of normal cells from a tumor. Efforts were then
made to determine whether sufficient normal cells could be isolated
from a tumor to do molecular studies with these cells. Normal
fibroblast and endothelial cells from a patient's tumor
(approximately 3 cm in size) were isolated by flow-cytometry. 2% of
the tumor cells were CD31.sup.+ endothelial cells and 8% were
CD140b.sup.+ fibroblasts (FIG. 6). Nine thousand fibroblasts and
two thousand endothelial cells were collected when 1/45 of the
tumor was used for flow cytometry. By extrapolation, it would have
been possible to isolate approximately 90,000 endothelial cells and
405,000 fibroblasts from the entire tumor.
[0408] FIG. 6 shows the isolation of normal tumor fibroblasts and
endothelial cells. Tumors were dissociated as described in the
methods section and tumor cells were stained with cytochrome
labeled with antibodies against -CD2, -CD3, -CD16, -CD18, -CD45,
-CD64, and anti-B38.1-APC (to eliminate hematopoietic cells and
tumor cells respectively), anti-CD140b-PE and anti-CD31-FITC. A:
the box shows the sorting gate for fibroblasts, which are
Lineage.sup.- CD31.sup.-CD140b.sup.+ cells. B: the box shows the
sorting gate for endothelial cells, which are CD31.sup.+
Lineage.sup.-cells.
[0409] Infection of breast cancer stem cells with an adenovirus
vector. Since the xenograft tumors can only be grown briefly in
tissue culture, conventional transfection methods are generally not
useful for gene expression studies and only viral vectors have the
potential to efficiently transduce the breast cancer stem cells.
Therefore, the ability of adenovirus vectors to infect T1 breast
cancer stem cells was tested. To do this, groups of 10,000 breast
cancer stem cells or control MCF-7 cells were infected with 0, 50,
500, or 5,000 LacZ adenovirus particles. FIG. 7 shows that we could
easily transduce greater than 90% of the stem cells and they were
more easily infected with the adenovirus vector than were the
control MCF-7 cells. This demonstrates that we can use adenovirus
vectors to transduce the stem cells with recombinant genes.
[0410] FIGS. 7 shows infection of breast cancer stem cells with an
adenovirus vector. Flow cytometry was used to isolate
CD44.sup.+CD24.sup.-/lowLineage.sup.- cells. The Tumor 1 stem cells
or control MCF-7 cells were infected with 0, or 500, or 5,000 LacZ
adenovirus particle/cell. Two days later, the cells were stained
with X-gal. Note that the Tumor 1 stem cells were easily infected
by the adenovirus vector.
[0411] The following data is a description of work that has been
done studying hematopoietic stem cells. It illustrates fundamental
stem cell properties, and it also demonstrates how the isolation of
stem cells enables one to first characterize these cells and then
to do molecular and biochemical studies to functionally
characterize them.
[0412] Adult stem cell numbers are strictly regulated. The
regulation of hematopoietic stem cell (HSC) homeostasis is not well
understood. We screened for genetic polymorphisms that were linked
to differences between mouse strains in the numbers of long-term
reconstituting HSCs or restricted progenitors in the bone marrow.
AKR/J mice had significantly higher frequencies and numbers of both
HSCs and restricted progenitors in their bone marrow than
C57BL/Ka-Thy-1.1 mice. The C57BL/Ka-Thy-1.1 alleles were partially
dominant. A locus on chromosome 17, including the H-2 complex, was
significantly linked to the frequency of long-term self-renewing
HSCs but showed no evidence of linkage to the frequency of
restricted progenitors. Conversely, a chromosome 1 locus exhibited
suggestive linkage to restricted progenitor frequencies but was not
linked to HSC frequency. This demonstrates that there are distinct
genetic determinants of the frequencies of HSCs and restricted
progenitors in vivo. The AKR/J chromosome 17 locus was not
sufficient to increase HSC frequencies when bred onto a C57BL
background. This suggests that to affect HSC frequencies, the
product(s) of this locus likely depend on interactions with
unlinked modifying loci. The present invention demonstrates that
stem cell expansion is under tight genetic regulation in an
animal.
[0413] Genomic analysis of hematopoietic stem cells. Hematopoietic
stem cells (HSCs) have self-renewal capacity and multilineage
developmental potentials. The molecular mechanisms that control the
self-renewal of HSCs are still largely unknown. A systematic
approach using bioinformatics and array hybridization techniques to
analyze gene expression profiles in HSCs was done. To enrich mRNAs
predominantly expressed in uncommitted cell lineages, 54 000 cDNA
clones generated from a highly enriched population of HSCs and a
mixed population of stem and early multipotent progenitor (MPP)
cells were arrayed on nylon membranes (macroarray or high-density
array), and subtracted with cDNA probes derived from mature lineage
cells including spleen, thymus, and bone marrow. Five thousand cDNA
clones with very low hybridization signals were selected for
sequencing and further analysis using microarrays on glass slides.
Two populations of cells, HSCs and MPP cells, were compared for
differential gene expression using microarray analysis. HSCs have
the ability to self-renew, while MPP cells have lost the capacity
for self-renewal. A large number of genes that were differentially
expressed by enriched populations of HSCs and MPP cells were
identified. These included transcription factors, signaling
molecules, and previously unknown genes.
[0414] Bmi-1 is required for HSC self-renewal. The gene expression
analysis of HSCs allowed us to identify genes potentially important
for self-renewal. After analysis of the gene expression data, we
began mechanistic studies to identify important stem cell
regulatory genes. A central issue in stem cell biology is to
understand the mechanisms that regulate self-renewal of HSCs, which
is required for hematopoiesis to persist for the lifetime of the
animal. We found that adult and E14.5 fetal mouse and adult human
hematopoietic stem cells express the proto-oncogene bmi-1. The
number of fetal liver HSCs, as measured by flow cytometry, was
normal in loss of function bmi-1 mice, and the bmi-1.sup.-/-HSCs
were able to migrate normally towards a chemokine gradient. In
post-natal bmi-1.sup.-/- mice, the number of HSCs, but not early
progenitor cells was markedly reduced. Both fetal liver and bone
marrow cells obtained from bmi-1.sup.-/- mice were able to
contribute only transiently to hematopoiesis when transplanted into
lethally irradiated recipients. There was no detectable
self-renewal of adult hematopoietic stem cells, indicating a cell
autonomous defect in bmi-1.sup.-/- mice. This study indicates that
expression of bmi-1 is essential for the generation of
self-renewing adult hematopoietic stem cells. See the manuscript by
Park et al., "Bmi-1 is required for maintenance of adult
self-renewing hematopoietic stem cells" Nature (2003).
[0415] Summary: The xenograft model developed by this laboratory
has made possible the analysis of human breast cancer cells at the
cellular level. Although cancer cell lines have proven useful for
many studies, the cell lines are adapted to the unique conditions
imposed by tissue culture and many of their properties clearly
differ from the cancer cells in patients' tumors (Porter &
Berry, 1964, Br. J. Cancer 17; Brown, 1997, Oncol. Res. 9:213-5).
Recently, the size of primary breast cancer tumors prior to
resection has markedly decreased. This has made biological and
biochemical studies using patient samples difficult. It is
contemplated that the xenograft model described in the preliminary
results ameliorates this problem. Preliminary results suggest that
the xenograft tumors appear to recapitulate the phenotypic and
biological diversity seen in the original patients' tumors.
Although there can be some differences in the mouse and human
tumors due to environmental factors, the NOD/SCID model described
here is the best available model of human breast cancer. Results
demonstrate that breast cancer cells reliably engraft in this
xenograft model and in the early passages reflect the cellular and
biological diversity found in the original human tumor. These tests
also show that different populations of cancer cells can differ in
their ability to form tumors.
EXAMPLE 2
Characterizing the Wnt/.beta.-Catenin Pathway in Human Breast
Cancer Tumors Using Systems and Methods of the Present
Invention
[0416] This Example provides illustrative screening methods using
the sytems and methods of the present invention. This example
describes, for example, how one could characterize the
Wnt/.beta.-catenin pathway in human breast cancer tumors using the
xenograft model described above. The Wnt/.beta.-catenin pathway
plays a role in the proliferation and self-renewal of normal stem
cells. Although a significant percentage of human breast cancers
appear to have constitutive activation of this critical pathway,
unlike colon cancer, it has not been definitively established what
role this pathway plays in the pathology of this disease in humans
(Candidus et,al., 1996, Cancer Res. 56:49-52; Sorlie et al., 1998,
Hum. Mutat. 12:215; Jonsson et al., 2000, Eur. J. Cancer 36:242-8;
Schlosshauer et al., 2000, Carcinogenesis 21:1453-6; Lin et al.,
2000, PNAS 97:4262-6; Wong et al., 2002, J. Pathol. 196:145-53).
The xenograft model described above can be used to characterize the
biological consequences of this pathway in human breast cancer
tumors. These tests are done using cancer cells directly after
removal from patients and early passage xenograft tumors.
[0417] The function of the Wnt/frizzled/.beta.-catenin signaling
pathway in multiple patients' tumors. Rationale: Almost 90% of
colon cancers contain mutations that result in activation of
.beta.-catenin. The most common mutations are in the APC gene,
which is involved in targeting .beta.-catenin for degradationn, or
mutations in the .beta.-catenin protein itself (Webster et al.,
2000, Genes Chromosomes Cancer 28:443-53; Taiple & Beachy,
2001, Nature 411:349-54). These latter mutations prevent
degradation. Although the cancer cells in many breast tumors appear
to have constitutively active of .beta.-catenin, in contrast to
colon cancer, mutations in the APC gene or .beta.-catenin itself
account for only 6-10% of these cases (Candidus et al., 1996,
Cancer Res. 56:49-52; Sorlie et al., 1998, Hum. Mutat. 12:215;
Jonsson et al., 2000, Eur. J. Cancer 36:242-8; Schlosshauer et al.,
2000, Carcinogenesis 21:1453-6; Lin et al., 2000, PNAS 97:4262-6;
Wong et al., 2002, J. Pathol. 196:145-53). Examination of the
Wnt/.beta.-catenin signaling pathway in breast cancer cells should
lead to new insights into the pathogenesis of this disease. There
are a large number of Wnt proteins that are thought to
differentially bind to different Frizzled receptors (Nusse et al.,
1991, Cell 64:231; Nusse, 1992, J. Steroid Biochem. Mol. Biol.
43:9-12; Cadigan & Nusse, 1997, Genes & Dev. 11:3286-305;
Nusse, 1999, Trends Genet. 15:1-3; Taiple & Beachy, 2001,
Nature 411:349-54). Only a subset of Wnts, and by inference
Frizzled receptors, can activate .beta.-catenin. Normally,
.beta.-catenin is bound to E-cadherin at the cell membrane.
Cytoplasmic .beta.-catenin forms a complex with the APC and Axin
proteins and facilitates .beta.-catenin phosphorylation by
GSK3.beta. (Sorlie et al., 1998, Hum. Mutat 12:215; Jonsson et al.,
2000, Eur. J. Cancer 36:242-8; Webster et al., 2000, Genes
Chromosomes Cancer 28:443-53). The phosphorylated .beta.-catenin is
then degraded via the ubiquitin degradation pathway. However, upon
activation of frizzled receptors by a Wnt, .beta.-catenin is
stabilized. The protein then translocates to the nucleus where it
forms a complex with the LGLS/BCL9, PYGO and TCF proteins to
activate transcription (Korinek et al., 1998, Mol. Cell Biol.
18:1248-56; Kramps et al., 2002, Cell 109:47-60). We believe that
our xenograft model and cellular assays are unique and powerful
tools for understanding this critical pathway. We analyze 10 tumors
that have constitutive .beta.-catenin signaling and 10 that do not.
These studies give new insights into the mechanisms by which the
Wnt pathway is activated and the consequences of this activation in
human breast cancer.
[0418] In mice, ectopic expression of various Wnt proteins results
in breast tumor formation, while in humans activated .beta.-catenin
in breast cancer cells is associated with expression of cyclin D1
and poor prognosis (Nusse & Varmus, 1982, Cell 31:99-109;
Nusse, 1991, Curr. Topics Microbiol. Immunol. 171:43-65; Nusse,
1992, J. Steroid Biochem. Mol Biol. 43:9-12; Lin et al., 2000, PNAS
97:4262-6). However, it is not known whether continuous
.beta.-catenin signaling is necessary for tumorigenic breast cancer
cells to form tumors. There are several possible roles that
constitutive .beta.-catenin signaling can play in human breast
cancer. First, it can be necessary for continued proliferation
and/or viability of the tumorigenic cancer cells. Next, it can be
necessary for the initiation of the tumor, but subsequent mutations
bypass the need for .beta.-catenin signaling. Third, it can make
the cancer cells more resistant to chemotherapy due to the
activation of downstream targets such as cyclin D1. Fourth,
constitutive .beta.-catenin signaling accelerates cancer cell
growth, but is not necessary for tumorigenicity. Finally, the role
of .beta.-catenin signaling in tumor formation might differ in
tumors with and without constitutive activation of .beta.-catenin.
For example, the former tumors might require .beta.-catenin
signaling whereas the latter tumors might require Wnt signals from
other tumor cells or they might be independent of .beta.-catenin
because they have constitutive activation of downstream targets
such as c-myc and/or cyclin D1. The tests described here are
designed to distinguish between these possibilities using a novel
xenograft model of human cancer. The data shows that the xenograft
model virtually recapitulates a human breast tumor. Thus, this
model allows us to study the Wnt pathway in de novo human tumors in
as physiological conditions as possible.
[0419] Is .beta.-catenin signaling required for tumor formation by
cancer cells isolated from multiple patients? The tests here
determine whether the .beta.-catenin pathway is obligate for breast
cancer cell growth or whether activation is not required for tumor
formation but does increase the rate of proliferation of the cancer
cells. Although the xenograft tumors appear to closely resemble
human tumors, over time selection pressure result in tumors that
are adapted to the mouse environment. The cancer cells in such
tumors differ in some ways with the cancer cells that made up the
original human tumors. We identify cancer cells from five different
xenograft tumors and five unpassaged tumors that have activated
.beta.-catenin (cytoplasmic and/or nuclear expression by
immunohistochemistry) and cancer cells from five xenograft tumors
and five unpassaged tumors that do not (membrane-associated
expression by immunohistochemistry). We select tumors that are
heterogeneous for important prognostic features that include
estrogen receptor/progesterone receptor (ER/PgR), primary tumor vs.
metastatic tumor, wild type vs. mutant p53, and amplification of
Her2/neu.
[0420] To identify cells that have constitutive activation of
.beta.-catenin, we take advantage of the observation that this
results in stabilization of .beta.-catenin and accumulation of the
protein in the cytoplasm and nucleus. When not activated,
.beta.-catenin is associated with the plasma membrane. We therefore
analyze the breast cancer cell population from each of the tumors
using immunohistochemistry to determine the sub-cellular
localization of .beta.-catenin and using flow cytometry to
determine the amount of .beta.-catenin expressed by each population
of cells. To do this, we use flow cytometry to isolate the Lineage-
cancer cells from multiple tumors. Viably frozen xenograft or
patient tumor cells are used for this analysis. The cancer cells
then are stained with an anti-.beta.-catenin-FITC antibody for
immunohistochemistry and flow cytometry analysis using the antibody
manufacturer's protocol (Transduction Laboratories). Cells with
activated .beta.-catenin have cytoplasmic/nuclear localization and
increased levels of the protein.
[0421] To determine the role of .beta.-catenin signaling in
tumorigenesis, Lineage.sup.- cancer cells isolated from each of the
20 tumors are infected with either an adenovirus vector or a
lentivirus vector that contains a dominant-negative (dn)
TCF4-IRES-GFP minigene or a control GFP virus (for details of virus
construction and use, see Clarke et al., 1995, PNAS 92: 11024-8).
The adenovirus vector expresses the dnTCF4 transiently for 1-3
weeks, while the lentivirus vector expresses the dnTCF4
permanently. The dnTCF4 adenovirus has already been made using a
dnTCF4 minigene (a gift from Eric Fearon). The dnTCF4 forms a
complex with .beta.-catenin thereby inhibiting transcriptional
transactivation by the activated .beta.-catenin. Note that the
dnTCF4 blocks signaling from all members of the TCF family that
mediate .beta.-catenin signaling (Eric Fearon, personal
communication). Limiting dilution tests are done to determine the
ability of the transduced cells to form colonies in vitro and
tumors in vivo. The tests here are done using cancer cells isolated
from either patient or human tumors by flow-cytometry. By
eliminating the lineage cocktail to eliminate the normal cells,
colony formation in tissue culture and tumor formation in mice by
cancer cells can be measured (The possible contributions of normal
stromal cells to the growth of tumorigenic cells are analyzed as
described below in aim 2B). To determine the role of .beta.-catenin
signaling on cancer cell growth and viability, five sets of 1,000,
5,000, 20,000, 50,000 and 100,000 Lineage.sup.- cancer cells from
each of the tumors infected with the dnTCF4 viruses (either the
adenovirus or lentivirus vectors) and control viruses are cultured
in vitro in medium containing the Notch ligand Delta and the number
of colonies that form are determined. The colonies in a control
tissue culture plate are stained with cytokeratin to confirm that
they arose from neoplastic cells (Ethier et al., 1993, Cancer Res
53:627-35). Two days after infection the cells are examined with a
fluorescent microscope to confirm that greater than 90% of the
cells were transduced by the virus. Similarly, in vivo limiting
dilution tests are done to determine whether the dnTCF4 viruses
affect tumor formation by the cancer cells isolated from the
different patients. After infection, ten sets of 5,000, 20,000,
50,000 and 100,000 Lineage.sup.- cancer cells are isolated by
flow-cytometry and then infected with the dnTCF4 adenovirus or
control adenovirus. The infected cells are injected into the breast
of NOD/SCID mice. We then determine the number of cancer cells
needed to form tumors in each group, the time needed to form tumors
in each group, the rate of growth of each group, and the size of
the tumors that form in each group. This allows us to determine
whether .beta.-catenin is necessary for tumor formation by cancer
cells that do or do not have constitutively activated
.beta.-catenin.
[0422] Subsequent tests depend on the results of the in vivo and in
vitro limiting dilution tests. If inhibition of .beta.-catenin
transcriptional transactivation blocks tumor formation or slows
tumor growth, then we begin to test whether downstream
.beta.-catenin targets such as cyclin D1 or c-myc are required for
tumorigenicity (Lin et al., 2000, PNAS 97:4262-6; Yu et al., 2001,
Nature 411:1017-21; Wong et al., 2002, J. Pathol. 196:145-53). To
do this, we infect the Lineage- cancer cells isolated by
flow-cytometry and infect the cells with either the control or
dnTCF4 adenovirus as well as a control gfp vector, a c-myc-IRES-gfp
retrovirus vector, a cyclin D1-IRES-rfp retrovirus vector, or both
the myc-IRES-gfp and the cyclin D1-IRES-rfp retrovirus vectors.
Infected cells are isolated by flow cytometry, and then ten sets of
5,000, 10,000, 20,000, 50,000 or 100,000 Lineage- cancer cells of
each test group are injected into mice. The mice are analyzed
weekly for the formation of tumors, and the rate of growth of each
test group. This allows us to determine whether enforced expression
of either c-myc and/or cyclin rescues the cells from inhibition of
.beta.-catenin signaling.
[0423] If inhibition of .beta.-catenin does not have any
discernable effects on tumor formation, we first confirm that both
of the dominant-negative viruses are inhibiting expression of the
dnTCF4 minigene. If not, we use another method to inhibit the
.beta.-catenin pathway. In addition to RNA-i and antisense
approaches (Sazani et al., 2001, Nucl. Acid Res. 29:3965-74; Caplen
et al., 2001, PNAS 98:9742-7; Martinez et al., 2002, Cell
110:563-74; Paul et al., 2002, Nat. Biotech. 29:505-8),
overexpression of Axin (which targets .beta.-catenin for
degradation) can be used to inhibit .beta.-catenin (Hedgepeth et
al., 1999, Mol. Cell Biol. 19:7147-57; Spink et al., 2000, EMBO
19:2270-9). If .beta.-catenin signaling was inhibited and there was
minimal or no effect on tumor formation, then we determine whether
there are more subtle changes on the cancer stem cells. Expression
of cyclin D1, whose expression is induced by .beta.-catenin, has
been associated with resistance to chemotherapy. Therefore, we
treat mice with Adriamycin (8 mg/kg) or Taxol (60 mg/kg) five days
after the dnTCF4-transduced or control cancer stem cells were
injected into mice to determine whether inhibition of
.beta.-catenin enhance the efficacy of chemotherapy. The effect on
tumor formation and tumor growth rate is determined as described
above.
[0424] Expected results. Although cancer cells in a significant
number of breast tumors have a constitutively active .beta.-catenin
signaling pathway, it is not known whether this pathway is
essential for malignant transformation. If the Wnt/.beta.-catenin
pathway is necessary for the cancer cells to form tumors, then
dominant-negative inhibitors block the ability of cancer cells to
form tumors. If constitutive .beta.-catenin signaling enhances
tumor cell growth after malignant transformation but is not
necessary for tumor formation, then the dominant-negative inhibitor
slow growth of the tumor cells but not block tumor formation. If
oncogenic mutations subsequent to tumor initiation make the cells
independent of Wnt signaling, then the dominant-negative inhibitor
do not affect tumor formation or growth. Finally, it is possible
that constitutive activation of the Wnt pathway contributes to
resistance to apoptosis and therefore makes the cells resistant to
chemotherapy.
[0425] In a model of mouse cancer, a brief inhibition of c-ras or
c-myc activity in cancer cells transformed by these genes resulted
in a permanent loss of tumorigenicity (Chin et al., 1999, Nature
400:468-72; Jain et al., 2002, Science 297:102-4). If this is also
true for .beta.-catenin signaling, then transient inhibition of
signaling by the adenovirus inhibit tumor formation. If inhibition
of .beta.-catenin signaling inhibits tumorigenicity, but the cells
remain viable and restoration of .beta.-catenin signaling enables
them to form tumors, then the adenovirus vector slow tumor
formation whereas the lentivirus vector inhibit tumor formation. If
.beta.-catenin signaling increases the rate of proliferation but is
not obligate for tumorigenicity, then both viral vectors delay
tumor formation and slow the growth of the tumors. If some tumors
rely on .beta.-catenin signaling and others rely on other pathways
or have constitutive activation of downstream effectors of
.beta.-catenin signaling, then some tumors are affected by the
viral vectors while others do not. The tests described above allow
us to answer these critical questions using a unique model
recapitulates human tumors. These tests for the first time
delineate the biological function(s) of .beta.-catenin signaling in
de novo human breast cancers.
[0426] The lentivirus can be made using other envelopes until one
is found that infects the cells efficiently (Hughes et al., 2002,
Mol. Ther. 5:16-24; Wang et al., 2002, PNAS 94:10705-10).
[0427] Note that with the lentivirus vector, infection efficiency
can only be in the range of 30-70%. This would mean that a
significant number of tumor cells would remain that could form
tumors. However if inhibition of .beta.-catenin signaling inhibits
tumor formation, then the resultant tumors would not express gfp.
Flow cytometry is used to measure gfp-expressing cells in the
tumors infected with the dnTCF4 and control viruses. The tumors
arising from the dnTCF4 group have a marked decrease in such cells
if .beta.-catenin signaling does play a role in tumor
formation.
[0428] Does inhibition of .beta.-catenin signaling alter the
phenotype of tumorigenic breast cancer cells? One of the
informative markers useful for the separation of tumorigenic and
non-tumorigenic breast cancer cells is CD44. Interestingly, CD44 is
one of the target genes that is transcriptionally upregulated by
.beta.-catenin and epithelial stem cells, but not their
differentiated progeny, are felt to express this marker (Liu et
al., 1997, PNAS 94:10705-10; van de Wetering et al., 2002, Cell
111:241-50). We contemplate that inhibition of .beta.-catenin
signaling result in the differentiation of the tumorigenic breast
cancer cells and cause them to lose expression of CD44. We further
contemplate that the CD44.sup.- non-tumorigenic cancer cells do not
have active .beta.-catenin. To test this, we use flow-cytometry to
isolate ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage- cancer cells from
Tumor 1, Tumor 2 and Tumor 3 and infect them with the dnTCF4
adenovirus or a control adenovirus. The cells are cultured in
tissue culture medium containing soluble Delta. We have found that
this medium allows the tumorigenic cells to grow in tissue culture
for 1-3 weeks. The cells are monitored for growth in vitro over a
3-week period. In addition, 1, 3 and 7 days after infection, the
dnTCF4 adenovirus or a control adenovirus infected cells are
analyzed by flow-cytometry for the expression of ESA, CD44 and
CD24.
[0429] Next, we determine if there is a difference in
.beta.-catenin signaling in the tumorigenic cancer cells, the
CD44.sup.+ cancer cells, or the CD44.sup.- cancer cells. To do
this, we use flow-cytometry to isolate
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage- tumorigenic cancer cells,
CD44.sup.+ cancer cells, and CD44.sup.- non-tumorigenic cancer
cells from tumor 1, tumor 2 and tumor 3. Each population of cells
are stained with an anti-.beta.-catenin antibody that has been
conjugated with APC. Each population of cells are analyzed by
fluorescent microscopy to determine whether the .beta.-catenin is
membrane bound (not constitutively active), and by flow-cytometry
to determine the amount of the protein in the cells. The level of
.beta.-catenin is associated with activity. In addition, we use
commercially available antibodies that recognize phosphorylated and
unphosphorylated .beta.-catenin. The phosphorylated form is marked
for degradation while the unphosphorylated form is active (van
Noort et al., 2002, J. Biol. Chem. 277:17901-5; van Noort et al.,
2002, Exp. Cell Res. 274-72). These tests allow us to determine
whether CD44 expression and .beta.-catenin signaling are linked in
patients' cancer cells.
[0430] CD44 is one of the best markers that allows one to
distinguish tumorigenic cancer cells from non-tumorigenic cancer
cells. Since CD44 is transcriptionally activated by .beta.-catenin,
then inhibition of .beta.-catenin signaling result in
downregulation of CD44.
[0431] Does the differential expression of the frizzled proteins
affect breast cancer stem cell fate in Tumor 1? Data suggest that
in Tumor 1, the tumorigenic stem cells express frizzled 2 and 6,
whereas the non-tumorigenic neoplastic cells express Wnt 3, 4, 7A,
7B, 10B, and 11. This suggests a paracrine system in this
particular tumor where the non-tumorigenic cells might drive the
proliferation of the cancer stem cells. Preliminary data also
suggest that in Tumor 1, the tumorigenic stem cells express
frizzled 2 and 6, whereas the non-tumorigenic neoplastic cells
express frizzled 2 and 7. It is possible that differential
expression of frizzled genes plays a role in cancer cell fate
decisions. The other possibility is that differential expression of
these genes is a function of differentiation or immortality but
does not directly regulate cell fate decisions in this tumor. This
Example illustrates systems of the present invention that find use
in distinguishing between these possibilities.
[0432] Tumor 1 tumorigenic cells express frizzled 6 and
non-tumorigenic cancer cells express frizzled 7. It is possible
that frizzled 6 enhances and frizzled 7 inhibits the proliferation
or self-renewal of the cancer cells. To test this possibility, in
vitro and in vivo clonogenic assays are done. Tumor 1 tumorigenic
and non-tumorigenic cancer cells are infected with a lentivirus
vector that expresses either frizzled 6-IRES-GFP or frizzled
7-IRES-GFP. A lentivirus is used rather than an adenovirus since
the former virus can infect and stably transduce a high proportion
of primary cells, whereas adenovirus transduction is often
transient. It is conceivable that expression of frizzled 6 confers
the ability to self renew to the cancer cells. If so, infection of
stem cells and/or non-tumorigenic cells with a lentivirus vector
containing a frizzled 6-IRES-GFP minigene can enhance
tumorigenicity of the stem cell or allow the previously
non-tumorigenic cells to form tumors. Conversely, enforced
expression of frizzled 7 can inhibit tumorigenicity. After
infection with either the frizzled or control virus, limiting
dilution tests are done to determine whether enforced expression of
each gene alters the ability of each population of cancer cells to
form tumors.
[0433] These tests allow us to determine whether enforced
expression of frizzled 6 increases stem cell proliferation and/or
self-renewal or expression of frizzled 7 inhibits tumorigenic
cancer cell proliferation and/or self-renewal. To test this
possibility, we isolate the tumorigenic
ESA.sup.+CD44.sup.+CD24.sup.-/lowLineage.sup.- cancer cells and the
other Lineage.sup.-, non-tumorigenic cancer cells are isolated by
flow-cytometry from each of the tumors. First, immunohistochemistry
are done using the anti-.beta.-catenin antibody to determine
whether there is a difference in the amount of active
.beta.-catenin in the tumorigenic and non-tumorigenic cells. Next,
we determine the amount of phosphorylated (inactivated) and
non-phosphorylated (active) .beta.-catenin the tumorigenic and
non-tumorigenic cells (van Noort et al., 2002, J. Biol. Chem.
277:17901-5).
[0434] Next, in vitro assays are designed to determine the affects
of each gene on colony formation by tumorigenic and non-tumorigenic
cancer cells in tissue culture. After isolation by flow cytometry,
each population of cells are infected with an identical MOI of
either the frizzled 6/GFP, frizzled 7/GRP or a control GFP virus.
Triplicate cultures of 100, 500, 1,000 and 5,000 cells are placed
in tissue culture medium. The total number of GFP.sup.+ colonies as
well as the total number of colonies and the number of GFP.sup.+
colonies are counted on days 3, 7, 14, 21 and 28. At the end of 21
days, we attempt to pass the cells to determine whether expression
of the particular frizzled gene affects self-renewal.
[0435] The influence of enforced expression of each frizzled gene
on the ability of the neoplastic cells to form tumors in the
NOD/SCID mice are determined. Normally, 200 Tumor 1 cells are
required to form a tumor. Therefore, the frizzled 6, frizzled 7 or
a control GFP lentivirus are used to infect 50, 100, 500, 1,000,
5,000, and 10,000 tumorigenic cancer cells or non-tumorigenic
cancer cells. The cells are injected into the immunodeficient mice.
The number of cells needed to form tumors and the rate of tumor
growth are monitored. After the tumors have reached one centimeter
in size, they are excised and analyzed by flow cytometry for
expression of GFP. By comparing the percentage of cells infected by
the GFP virus and frizzled/GFP virus, we are able to estimate the
efficiency of infection and the affect of the latter virus on
proliferation. These tests are replicated three times.
[0436] Predicted Results: In Tumor 1, different populations of
cells express different frizzled proteins, and the non-tumorigenic
cells appear to preferentially express Wnt proteins. This suggests
that certain populations of non-tumorigenic cells promote tumor
formation through Wnts. If .beta.-catenin signaling is
downregulated in the non-tumorigenic cells and active in the
tumorigenic subset, this is detected by the immunohistochemistry
analysis of the expression patterns of phosphorylated &
unphosphorylated .beta.-catenin in the non-tumorigenic and
tumorigenic cancer cells respectively. If there is no affect of the
particular frizzled/GFP virus, then a similar percentage of cells
would express GFP in each group and there is no difference in the
number-of cells needed to form a tumor. If the particular frizzled
virus decreases or increases tumorigenicity or proliferation, then
tumors infected with frizzled/GFP virus would have fewer or more
GFP.sup.+ cells and/or would require more or fewer cells to form
tumors, respectively.
[0437] If necessary, a Feline Leukemia Virus lentivirus based
vector system is used. This latter vector efficiently transduces
non-replicating cells, and results in prolonged expression of
transgenes. We can infect cells using a tet-inducible
dnTCF-IRES-GFP lentivirus flanked by gene insulators or a control
GFP lentivirus. 1-2 days prior to harvesting tumors, the transgene
is activated. GFP.sup.+breast cancer stem cells are harvested and
transplanted into the breasts of NOD/SCID mice. We continue to
induce the expression of the transgene in the mice, and we are able
to monitor them for the ability of the cells to form tumors.
[0438] The .beta.-catenin signaling pathway differs in the cancer
cells isolated from cancers with and without constitutively
activated .beta.-catenin. Rationale: Unlike colon cancer, mutations
in the .beta.-catenin signaling pathway have been detected in only
a minority of breast cancer cells. However, these studies have
concentrated only on APC and .beta.-catenin. Using the systems and
methods of the present invention, we closely examine the
.beta.-catenin pathway in each of the tumors that were analyzed at
the biological level in specific aim 1A.
[0439] Does the Wnt pathway differ in cancer cells isolated from
different tumors? In these experiments, we characterize the
Wnt/.beta.-catenin pathway in each of the tumors. To do this, we
use RT-PCR to amplify the coding sequence of .beta.-catenin, each
of the frizzled proteins, the low-density lipoprotein-related Wnt
receptors, APC, TCF family members, Axin, and Bcl-9 expressed by
the cancer cells from each of the 10 tumors with constitutive
activation of .beta.-catenin. RT-PCR products of the expressed
genes are sequenced to determine whether there are mutations in any
of the genes. Any possible mutant genes are confirmed by repeated
sequencing of an independent RT-PCR sample. If mutations are found,
we determine whether the mutations result in the constitutive
activation of the Wnt/.beta.-catenin pathway. To do this, the
mutated gene-IRES-GFP are cloned into the pCDNA3 eukaryotic
expression vector. For example, if we find a mutant frizzled 2,
then HEK 293 cells (which do not have activated B-catenin; Gazit et
al., 1999, Oncogene 18:5959-66) are transfected with the mutant
frizzled 2-IRES-GFP expression vector or a control IRES-GFP vector.
Cells are stained with an anti-.beta.-catenin-PE antibody and
fluorescent microscopy is done to determine whether the mutant
frizzled 6 causes cytoplasmic/nuclear localization of
.beta.-catenin, indicating activation of signaling. This assay
allows us to determine whether mutation of components of the
.beta.-catenin pathway result in aberrant signaling in human breast
cancer stem cells.
[0440] Expected results. Although constitutively active
.beta.-catenin is seen in the cancer cells in a significant number
of breast cancer tumors, the mechanism is not known. There are
differences in the signaling pathway in different tumor cells that
are detected by these studies. If a mutation in a Wnt receptor or
.beta.-catenin modifier is present, then the sequencing studies
detect this difference. If autocrine stimulation is present, then
we see expression of one of the Wnt ligands by the cancer
cells.
[0441] Does Wnt expression by different populations of tumor cells
in some tumors drive breast cancer cell growth? Perhaps more so
than any other type of cancer, a breast cancer tumor contains a
heterogeneous population of normal cells including mesenchymal
(stromal) cells, inflammatory cells, and endothelial cells that
interact with malignant cells to modulate tumor growth and
invasion. The purpose is to begin to understand the role of the Wnt
pathway in such interactions. We contemplate that normal stromal
elements including mesenchymal and endothelial cells produce
different Wnts that influence tumor cell proliferation and
invasion. Just unpassaged tumors are analyzed since the xenograft
tumors would be expected to have infiltrating normal mouse stromal
cells and analysis of the mouse cells would be too complicated.
Purification of these cells by flow-cytometry allow both molecular
and biological analysis of these cells without first placing the
cells in tissue culture. This is particularly important since the
normal cells are known to change expression of genes when cultured
in vitro.
[0442] The normal stromal cells are thought to play a role in the
proliferation of breast cancer cells. It is also likely that the
cell-cell interactions between cancer cells contribute to tumor
growth. Wnt signaling is one of the major pathways that normal
tissue cells use to talk to each other. Therefore, it is important
to understand how this pathway is regulated in tumors. Specific Wnt
proteins can activate specific frizzled receptors. Some frizzled
receptors signal through .beta.-catenin, while others signal
through different pathways. To understand how the various
populations of tumor cells within a tumor might talk to the
tumorigenic breast cancer cells through this pathway, we must first
determine which frizzled and Wnt genes are expressed by the normal
cells and the cancer cells from multiple patients' tumors.
Therefore, we identify the Wnt pathway genes that are expressed by
each population of normal cells and the cancer cells isolated from
the 5 patients' tumor samples that have constitutive .beta.-catenin
signaling and the cancer cells from 5 patients' tumors that do not
have constitutive activation of this protein.
[0443] Since our evidence suggests that there are differences in
the expression of Wnt and frizzled genes in the different
populations of cancer cells, it is important to isolate the
different phenotype subsets of cells in the cancer to do these
tests. This is because the apparently tumorigenic population of
cells is a minority population, and the genes that these cells
express might otherwise be missed in the analyses. Therefore,
flow-cytometry is used to isolate tumorigenic and non-tumorigenic
breast cancer cells, as well as normal endothelial cells and
fibroblasts from the patients' original tumor. This is done as
described in preliminary results and aim 1. RNA is isolated from
pools of 35,000 of each population of cells and then linear
amplification is done to make sufficient probe for the microarray
analysis (Ramalho-Santos et al., 2002, Science 298:597-600; Ivanova
et al., 2002, Science 107:3823; Terskikh et al., 2002, Blood
99:488-98; Akashi et al., 2003, Blood 101:383-9). To determine
which frizzled and Wnt genes are expressed by the each population
of cells found in each tumor, we probe an affymetrix microarray
chip (3 chips for each cell type) that includes the Wnt and
frizzled genes (the newly released U133 chip has the majority of
these genes).
[0444] Results are confirmed by quantitative RT-PCR of the
different populations of cancer cells isolated from the primary
tumors with and without activated .beta.-catenin in the cancer
cells. Real time RT-PCR is done to determine the level of
expression of each of the frizzled and Wnt genes by different
populations of normal and neoplastic tumor cells. To do this, we
make PCR primers for detection each of these genes. Each set of
primers span at least one exon so RT-PCR can be used to detect
expression of the mRNA in different populations of tumor cells.
Flow-cytometry is used to isolate the tumorigenic population of
cells identified in each of the tumors. Real-time PCR then is used
to measure the expression of each of the Wnt pathway-related RNAs
by each respective cell population identified in the microarray
analysis (reviewed in Bustin, 2000, J. Mol. Endocrinol. 25:169-93).
To do the real-time PCR gene expression analysis, mRNA is purified
from 3.times.10.sup.4 cells (isolated by flow-cytometry). Part of
the RNA is used to directly measure RNA amount by the Ribogreen RNA
quantitative method (Molecular Probes, Eugene, Oreg.), and part
used to measure rRNA and GAPDH expression (a control housekeeping
gene) via the Taqman real-time RT-PCR assay. Taken together, these
control measurements allow us to normalize expression of the genes
of interest between the different populations of cells (Bustin,
2000, J. Mol. Endocrinol. 25:169-93). Although fewer cells can be
used in this assay, analysis of RNA isolated from 3.times.10.sup.4
cells should result in a more accurate measurement of gene
expression.
[0445] Each frizzled receptor expressed by the different
populations of cancer cells from each tumor is analyzed for the
ability to activate .beta.-catenin and transform cells when
stimulated by each of the different Wnt genes that are expressed by
different populations of cells within a tumor. Two biological
systems are used for these studies. First, we use HEK 293 cells
transfected with each individual frizzled identified in this screen
to test the ability of the identified Wnts to activate
.beta.-catenin through the frizzled proteins expressed by the
tumorigenic cells. Next, we use a mammary epithelial cell line to
determine whether a particular Wnt or frizzled gene is able to
transform the cell line.
[0446] To measure the biochemical functions of the different Wnt
and Frizzled proteins expressed by the breast cancer cells, we use
a transient transfection assay as described by Gazit et al., 1999,
Oncogene 18:5959-66. In this assay, HEK 293T cells are transiently
transfected with a frizzled minigene or a control minigene and
aTCF-luciferase or control reporter minigene. To test the ability
of a particular Wnt protein to stimulate .beta.-catenin signaling,
a second group of HEK 293T cells are transfected with each of the
Wnt genes expressed by the various populations of tumor cells. The
frizzled-transfected cells are mixed with the Wnt-transfected cells
to measure paracrine activation of a particular frizzled receptor
expressed by the breast cancer stem cells activates .beta.-catenin
when stimulated by a particular Wnt protein expressed by one of the
various populations of tumor cells.
[0447] The C57MG cell line is used to determine whether activation
of particular frizzled receptors by particular Wnts causes
morphological transformation (Wong et al., 1994, Mol. Cell Biol.
14:6278-86). These cells undergo morphologic transformation when
exposed to Wnt-1, Wnt-2, Wnt-3A, Wnt-6 and Wnt-7A, but not Wnt4,
Wnt-5A, Wnt-5B and Wnt-7B. These data suggest that the
non-transforming Wnts signal differently than the transforming
Wnts, or that they signal through different receptors not expressed
by the C57MG cells. Therefore, to fully characterize the functions
of the different frizzled and Wnt proteins expressed by the cancer
cells in the patients' tumors, we must first determine which
frizzled genes are expressed by the C57MG cells. The cells are
transfected with minigenes that express any frizzled genes
expressed by tumorigenic breast cancer cells but not expressed by
the C57MG cells. Next, cells are cultured in the presence of
lethally irradiated fibroblasts or HEK 293T cells transfected with
individual Wnt genes that were expressed by the different
populations of tumor cells. The cells are analyzed for
morphological transformation as described by Shimizu et al., 1997,
Cell Growth Diff. 8:1349-58.
[0448] Next, we characterize the in vivo response of cancer cells
from the different patients' tumors to different Wnts made by the
tumor cells. The Wnt proteins are often found in the extracellular
matrix and difficult to prepare in soluble forms. Therefore, we
make control HEK 293 cell lines that express each of the Wnts made
by the various types of tumor cells present in 2 patients' tumors.
To do this, we first analyze HEK 293 cells to determine whether
they constitutively make any of the Wnt proteins. Next, we stably
transfect the HEK 293 cells with each of the Wnts made by the
patients' tumor cells. To determine the affect of Wnt stimulation
in the breast cancer cells by each of its ligands in vivo, 0, 10,
50, 100, 200, 500 and 1,000 Tumor 1 stem cells are mixed with
500,000 lethally irradiated control 293 cells or 293 cells
transfected with one or more relevant Wnt minigenes and then
injected into immunodeficient mice. Each injection is done in five
mice. The mice then are monitored weekly for tumor formation. If a
particular Wnt stimulates self renewing cell division, then either
fewer cells are needed to initiate a tumor and/or tumors form more
quickly. Conversely, if the ligand induces commitment to
differentiation, then more cells are required to form a tumor
and/or tumors take longer to form.
[0449] Expected results. The interaction of cancer cells with the
normal stromal cells in tumors is thought to be critical for tumor
formation and metastasis (Hanahan & Weinberg, 2000, Cell
100:57-70). The Wnt pathway is one of the central pathways by which
cells in normal tissues communicate (Cadigan & Nusse, 1997,
Genes & Dev. 11:3286-305). It is therefore likely that such
communications are maintained to some extent in tumors. The models
described in this proposal for the first time enable such studies
to be conducted using patients' tumor cells. If the stromal cells
indeed promote tumor growth through Wnt signaling, then the various
populations of stromal cells make specific Wnts that provide a
proliferative signal for the tumorigenic cancer cells.
[0450] To minimize these problems, all tests are done in triplicate
with different numbers of cells. Expression of a control RNA of a
known quantity is used to construct a standard curve to analyze the
data(reviewed in Bustin, 2002, J. Mol. Endocrinol. 25:169-193). If
necessary, new PCR primers are made, or RT is done with gene
specific primers recognizing a different part of the mRNA (oligo dT
primers are used for the RT reaction initially).
[0451] Summary: These tests using the systems and methods of the
present invention provide means for comprehensive detail the
molecular mechanisms by which the .beta.-catenin pathway is
activated in vivo in tumorigenic populations of breast cancer cells
obtained directly from multiple patients' tumors, and the
biological consequences of this activation in de novo breast cancer
cells.
EXAMPLE 3
Localization of .beta.-Catenin in Tumorigenic Cells
[0452] In normal hematopoietic cells, nuclear .beta.-catenin is
found only in the stem cell compartment. Reya et al. further
demonstrate that .beta.-catenin signaling is necessary for normal
stem cells to self-renew. A recently completed analysis of the
subcellular localization of .beta.-catenin in tumorigenic and
non-tumorigenic tumor 1 breast cancer cells further supports this
notion. Normally, the subcellular distribution of .beta.-catenin is
heterogeneous in cancer cells. In some cells, the protein is
located primarily in the outer membrane, while in others primarily
in the nucleus. The subcellular distribution of the protein differs
in the tumorigenic and non-tumorigenic cancer cells. The
.beta.-catenin is primarily located in the cytoplasm of the
non-tumorigenic cancer cells, while it is primarily in the nucleus
of the tumorigenic cells (FIG. 8). Since upon activation by a Wnt
signal, .beta.-catenin translocates from the cell membrane to the
nucleus to activate downstream target genes, this data supports the
hypothesis that Wnt signaling plays a role in the self-renewal of
breast cancer stem cells.
[0453] FIG. 8 shows subcellular localization of .beta.-catenin. A
FITC labeled anti-.beta.-catenin antibody was used to stain (A)
colon cancer cells, which have a constitutively activated
.beta.-catenin, (B) non-tumorigenic T1 breast cancer cells, and (C)
tumorigenic breast cancer cells. The tumorigenic and
non-tumorigenic cancer cells were isolated by flow cytometry as
described in the PNAS manuscript by Al-Hajj et al. Note that the
.beta.-catenin is located primarily in the nucleus of the colon
cancer cells and the breast cancer stem cells, but it is primarily
located on the surface of the non-tumorigenic cells.
[0454] To begin to understand the biological consequences of
.beta.-catenin signaling in breast cancer, we have tested our
dominant negative TCF-4 (dTCF4) adenovirus vector in several cell
lines. This adenovirus acts to inhibit .beta.-catenin signaling.
Two different breast cancer cell lines, SKBR3 and MCF7, and a
gastrointestinal tract cancer cell line, RKO, were infected with
the dTCF4 adenovirus or a control adenovirus (empty vector). Four
days after infection, the number of viable cells in each group was
determined. As shown in FIG. 9, the breast cancer cells infected
with the dTCF4 adenovirus, but not the control adenovirus, died.
These data show that the Wnt pathway does play a role in human
breast cancer.
[0455] FIG. 9 shows inhibition of .beta.-catenin signaling in
cancer cells. Triplicate cultures of SKBR3 cells (A), MCF7 cells
(B) and RKO cells (C) were infected with either an control
adenovirus (empty vector) or an adenovirus vector that expresses a
dominant-negative TCF4 minigene (dTCF4). With increasing virus
concentrations, SKBR3 cells and MCF7 cells, but not RKO cells, lost
viability. Note that the virus titers resulting in cell death were
those needed to efficiently infect most of the target cells with a
control GFP virus (data not shown). This experiment has been
repeated with similar results.
[0456] The observation that .beta.-catenin is located primarily in
the nucleus in the tumorigenic but not the non-tumorigenic cancer
cells taken together with the observation that inhibition of
.beta.-catenin signaling affects the viability of some breast
cancer cell lines shows that like normal stem cells, Wnt signals
can play a role in the self-renewal of cancer stem cells.
EXAMPLE 4
Identifying Stem Cell Cancer Markers
[0457] This Example describes how various stem cell cancer markers
were identified using microarray screens. The results of these
screens were processed and the names of the differentially
expressed genes are reported in Tables 4-9 (see above).
[0458] In order to generate gene expression profiles, human breast
tumorigenic cells which were initially isolated. A series of
samples were accumulated from human breast tumors or normal
tissues. These were generated as follows. Three passaged breast
tumors--breast tumor cells from patient 1, 2, 3 were engrafted on
mice. Each tumor was engrafted on three mice to make the triplicate
tumors. The breast tumorigenic cells were then isolated from these
tumors. Two or three unpassaged breast tumors from three patients
SUM, PE13, PE15 were labeled and sorted into tumorigenic cells (TG)
or non-tumorigenic cells (NTG). Both PE15-TG and PE15-NTG were
triplicate. Two or three normal breast samples were from breast
reduction patients. Breast epithelial cells (Breast) were isolated
with flow cytometry and used for microarray. Two or three normal
colon samples were collected freshly from colon patients. Colon
epithelial cells (Colon) were isolated with flow cytometry and used
for microarray. Two or three normal stem cell samples (normal bone
marrow) were collected from bone marrow donors. Hematopoietic stem
cells (HSC) were isolated with flow cytometry. Probes were made
from the following were made from the various cells types for use
in the microarray analysis.
[0459] In order to perform the various microarray screens
Affymetrix HG-U133 gene chips were used. The normalized gene
expression intensity was used to generate the data that was
collected in a number of large tables. The results in these tables
was processed and used to generate Tables 4, 5, 6, 7a, 7b, 7c, 7d
and 8, which present the names of the genes found to be
differentially expressed. For tables 4-6, candidate cancer markers
were sorted by identifying genes whose expression was greater or
less than 1.5 fold in unpassaged breast tumorigenic cells comparing
to non-tumorigenic cells or the normal stem cells (HSC). Table 6
shows only those genes found to be down regulated in UPTG vs.
UPNTG. Table 5 shows only those genes found to be up regulated in
UPTG vs. HSC. Table 4 shows only those genes found to be up
regulated in UPTG vs UPNTG. For tables 7a, 7b, 7c and 7d, cancer
markers were generated from the larger tables by standard T-test.
These tables were sorted based on T-score is <0.01 and ratio is
more than 2 fold. Table 7a shows only those genes found to be up
regulated in UPTG vs. HSC. Table 7b shows only those genes found to
be down regulated in UPTG vs. HSC. Table 7c shows only those genes
found to be up regulated in PTG vs HSC. Table 7d shows only those
genes found to be down regulated in PTG vs HSC.
EXAMPLE 5
Isolation and Enrichment of Cancer Stem Cells Based on Signature 1
and Signature 2 Cancer Stem Cell Markers
[0460] This example describes methods for isolating and enriching
for tumorigenic cancer stem cells from solid tumors based on the
differential expression of signature 1 and signature 2 cancer stem
cell markers identified by the present invention. Methods of
identifying additional cancer stem cell markers using isolated
signature 1 and signature 2 cancer stem cells are also
provided.
[0461] Tumor cells from a patient sample (solid tumor biopsy or
pleural effusion) or from a solid tumor passaged in a xenograft
mouse model are removed under sterile conditions. Tissue samples
are cut up into small pieces and then minced completely using
sterile blades. Single cell suspensions are then obtained by
enzymatic digestion and mechanical disruption. Specifically,
pleural effusion cells or the minced tumor pieces are mixed with
ultra-pure collangenase III in culture medium (200-250 units of
collagenase per mL) and incubated at 37.degree. C. for 3-4 hours
with pipetting up and down through a 10-mL pipette every 15-20 min.
Digested cells are filtered through a 45 ul nylon mesh, washed with
RPMI/20% FBS, and washed twice with HBSS.
[0462] Single cell tumor suspensions are sorted into tumorigenic
and non-tumorigenic cells based on cell surface markers. Cells are
counted, washed twice with HBSS containing 2% heat-inactivated calf
serum (HICS), and resuspended at 10.sup.6 cells per 100 ul.
Antibodies are added and the cells incubated with antibody for 20
min on ice followed by two washes with HBSS/2% HICS. Antibodies
include anti-ESA (Biomeda, Foster City, Calif.), anti-CD44,
anti-CD24, and Lineage markers anti-CD2, -CD3, -CD10, -CD16, -CD18,
-CD31, -CD64, and -CD140b (collective referred to as Lin;
PharMingen, San Jose, Calif.). Antibodies are directly conjugated
to fluorochromes to positively or negatively select cells
expressing these markers. In tissue collected from xenografts,
mouse cells are eliminated by selecting against H2Kd+ cells. Dead
cells are eliminated by using the viability dye 7AAD. Flow
cytometry is performed on a FACSVantage (Becton Dickinson, Franklin
Lakes, N.J.). Side scatter and forward scatter profiles are used to
eliminate cell clumps.
[0463] In some embodiments, cancer stem cells are isolated and
enriched based on their expression levels of transmembrane proteins
identified by the alpha-catenin gene expression signature.
Antibodies are generated against the extracellular domains of the
transmembrane proteins showing increased gene expression in the
alpha-catenin signature, including c-Met, EDG2, and DCBLD2 using
standard techniques, and the generated antibodies are then purified
and directly labeled with fluorochromes. Solid tumor cells are
dissociated and incubated with labeled antibodies against ESA,
CD44, CD24, Lineage markers, c-Met, EDG2, and DCBLD2 as described
above. Flow cytometry is then used to select for cells expressing
high levels of ESA, CD44, c-Met, EDG2, and DCBLD2 and select
against cells expressing CD24 and Lineage markers. Alternatively,
ESA+, CD44+, CD24-/low, and Lin- cells are first isolated as
described above, and this population of cancer stem cells (Al-Hajj
et al., 2003) is incubated with labeled antibodies against c-Met,
EDG2, and DCBLD2 followed by flow cytometry to positively select
cells expressing high levels of c-Met, EDG2, and DCBLD2 Thus is
obtained a tumor cell population enriched for ESA+, CD44+,
CD24-/low, Lin-, c-Met+, EDG2+, and DCBLD2+ signature 1 type cancer
stem cells.
[0464] The tumorigenicity of cells isolated based on an
alpha-catenin gene expression signature is then determined. 5,000,
1,000, 500, and 100 isolated ESA+, CD44+, CD24-/low, Lin-, c-Met+,
EDG2+, and DCBLD2+ cancer stem cells versus identical numbers of
ESA+, CD44+, CD24-/low, and Lin- cancer stem cells or unsorted
dissociated tumor cells are injected into the mammary fat pads of
NOD/SCID mice. Five days before cell injections, mice are prepared
by treatment with 30 mg/kg VP-16 via intraperitoneal injection and
the placement of estrogen pellets subcutaneously. The number of
injected cells required for consistent tumor formation in mice is
used to determine the fold enrichment for tumorigenic versus
non-tumorigenic cells based on isolating signature 1 cancer stem
cells.
[0465] In another embodiment cancer stem cells are isolated and
enriched based on differential expression of transmembrane proteins
identified by the E-cadherin gene expression signature. Antibodies
are generated against the extracellular domains of the
transmembrane proteins showing decreased gene expression in the
E-cadherin gene signature, including IL1R2 and E-cadherin, using
standard techniques, and once generated the antibodies are purified
and directly labeled with fluorochromes. Solid tumor cells are
dissociated and incubated with labeled antibodies against ESA,
CD44, CD24, Lineage markers, IL1R2, and E-cadherin as described
above. Flow cytometry is then used to select for cells expressing
high levels of ESA and CD44 and select against cells expressing
E-cadherin, IL1R2, CD24, and Lineage markers.
[0466] Alternatively, ESA+, CD44+, CD24-/low, and Lin- cells are
first isolated as described above, and this population of cancer
stem cells (Al-Hajj et al., 2003) is incubated with labeled
antibodies against E-cadherin and IL1R2 followed by flow cytometry
to select against cells expressing high levels of E-cadherin and
IL1R2. Thus is obtained a tumor cell population enriched for ESA+,
CD44+, CD24-/low, Lin-, IL1R2-, and E-cadherin- signature 2 type
cancer stem cells.
[0467] The tumorigenicity of the cells isolated based on an
E-cadherin gene expression signature is then determined. 5,000,
1,000, 500, and 100 isolated ESA+, CD44+, CD24-/low, Lin-, IL1R2-,
and E-cadherin- cancer stem cells versus identical numbers of ESA+,
CD44+, CD24-/low, and Lin- cancer stem cells or unsorted
dissociated tumor cells are injected into the mammary fat pads of
VP-16 and estrogen pretreated NOD/SCID mice. The number of injected
cells required for consistent tumor formation in mice is used to
determine the fold enrichment for tumorigenic versus
non-tumorigenic cells based on isolating cancer stem cells with a
signature 2 gene expression.
[0468] Also envisioned are cancer stem cells isolated and enriched
based on cytoplasmic proteins, including alpha-catenin, identified
by the alpha-catenin gene expression signature. Antibodies against
alpha-catenin are generated, purified, and directly labeled with
fluorochromes. Solid tumor cells are dissociated as described
above, and the cells fixed in 4% paraformaldehyde and permeabilized
with 0.5% Triton-X-100 detergent. Permeabilized tumor cells are
incubated with labeled antibodies against ESA, CD44, CD24, Lineage
markers, and alpha-catenin, and flow cytometry is then used to
select for cells expressing high levels of ESA and CD44 and select
against cells expressing alpha-catenin, CD24, and Lineage markers.
Alternatively, ESA+, CD44+, CD24-/low, and Lin- cells are first
isolated as described above and then fixed in 4% paraformaldehyde
and permeabilized with 0.5% Triton-X-100 detergent. Permeabilized
cells are then incubated with labeled antibodies against
alpha-catenin, and flow cytometry is used to select against cells
expressing high levels of alpha-catenin. Thus is obtained a tumor
cell population enriched for ESA+ CD44+ CD24-/low, Lin-, and
alpha-catenin-/low signature 1 type cancer stem cells.
[0469] To identify additional markers of cancer stem cells,
isolated populations of cancer stem cells with an alpha-catenin or
an E-cadherin gene expression signature are compared using
microarray analysis to each other, to non-tumorigenic solid tumor
cells, and to normal breast epithelium. Non-tumorigenic solid tumor
cells and normal breast epithelium are isolated by flow cytometry
as described in Example 4. Cancer stem cells with either sigature 1
or 2 gene expression are isolated by flow cytometry as described
above. Each population is independently isolated three times so
that microarray analysis can be performed in triplicate.
[0470] Total RNA is isolated from the different cell populations
using RNasy (Qiagen, Valencia, Calif.) according to the
manufacturer's protocol. Probes for microarray analysis are then
prepared according to Affymetrix protocols (Affymetrix, Santa
Clara, Calif.). Affymetrix HG-U133 gene chips are hybridized with
Cy3 versus Cy5 labeled probe sets representing the two isolated
cell populations being compared and washed according to standard
Affymetrix protocols. Arrays are scanned with an argon-ion laser
confocal microscope and the intensity for each probe set on the
array is assessed with Affymetrix Microarray Suite 4.0 software
according to Affymetrix procedures.
EXAMPLE 6
Screening for Small Molecules that Affect the Behavior of Cancer
Stem Cells
[0471] This example describes methods for screening agents to
identify those that inhibit cancer stem cell proliferation. ESA+,
CD44+, CD24-/low, Lin- cancer stem cells are isolated from patient
tumor samples or from tumors passaged through immunocompromised
mice as described herein. Isolated cancer stem cells are collected
by centrifugation and resuspended in defined culture medium
comprising a mixture of Ham's F12, 2% fetal calf serum, and B27
supplement and then cultured in suspension under conditions that
allow the proliferation of cancer stem cells. Equal numbers of
cells are plated per well in clear bottom microtiter plates. These
plates are referred to as assay plates. Agents from a chemical
library are diluted in culture medium in microtiter dilution plates
and then added to assay plates in triplicate. Wells in which no
agent is added and in which anisomyocin, a protein synthesis
inhibitor, is added are included on each assay plate as controls
for normal growth and no growth, respectively. Assay plates are
incubated with test agents for 7, 14, and 21 days. On these days
the number of colonies per well is determined by light
microscopy.
EXAMPLE 7
Targeting the Signature 1 Cancer Stem Cell Marker c-Met to Inhibit
Cancer Stem Cell Proliferation and Self-Renewal
[0472] This example describes methods for targeting tumors based on
the expression of cancer stem cell markers identified by the gene
expression profiles of the present invention and for assaying the
impact of this targeting. Gene expression signature 1 of the
present invention identifies increased c-Met expression in
signature 1 type cancer stem cells compared to normal breast
epithelium (FIG. 11). c-Met is a receptor tyrosine kinase whose
aberrant activation is linked to tumorigenesis and metastasis.
Methods of inactivating c-Met expressed by cancer stem cells can
reduce their proliferation and/or self-renewal properties and thus
inhibit solid tumor growth. Alternatively eliminating cancer stem
cells expressing high levels of c-Met can reduce tumor
proliferation and reduce the risk of tumor regeneration and/or
metastasis.
[0473] To target tumors, particularly those tumors comprising
cancer stem cells expressing increased levels of c-Met, monoclonal
antibodies against the extracellular domain of c-Met are produced.
F1 hybrid mice are immunized using purified recombinant
extracellular c-Met protein and the spleen from mice with
circulating antibodies that specifically recognize the immunizing
protein are used for hybridoma production. Hybridomas are again
screened for antibodies that specifically recognize c-Met
protein.
[0474] Antibodies generated against c-Met are assessed for
antagonistic versus agonist activities against c-Met using an assay
for cell proliferation. Human lung myofibroblast cell lines
expressing c-Met (MRC5) are cultured in Dulbecco's modified Eagle
medium (DMEM) containing 10%-fetal calf serum (FCS), 100 U/ml
penicillin, and 100 ug/ml streptomycin. Cells are plated at a
density of 10.sup.4 cell per well in 96-well tissue culture
microplates and allowed to spread for 24 hours. Subsequently cells
are cultured for an additional 12 hours in fresh DMEM with 2% FCS
at which point anti-c-Met versus control antibodies are added to
the culture medium in the presence or absence of c-Met ligand,
HGF/SF and 10 umol/L BrdU. Following BrdU labeling, the culture
media is removed, and the cells fixed at room temperature for 30
min in ethanol and reacted for 90 min with peroxidase-conjugated
monoclonal anti-BrdU antibody (clone BMG 6H8, Fab fragments). The
substrate is developed in a solution containing
tetramethylbenzidine and stopped after 15 min with 25 ul of 1 mol/L
H.sub.2SO.sub.4. The color reaction is measured with an automatic
ELISA plate reader using a 450 nm filter (UV Microplate Reader;
Bio-Rad Laboratories, Richmond, Calif.). All experiments are
performed in triplicate. Cells incubated with control antibody
alone serve as a control for baseline levels of cell proliferation.
Incubation of cells with HGF/SF serves as a positive control for
cell proliferation following c-Met activation. Anti-c-Met
antibodies that act as agonists to increase cell proliferation in
the absence of HGF/SF are not investigated further. Antagonist
anti-c-Met antibodies that block HGF/SF mediated stimulation of
cell proliferation and antibodies that fail to activate c-Met are
used to target cancer stem cells as described below.
[0475] In some embodiments, the effect of c-Met antibodies on
cancer stem cell proliferation is determined in culture. Tumor
cells from a patient tissue sample (a solid tumor biopsy, pleural
effusion, etc.) or from a tumor passaged in a xenograft mouse model
are removed under sterile conditions, dissociated, and signature 1
cancer stem cells that overexpress c-Met are isolated by flow
cytometry as described in Example 5 above. Additionally, signature
2 cancer stem cells and non-sorted tumor cells can also be included
for comparison. Sorted cancer stem cells are collected by
centrifugation and resuspended in defined culture medium comprising
a mixture of Ham's F12, 2% fetal calf serum, and B27 supplement
under conditions that allow the proliferation of tumor cells. Tumor
cells are cultured for 14 days in suspension to allow colony growth
specifically from tumorigenic cells (U.S. Ser. No. 09/920,517) and
then colonies are passaged by collecting tumor stem cell colonies
by centrifugation followed by enzymatic digestion and mechanical
disruption as described in Example 5 for 1 hour at 37.degree. C.
Dissociated cells are resuspended and equal numbers cultured in
fresh medium containing either antagonist anti-c-Met antibodies,
non-agonist anti-c-Met antibodies, antibodies pre-incubated with
c-Met blocking peptide, or control antibodies. Passaged
non-tumorigenic cells are capable only of forming small colonies
consisting of 2-4 cells, while tumorigenic cancer stem cells
continue to proliferate and the effect of different anti-c-Met
antibodies is determined by assessing the number and size of colony
growth by light microscopy.
[0476] In a second embodiment, the effect of antibodies against
c-Met on a tumor and particularly on cancer stem cell proliferation
is assessed in a xenograft model. Tumor cells from a patient tissue
sample (a solid tumor biopsy, pleural effusion, etc.) or from a
tumor passaged in a xenograft mouse model are removed under sterile
conditions, dissociated, and signature 1 cancer stem cells that
overexpress c-Met are isolated by flow cytometry as described in
Example 5 above. Additionally, signature 2 cancer stem cells and
non-sorted tumor cells can also be included for comparison. In
triplicate sets 5,000, 2,500, 1,000, and 200 sorted cancer stem
cells are incubated with antagonist anti-c-Met antibodies,
non-agonist anti-c-Met antibodies, anti-c-Met antibodies
pre-incubated with c-Met blocking peptide, or control antibodies at
37.degree. C. for an hour to allow antibody binding and then
injected into the mammary fat pads of NOD/SCID mice. Five days
before cell injections, mice are prepared by treatment with 30
mg/kg VP-16 via intraperitoneal injection and the placement of
estrogen pellets subcutaneously. Subsequent to injection, the
ability of the injected tumor cells to form tumors, the length of
time required for tumor formation, and the size of the tumors is
assessed.
[0477] In other embodiments, the effect of anti-c-Met antibodies on
cancer stem cell self renewal is examined. Cancer stem cell
colonies grown in suspension culture and treated with either
antagonist anti-c-Met antibodies, non-agonist anti-c-Met
antibodies, antibodies pre-incubated with blocking peptide, or
control antibodies as described above are passaged a second time.
Dissociated cells are then cultured in fresh medium in the absence
of antibody and the number of colonies that grow representing the
number of cancer stem cells present, and thus the self-renewal of
cancer stem cells in the presence of c-Met antibody, is determined.
Alternatively varying numbers of the dissociated tumor cells,
ranging from 50,000 down to 5,000, are injected into the mammary
fat pads of VP- 16 and estrogen pre-treated NOD/SCID mice and the
frequency rate of tumor formation for the number of injected cells
is determined.
[0478] In another embodiment the effect of targeting cancer stem
cells overexpressing c-Met on tumor growth in vivo is determined.
Tumor cells from a patient tissue sample (a solid tumor biopsy,
pleural effusion, etc.) or from a tumor passaged in a xenograft
mouse model are removed under sterile conditions, and prepared as
single cell suspensions, dissociated, and signature 1 cancer stem
cells that overexpress c-Met are isolated by flow cytometry as
described in Example 5 above. Additionally, signature 2 cancer stem
cells and non-sorted tumor cells can also be included for
comparison. In triplicate sets 5,000, 2,500, 1,000, and 200 sorted
cancer stem cells are injected into the mammary fat pads of VP-16
and estrogen pre-treated NOD/SCID mice. On the day of tumor cell
injection or alternatively once injected tumor cells have grown
into palpable tumors, naked antagonist antibodies against c-Met or
control antibodies are injected i.p. into tumor bearing mice. In an
alternative embodiment, the antibody is not a naked antagonistic
antibody, but a non-agonist anti-c-Met antibody conjugated to
therapeutic radionuclide iodine-131 to kill the targeted cancer
stem cell. Injections are repeated twice a week for two to three
weeks and the effect on tumor growth rate and size is assessed.
[0479] The embodiments of this example describe methods to
investigate the role of c-Met in cancer stem cell tumorigenicity.
If overexpression of c-Met by signature 1 type cancer stem cells
contributes to their tumorigenicity, it is envisioned that
antibodies against c-Met will inhibit tumor stem cell proliferation
and/or self renewal. Targeting c-Met could inhibit cell
proliferation so that cancer stem cells generate smaller colonies
in culture or tumors in xenograft models. Targeting c-Met can also
inhibit cancer stem self-renewal and thereby decrease the frequency
of tumor formation compared to control. Yet independent of the role
overexpression of c-Met plays in tumorigenicity, it is predicted
that targeted killing of signature 1 type cancer stem cells will
prove therapeutic against tumors in which cancer stem cells with an
alpha catenin profile are detected.
EXAMPLE 8
Therapeutic Targeting of the Signature 1 Cancer Stem Cell Marker
c-Met to Treat Cancer Patients
[0480] This example describes methods for treating cancer using
antibodies against c-Met to target tumors comprising cancer stem
cells in which an alpha-catenin gene expression profile has been
detected. The presence of cancer stem cells displaying an
alpha-catenin profile based on the alpha-catenin signature is first
determined from a tumor biopsy. Antibodies against c-Met are then
administered to a cancer patient whose tumor is determined to have
a signature 1 gene profile.
[0481] Tumor cells from a biopsy (solid tumor biopsy or pleural
effusion) from a patient diagnosed with cancer are removed under
sterile conditions. Tissue samples are cut up into small pieces and
then minced completely using sterile blades. To obtain single cell
suspensions, cells are subject to enzymatic digestion and
mechanical disruption. Specifically, pleural effusion cells or the
resulting tumor pieces are mixed with ultra-pure collangenase III
in culture medium (200-250 units of collagenase per mL) and
incubated at 37.degree. C. for 3-4 hours with pipetting up and down
through a 10-mL pipette every 15-20 min. Digested cells are
filtered through a 45 ul nylon mesh, washed with RPMI/20% FBS, and
washed twice with HBSS. Dissociated tumor cells are then incubated
with antibodies to detect cancer stem cells expressing an
alpha-catenin versus an E-cadherin gene profile, and the presence
of tumor stem cells expressing either an alpha-catenin and/or an
E-cadherin gene profile is determined by flow cytometry as
described in Example 5 above.
[0482] Cancer patients whose tumors are diagnosed as containing
cancer stem cells with an alpha-catenin gene expression profile are
then treated with anti-c-Met antibodies. Monoclonal non-agonist
anti-c-Met antibodies are generated as described above and
humanized using standard techniques. The antibodies are purified
and formulated with a suitable pharmaceutical carrier in PBS for
injection. Patients are treated with humanized anti-c-Met
antibodies, which can be chimeric, multimeric, heteromeric, single
chain form, or fragments thereof (such as Fv, Fab, Fab.sup.1,
F(ab.sup.1).sub.2, or other antigen-binding fragments), e.g., once
a week for at least 10 weeks or once a week for at least about 14
weeks. Each administration of the antibody should be a
pharmaceutically effective dose, e.g., about 2 to about 100 mg/ml
or about 5 to about 40 mg/ml. The antibody can be administered
prior to, concurrently with, or after standard chemotherapy
regimens using one or more chemotherapeutic agent, such as
oxaliplatin, fluorouracil, leucovorin, streptozocin, etc. Treated
patients will be monitored for tumor regression, reduction in the
incidences of new tumors, etc.
EXAMPLE 9
Restoring Expression of the Cancer Stem Cell Marker IL1R2 or Nov in
Signature 2 Cancer Stem Cells
[0483] This example describes methods for restoring expression of
proteins down-regulated in cancer stem cells and for assaying the
impact on the behavior of cancer stem cells when protein expression
is restored. IL1R2 is a non-signaling decoy receptor for IL-1 that
shows decreased expression in cancer stem cells with an E-cadherin
gene expression signature compared to normal breast epithelium
(Table 9; FIG. 12). IL-1 is a potent pro-inflammatory cytokine that
can stimulate the production of pro-tumorigenic cytokines, and thus
restoring IL1R2 expression in signature 2 type cancer stem cells
can help to counteract tumor growth.
[0484] In some embodiments genetic modification of cancer stem
cells is used to restore expression of IL1R2 and genetically
modified cancer stem cells are tested for tumorigenicity. Tumor
cells from a patient sample (solid tumor biopsy, pleural effusion,
etc) or from a biopsy passaged as a xenograft in an
immunocompromised mouse are dissociated and flow cytometry used to
isolate cancer stem cells expressing an E-cadher gene signature as
described in Example 5 above. Additionally, signature 1 cancer stem
cells and non-sorted tumor cells can also be included for
comparison. The isolated cancer stem cells are collected after flow
cytometry and resuspended in culture medium.
[0485] Cancer stem cells isolated based on an E-cadherin gene
expression signature are then genetically modified using a
replication incompetent lentivirus vector. Suitable expression
systems include the ViraPower.TM. Lentiviral Expression System
(Invitrogen, Carlsbad, Calif.), and viral particles are generated
according to the manufacturer's protocol. Three different
lentiviruses are constructed using standard methods of recombinant
DNA technology: 1) a lentivirus encoding recombinant IL1R2, either
transmembrane or soluble functional fragments of the IL1R2 protein
capable of binding and inactivating IL-1 cytokine are envisioned,
linked to an internal ribosomal entry site (IRES) GFP as a marker
of cell infection (IL1R2-IRES-GFP); 2) a control virus encoding
inactive IL1R2, in which the encoded IL1R2 does not contain a
functional IL-1 binding domain because of deletions, mutations,
etc. introduced into the coding domain, linked to an IRES GFP
(inactive IL1R2-IRES-GFP); and 3) a control virus encoding GFP
alone.
[0486] The proliferative and self-renewal properties of the
genetically modified cancer stem cells are determined in a
xenograft model. Triplicate set of 5,000, 1,000, and 200 isolated
signature 2 cancer stem cells are infected with equal
multiplicities of infection (MOI) of the IL1R2-IRES-GFP, inactive
IL1R2-IRES-GFP, or GFP lentiviruses in culture medium in
suspension. The infected cells are then washed in HBSS and injected
into the mammary fat pads of VP-16 and estrogen pre-treated
NOD/SCID mice. Tumor growth is monitored to assess the
proliferative capacity of the different genetically modified cancer
stem cells. After 28 days, xenografts from the mice are again
isolated and 50,000, 25,000, and 5,000 dissociated tumor cells are
repassaged into NOD/SCID mice. The frequency rate of tumor
formation per number of injected cells is then determined to assess
the self-renewal capacity of IL1R2-IRES-GFP versus inactive
IL1R2-IRES-GFP or GFP expressing cancer stem cells.
[0487] In an alternative embodiment, cancer stem cell with an
E-cadherin gene expression signature are genetically altered to
restore expression of nephroblastoma overexpressed gene (Nov). Nov
is a secreted protein associated with the extracellular matrix that
plays various biological roles including cell proliferation,
chemotaxis, and cellular adhesion. Nov has been implicated in cell
cycle control and slowing cell growth as high levels of Nov
expression are associated with less aggressive brain tumors and
conversely decreasing levels of Nov are associated with progression
of adrenocortical tumors to a malignant state. Thus restoring Nov
protein in solid tumors can help limit their growth.
[0488] To restore Nov expression, plasmid vectors encoding
recombinant Nov are introduced into signature 2 type cancer stem
cells. A plasmid vector expressing Nov under the control of a CMV
promoter is generated. A polynucleotide encoding full-length Nov is
isolated by PCR from a human cDNA library and cloned into the
multi-cloning site of the plasmid vector pcDNA3 (Invitrogen,
Carlsbad, Calif.) upstream of an IRES GFP to mark transfected
cells. The plasmid DNA is complexed with cationic lipids and used
to transfect signature 2 cancer stem cells in culture medium.
Plasmid DNA encoding GFP alone is used as a control. Transfected
cancer stem cells are then washed in HBSS, FACs sorted for GFP
expression, and triplicate sets of 5,000, 1,000, and 200 cells are
injected into the mammary fat pads of VP-16 and estrogen
pre-treated NOD/SCID mice. Tumor growth is monitored to assess the
proliferative capacity of the different genetically modified cancer
stem cells. After 28 days, xenografts from the mice are again
isolated and 50,000, 25,000, and 5,000 dissociated tumor cells are
repassaged into NOD/SCID mice. The frequency rate of tumor
formation per number of injected cells is then determined to assess
the self-renewal capacity of Nov expressing versus GFP only
expressing cancer stem cells.
[0489] These methods address whether decreased expression of IL1R2
or Nov by signature 2 type cancer stem cells contributes to their
tumorigenicity. It is envisioned that restoring IL1R2 or Nov
expression will reduce signature 2 cancer stem cell proliferation
and self-renewal and thus smaller tumors with reduced numbers of
tumorigenic cells will grow in mice. However, as IL1R2 and Nov have
anti-growth properties, it is further predicted that increasing
their expression in all cancer stem cells regardless of their
particular gene expression profile will inhibit or prevent tumor
growth.
EXAMPLE 10
Therapeutic Restoration of the Signature 2 Cancer Stem Cell Marker
Nov to Treat Cancer Patients
[0490] This example describes methods for treating cancer using
gene therapy to restore expression of Nov in solid tumors. The
presence of cancer stem cells displaying a signature 2 profile is
first determined from a tumor biopsy to identify patients that can
best respond to such a therapy. Plasmid vectors expressing
recombinant Nov are then administered to a cancer patient whose
tumor contains cancer stem cells expressing a signature 2 gene
profile.
[0491] Tumor cells from a patient sample (solid tumor biopsy or
pleural effusion) from a patient diagnosed with cancer are removed
under sterile conditions. Tissue samples are cut up into small
pieces and then minced completely using sterile blades. To obtain
single cell suspensions, cells are subject to enzymatic digestion
and mechanical disruption. Either pleural effusion cells or the
resulting tumor pieces are mixed with ultra-pure collangenase III
in culture medium (200-250 units of collagenase per mL) and
incubated at 37.degree. C. for 3-4 hours with pipetting up and down
through a 10-mL pipette every 15-20 min. Digested cells are
filtered through a 45 ul nylon mesh, washed with RPMI/20% FBS, and
washed twice with HBSS. Dissociated tumor cells are then incubated
with antibodies to detect cancer stem cells expressing a signature
2 versus a signature 1 gene profile, and the presence of tumor stem
cells expressing either a signature 2 and/or a signature 1 gene
profile is determined by flow cytometry as described in Example 5
above.
[0492] Cancer patients whose tumors are diagnosed as containing
cancer stem cells with a signature 2 gene expression profile are
then treated with a therapeutically effective amount of plasmid
vectors encoding Nov. In the some embodiment the plasmid vector is
delivered by intratumor injection and is formulated in phosphate
buffered saline with physiologic levels of calcium (0.9 mM).
Alternatively the DNA is formulated in solutions containing higher
quantities of Ca++, from 1 mM and 2M. The DNA can be formulated
with other cations such as zinc, aluminum, and others.
Therapeutically effective amounts of a plasmid vector are in the
range of about 0.001 ug to about 1 g. A most some therapeutic
amount is in the range of about 0.025 mg to about 5 mg. The plasmid
vector is delivered monthly for 6-12 months, and then every 3-12
months as a maintenance dose. Alternative treatment regimens can be
developed and can range from daily, to weekly, to every other
month, to yearly, to a one-time administration depending upon the
severity of the disease, the age of the patient, and such other
factors. The DNA therapy can be administered prior to, concurrently
with, or after standard chemotherapy regimens using one or more
chemotherapeutic agent, such as oxaliplatin, fluorouracil,
leucovorin, streptozocin, etc. Treated patients will be monitored
for tumor regression, reduction in the incidences of new tumors,
etc.
EXAMPLE 11
Combination Therapy to Treat Cancer Patients with Tumors that
Contain both Signature 1 and 2 Cancer Stem Cells
[0493] This example describes methods for treating cancer using
combination antibody and gene therapy to both target c-Met in
cancer stem cells with a signature 1 gene expression profile and
restore expression of Nov in solid tumors containing cancer stem
cells with a signature 2 gene expression profile. The presence of
cancer stem cells displaying both a signature 1 and 2 profile is
first determined from a tumor biopsy as described above. Antibodies
against c-Met and plasmid vectors expressing recombinant Nov are
then administered to a cancer patient whose tumor contains cancer
stem cells expressing a signature 1 and signature 2 gene profile as
described above.
EXAMPLE 12
Lysophosphatidic Acid (LPA) and LPA Receptor EDG2 in Cancer Stem
Cells
[0494] This example describes methods for assessing the effects of
modulating LPA signaling and signaling by the LPA receptor EDG2 on
the proliferation and self-renewal of cancer stem cells.
Lysophosphatidic acid (LPA) is a bioactive phospholipid that
stimulates cell proliferation over differentiation, morphological
changes, and tumor cell invasion. LPA promotes growth of ovarian
tumors and is found at high concentrations in patients with ovarian
carcinomas, suggestive of an important role in ovarian cancers.
Elevated levels of LPA have also been detected in patients with
endometrial and cervical cancers (Mills and Moolenaar, 2003).
Cancer stem cells that display an alpha gene expression signature
comprise increased expression of Endothelial differentiation gene 2
(EDG2) a G-protein coupled receptor (GPCR) that belongs to a family
of receptors activated by LPA (Table 9; FIG. 11). Increased
expression of EDG2 in cancer stem cells can implicate
responsiveness to LPA more broadly in tumorigenesis. Yet
interestingly increased expression levels of EDG2 are associated
with decreased cell growth rates via LPA-independent induction of
apoptosis (Fang et al., 2000) suggesting that antagonizing
LPA-dependent signaling but enhancing LPA-independent apoptosis
must be balanced to counteract tumor cell growth.
[0495] In some embodiments the effect of LPA on cancer stem cell
behavior is determined. Cancer stem cells with both an
alpha-catenin and an E-cadherin gene expression signature are
isolated by flow cytometry based on differential protein expression
as described in Example 5 above and the effect of the addition of
exogenous LPA on cancer stem cell proliferation is determined.
Sorted cancer stem cells are collected by centrifugation and
resuspended in defined culture medium containing 0.1% (w/v) fatty
acid-free BSA. Equal numbers of cells are grown in suspension
culture in multi-well culture dishes for up to two weeks in the
presence of 0.1 uM, 1 uM, and 10 uM 1-oleoyl LPA (Sigma) or vehicle
control. Each condition is performed in triplicate, and the number
and size of tumor colonies generated under each condition is
assessed by light microscopy. Alternatively equal numbers of cancer
stem cells are plated in suspension culture in multi-well culture
dishes and allowed to grow for several days. Established tumor
colonies are then treated overnight in the presence or absence of
0.1 uM, 1 uM, or 10 uM 1-oleoly LPA and pulsed with
[.sup.3H]-thymidine for the last 8 hours. [.sup.3H]-thymidine
incorporation is quantitated to assess the effect of LPA on cell
proliferation.
[0496] In another embodiment the presence and effect of endogenous
LPA on cancer stem cell properties is determined. One potential
source of endogenous LPA is the tumor cells themselves, which then
act in a paracrine fashion to promote proliferation of cancer stem
cells. To detect the presence of endogenously produced LPA, tumor
cells are dissociated into single cell suspension by enzymatic
digestion, resuspended in defined culture medium, and grown for
several days to establish tumor colonies. LPA is butanol-extracted
from conditioned medium and quantified using a radioenzymatic assay
as previously described (Saulnier-Blache et al., 2000).
[0497] If LPA is produced by cultured tumor cells, the effect of
reducing this endogenous LPA signaling can be assessed. The
membrane-associated lysophosphatidic acid phosphatase (ACP6)
degrades both extracellular and membrane-bound LPA, playing a
prominent role in maintaining low LPA levels and limiting cellular
responses to LPA (Fang et al., 2000). Increasing levels of ACP6 in
;tumor cells is thus used to decrease LPA levels and reveal the
effect of endogenous LPA on cancer stem cell behavior. Tumor cells
are isolated as above and transfected with a plasmid vector capable
of expressing ACP6 linked to an IRES GFP to detect transfected
cells. A plasmid vector expressing GFP alone is used as a control.
Cells are transfected overnight using lipofectamine reagent
(Invitrogen, Carlbad, Calif.) according to the manufacturer's
protocol and flow cytometry is used to isolated transfected GFP
positive tumor cells 24 hours later. Equal numbers of tumor cells
are plated in suspension culture in multi-well culture dishes and
allowed to grow. The number and size of tumor colonies is then
assessed. LPA production is again quantified from ACP6 expressing
versus control transfected tumor cells to determine the
fold-reduction in LPA production. Alternatively cancer stem cells
are isolated by flow cytometry as described in Example 5 above and
resuspended in cultured medium from ACP6 expressing versus control
transfected tumor cells and their ability to form tumor colonies in
vitro examined.
[0498] In another embodiment the effect of targeting the LPA
receptor EDG2 with an agonist antibody on cancer stem cell
properties is determined. EDG2 is believed to act as a negative
regulator of cell growth, suggesting that EDG2-selective agonists
can limit tumor growth and survival (Fang et al., 2000).
Overexpression of EDG2 in signature 1 cancer stem cells suggests
that regulation of this GCPR can play a role in the tumorigenic
properties of cancer stem cells. Antibodies against EDG2 are
generated by standard immunization techniques using peptides from
the extracellular domains of EDG2 that lack signals for
glycoslyation, and agonist antibodies that fail to activate
LPA-dependent cytoplasmic Ca++ increases but activate
LPA-independent apoptosis are identified.
[0499] The effect of EDG2 agonist antibodies on cancer stem cells
expressing high (signature 1) and low (signature 2) levels of EDG2
can then be investigated. In some embodiments, the effect of
agonist EDG2 antibodies on cancer stem cell proliferation is
determined in culture. Signature 1 and signature 2 cancer stem
cells are isolated from a patient tissue sample (a solid tumor
biopsy, pleural effusion, etc.) or from a tumor passaged in a
xenograft mouse model as described in Example 5 above. Isolate
tumor stem cells are collected by centrifugation and equal numbers
resuspended in defined culture medium containing either agonist
anti-EDG2 antibodies, non-agonist anti-EDG2 antibodies, or control
antibodies. The number and size of colonies generated by signature
1 versus signature 2 cancer stem cells in the presence of the
different EDG2 or control antibodies is determined by light
microscopy.
[0500] In a second embodiment, the effect of agonist antibodies
against EDG2 on cancer stem cell proliferation is assessed in a
xenograft model. In triplicate sets 5,000, 2,500, 1,000 and 200
isolated cancer stem cells are incubated with agonist anti-EDG2,
non-agonist anti-EDG2, or control antibodies at 37.degree. C. for
an hour to allow antibody binding and then injected into the
mammary fat pads of VP-16 and estrogen pretreated NOD/SCID mice.
Following injection, the ability of the cancer stem cells to form
tumors, the length of time required for tumor formation, and the
size of the tumors is assessed.
[0501] In another embodiment the effect of agonist anti-EDG2
antibodies on tumor growth in vivo is determined. Cells from a
primary tumor are cut up with scissors into small pieces that are
then minced with a blade in sterile RPMI medium on ice to yield
2.times.2 mm pieces. The tumor pieces are washed in serum-free HBSS
and implanted into the mammary fat pads ofVP-16 and estrogen
pre-treated NOD/SCID mice. Cells from pleural effusions are washed
with serum-free HBSS, suspended in serum free-RPMI/Matrigel mixture
(1:1 volume), and cell suspensions are injected in the mammary fat
pads of NOD/SCID mice. Alternatively, tumor cells are dissociated
and cancer stem cells are isolated by flow cytometry as described
in Example 5 above and triplicate sets of 5,000, 2,500, 1,000, and
200 isolated cancer stem cells are injected into NOD/SCID mice. On
the day of tumor cell injection or alternatively once injected
tumor cells have grown into palpable tumors, naked agonist
antibodies against EDG2 or control antibodies are injected i.p.
into tumor bearing mice. Injections are repeated twice a week for
two to three weeks and the effect on tumor growth rate is
assessed.
[0502] The embodiments of this example describe methods to
investigate the role of LPA and the LPA receptor EDG2 in cancer
stem cell tumorigenicity. It is envisioned that targeting LPA
production or EDG2 will inhibit cancer stem cell proliferation and
thus act therapeutically against tumor growth.
EXAMPLE 13
Therapeutic Targeting of the Signature 1 Cancer Stem Cell Marker
EDG2 to Treat Cancer Patients
[0503] This example describes methods for treating cancer using
agonist antibodies against the LPA receptor EDG2 to inhibit the
proliferation of cancer stem cells in a cancer patient. Monoclonal
agonist anti-EDG2 antibodies are generated as described above and
humanized using standard techniques. The antibodies are purified
and formulated with a suitable pharmaceutical carrier in PBS for
injection. Patients are treated with humanized anti-EDG2
antibodies, which can be chimeric, multimeric, heteromeric, single
chain form, or fragments thereof (such as Fv, Fab, Fab.sup.1,
F(ab.sup.1).sub.2, or other antigen-binding fragments), such as
once a week for at least 10 weeks or once a week for at least about
14 weeks. Each administration of the antibody should be a
pharmaceutically effective dose, e.g., about 2 to about 100 mg/ml
or about 5 to about 40 mg/ml. The antibody can be administered
prior to, concurrently with, or after standard chemotherapy
regimens using one or more chemotherapeutic agent, such as
oxaliplatin, fluorouracil, leucovorin, streptozocin, etc. Treated
patients will be monitored for tumor regression, reduction in the
incidences of new tumors, etc.
EXAMPLE 14
Inhibiting Gamma-Secretase Activity in Cancer Stem Cells
[0504] This example describes methods for modulating
gamma-secretase activity and thus inhibiting Notch signaling in
cancer stem cells and assays for determining the effect of
inhibiting gamma secretase on the behavior of cancer stem cells.
Cancer stem cell gene expression signature 1 reveals decreased
expression of Nicastrin (NCSTN) an essential component of the
multimeric gamma-secretase complex that proteolytically cleaves the
Notch receptor upon ligand binding. Notch cleavage results in
release of an intracellular domain (NICD) that enters the nucleus
and activates transcription. Notch signaling is involved in the
process of lateral inhibition between adjacent cell fates and plays
an important role in cell fate determination during asymmetric cell
divisions. Furthermore, unregulated Notch signaling has been linked
to the formation of a number of human cancers where it can alter
the developmental fate of tumor cells to maintain them in an
undifferentiated and proliferative state (Brennan and Brown,
2003).
[0505] Nicastrin is involved in stabilizing presenilin, the
catalytic subunit of the gamma-secretase, and is required for gamma
secretase activity and Notch signaling. However, Nicastrin can also
play an inhibitory role in gamma-secretase activity as fibroblasts
from heterozygotes nicastrin mice unexpectedly display increased
gamma-secretase activity compared to the complete absence of
activity in the knock out mice (Li et al., 2003) suggesting that
decreased Nicastrin expression in signature 1 cancer stem cells can
actually increase gamma-secretase activity and Notch signaling in
these cancer stem cells. Thus whereas methods for eliminating
Nicastrin expression can be therapeutic in shifting cancer stem
cells from an undifferentiated and proliferative state to a
differentiated state, tumors derived from signature 1 cancer stem
cells can be particularly suitable for this type of therapy.
[0506] In some embodiments of the present invention, small
interfering RNAs (siRNAs) are used to decrease expression of
Nicastrin in cancer stem cells. siRNAs designed to target human
Nicastrin (5'-GGGCAAGTTTCCCGTGCAGTT-3', SEQ ID NO:1, for example)
and a mutated control are chemically synthesized, annealed, and
transfected into tumor stem cells using standard techniques
(Elbashir et al., 2001). Alternatively plasmid vectors such as
pSilencer (Ambion, Austin, Tex.) are used to transcribe siRNAs
using a RNA polymerase III promoter. Knock down of Nicastrin is
first tested by analyzing protein expression in human fibroblast
cell lines transfected with Nicastrin siRNAs versus Nicastrin
mismatched control siRNAs using Western blot. Only siRNAs that
decrease Nicastrin expression most strongly are used for further
experimentation.
[0507] To determine if siRNA knock down of Nicastrin affects Notch
signaling in cancer stem cells, the nuclear localization of the
NICD is determined following transfection with Nicastrin versus
control siRNAs. Cancer stem cells are isolated from solid tumors as
described in Example 5 and equal numbers of cells are transfected
with Nicastrin siRNA versus control siRNA in suspension culture.
After 24 hours the subcellular localization of endogenous Notch 1
is determined by biochemical cell fractionation. Cancer stem cells
are extracted and separated into cytoplasmic and nuclear components
on a sucrose-density gradient. Equal protein from each component is
separated by SDS-PAGE, blotted onto nitrocellulose, and probed with
anti-Notch1.IC (Ledmond et al., 2000). The relative amount of
Notch.IC in the nuclear fraction serves as an indication of the
level of Notch signaling.
[0508] To determine if decreased gamma secretase activity by
reductions in Nicastrin expression affects cancer stem cell
behavior, the proliferation and self-renewal of cancer stem cells
is determined in a xenograft model. Triplicate set of 5,000, 1,000,
and 200 cancer stem cells with either an alpha-catenin or an
E-cadherin gene expression signature are isolated according to
Example 5 and are transfected with Nicastrin or control siRNAs in
culture medium in suspension. After 24 hours the transfected cells
are washed in HBSS and injected into the mammary fat pads of VP-16
and estrogen pre-treated NOD/SCID mice. Tumor growth is monitored
to assess the proliferative capacity. After 28 days, xenografts
from the mice are isolated and dissociated tumor cells are analyzed
by flow cytometry as described in Example 5 to determine the number
of ESA+, CD44+, CD24-/low, and Lin-; ESA+, CD44+, CD24-/low, Lin-,
c-Met+, EDG2+, and DCBLD2+; and ESA+, CD44+, CD24-/low, Lin-,
E-cadherin-, and IL1R2- cancer stem cells present per 1000 tumor
cells.
[0509] In alternative embodiments, gamma secretase activity was
decreased using the small-molecule inhibitor L-685,458 (Yan et al.,
2004, J. Neurosci. 24:2942) and the effect on tumor growth was
assessed in a xenograft model. 20,000 PE13 passaged human breast
tumor cells were injected into the mammary fat pads of NOD/SCID
mice. The mice were then injected subcutaneously daily with 9 mg/kg
L-685,458 (n=5) or vehicle control (n=7) for 25 days. Starting on
day 11, the tumor volume was measured three times a week for a
total of 48 days. Treatment with L-685,458 significantly inhibited
the growth of injected tumor cells with the average tumor volume
reduced compared to control animals throughout the study (FIG.
13A). The tumor volumes for individual mice are plotted in FIG.
13B. Thus inhibiting gamma secretase activity by using a small
molecule gamma secretase inhibitor predicted to reduce Notch
signaling reduced tumor growth.
EXAMPLE 15
Isolated Cancer Stem Cells from Colon Cancer Display Differential
Expression of Alpha-Catenin and E-Cadherin
[0510] This study extended the differential expression of
alpha-catenin and E-cadherin in the gene expression signatures of
the present invention to colon cancers. Real-time PCR again showed
the differential expression of alpha-catenin and E-cadherin in
three breast cancer tumors (FIG. 14). To investigate the expression
of alpha-catenin and E-cadherin in colon cancer, tumorigenic and
nontumorigenic cells from colon tumor biopsies were isolated by
flow cytometry based on their differential expression of ESA, CD44,
CD24, and Lineage markers as described above and in Al-Hajj et al.,
2003. Total RNA was extracted from isolated tumorigenic cancer stem
cells, non-tumorigenic tumor cells, and normal colon epithelium and
the relative levels of RNA encoding alpha-catenin and E-cadherin
were determined by real-time RT-PCR. As shown in FIG. 15
tumorigenic cancer cells show differential expression of
alpha-catenin and E-cadherin similar to the E-cadherin gene
expression signature with unchanged to increased levels of
alpha-catenin and decreased levels of E-cadherin. This differential
expression can be used to diagnose and treat metastatic colon
cancer stem cells as described in detail below.
EXAMPLE 16
Using the Alpha-Catenin and E-Cadherin Gene Expression Signatures
to Assess the Presence of and Metastatic Potential of Cancer Stem
Cells
[0511] This example describes methods for monitoring the presence
of and metastatic potential of cancer stem cells using the gene
expression signatures of the present invention. In some embodiments
the presence of and metastatic potential of cancer stem cells is
monitored by assessing E-cadherin and alpha-catenin expression and
E-cadherin, alpha-catenin, and beta-catenin protein localization.
E-cadherin, alpha-catenin, and/or beta-catenin are essential
components of adherens junctions, sites of cell-cell adhesion
between epithelial cells. Assembly of adherens junctions is
regulated by gamma secretase proteolytic cleavage of E-cadherin.
E-cadherin cleavage results in the disassembly of the adherens
junction complex and increased levels of E-cadherin, alpha-catenin,
and beta-catenin proteins in the cytoplasm that in turn can
contribute to nuclear accumulation of beta-catenin and activation
of the Wnt signaling pathway (Marambaud et al., 2002, EMBO
21:1948). Consistent with this, cytoplasmic E-cadherin and nuclear
localized beta-catenin are associated with mesenchyme-like cell
that have lost normal epithelial adhesive contacts at the invasive
front of a tumor (Brabletz et al., 2001, PNAS 98:10356).
Furthermore, these mesenchyme-like cells show proliferative
activity and can generate metastases containing well-differentiated
cell populations that characterize the original tumor consistent
with these cells representing tumor stem cells.
[0512] The identification of reduced expression of either
alpha-catenin or E-cadherin in signature 1 and signature 2 cancer
stem cells respectively further indicates that cancer stem cells
are both tumorigenic and metastatic. Downregulation of Nicastrin in
signature 1 cancer stem cells and the potential increased
activation of gamma secretase as discussed in detail in above can
further facilitate loss of cell-cell contact and contribute to
metastasis in signature I type cancer stem cells. Thus the present
invention enables the use of the differential expression of
E-cadherin and alpha-catenin and localization of E-cadherin,
alpha-catenin, and beta-catenin to monitor the metastatic potential
of tumor stem cells.
[0513] In some embodiments of this invention, the activity of gamma
secretase is inhibited and the effect on alpha-catenin,
beta-catenin, and E-cadherin expression in cancer stem cells is
determined. To inhibit gamma-secretase activity a small-molecule
inhibitors L-685,458 was used (Yan et al., 2004, J. Neurosci.
42:2942). 20,000 PE13 tumor cells were injected into the mammary
fat pads of VP-16 and estrogen pre-treated NOD/SCID mice. The mice
were then injected subcutaneously daily with 9 mg/kg L-685,458 or
vehicle control for 25 days. After the 25 days and one week after
the last injection, biopsies are taken from L-685,458 treated and
control treated mice. Biopsies are fresh frozen in liquid nitrogen,
embedded in O.C.T., and cut on a cryostat as 10 um sections onto
glass slides. Alternatively biopsies are formalin-fixed,
paraffin-embedded, and cut on a microtome as 10 um section onto
glass slides.
[0514] In some embodiments indirect double immunohistochemistry is
combined with laser capture microdissection to determine if the
cytoplasmic localization of E-cadherin and/or nuclear localization
of beta-catenin in potentially metastatic tumor cells (Brabletz et
al., 2001) is indicative of cancer stem cells and to monitor
changes induced by treatment with the gamma secretase inhibitor
L-685,458. Frozen sections of tumor biopsies are fixed with 4%
paraformaldehyde, blocked in 3% normal goat serum, and incubated
with biotin-conjugated anti-beta-catenin antibodies. Biotin is
detected by the enzymatic activity of horseradish peroxidase
(HRP)-conjugated avidin using a colored substrate. Next sections
are incubated with alkaline phosphatase (AP)-conjugated
anti-E-cadherin or alpha-catenin antibodies, and AP enzymatic
activity is detected using a different colored substrate. Cells on
the leading edge of the tumor with a mesenchymal morphology,
cytoplasmic localization of either E-cadherin or alpha-catenin
and/or nuclear localization of beta-catenin are identified as
potential tumorigenic and metastatic cancer stem cells. To confirm
these cells are cancer stem cells laser-capture microdissection is
performed using a Leica AS LMD instrument. Total RNA is extracted
from the microdissected sample using RNeasy Micro Kit (Qiagen)
according to the manufacture's protocol. The isolated RNA is used
for Taqman quantitative RT-PCR analysis using standard techniques.
Primer and probe sets for genes that comprise signature 1,
signature 2, CD44, CD24, and Lineage markers are designed over
exon-intron borders. Each primer/probe set is used to quantify the
level of gene expression from laser captured metastatic cells
compared to cancer stem cell populations isolated according to
Example 5 or normal breast epithelium isolated according to Example
4 to determine if metastatic cells are also tumorigenic and if
treatment with L-685,458 changes the metastatic or tumorigenic
markers compared to control.
[0515] In another embodiment multi-color quantitative
immunofluorescence is used to determine the subcellular
localization and expression levels of alpha-catenin and E-cadherin
or the nuclear localization of beta-catenin in cancer stem cells to
assess their metastatic potential and changes associated with
L-685,458 treatment. Frozen sections of tumor biopsies are fixed
with 4% paraformaldehyde, blocked in 3% normal goat serum, and
incubated with fluorescently labeled antibodies against CD44, CD24,
and on alternating adjacent sections either alpha-catenin,
beta-catenin, or E-cadherin. In alternative embodiments antibodies
to other cancer stem cell markers of either the alpha-catenin
and/or E-cadherin gene expression signatures can be used. For
example antibodies to NCSTN and MET can be used on alternating
adjacent sections to assess the presence of type 1 cancer stem
cells by decreased expression of NCSTN and increased expression of
MET. Similarly, antibodies to IL1R2 and SHC1 can be used to assess
the presence of type 2 cancer stem cells by decreased expression of
IL1R2 and increased expression of SHC1.
[0516] Cancer stem cells are identified as lineage- cells based on
their neoplastic morphology (Al-Hajj et al., 2003) and as CD44+ and
CD24- by the presence and absence, respectively, of a fluorescent
signal. Total expression levels as well as the ratio of membrane to
cytoplasmic localized of alpha-catenin and E-cadherin, or any
combination of type 1 or type 2 cancer stem cell markers of the
present invention, is determined by quantitative immunofluorescence
(Dunn et al., 1994; Kirchner et al., 2003) using a Quantics CCD
camera equipped with an EEV 57-10 GI Chip (Photometrics, Tucson,
Ariz.) generating 12-bit digital data. Nuclear localization of
beta-catenin is also assessed.
[0517] It is expected that proliferating mesenchymal cells at the
leading edge of a tumor with cytoplamic E-cadherin and nuclear
beta-catenin will also prove to be tumorigenic cancer stem cells.
If gamma secretase activity contributes to the metastatic potential
of cancer stem cells through cleavage of E-cadherin, it is
predicted that gamma secretase inhibitors should reduce both the
number of these cells and the cytoplasmic expression of E-cadherin
and alpha-catenin.
EXAMPLE 17
Targeting the Signature 1 Cancer Stem Cell Marker DCBLD2 to Inhibit
Metastasis
[0518] This example describes methods for targeting cancer stem
cells based on the expression of cancer stem cell markers
identified by the gene expression signatures of the present
invention and for assaying the impact of this targeting on tumor
metastasis potential. Specifically, metastasis is monitored by
alpha-catenin and E-cadherin expression levels and E-cadherin,
alpha-catenin, and beta-catenin subcellular localization in cancer
stem cells after targeting a transmembrane protein that can
contribute to tumor metastasis and that is overexpressed in cancer
stem cells. Gene expression signature 1 of the present invention
identifies increased DCBLD2 expression in signature 1 cancer stem
cells compared to normal breast epithelium (FIG. 11). DCBLD2 is a
type-I transmembrane protein structurally similar to the
neurophilins, cell surface receptors for semaphorins that mediate
axon repulsion and attraction in the nervous system. CUB and
discoidin domains present in DCBLD2 have been linked to the
regulation of cell aggregation and migration. Furthermore, DCBLD2
is overexpressed in highly metastatic cancers, and thus targeting
cells expressing high levels of DCBLD2 could eliminate cancer stem
cells with high metastatic potential.
[0519] To target cancer stem cells with increased expression of
DCBLD2, monoclonal antibodies against the extracellular domain of
DCBLD2 are produced. F1 hybrid mice are immunized using purified
recombinant extracellular DCBLD2 protein and the spleen from mice
with circulating antibodies that specifically recognize the
immunizing protein are used for hybridoma production.
[0520] Antibodies against the different domains of DCBLD2 are then
used as therapeutic agents in a mouse xenograft model. Cells from a
primary tumor are cut up with scissors into small pieces that are
then minced with a blade in sterile RPMI medium on ice to yield
2.times.2 mm pieces. The tumor pieces are washed in serum-free HBSS
and implanted into the mammary fat pads of VP-16 and estrogen
pre-treated NOD/SCID mice. Alternatively, cancer stem cells with an
alpha-catenin gene expression signature are isolated as described
in Example 5 above and 5,000 down to 200 isolated cells are
injected into NOD/SCID mice. Once palpable tumors are formed, mice
are injected i.p. with antibodies against DCBLD2 or control
antibodies every third day for two weeks. Mice are sacrificed at
various times during the treatment and the tumor assessed for the
presence and number of metastatic tumor stem cells at the leading
edge of the tumors using qualitative immunofluorescence as
described in detail above.
EXAMPLE 18
Using E-Cadherin, Alpha-Catenin, Table 4 and Table 6 Genes
Differentially Expressed by Cancer Stem Cells, and/or Beta-Catenin
Expression and Protein Localization to Determine the Metastatic
Potential of Cancer Stem Cells in a Patient Biopsy
[0521] This example describes methods for monitoring the presence
of metastatic cancer stem cells in a patient biopsy by E-cadherin
and/or alpha-catenin expression and E-cadherin, alpha-catenin, one
or more of the genes listed in tables 4 and 6 that are
differentially expressed by cancer stem cells and non-tumorigenic
cancer cells, and/or beta-catenin protein localization. A patient
tumor biopsy is taken and embedded in O.C.T., and cut on a cryostat
as 10 um sections onto glass slides. Alternatively biopsies are
formalin-fixed, paraffin-embedded, and cut on a microtome as 10 um
section onto glass slides. Slides are then processed for
quantitative immunofluorescence for alpha-catenin, E-cadherin
protein, and/or beta-catenin expression and localization as
described in Example 14 above. Patients with cancer stem cells with
low expression of either alpha-catenin or E-cadherin combined with
increase protein in the cytoplasm relative to associated with
adherens junctions are assessed as at high risk for metastasis and
therapy adjusted accordingly.
EXAMPLE 19
Using Cancer Stem Cells Markers to Determine the Tumorigenic
Potential of Circulating Metastatic Tumor Cells in a Cancer
Patient
[0522] This example describes methods for determining the
tumorigenicity of tumor cells circulating in the peripheral blood
of a cancer patient. Tumor burden is a critical factor in the
clinical outcome of cancer patients, and the frequency of
metastasis, relapse, and death appears to correlate with levels of
circulating tumor cells (Wong, 2003, Oncol. Reports 10:229).
Currently quantitative RT-PCR is used against a wide range of tumor
markers to determine the presence of tumor cells with varying
success (Wong, 2003, Oncol. Reports 10:229). There is thus a need
for sensitive, specific, and non-invasive blood tests to assess
tumor burden to determine the need for more intensive therapeutic
intervention. The cancer stem cell gene signatures of the present
invention further enables one to identify circulating cells as not
only metastatic but also tumorigenic. Blood from patients is
collected and the presence of cancer stem cells is determined using
flow cytometry as described in Example 5. Furthermore, the isolated
tumor stem cells can be injected in the mammary fat pads of VP-16
and estrogen pretreated NOD/SCID mice to assess tumorigenicity. The
presence and tumorigenicity of tumor cells in the blood of a
patient can be monitored over time to determine the effect of a
cancer therapy.
EXAMPLE 20
The Alpha-Catenin Signature Predicts Poor Clinical Outcome
[0523] This example describes the identification of the
alpha-catenin signature as predictive of clinical outcome of early
breast cancer including metastasis and overall survival.
Futhermore, use of the alpha-catenin gene signature to classify
tumor samples into low and high risk for the purpose of prognosis
and therapy selection is provided.
[0524] The genome-wide analysis of solid tumor stem cell gene
expression of the present invention identified gene profiles that
subclassify tumors and thus can be useful in predicting clinical
outcome. The genes differentially expressed in tumor stem cells
were divided into solid tumor stem cell gene signatures based on
the correlation of their expression with alpha-catenin and then
further selected based on their fold or percentage expression
change change in tumor stem cells with undetectable or low levels
of alpha-catenin compared to normal breast tissue and alpha-catenin
non-deficient tumor stem cells. Genes with undetectable to low
expression in tumor stem cells comprising low to undetectable
alpha-catenin expression were identified as having a positive
correlation, from 0.9 to 1, with alpha-catenin expression in all
tumor stem cells as well as expression levels lower by 90% or more
in tumor stem cells comprising low to undectable alpha-catenin
compared to normal breast tissue and alpha-catenin non-deficient
tumor stem cells. Genes with elevated expression in tumor stem
cells comprising low to undetectable alpha-catenin expression were
identified as having a negative correlation, from -0.9 to -1, with
alpha-catenin expression in all tumor stem cells as well as
expression levels in tumor stem cells comprising low to undectable
alpha-catenin expression that are 9 fold or more than in normal
breast tissue and alpha-catenin non-deficient tumor stem cells.
Together these genes comprise the alpha-catenin signature 1 (Table
9). A second alpha-catenin signature (alpha-catenin signature 2)
was then generated by further including genes that slightly
violated the fold or expression change criteria described above but
were subjectively determined to be therapeutically and/or
biologically interesting genes: one gene with undetetable to low
expression and three genes with elevated expression (underlined in
Table 9). A third alpha-catenin signature (alpha-catenin signature
3) was then generated by excluding genes from alpha-catenin
signature 2: nine genes with undetectable to low expression and
fifteen genes with elevated expression (Table 9).
[0525] The genes differentially expressed in tumor stem cells were
also divided into solid tumor stem cell gene signatures based on
the correlation of their expression with E-cadherin and then
further selected based on their fold or percentage expression
change change in tumor stem cells with undetectable or low levels
of E-cadherin compared to normal breast tissue and E-cadherin
non-deficient tumor stem cells. Genes with undetectable to low
expression in tumor stem cells comprising low to undetectable
E-cadherin expression were identified as having a positive
correlation, from 0.9 to 1, with E-cadherin expression in all tumor
stem cells as well as expression levels lower by 85% or more in
tumor stem cells comprising low to undectable E-cadherin compared
to normal breast tissue and E-cadherin non-deficient tumor stem
cells. Genes with elevated expression in tumor stem cells
comprising low to undetectable E-cadherin expression were
identified as having a negative correlation, from -0.9 to -1, with
E-cadherin expression in all tumor stem cells as well as expression
levels in tumor stem cells comprising low to undectable E-cadherin
expression that are 2.5 fold or more-than in normal breast tissue
and E-cadherin non-deficient tumor stem cells. Together these genes
comprise the E-cadherin signature 1. A second E-cadherin signature
(E-cadherin signature 2) was then generated by further including
genes that slightly violated the fold or expression change criteria
described above but were subjectively determined to be
therapeutically and/or biologically interesting genes: one gene
with elevated expression (underlined in Table 9). A third
E-cadherin signature (E-cadherin signature 3) was then generated by
excluding genes from E-cadherin signature 2 that were subjectively
determined not to be therapeutically and/or biologically
interesting genes: six genes with undetectable to low expression
and six genes with elevated expression (Table 9).
[0526] To assess the ability of cancer stem cell gene signatures to
predict metastasis and death two independent cancer patient
populations were used: 295 consecutive early breast cancer patients
from the Netherlands Cancer Institute (van de Vijver et al., 2002,
N. Eng. J. Med. 347:1999) and 286 lymph node negative breast cancer
patients from the Erasmus Medical Center (Wang et al., 2005, Lancet
365:671). The gene expression from both patient populations had
been analyzed by microarray analysis. The alpha-catenin signature 2
was compared against gene expression analysis from these two
independent cancer patient populations resulting in alpha-catenin
profile 4 and alpha-catenin profile 5, respectively (Table 9).
Similarly, the E-cadherin signature 2 was compared against gene
expression analysis from these two patient populations resulting in
E-cadherin profile 4 and E-cadherin profile 5, respectively (Table
9).
[0527] Correlation and Cox proportional hazard survival analysis of
microarray data from 295 consecutive early breast cancer patients
from the Netherlands Cancer Institute (van de Vijver et al., 2002,
N. Eng. J. Med. 347:1999) identified 125 patient tumors with a gene
expression profile (alpha-catenin profile 4) that positively
correlated with the alpha-catenin signature 2, and showed
alpha-catenin signature 2 as significantly predictive of metastasis
with a univariate hazard ratio of 1.15 per 0.1 correlation
(P=5.9.times.10.sup.-4) and significantly predictive of death with
a univariate hazard ratio of 1.24 per 0.1 correlation
(P=3.7.times.10.sup.-7). Furthermore, correlation and chi-square
analysis of the microarray data from 286 lymph-node negative breast
cancer patients from the Erasmus Medical Center (Wang et al., 2005,
Lancet 365:671) revealed that patient tumors with a gene expression
profile (alpha-catenin profile 5) that correlated with the
alpha-catenin signature 2 (n=77) had an increased risk of
metastasis (P=0.67). Thus a tumor stem cell gene signature, such as
the alpha-catenin expression signature 2 provides a gene signature
for tumors with high risk of metastasis and death, and is thus a
gene signature that predicts a poor prognosis. Although any
particular gene of the alpha-catenin expression signature can or
can not have either reduced expression or elevated expression in a
tumor sample, the expression level and its relationship with the
other genes in the signature creates a unique solid tumor stem cell
signature that can be used to classify a tumor sample.
[0528] A similar comparison using the E-cadherin gene expression
signature described above was again used to assess clinical outcome
as summarized in Table 10. Correlation and Cox proportional hazard
survival analysis of microarray data from 295 consecutive early
breast cancer patients from the Netherlands Cancer Institute
identified 240 patient tumors with a gene expression profile
(E-cadherin profile 4) that positively correlated with the
E-cadherin signature 2, and showed E-cadherin signature 2 as
predictive of metastasis with a univariate hazard ratio for
metastasis of 0.981 per 0.1 correlation (P=0.59) and predictive of
death with a univariate hazard ratio of 0.938 per 0.1 correlation
(P=0.1). Combining the alpha-catenin and E-cadherin gene expression
signatures was also predictive of metastasis in patients
(univariate hazard ratio for metastasis of 1.28 per 0.1 correlation
(P=4.2.times.10.sup.-4)). In addition, correlation and chi-square
analysis of microarray data from 286 lymph-node negative breast
cancer patients from the Erasmus Medical Center (Wang et al., 2005,
Lancet 365:671) showed that patient tumors with a gene expression
profile (E-cadherin gene profile 5) that correlated with the
E-cadherin gene signature (n=198) had an increased risk of
metastasis (P=0.57).
[0529] Because of their different abilities in the prediction of
clinical outcome, the alpha catenin signature 2 and E-cadherin
signature 2 were further correlated against gene expression
patterns of different tumor subclasses. Microarray analysis has
been used to segregate breast carcinomas based on gene expression
into five distinct subclasses: Luminal A, Luminal B, ERBB2, Basal,
and Normal-like of which the Luminal A subclass has the best
prognosis and the Basal subclass has the poorest prognosis (Sorlie
et al., 2001, PNAS 98:10869). The correlation of the alpha-catenin
signature 2 with these different tumor subclasses is strongest to
the Basal subclass and is negative with the Luminal A subclass
(FIG. 16) again highlighting the alpha-catenin signature as a good
predictor of poor prognosis. In contrast the E-cadherin signature
correlates negatively with the Basal subtype while correlating most
positively with the Luminal A subtype (FIG. 17) suggesting that
these two tumor stem cell signatures identify two different tumor
types with different clinical outcomes.
[0530] In addition to the solid tumor stem cell gene signature, one
or more individual genes that comprise the solid tumor stem cell
gene signatures are significantly predictive of metastasis and
death in the 295 patients from the Netherlands Cancer Institute
suggesting that one or more of these genes can be used in place of
the entire solid tumor stem cell gene signature as described above.
In the case of the alpha-catenin gene signature it was discovered
that the following genes GALC, CTSL2, FOXQ1, MYEOV, RB1, and SLC7A5
were significantly predictive of metastases and death. Expression
of low to undetectable levels of GALC compared to a reference set
of expression across all tumor samples (described in van't Veer et
al., 2002, Nature 415:530 and van de Vijver et al., 2002, N. Eng.
J. Med. 347:1999) was significantly predictive of metastasis with a
univariate hazard ratio of 0.632 per 0.1 correlation
(P=8.1.times.10.sup.-3) and significantly predictive of death with
a univariate hazard ratio of 0.583 per 0.1 correlation
(P=5.4.times.10.sup.-3). Expression of elevated levels of CTSL2
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.52 per 0.1
correlation (P=1.7.times.10.sup.--6) and significantly predictive
of death with a univariate hazard ratio of 1.86 per 0.1 correlation
(P=4.0.times.10.sup.-11). Expression of elevated levels of FOXQ1
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.44 per 0.1
correlation (P=1.7.times.10.sup.-3) and significantly predictive of
death with a univariate hazard ratio of 1.73 per 0.1 correlation
(P=1.6.times.10.sup.-5). Expression of elevated levels of MYEOV
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 1.76 per 0.1
correlation (P=2.2.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 2.09. per 0.1 correlation
(P=5.9.times.10.sup.-3). Expression of elevated levels of RB1
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 0.72 per 0.1
correlation (P=1.6.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 0.664 per 0.1 correlation
(P=6.8.times.10.sup.-3). Expression of elevated levels of SCL7A5
compared to the reference set was significantly predictive of
metastasis with a univariate hazard ratio of 3 per 0.1 correlation
(P=2.6.times.10.sup.-4) and significantly predictive of death with
a univariate hazard ratio of 3.52 per 0.1 correlation
(P=1.1.times.10.sup.-4).
[0531] In addition, several of the genes comprising the E-cadherin
gene expression signature were predictive alone including some with
low to undetectable expression: IL8 and KRT6B and some with
elevated expression: RNASEL and C17orf27. Expression of low to
undectable levels of IL8 compared to the reference set was
significantly predictive of metastasis with a univariate hazard
ratio of 1.17 per 0.1 correlation (P=5.2.times.10.sup.-2) and
significantly predictive of death with a univariate hazard ratio of
1.3 per 0.1 correlation (P=3.0.times.10.sup.-3). Expression of low
to undetectable levels of KRT6B compared to the reference set was
significantly predictive of metastasis univariate hazard ratio of
1.35 per 0.1 correlation (P=3.9.times.10.sup.-2) and significant
predictive of death with aunivariate hazard ratio of 1.54 per 0.1
correlation (P=4.7.times.10.sup.-3). Expression of elevated levels
of RNASEL compared to the reference set was significantly
predictive of metastasis with a univariate hazard ratio of 0.655
per 0.1 correlation (P=3.7.times.10.sup.-2) and significantly
predictive of death with a univariate hazard ratio of 0.498 per 0.1
correlation (P=1.4.times.10.sup.-3). Elevated expression levels of
C17orf27 compared to the reference set was significantly predictive
of metastasis with a univariate hazard ratio of 2.35 per 0.1
correlation (P=1.5.times.10.sup.-2) and significantly predictive of
death with a univariate hazard ratio of 3.19 per 0.1 correlation
(P=3.1.times.10.sup.-3).
[0532] The identification of the alpha-catenin gene signature as
predictive of poor prognosis suggests its use clinically in
providing a prognosis and selecting a therapy for patients. The
alpha-catenin gene expression signature was discovered from a
comparison of cancer stem cells against normal breast tissue, its
prognostic ability was identified from microarray analysis of
unfractionated, and thus heterogenous, breast tumor samples
normalized against a reference set of tumor samples (van't Veer et
al., 2002, Nature 415:530; van de Vijver et al., 2002, N. Eng. J.
Med. 347:1999) or scaled to a target intensity (Wang et al., 2005,
Lancet 365:671). Thus unfractioned tumor samples including but not
limited to solid tissue biopsies, fine needle aspirations, or
pleural effusions can be used for detecting the alpha-catenin
signature in cancer patients.
[0533] To test additional patients, a tumor sample is obtained and
is fresh-frozen for storage in liquid nitrogen at -180 .degree. C.
before analysis. RNA is extracted from the tumor sample and
fluorescently labeled cDNA probes are generated for microarray
analysis using standard techniques in the art. cDNA probes from the
patient sample are hybridized on DNA microarrays containing genes,
or fragments thereof, which comprise an alpha-catenin signature.
The hybridization is performed in combination with a reference
sample composed of a pool of cDNAs from a number of tumor samples
that are labeled with a complementary fluorophore. The hybridized
array is scanned and the fluorescence intensities quantified,
normalized, and corrected to yield the transcript abundance of each
gene as an intensity ratio with respect to that of the signal of
the reference sample. Alternatively the isolated RNA is used for
quantitative RT-PCR using primer sets that specifically amplify the
gene that comprise the alpha-catenin signature. The gene expression
profile in the patient sample is then correlated with the
alpha-catenin signature. The detection of a positive correlation
with the alpha-catenin signature is used to categorize a tumor as
high risk and an appropriate therapy is thus administered and the
signature can further be used over time to monitor the chosen
therapy. Alternatively, if no correlation or a negative correlation
with the alpha-catenin signature is detected in the sample, a
patient can be monitored over time for the appearance of the
signature.
[0534] All publications and patents mentioned in the above
specification are herein incorporated by reference. Various
modifications and variations of the described method and system of
the invention will be apparent to those skilled in the art without
departing from the scope and spirit of the invention. Although the
invention has been described in connection with specific some
embodiments, it should be understood that the invention as claimed
should not be unduly limited to such specific embodiments. Indeed,
various modifications of the described modes for carrying out the
invention which are obvious to those skilled in the relevant fields
are intended to be within the scope of the following claims.
Sequence CWU 1
1
1 1 21 DNA Homo sapiens 1 gggcaagttt cccgtgcagt t 21
* * * * *